
<html lang="en"     class="pb-page"  data-request-id="8bfa91ac-2c58-440e-8b58-ee2cbc81ceb3"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2020.63.issue-13;article:article:10.1021/acs.jmedchem.0c00055;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Identification of N-Phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine Derivatives as Novel, Potent, and Selective NF-κB Inducing Kinase (NIK) Inhibitors for the Treatment of Psoriasis" /></meta><meta name="dc.Creator" content="Yuqin  Zhu" /></meta><meta name="dc.Creator" content="Yuxiang  Ma" /></meta><meta name="dc.Creator" content="Weidong  Zu" /></meta><meta name="dc.Creator" content="Jianing  Song" /></meta><meta name="dc.Creator" content="Hua  Wang" /></meta><meta name="dc.Creator" content="You  Zhong" /></meta><meta name="dc.Creator" content="Hongmei  Li" /></meta><meta name="dc.Creator" content="Yanmin  Zhang" /></meta><meta name="dc.Creator" content="Qianqian  Gao" /></meta><meta name="dc.Creator" content="Bo  Kong" /></meta><meta name="dc.Creator" content="Junyu  Xu" /></meta><meta name="dc.Creator" content="Fei  Jiang" /></meta><meta name="dc.Creator" content="Xinren  Wang" /></meta><meta name="dc.Creator" content="Shuwen  Li" /></meta><meta name="dc.Creator" content="Chenhe  Liu" /></meta><meta name="dc.Creator" content="Haichun  Liu" /></meta><meta name="dc.Creator" content="Tao  Lu" /></meta><meta name="dc.Creator" content="Yadong  Chen" /></meta><meta name="dc.Description" content="A series of N-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives with NF-κB inducing kinase (NIK) inhibitory activity were obtained through structure-based drug design and synthetic chemistry. A..." /></meta><meta name="Description" content="A series of N-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives with NF-κB inducing kinase (NIK) inhibitory activity were obtained through structure-based drug design and synthetic chemistry. A..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="June 1, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c00055" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00055" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c00055" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00055" /></link>
        
    
    

<title>Identification of N-Phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine Derivatives as Novel, Potent, and Selective NF-κB Inducing Kinase (NIK) Inhibitors for the Treatment of Psoriasis | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c00055" /></meta><meta property="og:title" content="Identification of N-Phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine Derivatives as Novel, Potent, and Selective NF-κB Inducing Kinase (NIK) Inhibitors for the Treatment of Psoriasis" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/large/jm0c00055_0019.jpeg" /></meta><meta property="og:description" content="A series of N-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives with NF-κB inducing kinase (NIK) inhibitory activity were obtained through structure-based drug design and synthetic chemistry. Among them, 4-(3-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-4-morpholinophenyl)-2-(thiazol-2-yl)but-3-yn-2-ol (12f) was identified as a highly potent NIK inhibitor, along with satisfactory selectivity. The pharmacokinetics of 12f and its ability to inhibit interleukin 6 secretion in BEAS-2B cells were better than compound 1 developed by Amgen. Oral administration of different doses of 12f in an imiquimod-induced psoriasis mouse model showed effective alleviation of psoriasis, including invasive erythema, swelling, skin thickening, and scales. The underlying pathological mechanism involved attenuation of proinflammatory cytokine and chemokine gene expression, and the infiltration of macrophages after the treatment of 12f. This work provides a foundation for the development of NIK inhibitors, highlighting the potential of developing NIK inhibitors as a new strategy for the treatment of psoriasis." /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta><meta name="twitter:description" content="A series of N-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives with NF-κB inducing kinase (NIK) inhibitory activity were obtained through structure-based drug design and synthetic chemistry. Among them, 4-(3-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-4-morpholinophenyl)-2-(thiazol-2-yl)but-3-yn-2-ol (12f) was identified as a highly potent NIK inhibitor, along with satisfactory selectivity. The pharmacokinetics of 12f and its ability to inhibit interleukin 6 secretion in BEAS-2B cells were better than compound 1 developed by Amgen. Oral administration of different doses of 12f in an imiquimod-induced psoriasis mouse model showed effective alleviation of psoriasis, including invasive erythema, swelling, skin thickening, and scales. The underlying pathological mechanism involved attenuation of proinflammatory cytokine and chemokine gene expression, and the infiltration of macrophages after the treatment of 12f. This work provides a foundation for the development of NIK inhibitors, highlighting the potential of developing NIK inhibitors as a new strategy for the treatment of psoriasis." /></meta><meta name="twitter:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/large/jm0c00055_0019.jpeg" /></meta><meta name="twitter:title" content="Identification of N-Phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine Derivatives as Novel, Potent, and Selective NF-κB Inducing Kinase (NIK) Inhibitors for the Treatment of Psoriasis" /></meta>
        
            <meta property="og:type" content="Article" /></meta>
        

        
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c00055"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/ke1q~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-6ee29527b3d8ff00a106.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00055">
            
        





































    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-12/achre4.2021.54.issue-12/20210615/achre4.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-25/aamick.2021.13.issue-25/20210630/aamick.2021.13.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-6/aapmcd.2021.3.issue-6/20210611/aapmcd.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-6/abseba.2021.7.issue-6/20210614/abseba.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-12/accacs.2021.11.issue-12/20210618/accacs.2021.11.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-12/acncdm.2021.12.issue-12/20210616/acncdm.2021.12.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-6/aelccp.2021.6.issue-6/20210611/aelccp.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-6/aeecco.2021.1.issue-6/20210611/aeecco.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-6/aewcaa.2021.1.issue-6/20210611/aewcaa.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-6/aidcbc.2021.7.issue-6/20210611/aidcbc.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-6/amlcef.2021.3.issue-6/20210607/amlcef.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-6/amclct.2021.12.issue-6/20210610/amclct.2021.12.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-25/acsodf.2021.6.issue-25/20210629/acsodf.2021.6.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-25/ascecg.2021.9.issue-25/20210628/ascecg.2021.9.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-25/ancham.2021.93.issue-25/20210629/ancham.2021.93.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-25/bichaw.2021.60.issue-25/20210629/bichaw.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-6/bomaf6.2021.22.issue-6/20210614/bomaf6.2021.22.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-12/cmatex.2021.33.issue-12/20210622/cmatex.2021.33.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-6/cgdefu.2021.21.issue-6/20210602/cgdefu.2021.21.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-12/enfuem.2021.35.issue-12/20210617/enfuem.2021.35.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-12/esthag.2021.55.issue-12/20210615/esthag.2021.55.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-6/estlcu.2021.8.issue-6/20210608/estlcu.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-25/iecred.2021.60.issue-25/20210630/iecred.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-12/inocaj.2021.60.issue-12/20210621/inocaj.2021.60.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-25/jafcau.2021.69.issue-25/20210630/jafcau.2021.69.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-6/jceaax.2021.66.issue-6/20210610/jceaax.2021.66.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-6/jceda8.2021.98.issue-6/20210608/jceda8.2021.98.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-6/jctcce.2021.17.issue-6/20210608/jctcce.2021.17.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/jmcmar.2021.64.issue-12/20210624/jmcmar.2021.64.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-12/joceah.2021.86.issue-12/20210618/joceah.2021.86.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-24/jpcafh.2021.125.issue-24/20210624/jpcafh.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-24/jpcbfk.2021.125.issue-24/20210624/jpcbfk.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-24/jpccck.2021.125.issue-24/20210624/jpccck.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-24/jpclcd.2021.12.issue-24/20210624/jpclcd.2021.12.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-6/jprobs.2021.20.issue-6/20210604/jprobs.2021.20.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-25/jacsat.2021.143.issue-25/20210630/jacsat.2021.143.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-6/jamsef.2021.32.issue-6/20210602/jamsef.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-25/langd5.2021.37.issue-25/20210629/langd5.2021.37.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-12/mamobx.2021.54.issue-12/20210622/mamobx.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-6/mpohbp.2021.18.issue-6/20210607/mpohbp.2021.18.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-12/orlef7.2021.23.issue-12/20210618/orlef7.2021.23.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-12/orgnd7.2021.40.issue-12/20210628/orgnd7.2021.40.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c00055&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c00055&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c00055&amp;href=/doi/10.1021/acs.jmedchem.0c00055" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 13</span><span class="cit-fg-pageRange">, 6748-6773</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/13" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c00022" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c00013" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Identification of <i>N</i>-Phenyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine Derivatives as Novel, Potent, and Selective NF-κB Inducing Kinase (NIK) Inhibitors for the Treatment of Psoriasis</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Yuqin Zhu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yuqin Zhu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Sciences, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yuqin++Zhu">Yuqin Zhu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yuxiang Ma</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yuxiang Ma</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yuxiang++Ma">Yuxiang Ma</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Weidong Zu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Weidong Zu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Sciences, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Weidong++Zu">Weidong Zu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jianing Song</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jianing Song</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Sciences, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jianing++Song">Jianing Song</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hua Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hua Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hua++Wang">Hua Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">You Zhong</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">You Zhong</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=You++Zhong">You Zhong</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hongmei Li</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hongmei Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Sciences, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hongmei++Li">Hongmei Li</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yanmin Zhang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yanmin Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Sciences, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yanmin++Zhang">Yanmin Zhang</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4075-7556" title="Orcid link">http://orcid.org/0000-0002-4075-7556</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Qianqian Gao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Qianqian Gao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Sciences, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Qianqian++Gao">Qianqian Gao</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Bo Kong</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Bo Kong</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Sciences, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Bo++Kong">Bo Kong</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Junyu Xu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Junyu Xu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Sciences, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Junyu++Xu">Junyu Xu</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4918-0693" title="Orcid link">http://orcid.org/0000-0002-4918-0693</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Fei Jiang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Fei Jiang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Sciences, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Fei++Jiang">Fei Jiang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xinren Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xinren Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Sciences, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xinren++Wang">Xinren Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Shuwen Li</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shuwen Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Sciences, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shuwen++Li">Shuwen Li</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Chenhe Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Chenhe Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Sciences, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Chenhe++Liu">Chenhe Liu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Haichun Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Haichun Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Sciences, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Haichun++Liu">Haichun Liu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Tao Lu</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tao Lu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Sciences, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, P. R. China</div><div class="loa-info-affiliations-info">State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, P. R. China</div></div><span class="conrtib-corresp"><strong>*</strong>T.L.: phone, +86-25-86185180; fax, +86-25-86185179; email, <a href="/cdn-cgi/l/email-protection#29455c5d4846694a595c074c4d5c074a47"><span class="__cf_email__" data-cfemail="81edf4f5e0eec1e2f1f4afe4e5f4afe2ef">[email protected]</span></a></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tao++Lu">Tao Lu</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Yadong Chen</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yadong Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Sciences, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, P. R. China</div></div><span class="conrtib-corresp"><strong>*</strong>Y.C.: phone, +86-25-86185153; fax, +86-25-861851170; email, <a href="/cdn-cgi/l/email-protection#7a031e19121f143a190a0f541f1e0f541914"><span class="__cf_email__" data-cfemail="39405d5a515c57795a494c175c5d4c175a57">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yadong++Chen">Yadong Chen</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2189-9356" title="Orcid link">http://orcid.org/0000-0002-2189-9356</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00055&amp;href=/doi/10.1021%2Facs.jmedchem.0c00055" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 13</span><span class="cit-pageRange">, 6748–6773</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">June 1, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>12 January 2020</li><li><span class="item_label"><b>Published</b> online</span>1 June 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 9 July 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c00055" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00055</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D6748%26pageCount%3D26%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DYuqin%2BZhu%252C%2BYuxiang%2BMa%252C%2BWeidong%2BZu%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D13%26contentID%3Dacs.jmedchem.0c00055%26title%3DIdentification%2Bof%2BN-Phenyl-7H-pyrrolo%255B2%252C3-d%255Dpyrimidin-4-amine%2BDerivatives%2Bas%2BNovel%252C%2BPotent%252C%2Band%2BSelective%2BNF-%25CE%25BAB%2BInducing%2BKinase%2B%2528NIK%2529%2BInhibitors%2Bfor%2Bthe%2BTreatment%2Bof%2BPsoriasis%26numPages%3D26%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D6773%26publicationDate%3DJuly%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c00055"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1803</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">5</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c00055" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Identification of N-Phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine Derivatives as Novel, Potent, and Selective NF-κB Inducing Kinase (NIK) Inhibitors for the Treatment of Psoriasis&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Yuqin&quot;,&quot;last_name&quot;:&quot;Zhu&quot;},{&quot;first_name&quot;:&quot;Yuxiang&quot;,&quot;last_name&quot;:&quot;Ma&quot;},{&quot;first_name&quot;:&quot;Weidong&quot;,&quot;last_name&quot;:&quot;Zu&quot;},{&quot;first_name&quot;:&quot;Jianing&quot;,&quot;last_name&quot;:&quot;Song&quot;},{&quot;first_name&quot;:&quot;Hua&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;You&quot;,&quot;last_name&quot;:&quot;Zhong&quot;},{&quot;first_name&quot;:&quot;Hongmei&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Yanmin&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Qianqian&quot;,&quot;last_name&quot;:&quot;Gao&quot;},{&quot;first_name&quot;:&quot;Bo&quot;,&quot;last_name&quot;:&quot;Kong&quot;},{&quot;first_name&quot;:&quot;Junyu&quot;,&quot;last_name&quot;:&quot;Xu&quot;},{&quot;first_name&quot;:&quot;Fei&quot;,&quot;last_name&quot;:&quot;Jiang&quot;},{&quot;first_name&quot;:&quot;Xinren&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Shuwen&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Chenhe&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Haichun&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Tao&quot;,&quot;last_name&quot;:&quot;Lu&quot;},{&quot;first_name&quot;:&quot;Yadong&quot;,&quot;last_name&quot;:&quot;Chen&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;06&quot;,&quot;day&quot;:&quot;01&quot;,&quot;issue&quot;:&quot;13&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;6748-6773&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c00055&quot;},&quot;abstract&quot;:&quot;A series of N-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives with NF-κB inducing kinase (NIK) inhibitory activity were obtained through structure-based drug design and synthetic chemistry. Among them, 4-(3-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-4-morpholinophenyl)-2-(thiazol-2-yl)but-3-yn-2-ol (12f) was identified as a highly potent NIK inhibitor, along with satisfactory selectivity. The pharmacokinetics of 12f and its ability to inhibit interleukin 6 secretion in BEAS-2B cells were better than compound 1 developed by Amgen. Oral administration of different doses of 12f in an imiquimod-induced psoriasis mouse model showed effective alleviation of psoriasis, including invasive erythema, swelling, skin thickening, and scales. The underlying pathological mechanism involved attenuation of proinflammatory cytokine and chemokine gene expression, and the infiltration of macrophages after the treatment of 12f. This work provides a foundation for the development of NIK inhibitors, highlighting the potential o&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00055&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00055" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00055&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00055" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00055&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00055" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00055&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00055&amp;href=/doi/10.1021/acs.jmedchem.0c00055" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c00055" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c00055" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (10 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c00055%26sid%3Dliteratum%253Aachs%26pmid%3D32479083%26genre%3Darticle%26aulast%3DZhu%26date%3D2020%26atitle%3DIdentification%2Bof%2BN-Phenyl-7H-pyrrolo%255B2%252C3-d%255Dpyrimidin-4-amine%2BDerivatives%2Bas%2BNovel%252C%2BPotent%252C%2Band%2BSelective%2BNF-%25CE%25BAB%2BInducing%2BKinase%2B%2528NIK%2529%2BInhibitors%2Bfor%2Bthe%2BTreatment%2Bof%2BPsoriasis%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D13%26spage%3D6748%26epage%3D6773%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (6)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290758" title="Anatomy">Anatomy</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/13" title="Go to Volume 63, Issue 13"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/jmcmar.2020.63.issue-13/20200709/jmcmar.2020.63.issue-13.largecover.jpg" alt="Go to Volume 63, Issue 13"/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/medium/jm0c00055_0019.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/large/jm0c00055_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00055&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">A series of <i>N</i>-phenyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine derivatives with NF-κB inducing kinase (NIK) inhibitory activity were obtained through structure-based drug design and synthetic chemistry. Among them, 4-(3-((7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)-4-morpholinophenyl)-2-(thiazol-2-yl)but-3-yn-2-ol (<b>12f</b>) was identified as a highly potent NIK inhibitor, along with satisfactory selectivity. The pharmacokinetics of <b>12f</b> and its ability to inhibit interleukin 6 secretion in BEAS-2B cells were better than compound <b>1</b> developed by Amgen. Oral administration of different doses of <b>12f</b> in an imiquimod-induced psoriasis mouse model showed effective alleviation of psoriasis, including invasive erythema, swelling, skin thickening, and scales. The underlying pathological mechanism involved attenuation of proinflammatory cytokine and chemokine gene expression, and the infiltration of macrophages after the treatment of <b>12f</b>. This work provides a foundation for the development of NIK inhibitors, highlighting the potential of developing NIK inhibitors as a new strategy for the treatment of psoriasis.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_62404" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_62404" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">As a common chronic inflammatory skin disease, psoriasis affects approximately 2–4% of the worldwide population. Psoriasis can be divided into psoriasis vulgaris, pustular psoriasis, erythropoietic psoriasis, and arthritic psoriasis.<a onclick="showRef(event, 'ref1 ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3">(1−3)</a> Regardless of the type, it is characterized by associated histological and pathological features, including exaggerated angiogenesis, abnormal growth, differentiation of keratinocytes, and prominent immune cell infiltration, such as T cells, neutrophils, and macrophages.<a onclick="showRef(event, 'ref4 ref5 ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref4 ref5 ref6 ref7">(4−7)</a> Like other autoimmune and inflammatory diseases, the complex pathogenesis of psoriasis determines the multidirectional and multipath nature of drug development.</div><div class="NLM_p">Indeed, biomacromolecules targeting autoimmune and inflammatory processes, particularly belimumab (Benlysta), has contributed significantly in patient care.<a onclick="showRef(event, 'ref8 ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref8 ref9 ref10">(8−10)</a> Despite substantial advances in the treatment of autoimmune diseases such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), there is still an urgent need for effective psoriasis treatment strategies.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> In arthritic psoriasis, monoclonal antibodies (mAbs) and recombinant proteins targeting cytokines and receptors, such as IL-12, IL-17, IL-23, TNFα, and TNFR II, have become a research hotspot for major pharmaceutical giants represented by Pfizer Inc. and Janssen Biotech Inc.<a onclick="showRef(event, 'ref12 ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref12 ref13 ref14">(12−14)</a> Small molecule inhibitors yet provide an alternative when biomacromolecules targeting specific extracellular cytokines cannot reliably achieve disease remission.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Janus kinase (JAK) is a popular target that has been studied for the treatment of psoriasis. There exist nonselective or low-selective JAK inhibitors tofacitinib,<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> ruxolitinib,<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> and baricitinib,<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> but anemia and other hematological toxicities (e.g., dose-dependent neutropenia and significant lymphopenia) are often caused by inhibition of the JAK2 subunit which prompts researchers to develop more selective JAK inhibitors.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Peficitinib as a selective JAK1/3 inhibitor is in phase II clinical trials for the treatment of psoriasis.<a onclick="showRef(event, 'ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref20 ref21">(20,21)</a> BMS-986165 developed by Bristol-Myers Squibb is currently in phase III clinical trials as a potential treatment for psoriasis.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Besides, other types of inhibitors are developed to target autoimmune-disease associated with intracellular proteins such as BTK and SYK.<a onclick="showRef(event, 'ref23 ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref23 ref24 ref25">(23−25)</a> It was believed that patients would benefit from combination therapies where multiple pathways or synergies are involved in improving efficacy.<a onclick="showRef(event, 'ref15 ref26'); return false;" href="javascript:void(0);" class="ref ref15 ref26">(15,26)</a></div><div class="NLM_p">NF-κB inducing kinase (NIK, also known as MAP3K14) is an essential noncanonical NF-κB signaling mediator downstream of the corresponding ligands of TNF superfamily receptors, including CD40, CD27, lymphotoxin β receptor, BAFF-R, receptor activator of NF-κB (RANK), OX40, and Fn14 (TWEAK-R). In the basal or resting state, TRAF3 links NIK to TRAF2-cIAPs E3 complex, promoting cIAPs-mediated Lys48 ubiquitination and proteasomal degradation of NIK by the E3 ligase. Once the homeostasis is perturbed, such as the stimulation of CD40L or BAFF, NIK would accumulate in the cell, leading to phosphorylation of IKKα, p100 processing as well as increased p52 protein levels. p52 then interacts with RelB to form p52/RelB heterodimer, which translocates into the nucleus and triggers the expression of inflammaory cytokines and chemokines.<a onclick="showRef(event, 'ref27 ref28 ref29 ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref27 ref28 ref29 ref30 ref31">(27−31)</a> Dysfunction of the NIK protein drives the development of many autoimmune and inflammatory diseases. In synovial endothelial cells of RA patients, NIK is highly expressed, along with the increased BAFF serum levels.<a onclick="showRef(event, 'ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref32 ref33">(32,33)</a> Furthermore, <i>Peli1</i>-deficiency mice exhibited splenic CD19<sup>+</sup> B cell hyperproliferation and increased production of its antigen-specific antibodies (IgM, IgG2a, and IgG3), due to accumulation of NIK in the cell, leading to spontaneous SLE.<a onclick="showRef(event, 'ref27 ref30'); return false;" href="javascript:void(0);" class="ref ref27 ref30">(27,30)</a> Related liver disease studies also show that one of the common pathological features in patients with primary biliary cirrhosis is hepatocyte-specific overexpression of NIK, which further promotes liver inflammation and injury.<a onclick="showRef(event, 'ref34 ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref34 ref35 ref36">(34−36)</a> Similarly, NIK plays a direct or indirect role in the pathogenesis of psoriasis.<a onclick="showRef(event, 'ref37 ref38 ref39 ref40 ref41 ref42'); return false;" href="javascript:void(0);" class="ref ref37 ref38 ref39 ref40 ref41 ref42">(37−42)</a> In 2015, Etemadi et al. reported that TRAF2<sup>–/–</sup> but not wild-type keratinocytes showed increased levels of NIK and p52, which led to many psoriasis associated-inflammatory gene expression, including Csf1 (M-CSF), IL-23, TNFSF9 (4-1BBL), Cr1l, and Cxcl16.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> In addition to local tissue cell-associated inflammatory regulation, dysfunctional NIK also mediates the behavior of immune T cells in autoimmune-like disease. It has recently been established that NIK signaling not only promotes the differentiation of αβ T and γδ T cells but also acts as the hardwiring in thymic epithelial cells to mediate γδ T cell cytokine production.<a onclick="showRef(event, 'ref38 ref39 ref40'); return false;" href="javascript:void(0);" class="ref ref38 ref39 ref40">(38−40)</a> Furthermore, in TRAF2-ablated DKO mice, constitutive NF-κB2 activity resulting from NIK accumulation triggers aberrant enhancement of T cell activation and premature differentiation of Th17 effector T cells, but not T-helper 1 (Th1), and eventually develops autoimmune diseases such as psoriasis. Subsequent research confirmed that the corresponding inflammatory phenotype of the DKO mice could be reversed by a haplodeficiency of NIK.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Accordingly, development of novel NIK inhibitors for the treatment of psoriasis has extremely high research value.</div><div class="NLM_p">Currently, the design and application of NIK inhibitors are scarce, and only a few cases of NIK inhibitors have been reported. Amgen is the first to design a series of compounds containing alkynol fragments, which have good NIK inhibitory potency with a typical representative being compound <b>1</b> (<i>K</i><sub>i</sub> = 0.4 ± 0.3 nM, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). In 2016, Chen’s group confirmed the efficacy of <b>1</b> on toxin-induced acute hepatitis and liver injury.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> After the X-ray crystal structure of the NIK kinase domain was determined, Janssen Pharmaceuticals and Genentech discovered another series of NIK inhibitors with high NIK inhibitory activity and selectivity (compounds <b>2</b>–<b>4</b>).<a onclick="showRef(event, 'ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref29 ref30">(29,30)</a> Compounds <b>2</b> and <b>3</b> can effectively inhibit LTβR-mediated p52/RelB nuclear translocation and the expression of related target genes. Both are in the preclinical stage, and the initial indication is the same as SLE.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/medium/jm0c00055_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/large/jm0c00055_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Representative NIK inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/large/jm0c00055_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00055&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Although the efficacy of NIK small molecule inhibitors against SLE and toxin-induced liver inflammation and injury has been well established (compounds <b>3</b> and <b>1</b>, respectively), there is no reported case of NIK small molecule inhibitor as potential therapeutics for psoriasis.<a onclick="showRef(event, 'ref28 ref36'); return false;" href="javascript:void(0);" class="ref ref28 ref36">(28,36)</a> In this study, we report the design and synthesis of <i>N</i>-phenyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine derivatives as novel NIK inhibitors. A promising lead molecule <b>12f</b> was identified from this series after a joint effort of medicinal chemistry synthesis and bioassay evaluation of kinase selectivity, macrophage nitric oxide secreted inhibition, and T cell antiproliferation screening. The pharmacokinetics (PK) properties of <b>12f</b> were also evaluated, and it is more stable than the starting compound <b>1</b> developed by Amgen. The in vivo study in an imiquimod (IMQ)-induced psoriasis mouse model demonstrated that compound <b>12f</b> could significantly improve the disease phenotype, and it also showed evidence of the underlying pathological characteristics.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00268" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00268" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Structure-Based Design Strategy</h3><div class="NLM_p">Indolinoline-based compound <b>1</b> (developed by Amgen) is the first NIK inhibitor that has been shown to be effective in vivo when administered by injection in acute hepatitis and liver injury models.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> Analysis of the binding pattern of ligand <b>1</b> to NIK indicated that the interaction surface in the solvent accessible region showed onset of van der Waals clashes. The size of this region may allow us to open the tetrahydropyrrole ring and grow new substituents at the appropriate site. Moreover, we hypothesized that the pyrimidine ring grows into a pyrrolopyrimidine fragment that could engage the hinge region with potential H-bond (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A). Starting from compound <b>1</b>, a structure-based design including ring-opening of tetrahydropyrrole, cyclization of the aminopyrimidine ring, and the introduction of hydrophilic groups was utilized, resulting in a new molecule <b>12k</b> with a distinct scaffold (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B).</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/medium/jm0c00055_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/large/jm0c00055_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Binding mode of ligand <b>1</b> with NIK and the assumptions of design strategies. (B) Design strategy from compound <b>1</b> to compound <b>12k</b>. The corresponding NIK inhibitory activities were displayed. (C) Overlay of compound <b>12k</b> to ligand <b>1</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4G3E">4G3E</a>). Only the hydrogen bonding interaction between <b>12k</b> and NIK is presented.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/large/jm0c00055_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00055&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Subsequently, compound <b>12k</b> was docked into the NIK crystal structure (RCSB PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4G3E">4G3E</a>) to investigate the compatibility of <b>12k</b> with the target. As shown in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>C, overlay of compounds <b>1</b> and <b>12k</b> in the active site looks reasonable. Besides, a similar binding pattern of <b>12k</b> with NIK protein was surfaced, compared to that of compound <b>1</b>. The 4-aminopyrrolo[2,3-<i>d</i>]pyrimidine unit forms two conserved hydrogen bonds with Leu474 in the hinge region of NIK. The acetylenic alcohol unit forms two hydrogen bonds with Glu442 and Phe537 in the α-C helix and the DFG region, respectively. The thiazole nitrogen atom captures Asp536 to form hydrogen-bond interaction. The methylpiperazine fits into the solvent accessible region near the G-loop. The next work demonstrated moderate NIK inhibitory activity (IC<sub>50</sub> = 78.3 ± 5.53 nM, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B). Following this design idea, structural optimization was performed on compound <b>12k</b>, and a series of molecules were synthesized and evaluated in our kinase assay.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Chemsitry</h3><div class="NLM_p">Synthetic routes to the <i>N</i>-phenyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine analogs are depicted in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. Compound <b>7</b> was obtained in two steps starting with 4-chloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine. In the second step, AgOTf was used as a catalyst and the electron-withdrawing tosyl protecting group allowed the nucleophilic aromatic reaction to occur readily. After the nitro reduction reaction with Fe/NH<sub>4</sub>Cl, subsequent diazotization reaction afforded <b>10</b> in acceptable yield. Removal of the <i>N</i>-tosyl group was carried out to provide <b>11</b> using LiOH or NaOH in EtOH. Target compounds <i>N</i>-phenyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine analogs <b>12</b> were obtained via the Sonogashira coupling reaction. Conversion of intermediate <b>9</b> to target analogs <b>14</b> was then achieved in two steps: the deprotection step and the condensation reaction of <b>13</b> with acyl chloride or isocyanate in the presence of Et<sub>3</sub>N. Similarly, using Et<sub>3</sub>N as a base, the nucleophilic attack of the piperazine nitrogen atom to appropriate acyl chloride gave <b>15</b>. Then, we constructed the alkynol fragment on the core skeleton via the coupling reaction and obtained the target compound <b>16</b>. As shown in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>, compounds <b>21a</b>–<b>21f</b> were prepared in good overall yields via a six-steps conversion, similar to the reactions shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. The difference was in the reaction step a, using AgOTf or Pd<sub>2</sub>(dba)<sub>3</sub> as a catalyst and 2-fluoro-5-nitroaniline as a starting material to react with the appropriate nitrogen-containing aromatic heterocyclic compounds.</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/medium/jm0c00055_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/large/jm0c00055_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of <i>N</i>-Phenyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine Analogs<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/large/jm0c00055_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00055&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) TsCl, NaH, THF, 0 °C; (b) AgOTf, dioxane, 130 °C; (c) corresponding amine, K<sub>2</sub>CO<sub>3</sub>, DMF, 90 °C or relative alcohol, NaH, DMF, 0 °C; (d) Fe, NH<sub>4</sub>Cl, 75% EtOH; (e) NaNO<sub>2</sub>, KI, <i>p</i>-TsOH, CH<sub>3</sub>CN/H<sub>2</sub>O, 0 °C to rt; (f) NaOH, 95% EtOH, 40 °C; (g) PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub>, CuI, Et<sub>3</sub>N/THF = 1:3; (h) appropriate acyl chloride or isocyanate, Et<sub>3</sub>N, DMF, 0 °C; (i) appropriate sulfonyl chloride or acetyl chloride, Et<sub>3</sub>N, DMF, 0 °C.</p></p></figure><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/medium/jm0c00055_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/large/jm0c00055_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compounds <b>21a</b>–<b>21f</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/large/jm0c00055_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00055&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) when X = Cl, AgOTf, dioxane, 130 °C or when X = Br, Pd<sub>2</sub>(dba)<sub>3</sub>, K<sub>2</sub>CO<sub>3</sub>, <i>t</i>-BuOH, 100 °C; (b) morpholine, K<sub>2</sub>CO<sub>3</sub>, DMF, 90 °C; (c) Fe, NH<sub>4</sub>Cl, 75% EtOH; (d) NaNO<sub>2</sub>, KI, <i>p</i>-TsOH, CH<sub>3</sub>CN/H<sub>2</sub>O, 0 °C to room temperature; (e) PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub>, CuI, THF/Et<sub>3</sub>N = 3:1, 40 °C.</p></p></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Structure–Activity Relationship (SAR) Studies</h3><div class="NLM_p">The structural modification starting with the 1-methylpiperazine ring in <b>12k</b> as hydrophilic groups at this position may help improve potency and modulate physical properties. Removal of 1-methylpiperazinyl is not tolerated, and <b>12a</b> loses NIK inhibitory activity. The introduction of “–N(CH<sub>3</sub>)<sub>2</sub>” to the 2-position of the phenyl ring (<b>12b</b>) (IC<sub>50</sub> = 22.5 ± 3.18 nM) is well tolerated and showed enhanced activity compared to <b>12k</b> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). To investigate whether substitution of flexible chain-like hydrophilic groups has an impact on the potency, analogs <b>12c</b> and <b>12d</b> were synthesized and we observed that the methyl ether group could retain the activity. We also examined five- or six-membered cyclic hydrophilic groups including pyrrole (<b>12e</b>), morpholine (<b>12f</b>), piperazine (<b>12g</b>), functionalized piperazine rings with different substituents (<b>12h</b>–<b>12l</b>). Among these compounds, it is noteworthy that <b>12f</b> stood out for its enhanced NIK inhibitory activity (IC<sub>50</sub> = 9.87 ± 0.15 nM) compared to compound <b>12k</b>. Besides, (<i>S</i>)-3-methylpiperazine (<b>12i</b>, IC<sub>50</sub> = 69.16 ± 5.19 nM) showed better activity than that of <b>12h</b> and <b>12j</b>. The introduction of a larger ethyl group than the methyl group on the “–N–” atom of the piperazine ring had no effect on the inhibitory activity against NIK (<b>12k</b>–<b>12l</b>). In order to obtain compounds with different TPSA values (forecast with ChemBioDraw software), we introduced functional groups containing different numbers of the oxygen atom on the piperazine nitrogen site. Fortunately, the corresponding compounds (<b>16a</b>–<b>16c</b>) exhibited good inhibitory potency similar to that of <b>12f</b>. Bulkier rings such as 4-(piperidin-4-yl)morpholine (<b>12m</b>, IC<sub>50</sub> = 15.3 ± 2.25 nM) and 1-methyl-1,4-diazepane (<b>12n</b>, IC<sub>50</sub> = 60.1 ± 5.62 nM) retained the activity, suggesting that the cavity of the solvent accessible area could accommodate larger substituents. An oxygen atom was introduced to link the phenyl and six-membered cyclic hydrophilic group, <b>12o</b> and <b>12p</b>, but showed decreased inhibitory efficiency against NIK. Taken together, exploration of the solvent accessible area showed that a hydrophilic group at the 2-position of phenyl is necessary for the activity.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Optimization of the Hydrophilic Substituents in the Solvent Accessible Area</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/medium/jm0c00055_0013.gif" alt="" id="GRAPHIC-d7e1007-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/medium/jm0c00055_0014.gif" alt="" id="gr13" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Kinase inhibition assay was performed at 10 μM ATP concentration, and the values are the mean ± SD from two independent experiments.</p></div></div><div></div></div><div class="NLM_p">Further investigation focused on the interactions of the alkynol fragment with the back pocket, as presented in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>. Several tertiary alcohol fragments were examined, based on their shapes, sizes, and electrical properties. The inhibitory activity toward NIK of <b>12q</b> was largely lost. This may be due to the loss of the aforementioned H-bond interactions formed between thiazole and pocket residues. By comparison of the affinity of <b>12r</b> and <b>12s</b> with NIK protein, the five-membered ring seems to be more suitable for the volume of the back pocket than the six-membered ring. Interestingly, replacement of the cyclopentyl with thiophene substituent resulted in an approximately 40-fold increase in potency of the inhibitors (<b>12t</b> and <b>12u</b>), suggesting the importance of electrical properties of aromatic heterocycles. Deduced from our design strategy shown in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>, the molecular flexibility of the <i>N</i>-phenylpyrimidine-4-amine skeleton was higher than the 4-(indolin-1-yl)pyrimidine-2-amine, which may be harmful to the orientation of the alkyne. Considering this, we hypothesized that a more flexible linker such as an amide bond could perform better when the corresponding fragment passes through the methioine gatekeeper into the back pocket. However, the results are negative (compare <b>12s</b> with <b>14b</b> or <b>14c</b> with <b>12f</b>, respectively). Specifically, compounds <b>14a</b> and <b>14b</b> exhibited the same level of inhibition against NIK, despite the different lengths of respective linkers. On the basis of the principle of electronic isosterism, the introduction of an amide bond to replace alkynyl linker of <b>12f</b> yields <b>14c</b>, leading to a large decrease in its inhibitory activity against NIK.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Structures and Their Inhibitory Activities against NIK of Target Compounds</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/medium/jm0c00055_0015.gif" alt="" id="GRAPHIC-d7e1075-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/medium/jm0c00055_0016.gif" alt="" id="gr14" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Kinase inhibition assay was performed at 10 μM ATP concentration, and the values are the mean ± SD from two independent experiments.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">nd: not determined.</p></div></div><div></div></div><div class="NLM_p">As shown in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>, the 2-aminopyrimidine unit was introduced into the backbone to replace the pyrrolopyrimidine fragment of <b>12k</b>, and compound <b>21a</b> exhibited a similar excellent inhibitory activity to <b>12f</b>. Subsequently, different nitrogen-containing aromatic heterocycle fragments were introduced to investigate the binding tolerance of NIK the hinge region. Indeed, the ring-opening treatment of the dihydroindole skeleton increases the flexibility of the molecule, and this is not conducive to the formation of crucial hydrogen bonds in the hinge region. Interestingly, 7-azaindole (<b>21b</b>) and 1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidine (<b>21e</b>) structural units (IC<sub>50</sub> = 6.59 ± 0.09 nM and 8.63 ± 0.31 nM, respectively) can still capture the hinge region interactions, which confirms the feasibility of cyclization strategy. On the basis of the prediction that the 5-position of 7-azaindole could be a potential metabolic site, we introduced fluorine or chlorine atom to the position. The corresponding compounds were then excluded because of their reduced inhibition toward NIK, which might be due to clashes with the binding pocket (<b>21c</b> and <b>21d</b>). Reduced potency of compound <b>21f</b> (IC<sub>50</sub> = 179 ± 5.68 nM) confirms the importance of the “–NH–” unit to maintain the optimal “two-anchor” type hydrogen bonding interactions at the hinge binding mode.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Optimization of the Nitrogen Heterocyclic Aromatic Substituents in the Hinge Area</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/medium/jm0c00055_0017.gif" alt="" id="GRAPHIC-d7e1138-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/medium/jm0c00055_0018.gif" alt="" id="gr15" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Kinase inhibition assay was performed at 10 μM ATP concentration, and the values are the mean ± SD from two independent experiments.</p></div></div><div></div></div><div class="NLM_p">Taken together, we investigated the NIK inhibitory activities of a series of <i>N</i>-phenyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine derivatives by exploring hydrophilic groups in the solvent accessible region, scaffolds engaging the hinge region as well as back pocket binding fragments. Compound <b>12f</b> showed optimal NIK inhibitory activity, and thus the binding mode of compound <b>12f</b> within NIK was elucidated using a docking model (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). Similarly, the pyrrolopyrimidine unit forms two conserved hydrogen bonds with Leu474. What is noticeable is the generation of a new hydrogen bond between the oxygen atom of the morpholine ring and Arg410 or Gly411, respectively (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A and <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B). This interaction further anchors the spatial conformation of the ligand in the pocket, which likely contributes to the inhibitory activity against NIK (compare <b>12f</b> with <b>12k</b>).</div><figure id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/medium/jm0c00055_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/large/jm0c00055_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Binding mode analysis of compound <b>12f</b> to NIK protein. The solvent accessible region of NIK protein occupied by hydrophilic fragment of the ligand is particularly highlighted. (A) Compound <b>12f</b> docked into NIK (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4G3E">4G3E</a>). (B) Compound <b>12f</b> docked into NIK (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6G4Y">6G4Y</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/large/jm0c00055_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00055&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Kinase-Inhibition Profile of Compound <b>12f</b></h3><div class="NLM_p">The pyrrolopyrimidine fragment has been widely used as a core moiety to construct hydrogen-bonding interactions between the small molecule and the hinge region. Thus, a wild-type screening (Reaction Biology Corp.) was performed to investigate the selectivity of <b>12f</b> against 268 kinases (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A and <a href="/doi/suppl/10.1021/acs.jmedchem.0c00055/suppl_file/jm0c00055_si_001.pdf" class="ext-link">Table S1</a>). To better estimate the binding potency against six types of selected kinases, the IC<sub>50</sub> value of compound <b>12f</b> was determined (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B). Compound <b>12f</b> displayed around 4- to 20-fold higher inhibitory activity against NIK (IC<sub>50</sub> = 9.7 ± 1.7 nM) than Aurora B (IC<sub>50</sub> = 43.2 ± 3.4 nM), TRKC (IC<sub>50</sub> = 50.1 ± 4.7 nM), LRRK2 (IC<sub>50</sub> = 94.6 ± 8.4 nM), and ACK1 (IC<sub>50</sub> = 191.7 ± 5.3 nM). It should be mentioned that <b>12f</b> also has weak inhibitory activities against JAK1 (IC<sub>50</sub> = 182.6 ± 6.4 nM) and JAK3 (IC<sub>50</sub> = 892 ± 5.2 nM). Taken together, these data establish <b>12f</b> as a selective and highly potent inhibitor of NIK with satisfactory selectivity.</div><figure id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/medium/jm0c00055_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/large/jm0c00055_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) A wild-type screening (Reaction Biology Corp.) was performed to investigate the selectivity of <b>12f</b> against 268 kinases in a single-dose duplicate mode at a concentration of 1 μM. The 10 μM ATP concentration was conducted. Staurosporine served as a positive control, where % Ctrl = [(test compound signal – positive control signal)/(negative control signal – positive control signal)] × 100. (B) Further inhibitory activity of compound <b>12f</b> against selected kinases using the P<sup>33</sup>-radiolabeled assay. The values are the mean from two independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/large/jm0c00055_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00055&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Nitric Oxide Production Inhibitory and Antiproliferative Activity of Selected Compounds in Vitro</h3><div class="NLM_p">Previous studies indicate that NIK inhibitors have essential effects on B cell survival, T cell proliferation, and macrophage infiltration in the pathogenesis of autoimmune diseases such as SLE and psoriasis.<a onclick="showRef(event, 'ref28 ref38 ref41'); return false;" href="javascript:void(0);" class="ref ref28 ref38 ref41">(28,38,41)</a> Thus, the nitric oxide (NO) production-inhibitory activity of J774 peritoneal macrophages and the antiproliferative activity against primary T cells isolated from the spleen were considered for the next screening. A total of 15 compounds were selected for cell activity assay. Using compound <b>1</b> as a positive control, we can see that most of the compounds showed satisfactory activities, and eight compounds (<b>12f</b>, <b>12g</b>, <b>12i</b>, <b>12k</b>, <b>12l</b>, <b>12n</b>, <b>12o</b>, and <b>21b</b>) presented higher inhibition rates than 60% (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). Encouragingly, with the stimulation of 1 μM LPS, the inhibition rate of compound <b>12f</b> on macrophage NO production was as high as 86.28 ± 0.09%, and its low toxicity was further proven in <a href="/doi/suppl/10.1021/acs.jmedchem.0c00055/suppl_file/jm0c00055_si_001.pdf" class="ext-link">Figure S1</a>. Besides, we also determined whether the selected compounds affect the proliferation of primary T cells, which were isolated from the spleen. Consistently, compounds <b>12f</b>, <b>12i</b>, and <b>21b</b> showed better antiproliferative activities against splenic T cells than others, at different concentrations of 2 μM and 0.4 μM. These data confirmed compound <b>12f</b> to be a highly potent anti-inflammatory NIK inhibitor, which was considered for further studies.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Anti-Inflammatory Activity Screening of Selected Compounds in Vitro</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" align="center">NO inhibition rate (%)<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="rowsep1 colsep0" colspan="2" align="center">proliferation-inhibitory rate (%)<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">NIK IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">at 1 μM</th><th class="colsep0 rowsep0" align="center">at 2 μM</th><th class="colsep0 rowsep0" align="center">at 0.4 μM</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">4.7 ± 0.12</td><td class="colsep0 rowsep0" align="left">43.90 ± 0.12</td><td class="colsep0 rowsep0" align="left">59.57 ± 0.09</td><td class="colsep0 rowsep0" align="left">19.04 ± 0.03</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12c</b></td><td class="colsep0 rowsep0" align="left">72.4 ± 3.12</td><td class="colsep0 rowsep0" align="left">47.97 ± 0.13</td><td class="colsep0 rowsep0" align="left">27.85 ± 0.10</td><td class="colsep0 rowsep0" align="left">13.31 ± 0.04</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12f</b></td><td class="colsep0 rowsep0" align="left">9.87 ± 0.15</td><td class="colsep0 rowsep0" align="left">86.28 ± 0.09</td><td class="colsep0 rowsep0" align="left">62.29 ± 0.04</td><td class="colsep0 rowsep0" align="left">35.96 ± 0.07</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12g</b></td><td class="colsep0 rowsep0" align="left">47.9 ± 3.48</td><td class="colsep0 rowsep0" align="left">67.99 ± 0.07</td><td class="colsep0 rowsep0" align="left">39.87 ± 0.06</td><td class="colsep0 rowsep0" align="left">20.33 ± 0.14</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12i</b></td><td class="colsep0 rowsep0" align="left">69.16 ± 5.19</td><td class="colsep0 rowsep0" align="left">62.86 ± 0.24</td><td class="colsep0 rowsep0" align="left">49.51 ± 0.19</td><td class="colsep0 rowsep0" align="left">38.05 ± 0.24</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12k</b></td><td class="colsep0 rowsep0" align="left">78.3 ± 5.53</td><td class="colsep0 rowsep0" align="left">78.46 ± 0.04</td><td class="colsep0 rowsep0" align="left">43.70 ± 0.13</td><td class="colsep0 rowsep0" align="left">33.03 ± 0.05</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12l</b></td><td class="colsep0 rowsep0" align="left">34.5 ± 7.20</td><td class="colsep0 rowsep0" align="left">67.36 ± 0.16</td><td class="colsep0 rowsep0" align="left">33.67 ± 0.19</td><td class="colsep0 rowsep0" align="left">24.12 ± 0.24</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12m</b></td><td class="colsep0 rowsep0" align="left">15.3 ± 2.25</td><td class="colsep0 rowsep0" align="left">57.69 ± 0.20</td><td class="colsep0 rowsep0" align="left">34.52 ± 0.09</td><td class="colsep0 rowsep0" align="left">32.17 ± 0.11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12n</b></td><td class="colsep0 rowsep0" align="left">60.1 ± 5.62</td><td class="colsep0 rowsep0" align="left">67.34 ± 0.13</td><td class="colsep0 rowsep0" align="left">47.73 ± 0.16</td><td class="colsep0 rowsep0" align="left">35.54 ± 0.21</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12o</b></td><td class="colsep0 rowsep0" align="left">112 ± 8.94</td><td class="colsep0 rowsep0" align="left">68.29 ± 0.11</td><td class="colsep0 rowsep0" align="left">42.90 ± 0.18</td><td class="colsep0 rowsep0" align="left">19.93 ± 0.15</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16a</b></td><td class="colsep0 rowsep0" align="left">17.8 ± 1.49</td><td class="colsep0 rowsep0" align="left">29.27 ± 0.07</td><td class="colsep0 rowsep0" align="left">31.46 ± 0.08</td><td class="colsep0 rowsep0" align="left">16.23 ± 0.04</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16b</b></td><td class="colsep0 rowsep0" align="left">8.22 ± 0.26</td><td class="colsep0 rowsep0" align="left">34.45 ± 0.08</td><td class="colsep0 rowsep0" align="left">32.52 ± 0.12</td><td class="colsep0 rowsep0" align="left">14.02 ± 0.10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16c</b></td><td class="colsep0 rowsep0" align="left">16.2 ± 1.07</td><td class="colsep0 rowsep0" align="left">37.19 ± 0.13</td><td class="colsep0 rowsep0" align="left">32.26 ± 0.20</td><td class="colsep0 rowsep0" align="left">16.91 ± 0.14</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21a</b></td><td class="colsep0 rowsep0" align="left">11.4 ± 0.81</td><td class="colsep0 rowsep0" align="left">58.53 ± 0.16</td><td class="colsep0 rowsep0" align="left">31.44 ± 0.25</td><td class="colsep0 rowsep0" align="left">27.39 ± 0.09</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21b</b></td><td class="colsep0 rowsep0" align="left">6.59 ± 0.09</td><td class="colsep0 rowsep0" align="left">60.37 ± 0.18</td><td class="colsep0 rowsep0" align="left">50.23 ± 0.06</td><td class="colsep0 rowsep0" align="left">19.01 ± 0.13</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21e</b></td><td class="colsep0 rowsep0" align="left">8.63 ± 0.31</td><td class="colsep0 rowsep0" align="left">35.85 ± 0.25</td><td class="colsep0 rowsep0" align="left">24.70 ± 0.14</td><td class="colsep0 rowsep0" align="left">14.77 ± 0.21</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">Using Griess reagents method, NO inhibition rate % = [(model group NO concentration – compound group NO concentration)/(model group NO concentration – control group NO concentration)] × 100. The values are the mean ± SD from three independent experiments, <i>n</i> = 3.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">Con A-induced primary T cell proliferation was investigated under the treatment of selected compounds. Proliferation-inhibitory rate (%) = [(test hole absorbance – blank hole absorbance)/(control hole absorbance – blank hole absorbance)] × 100. The values are the mean ± SD from three independent experiments, <i>n</i> = 3.</p></div></div></div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Resolution of Enantiomers and Determination of the Dominant Configuration</h3><div class="NLM_p">Given the outstanding enzyme and cell inhibitory activities of <b>12f</b>, further work focused on the resolution of its enantiomers and determination of respective activities. Under the specific chiral separation conditions, compound <b>12f</b> was resolved into <b>22</b> and <b>23</b>. As presented in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>, compound <b>22</b> displayed about 11-fold higher inhibitory activity against NIK (IC<sub>50</sub> = 11.98 ± 3.13 nM) than <b>23</b> (IC<sub>50</sub> = 135.70 ± 7.96 nM). Besides, <b>22</b> was more effective in inhibiting NO release of LPS-induced J774 macrophages. Inconsistently, at high and low dosing concentrations, these three compounds had similar inhibitory potency on the proliferation of T cells stimulated by Con A in vitro. It is also interesting that <b>12f</b> and its enantiomer <b>23</b> were both less toxic to normal T cell growth than <b>22</b> (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). In summary, compound <b>12f</b>, as a racemate, can exhibit similar anti-T cell proliferation activity and lower toxicity compared to that of the dominant enantiomer <b>22</b>. Thus, <b>12f</b> was considered for further studies on the biological mechanism and efficacy evaluation in vivo.</div><figure id="sch3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/medium/jm0c00055_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/large/jm0c00055_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Compound <b>12f</b> Enantiomeric Resolution and Determination of the Dominant Configuration<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/large/jm0c00055_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00055&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p><span class="fn-label"><sup>a</sup></span>Enantiomeric resolution of compound <b>12f</b> was preformed. Mobile phase: hexane/EtOH = 50:50, v/v.</p><p><span class="fn-label"><sup>b</sup></span>Using Griess reagents method, NO inhibition rate % = [(model group NO concentration – compound group NO concentration)/(model group NO concentration – control group NO concentration)] × 100. The values are the mean ± SD from three independent experiments, n = 3.</p><p class="last"><span class="fn-label"><sup>c</sup></span>Con A-induced primary T cell proliferation was investigated under the treatment of selected compounds. Proliferation-inhibitory rate (%) = [(test hole absorbance – blank hole absorbance)/(control hole absorbance – blank hole absorbance)] × 100. The values are the mean ± SD from three independent experiments, n = 3.</p></p></figure><figure id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/medium/jm0c00055_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/large/jm0c00055_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Toxicity comparison between <b>12f</b> and its enantiomers (<b>22</b>, <b>23</b>) against normal growth of T cells at 10 μM concentration. Proliferation-inhibitory rate (%) = [(test hole absorbance – blank hole absorbance)/(control hole absorbance – blank hole absorbance)] × 100. The values are the mean ± SD from three independent experiments, <i>n</i> = 3.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/large/jm0c00055_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00055&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> PK Data of Selected Compounds across Multiple Species in Vitro and in Vivo</h3><div class="NLM_p">A note to mention is that compound <b>1</b> was developed by Amgen as a NIK inhibitor, and then Chen’s group disclosed its efficacy on acute hepatitis liver injury in 2016.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> In addition, as shown in <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>, our work revealed its moderate liver microsomal metabolic stability in human species but poor metabolic-stability for monkey, dog, and rat liver microsomes (<i>T</i><sub>1/2</sub> ranged from 6.6 to 9.8 min). Conversely, compound <b>12f</b> exhibited better metabolic stability in human liver microsomes (HLMs), monkey liver microsomes (MLMs), dog liver microsomes (DLMs), rat liver microsomes (RLMs), consistent with the lower clearance data in vitro (ranged between 32.4 (μL/min)/mg and 76.8 (μL/min)/mg).</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Pharmacokinetics of Compounds <b>1</b> and <b>12f</b> in Liver Microsomes of Multiple Species</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">species</th><th class="colsep0 rowsep0" align="center" char="."><i>R</i><sup>2</sup> <a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>1/2</sub> (min)<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char=".">CL<sub>int,microsome</sub> ((μL/min)/mg proteins)<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char=".">CL<sub>int,in vivo</sub> ((mL/min)/kg)<a class="ref internalNav" href="#t5fn4" aria-label="d">d</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">human</td><td class="colsep0 rowsep0" align="char" char=".">0.9956</td><td class="colsep0 rowsep0" align="char" char=".">33.940</td><td class="colsep0 rowsep0" align="char" char=".">40.844</td><td class="colsep0 rowsep0" align="char" char=".">38.598</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">monkey</td><td class="colsep0 rowsep0" align="char" char=".">0.9996</td><td class="colsep0 rowsep0" align="char" char=".">6.659</td><td class="colsep0 rowsep0" align="char" char=".">208.147</td><td class="colsep0 rowsep0" align="char" char=".">299.732</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">dog</td><td class="colsep0 rowsep0" align="char" char=".">0.9982</td><td class="colsep0 rowsep0" align="char" char=".">7.219</td><td class="colsep0 rowsep0" align="char" char=".">192.014</td><td class="colsep0 rowsep0" align="char" char=".">276.501</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="char" char=".">0.9687</td><td class="colsep0 rowsep0" align="char" char=".">9.816</td><td class="colsep0 rowsep0" align="char" char=".">141.205</td><td class="colsep0 rowsep0" align="char" char=".">254.169</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12f</b></td><td class="colsep0 rowsep0" align="left">human</td><td class="colsep0 rowsep0" align="char" char=".">0.9060</td><td class="colsep0 rowsep0" align="char" char=".">42.882</td><td class="colsep0 rowsep0" align="char" char=".">32.422</td><td class="colsep0 rowsep0" align="char" char=".">30.639</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">monkey</td><td class="colsep0 rowsep0" align="char" char=".">0.9809</td><td class="colsep0 rowsep0" align="char" char=".">18.048</td><td class="colsep0 rowsep0" align="char" char=".">76.797</td><td class="colsep0 rowsep0" align="char" char=".">110.588</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">dog</td><td class="colsep0 rowsep0" align="char" char=".">0.9765</td><td class="colsep0 rowsep0" align="char" char=".">32.385</td><td class="colsep0 rowsep0" align="char" char=".">43.312</td><td class="colsep0 rowsep0" align="char" char=".">62.369</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="char" char=".">0.9215</td><td class="colsep0 rowsep0" align="char" char=".">30.790</td><td class="colsep0 rowsep0" align="char" char=".">45.016</td><td class="colsep0 rowsep0" align="char" char=".">81.028</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last"><i>R</i><sup>2</sup> is the correlation coefficient of the linear regression for determination of the kinetic constant.</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last">Elimination half-life (<i>T</i><sub>1/2</sub>).</p></div><div class="footnote" id="t5fn3"><sup><sup>c</sup></sup><p class="last">Intrinsic clearance in LMs (CL<sub>int,in vitro</sub>),</p></div><div class="footnote" id="t5fn4"><sup><sup>d</sup></sup><p class="last">Intrinsic hepatic clearance (CL<sub>int,in vivo</sub>). CL<sub>int,in vivo</sub> = CL<sub>int,in vitro</sub> ((mL/min)/mg microsomal protein) × scaling factor (physiological parameter) = CL<sub>int,in vitro</sub> ((mL/min)/mg microsomal protein) × microsomal protein (mg protein/g liver) × liver weight (g liver/kg body weight).</p></div></div></div><div class="NLM_p">Inspired by the favorable in vitro stability properties of compound <b>12f</b>, we performed in vivo pharmacokinetic assessment using intravenous (iv) and per os (po) administration to Sprague Dawley rat (shown in <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). After iv administration of <b>12f</b> at a dose of 1.0 mg/kg, the plasma concentration (<i>C</i><sub>0</sub>) reached 377 ng/mL, the area under the curve (AUC<sub>0–∞</sub>) was 419 ng·h/mL, and the half-life was 0.944 h with low clearance. Besides, compound <b>12f</b> exhibited compatible pharmacokinetic properties under po administration (<i>C</i><sub>max</sub> reached 772 ng/mL at 0.833 h postdosing, AUC<sub>0–∞</sub> = 2680 ng/mL·h, <i>T</i><sub>1/2</sub> = 1.39 h, and <i>F</i> = 64.0%). Overall, these data, especially high oral bioavailability, demonstrate better pharmacokinetic properties of <b>12f</b> than compound <b>1</b> in rat.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. PK Parameter of Compound <b>12f</b> in Sprague Dawley Rat<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">PK parameters (<i>n</i> = 3)<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">iv (1.0 mg/kg)</th><th class="colsep0 rowsep0" align="center">SD</th><th class="colsep0 rowsep0" align="center">PK parameters (<i>n</i> = 3)<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">po (10 mg/kg)</th><th class="colsep0 rowsep0" align="center">SD</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>0–∞</sub> (ng·h/mL)</td><td class="colsep0 rowsep0" align="left">419</td><td class="colsep0 rowsep0" align="left">54.8</td><td class="colsep0 rowsep0" align="left">AUC<sub>0–∞</sub> (ng·h/mL)</td><td class="colsep0 rowsep0" align="left">2680</td><td class="colsep0 rowsep0" align="left">111</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>0</sub> (ng/mL)</td><td class="colsep0 rowsep0" align="left">377</td><td class="colsep0 rowsep0" align="left">56.1</td><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (ng/mL)</td><td class="colsep0 rowsep0" align="left">772</td><td class="colsep0 rowsep0" align="left">60</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="left">0.944</td><td class="colsep0 rowsep0" align="left">0.112</td><td class="colsep0 rowsep0" align="left"><i>T</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="left">1.39</td><td class="colsep0 rowsep0" align="left">0.0987</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>V</i><sub>d</sub> (L/kg)</td><td class="colsep0 rowsep0" align="left">2.73</td><td class="colsep0 rowsep0" align="left">0.393</td><td class="colsep0 rowsep0" align="left"><i>T</i><sub>max</sub> (h)</td><td class="colsep0 rowsep0" align="left">0.833</td><td class="colsep0 rowsep0" align="left">0.289</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CL ((mL/kg)/min)</td><td class="colsep0 rowsep0" align="left">40.3</td><td class="colsep0 rowsep0" align="left">4.93</td><td class="colsep0 rowsep0" align="left"><i>F</i> (%)</td><td class="colsep0 rowsep0" align="left">64.0</td><td class="colsep0 rowsep0" align="left">2.7</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">Individual plasma concentration–time data of <b>12f</b>, after an iv/po dose of 1/10 mg kg<sup>–1</sup> in Sprague Dawley rat, respectively. Corresponding in vivo pharmacokinetic parameters are given. Injection (iv) formulation: prescription, DMSO/PEG200/saline = 20:20:60, v/v/v, concentration 0.2 mg·mL<sup>–1</sup>. Oral formulation: 0.5% CMC-Na/0.2% Tween 80, concentration 1 mg·mL<sup>–1</sup>.</p></div><div class="footnote" id="t6fn2"><sup><sup>b</sup></sup><p class="last">PK parameters are the mean ± SD from three independent experimental rats, <i>n</i> = 3.</p></div></div></div></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Compound <b>12f</b> Blocks LPS-Induced Secretion of IL-6 in BEAS-2B Cells and Expression of Inflammation-Related Genes in J774 Macrophages</h3><div class="NLM_p">The most noticeable features in the pathogenesis of psoriasis are excessive secretion of various cell chemokines and proinflammatory factors in epidermal and dermal cells.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> Thus, we further figured out the effects of compounds <b>12f</b> and <b>1</b> on the secretion of interleukin-6 (IL-6) in BEAS-2B cells. As seen in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A, within a specific concentration range, both compounds exhibited a dose-dependent inhibition of IL-6 secretion against inflammatory model cells. Compound <b>12f</b> has a relatively higher inhibitory activity than compound <b>1</b>, and it inhibits IL-6 secretion at concentrations ranging from 14 nM to 10 μM. Next, we determined the effectiveness of <b>12f</b> in regulating inflammation-related gene expression in J774 macrophage (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>B). The results showed that the mRNA levels of inflammatory cytokines and chemokines (including TNFα, IL-6, IL-23, IL-1β, and CCL3, respectively) were increased in response to the stimulation of LPS but notably decreased by administrating <b>12f</b>. Moreover, the expression of nitric oxide synthase 2 (NOS2) is generally up-regulated in the occurrence of various inflammatory diseases.<a onclick="showRef(event, 'ref45 ref46'); return false;" href="javascript:void(0);" class="ref ref45 ref46">(45,46)</a> Interestingly, NOS2 levels in J774 macrophages showed a markedly negative regulatory response to the administration of <b>12f</b>.</div><figure id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/medium/jm0c00055_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/large/jm0c00055_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (A) The culture supernatant IL-6 levels in LPS-induced BEAS-2B cells were analyzed and quantified by ELISA. (B) Quantitative PCR analysis of the mRNA levels of exocrine inflammatory factors (TNFα, IL-6, IL-23, IL-1β), chemokine (CCL3), and cytokine (NOS2) in LPS-stimulated J774 cells. <i>P</i> values are determined by two-tailed Student’s <i>t</i> test: between the normal and model group, <sup>#</sup><i>P</i> < 0.05, <sup>##</sup><i>P</i> < 0.005,<sup>###</sup><i>P</i> < 0.0005; between model and <b>12f</b> treatment groups, n.s. (not significant), *<i>P</i> < 0.05, **<i>P</i> < 0.005, ***<i>P</i> < 0.0005. Data are represented as the mean ± SD from two (A) and three (B) biological replicates.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/large/jm0c00055_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00055&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Treatment of 12f Attenuates Psoriasis-like Phenotype in Imiquimod Model Mice</h3><div class="NLM_p">After obtaining promising in vitro activities and in vivo PK results, we further explored the in vivo pharmacological efficacy of compound <b>12f</b> on the IMQ-induced psoriasis model using C57 mice. In order to establish a psoriasis-like dermatitis model, 5% imiquimod cream was evenly applied to the back skin of C57 mice (for seven consecutive days, q.d.). Moreover, <b>12f</b> was administered orally on the third day and continued until the end of the experiment (12f-I, 60 mg/kg; 12f-II, 120 mg/kg, i.g./q.d.). The model group of mice exhibited a typical psoriasis-like dermatitis phenotype, including invasive erythema, roughness, swelling, and scales. In contrast, the symptoms of the administration group (12f-I, 12f-II) were significantly attenuated (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>A). Hematoxylin and eosin staining revealed the occurrence of epidermal acanthosis, as shown in <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>B, and the model group had significant morphological and pathological changes in the back skin compared to the normal and drug-treated groups, such as increased skin thickness and severe scales. Statistical analysis of the back skin thickness of six mice in different experimental groups showed that the skin thickness of the administration group changed little under the induction of IMQ, confirming a dose-dependent enhancement of <b>12f</b> treatment efficacy (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>C). The spleen index of the <b>12f</b> administration group was slightly lower than that of the model group, reflecting that IMQ’s activation of systemic immunity was suppressed to a certain extent (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>D). Consistently, ELISA detection of TNFα and IL-17A in serum revealed that <b>12f</b> could inhibit mouse secretion of both cytokines in a dose-dependent manner (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>E).</div><figure id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/medium/jm0c00055_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/large/jm0c00055_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. (A) Representative images of dorsal back from wild-type C57 mice untreated or treated with IMQ or <b>12f</b> for 7 or 4 days. (B) Hematoxylin and eosin (H&E) staining of skin sections from the dorsal back (normal group, IMQ and <b>12f</b> were untreated; model group, only IMQ treatment; 12f-I/12f-II, at 60 mg/kg or 120 mg/kg doses of <b>12f</b> treatment, along with IMQ induction). Scale bar, 50 μm. (C) Epidermal thickness was measured in six randomly chosen fields. (D) The weight of the mouse spleen was counted, and each point represents the value of the spleen weight of a mouse. (E) TNF-α and IL-17A in the mouse serum were analyzed and quantified by ELISA. Data are shown as the mean ± SEM based on three independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/large/jm0c00055_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00055&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Compound <b>12f</b> Suppressed Epidermal and Dermal Cell Proliferation and Macrophage Infiltration in Mouse Back Skin Tissues through Regulating NF-κB2 Signaling Pathway</h3><div class="NLM_p">Characteristics of psoriasis lesions include excessive cell proliferation in epidermal and dermal tissues and infiltration of immune cells such as macrophages. After orally administering compound <b>12f</b> to C57 mice for 4 days, we quantified the population of Ki67<sup>+</sup> cells in psoriatic lesions by immunohistochemistry to reveal the extent of epidermal and dermal cell proliferation in skin tissue. As shown in <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>A, the population of Ki67<sup>+</sup> cells in the back skin of the mice was obviously reduced when treated with a low dose of <b>12f</b> (12f-I, 60 mg/kg), compared to the model group mice. Moreover, by comparing the experimental results of the high and low dose groups, we obtained preliminary dose–effect relationship of <b>12f</b> on the inhibition of cell proliferation in psoriatic skin tissue: normalized to the model group, the 12f-I (60 mg/kg) and the 12f-II (120 mg/kg) group Ki67 expression percentage decreased by approximately 55% and 83%, respectively (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>B). Subsequently, we investigated the effect of compound <b>12f</b> on the infiltration of macrophages in the pathogenesis of psoriasis model mice (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>C). The results of F4/80 immunofluorescence images showed that the recruitment of macrophages from the back skin tissue of the model group was notably up-regulated following the induction of IMQ. In contrast, treatment with high or low doses of <b>12f</b> (12f-I and 12f-II) notably alleviated this symptom.</div><figure id="fig8" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/medium/jm0c00055_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/large/jm0c00055_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. (A) Representative skin sections from the back of the mice, which were stained with Ki67 antibody (normal group, IMQ and <b>12f</b> were untreated; model group, only IMQ treatment; 12f-I/12f-II, at 60 mg/kg or 120 mg/kg doses of <b>12f</b> treatment, respectively, along with IMQ induction). Scale bar, 50 μm. (B) The percentage of Ki67<sup>+</sup> cells in the total cells was analyzed by ImageJ software. (C) F4/80 immunofluorescence staining revealed the recruitment of macrophages in the back skin tissue of C57 mice. <i>P</i> values are determined by two-tailed Student’s <i>t</i> test: compared with normal group, <sup>#</sup><i>P</i> < 0.05, <sup>##</sup><i>P</i> < 0.005,<sup>###</sup><i>P</i> < 0.0005; compared with model group, *<i>P</i> < 0.05, **<i>P</i> < 0.005, ***<i>P</i> < 0.0005. Data are represented as the mean ± SD.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/large/jm0c00055_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00055&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Consistent with the above data, compound <b>12f</b> at different doses exhibited dose-dependent inhibition of the NF-κB2 pathway by targeting the NIK protein. Furthermore, from <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>A and <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>B, we found that the levels of p52, downstream of NIK, in the model group were obviously higher than that in the administration group, and it decreased with increasing dosing of <b>12f</b>. We also found reduced expression of genes associated with the NF-κB2 signaling pathway, such as TNFα, IL-6, IL-10, and IL-12, which in turn validated the critical role of NIK in the development of psoriasis (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>C). Related pathological regulation responding to <b>12f</b> treatment in psoriasis mice was demonstrated (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>D). Together, these results suggest that <b>12f</b> treatment can relieve epidermal and dermal cell proliferation and macrophage infiltration in mouse back skin tissues by targeting NIK to regulate the activation of the NF-κB2 signaling pathway.</div><figure id="fig9" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/medium/jm0c00055_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/large/jm0c00055_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. (A) After oral administration of compound <b>12f</b> (12f-I, 60 mg/kg; 12f-II, 120 mg/kg), the levels of NF-κB2 signaling pathway-related proteins (p100 and p52) were monitored. Quantitative analysis was normalized to GAPDH. (B) The relative optical densities of specific proteins were recorded. (C) Quantitative analysis of mRNA levels in the skin of the back of mice (TNFα, IL-6, IL-10, IL-12) to investigate the effect of high and low doses of <b>12f</b> treatment on the expression of immune regulation-related genes induced by IMQ in mice. (D) Pathological signal response to the treatment of <b>12f</b> as the NIK inhibitor was depicted. <i>P</i> values are determined by two-tailed Student’s <i>t</i> test: between normal and model group, <sup>#</sup><i>P</i> < 0.05, <sup>##</sup><i>P</i> < 0.005,<sup>###</sup><i>P</i> < 0.0005; between model and <b>12f</b> treatment groups, n.s. (not significant), *<i>P</i> < 0.05, **<i>P</i> < 0.005, ***<i>P</i> < 0.0005. Data are presented as the mean ± SD of three independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/large/jm0c00055_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00055&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i23">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64874" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64874" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In this study, we reported the design and synthesis of <i>N</i>-phenyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine derivatives as novel NIK inhibitors. Through structure–activity relationship studies, compound <b>12f</b> was identified as a highly potent NIK inhibitor with high selectivity over 268 wild-type kinases. Besides, compound <b>12f</b> exhibited excellent NO production-inhibitory and antiproliferative activities against macrophages (J744) and splenic T cells, respectively. Compound <b>12f</b> performed better than a known NIK inhibitor compound <b>1</b> developed by Amgen in PK properties and blocking ability toward the secretion of IL-6 induced by LPS in BEAS-2B cells. Encouragingly, down-regulation of inflammation-related cytokines (including TNFα, IL-6, IL-10, IL-12, IL-23, IL-1β, and NOS2) and chemokine (CCL3) gene expression in vitro or in vivo reduced secretion of proinflammatory factors (TNFα, IL-17A) in serum, the relieved psoriasis-like phenotype, and the results of hematoxylin and eosin staining, Ki67 immunohistochemistry, and F4/80 immunofluorescence staining indicated that treatment of IMQ-induced mice with compound <b>12f</b> attenuated the pathological features of psoriasis. Altogether, this work provided a new idea for the design and development of NIK inhibitors and suggests the possibility of using NIK inhibitors as a new treatment of psoriasis for the first time.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i24">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_57884" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_57884" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Kinase Inhibition Assay. ADP-Glo Kinase Assay</h3><div class="NLM_p last">ADP-Glo kinase assay was performed by Nanjing Anacon Biotechnology Co., Ltd., which is one of our partners. Reagents: human recombination MAP3K14 protein (Carna, catalog no. 07-102), NIK ADP-Glo assay kit (Promega, catalog no. V9101). The assay contains two steps: (1) Add an equal volume of ADP-Glo reagent to terminate the kinase reaction and deplete the remaining ATP after the kinase reaction. (2) Add the kinase detection reagents to simultaneously convert ADP to ATP and allow the newly synthesized ATP to be measured using a luciferase/luciferin reaction. Reaction procedure was the following. (1) Preparation of the following buffer solution involved (a) general reaction buffer containing 2 mM DTT, 2 mM MgCl<sub>2</sub>, 100 μM Na<sub>3</sub>VO<sub>4</sub>, 0.02 mg/mL BSA, Tris, pH 7.5, 5% DMSO; (b) 2.5× NIK (5 nM) assay buffer; (c) 2.5× ATP (25 μM) assay buffers. (2) For the 96-well plate, add 1.0 μL of compound in DMSO (final concentration of DMSO, 5%) to the wells of the reaction plate. Positive and negative control wells used buffer only. (3) In the compound and positive control wells, 2 μL of 2.5× NIK and 4 μL of 2.5× ATP were delivered. Besides, 2 μL of 2.5× ATP and 2 μL of assay buffers were utilized for negative control wells. The reaction mixture was incubated for 120 min at room temperature. (4) After addition and incubation of 5 μL of ADP-Glo reagent for 40 min, deliver the 10 μL of detection reagent into the wells and incubate for an additional 40 min. (5) Luminescence measurement was done, using a luminometer. Luminescence can be correlated to ADP concentrations by using an ATP-to-ADP conversion curve. IC<sub>50</sub> values and curve fits were obtained by Prism (GraphPad Software).</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> Wild-Type Kinase Screening</h3><div class="NLM_p last">To determinate the selectivity of <b>12f</b> over different kinases, a wild-type screening was performed by Reaction Biology Corp. (Malvern PA), using HotSpot kinase assay as described previously.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> The average % inhibition over 268 kinases were reported (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00055/suppl_file/jm0c00055_si_001.pdf" class="ext-link">Supporting Information Table S1</a>).</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Griess Reagents Method for Detecting Nitric Oxide Production in J744 Peritoneal Macrophages</h3><div class="NLM_p last">Analysis of macrophage nitric oxide production was carried out according to the methods described in the previous literature.<a onclick="showRef(event, 'ref48 ref49'); return false;" href="javascript:void(0);" class="ref ref48 ref49">(48,49)</a> Peritoneal macrophages (J774) were seeded in a 96-well plate (2 × 10<sup>4</sup> cells/mL, 200 uL per well), with a medium (5% bovine fetal serum, 1% penicillin–streptomycin, 1% nonessential amino acid, and 2% <span class="smallcaps smallerCapital">l</span>-glutamine). After 24 h incubation in 5% CO<sub>2</sub> at 37 °C, the medium was discarded. The supplemented medium 1640 197 μL/well was added. Subsequently, 2 μL of DMSO with or without test compound (1 μM concentration, 3 replicate wells per sample) was added to the test drug group or LPS model control group. For the blank group, 2 μL of the medium was spiked into corresponding wells. After 2 h incubation in 5% CO<sub>2</sub> incubator at 37 °C, 1 μL of PBS-configured LPS (200 ug/mL) was added to the LPS control group and each test group to a final concentration of 1 ug/mL and cultured for an additional 22 h. Then, 100 μL of supernatant from each well was transferred to a new 96-well plate. The supernatant was finally treated with 100 μL of Griess reagents (1% sulfa, 0.1% naphthalenediamine dihydrochloride, and 2.5% phosphoric acid). Finally, using linear regression analysis of the standard curve (serial double dilutions of sodium nitrite from 200 μmol/L to the 11th dilution) of obtained NO concentrations in the supernatants, absorbance was determined at 540 nm by using the microplate reader.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Antiproliferation Assay of Con A-Activated Spleen T Cell</h3><div class="NLM_p last">The primary T-cells were isolated from the splenocyte samples using EasySep mouse T cell isolation kit (Stemcell Technologies, catalog no. 19851). T cells were suspended in RPMI with 10% PBS (1% penicillin/streptomycin, 2% glutamine) and seeded in 96-well culture plates at a density of 2 × 10<sup>6</sup>/mL cells per well. Con A (Sigma) at 5 μg/mL was used to stimulate the T cell proliferation in the presence or absence of NIK inhibitors (2 μM and 0.4 μM concentration, 3 replicate wells per sample). Then, the plates were incubated for 48 h at 37 °C 5% CO<sub>2</sub>. Compound’s ability to inhibit Con A dependent primary T cell proliferation was measured by using CCK-8 assay (MedChemExpress) according to the manufacturer’s instructions.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> The toxicity analysis for normal T cells growth was also performed, and corresponding data are shown in <a href="/doi/suppl/10.1021/acs.jmedchem.0c00055/suppl_file/jm0c00055_si_001.pdf" class="ext-link">Supporting Information Figure S1</a>.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> Measurement of IL-6 Production in LPS-Induced Human BEAS-2B Cells</h3><div class="NLM_p last">Human BEAS-2B cell line was purchased from the American Type Culture Collection (ATCC, catalog no. CM-1075). BEAS-2B cells were resuscitated and cultured (Complete growth medium, 89% DMEM, 10% FBS, 1% penicillin–streptomycin). Then, the logarithmic growth phase of BEAS-2B cells was seeded into 96-well plates at 5000 cells/well and incubated under 5% CO<sub>2</sub> for 24 h at 37 °C. After the cells were attached, the test group, the positive control group (dexamethasone), the model group, and the blank control group were set before the treatment of compounds <b>12f</b> and <b>1</b> (10–0.014 μM, 7 concentrations, 3 replicate-wells). After 8 h of administration, 0.1 mL of LPS (20 μg/mL) was added to each well to stimulate BEAS-2B cells for 24 h. The IL-6 levels in the supernatant of the culture were determined by using the human IL-6 ELISA kit (MultiSciences, catalog no. 70-EK1062).</div></div><div id="sec4_5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> Pharmacokinetic Evaluation of Compound <b>12f</b>. Metabolic Stability in Liver Microsomes</h3><div class="NLM_p last">The metabolic stability of compounds <b>12f</b> and <b>1</b> on liver microsomes of different species was determined according to the procedures described by 3D BioOptima Co. Ltd., including RLMs (rat liver microsomes), DLMs (dog liver microsomes), CLMs (monkeys liver microsomes), and HLMs (human liver microsomes). To each well (T0, T5, T15, T30, T60, NCF60), a solution of compound <b>12f</b>, <b>1</b>, or the control working solution was added. Subsequently, 80 μL/well was added to every plate, the mixture of microsome solution, and compound <b>12f</b> or <b>1</b> was incubateed at 37 °C for 10 min. 10 μL of 100 mM potassium phosphate buffer/well was added to NCF60, and the mixture was incubated at 37 °C for 1 h. After prewarming, 10 μL/well was added to every plate to start reaction. Reactions were terminated at 5, 15, 30, and 60 min of incubation with a chilled mixture of tolbutamide and labetalol (1:1). The mixture was vortexed for 5 min, centrifuged at 4000 rpm for 20 min at 4 °C, and the supernatants were analyzed by LC–MS/MS. The data were analyzed by the first order kinetics to calculate <i>t</i><sub>1/2</sub> and Cl. Drug elimination rate constant <i>k</i> (min<sup>–1</sup>), elimination half-life <i>T</i><sub>1/2</sub> (min), and in vitro intrinsic clearance CL<sub>int</sub> (μL·min<sup>–1</sup>·mg<sup>–1</sup> protein) were calculated according to the following equations: <i>k</i> = −slope, <i>T</i><sub>1/2</sub> = 0.693/<i>k</i>, CL<sub>int</sub>, in vitro = <i>k</i>/<i>C</i><sub>protein</sub>, where <i>C</i><sub>protein</sub> (mg·mL<sup>–1</sup>) is the microsomal protein concentration in the incubation.<a onclick="showRef(event, 'ref51 ref52'); return false;" href="javascript:void(0);" class="ref ref51 ref52">(51,52)</a></div></div><div id="sec4_5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> Pharmacokinetic (PK) Study</h3><div class="NLM_p last">To determine oral bioavailability, 3 SD rats (Beijing Charles River Laboratories) per group were treated with <b>12f</b> by a single intravenous (iv) bolus or oral gavage administration at the doses of 1 and 10 mg/kg, respectively. Injection formulation of compound <b>12f</b> was prepared in solution (DMSO/PEG200/saline = 20:20:60, v/v/v). Suspension of <b>12f</b> in normal saline containing 0.5% CMC-Na and 0.2% Tween 80 was done to obtain the oral formulation and using LC–MS/MS-based methods to quantify drug concentration in plasma. Pharmacokinetic parameters were estimated using Phoenix WinNonlin (version 6.3) from mean plasma concentration–time profiles. The area under the curve (AUC) was calculated from time versus concentration data using the linear trapezoidal rule. The oral bioavailability is calculated as the ratio of AUC for <b>12f</b> from po and iv dosages. The calculation is normalized by relative doses. For <b>12f</b> plasma samples, an aliquot of 30 μL of the sample was added with 150 μL of ACN which contains verapamil, 5 ng·mL<sup>–1</sup>, and glibenclamide, 50 ng·mL<sup>–1</sup> for protein precipitation. The mixture was vortexed for 10 min and centrifuged at 3700 rpm for 10 min. Then 70 μL of supernatant was added with 70 μL of water and vortexed for 10 min. An aliquot of 15 μL of the mixture was injected into the system and subjected to LC–MS/MS analysis using an Agilent Technologies 6430 triple quad LC/MS system. Chromatogram signals were integrated and calibrated using Agilent MassHunter Workstation Software B.06.00. Pharmacokinetic parameters were derived by noncompartmental analysis from individual <b>12f</b> plasma concentration versus time profiles (Phoenix WinNonlin, version 6.3).</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> Animal Models</h3><div class="NLM_p last">The IMQ-induced psoriasis-like disease model was performed in a similar way as previously reported in the literature (van der Fits et al., 2009).<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> Otherwise, C57 mice were purchased from the Institute of Model Animals, Nanjing University. All animals are housed in specific pathogen-free facilities and used in accordance with the regulations of the Animal Ethics Committee of China Pharmaceutical University. Imiquimod is produced by Sichuan Mingxin Pharmaceutical Co., Ltd. (Chinese Medicine Standard, H20030129). In particular, the mice treated with <b>12f</b> (same as normal group and model group, <i>n</i> = 6) were divided into two dose groups (12f-I, 60 mg/kg; 12f-II, 120 mg/kg). After shaving the spinal hair, the mice received about 65 mg imiquimod cream (5%) topically on the back skin daily, and the normal group received Vaseline for 7 days. Samples (blood and back skin tissue) were taken on the second day after the end of IMQ treatment.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> Immunohistochemistry of Back Skin Tissue Sections</h3><div class="NLM_p last">Omarin-fixed, paraffin-embedded blocks were selected from the back skin tissue of each group of mice, and 3 μm thick tissue sections were cut out for hematoxylin–eosin (H&E) staining. On the other side, samples of back skin (3 mm diameter) were dipped into TissueTek (Shanghai Rantai Biotechnology Co., Ltd.), snap-frozen in liquid nitrogen, and stored at 80 °C until use. Six micrometer frozen sections of frozen skin were cut using a cryostat (Jung Frigocut 2800 ELeica). IHC staining was performed in accordance with standard procedures. The following primary antibodies were used: Ki67 (FcMRCS, catalog no. YM6189), F4/80 (abcam, catalog no. SP115). Slides were incubated overnight at 4 °C or for 1 h at room temperature. This was followed by incubation for 30 min with biotin-linked secondary. After washing with PBS, DAPI was incubated at room temperature for 1 h and observed with a confocal laser scanning microscope (LSM 700, Zeiss, CA, USA). Histopathological evaluation was performed blindly by two pathologists. Two pathologists conducted the histopathological evaluation using a random, blindly selected manner.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> Mouse Serum ELISA Assay</h3><div class="NLM_p last">After the end of the administration, the corresponding blood samples were collected from the mice in each group and left at 4 °C for 12 h. Following centrifugation, TNFα (Arigo, catalog no. ARG80206) and IL-17A (Immunoway, catalog no. KE1180) levels in mouse serum were determined by ELISA according to the manufacturer’s protocol.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> Quantitative PCR Assay of Target Gene</h3><div class="NLM_p last">The detection of target gene expression (TNFα, IL-6, IL-10, IL-12, IL-23, IL-1β, CCL3, NOS2) follows the universal SYBR green wuantitative PCR protocol. Special instructions for setting up reaction steps are the following. For NTC reactions, add 4 μL of water to the reaction tube. For experimental reactions, add 4 μL of cDNA solution to the reaction tube. Centrifuge all tubes briefly. Visually confirm that all tubes or wells contain sample at the bottom at the correct volume. Carefully aliquot 16 μL of template master mix into each qPCR tube or plate well. Mix reactions well and spin if needed. Cap tubes or seal the PCR plate and label (according to instrument requirements). (Make sure the labeling does not obscure instrument excitation/detection light path.) Run samples as per instrument manufacturer recommendations. Run the samples following the instrument’s operating procedures and also refer to the instrument manual to analyze the data.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> Western Blot</h3><div class="NLM_p last">The operation of Western blot analysis follows our previous report.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> The protein extract of the back skin tissue of C57 mice was prepared for Western blot analysis of GAPDH, p100, and p52. The levels of target proteins were determined using a gel imaging system (ChemiScope 2850, Clinx Science Instruments Co., Ltd., Shanghai, China) and normalized to that of the reference band.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> Molecular Modeling</h3><div class="NLM_p last">The X-ray cocrystal structure of the NIK protein binding with corresponding small molecules was retrieved from the Protein Data Bank<a onclick="showRef(event, 'ref28 ref30'); return false;" href="javascript:void(0);" class="ref ref28 ref30">(28,30)</a> (PDB codes <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4G3E">4G3E</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6G4Y">6G4Y</a>). Compounds <b>12f</b> or <b>12k</b> were prepared using the ligand Preparation Wizard in Maestro with standard settings. Following the standard procedure suggested by Schrodinger, the NIK protein was preprocessed, and then a grid of NIK proteins was generated using Glide (version 11.5). The conformational ensembles were docked flexibly using Glide with standard settings in both standard and extra precision mode. Only poses with low energy conformations and good hydrogen bond geometries were considered. Pymol was used to display the small molecule ligand–protein docking results. Finally, the editing of pictures was performed using HprSnap7.</div></div><div id="sec4_11_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> General Procedures</h3><div class="NLM_p last">Unless otherwise specified, reagents were purchased from commercial suppliers and used without further purification. Melting points were determined by a X-4 digital-display micromelting-point apparatus (Beijing Tech Instrument Company, Ltd., Beijing, China). NMR spectra were recorded on a Bruker AVANCE AV-600 spectrometer (400 or 300 MHz for <sup>1</sup>H, 100 or 75 MHz for <sup>13</sup>C). Mass spectra were obtained on the Agilent 1100 LC/MSD mass spectrometer (Agilent, USA) and Q-tofmicro MS (Micromass Company). All reactions were monitored by TLC (Merck Kieselgel GF254), and spots were visualized with UV light or iodine. The purity of biologically evaluated compounds was ≥95% as determined by HPLC.</div></div><div id="sec4_11_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> Preparation of 4-Chloro-7-tosyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>6</b>)<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a></h3><div class="NLM_p last">To a solution of 4-chloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (6.14 g, 40 mmol) in dry THF (60 mL) under Ar atmosphere at 0 °C, NaH (60%, 4.80 g, 120 mmol) was added in portions within 5 min under vigorous stirring. The reaction mixture was stirred for a further 30 min after completion of the addition, then TsCl (11.44 g, 60 mmol) dissolved in THF (40 mL) was added dropwise while keeping the temperature between 5 and 10 °C. The resulting suspension was allowed to reach room temperature and stirred for 4.0 h. The mixture was poured slowly into vigorously stirred ice–water to quench excessive NaH. The resulting mixture was extracted with EA (150 mL × 3), and the combined organic layers were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under vacuum. The residue was chromatographed, eluting with a gradient of 10% EA/PE to afford title compound (11.25 g, 91%) as a white solid. [M + H]<sup>+</sup>: 308.1.</div></div><div id="sec4_11_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> General Procedure A for the Synthesis of Compounds <b>7</b>, <b>17a</b>, <b>17e</b>, and <b>17f</b></h3><div class="NLM_p last">A mixture of compound <b>6</b> or corresponding 4-chloropyrimidine derivatives (5 mmol), 2-fluoro-5-nitroaniline (1.17 g, 7.5 mmol), was treated with AgOTf (1.28 g, 5 mmol) in dioxane (20 mL) and stirred at 130 °C for about 6 h. The mixture was filtered, and the filtrate was concentrated under vacuum. The residue was chromatographed, eluting with a gradient of 20% to 100% EA/PE to afford the title compound (67–95%) as a yellow solid.</div></div><div id="sec4_11_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> General Procedure B for the Synthesis of Compounds <b>17b</b>–<b>17d</b></h3><div class="NLM_p last">A mixture of corresponding 4-bromo-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine derivatives (10 mmol, 1.0 equiv), 2-fluoro-5-nitroaniline (15 mmol, 1.5 equiv), Pd<sub>2</sub>(dba)<sub>3</sub> (0.5 mmol, 5% mmol), X-Phos (1 mmol, 10% mmol), K<sub>2</sub>CO<sub>3</sub> (0.15 mmol, 10% mmol) in <i>t</i>-BuOH (60 mL) was stirred at 100 °C for 4.0 h under N<sub>2</sub> atmosphere. After completion of reaction, the mixture was evaporated under vacuum. The residue was chromatographed, eluting with a gradient of 4–5% DCM/MeOH to afford title compounds <b>17b</b>–<b>17d</b> (yield, 37–85%) as a yellow solid.</div></div><div id="sec4_11_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> General Procedure C for the Synthesis of Compounds <b>8b</b>–<b>8n</b> (Method C-I), <b>8o</b> and <b>8p</b> (Method C-II), and <b>18a</b>–<b>18f</b></h3><div class="NLM_p"><i>Method C-I:</i> To a suspension of corresponding (2-fluoro-5-nitrophenyl)pyrimidine derivatives (3.0 mmol), K<sub>2</sub>CO<sub>3</sub> (1.45 g, 10.5 mmol) in DMF (6 mL), the corresponding secondary amine (9 mmol, 3.0 equiv) was added. The resulting mixture was stirred at 90 °C for about 3 h. After completion of reaction, the mixture was then poured into ice–water. A yellow precipitate formed and was collected by filtration to afford the crude title compounds <b>8b</b>–<b>8n</b> or <b>18a</b>–<b>18f</b> as yellow solids, which were used without further purification.</div><div class="NLM_p last"><i>Method C-II:</i> To a stirred ice-cooled suspension of NaH (60%, 600 mg, 15 mmol) in DMF (2 mL), the corresponding alcohol (18 mmol, 6.0 equiv) in dry DMF (6 mL) was added dropwise under N<sub>2</sub> atmosphere. The reaction mixture was stirred at 0 °C for an additional 30 min. Subsequently, a solution of compound <b>7</b> (1.28 g, 3.0 mmol) in DMF (4 mL) was added dropwise. The mixture was allowed to reach room temperature and stirred for an additional 2.0 h. The post-reaction treatment was similar to method C-I and afforded the crude title compounds <b>8o</b> and <b>8p</b>, which were used without further purification.</div></div><div id="sec4_11_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> General Procedure D for the Synthesis of Compounds <b>9b</b>–<b>9p</b> and <b>19a</b>–<b>19f</b></h3><div class="NLM_p last">To a solution of 5-nitrophenyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine derivatives (3.0 mmol) in ethanol (21 mL) and water (3 mL), iron (1.68 g, 30 mmol) and ammonium chloride (1.61 g, 30 mmol) were added and refluxed for 1.0 h. The reaction mixture was filtered through Celite and washed with MeOH. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under vacuum. The residue was chromatographed, eluting with a gradient of 1–5% DCM/MeOH to afford title compounds <b>9b</b>–<b>9p</b> and <b>19a</b>–<b>19f</b> (yield, 21–88%) as a white solid.</div></div><div id="sec4_11_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> General Procedure E for the Synthesis of Compounds <b>10b</b>–<b>10p</b> and <b>20a</b>–<b>20f</b></h3><div class="NLM_p last">To a solution of compounds <b>9b</b>–<b>9p</b> or <b>19a</b>–<b>19f</b> (1.5 mmol) in CH<sub>3</sub>CN (4.5 mL) was added <i>p</i>-TsOH (774.9 mg, 4.5 mmol). The thick suspension was cooled to 0 °C, and a solution of sodium nitrite (207.0 mg, 3.0 mmol) and KI (622.5 mg, 3.75 mmol) in water (1.1 mL) was added dropwise while keeping the temperature between 0 and 5 °C. The mixture was allowed to reach room temperature and stirred for 2.0 h. To the mixture were added water (40 mL) and 2 M aq Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> (4 mL). The mixture was extracted with CH<sub>2</sub>Cl<sub>2</sub> (50 mL × 3). The combined organic layers were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under vacuum. The residue was chromatographed, eluting with a gradient of 0.5–4% DCM/MeOH to afford title compounds <b>10b</b>–<b>10p</b> and <b>20a</b>–<b>20f</b> (yield, 37–75%) as a yellow or white solid.</div></div><div id="sec4_11_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> General Procedure F for the Synthesis of Compounds <b>11b</b>–<b>11m</b> and <b>13</b></h3><div class="NLM_p last">Compounds <b>10b</b>–<b>10m</b> or <b>9</b> (1.0 mmol) was dissolved in EtOH (4.0 mL). The mixture was treated with NaOH (144 mg, 3.0 mmol) and heated at 40 °C for 2.0 h. After completion of reaction, the mixture was evaporated under vacuum. The residue was chromatographed, eluting with a gradient of 4–10% DCM/MeOH to afford title compounds <b>11b</b>–<b>11m</b> or <b>13</b> (yield, 56–79%) as a yellow solid.</div></div><div id="sec4_11_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> General Procedure G for the Synthesis of Compounds <b>14a</b>–<b>14c</b> and <b>15a</b>–<b>15c</b></h3><div class="NLM_p last">To a stirred ice-cooled solution of <b>11g</b> or <b>13</b> (0.5 mmol) in dry DMF (1.5 mL, replaced by THF when the synthesis of <b>15a</b>–<b>15c</b> was conducted), the corresponding sulfonyl chloride, acetyl chloride, or isocyanate (0.55 mmol, 1.1 equiv) in dry DMF or THF (1 mL) was added dropwise under N<sub>2</sub> atmosphere. Subsequently, Et<sub>3</sub>N (1.0 mmol, 2.0 equiv) in DMF or THF (1.5 mL) was added dropwise. The mixture was allowed to reach room temperature and stirred for 2.0 h. The mixture was extracted with EA (30 mL × 3). The combined organic layers were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under vacuum. The residue was chromatographed, eluting with a gradient of 2–5% DCM/MeOH to afford title compounds <b>14a</b>–<b>14c</b> or <b>15a</b>–<b>15c</b> (yield, 28–78%) as a white or yellow solid.</div></div><div id="sec4_11_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> General Procedure H for the Synthesis of Compounds <b>12a</b>–<b>12u</b>, <b>16a</b>–<b>16c</b>, and <b>21a</b>–<b>21f</b></h3><div class="NLM_p last">To a mixture of compounds <b>11a</b>–<b>11u</b>, <b>15a</b>–<b>15c</b>, or <b>20a</b>–<b>20f</b> (1.0 equiv), PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub> (5% mmol), CuI (10% mmol) in THF/Et<sub>3</sub>N = 3:1 (total concentation: 0.2 M), a solution of the corresponding terminal alkynes in THF (1 mL) was added dropwise. In some cases, dry DMF (2 mL) was added to the reaction system to keep the starting materials dissolved completely. After completion of reaction, the mixture was evaporated under vacuum. The residue was chromatographed, eluting with a gradient of 4–11% DCM/MeOH to afford title compounds <b>12a</b>–<b>12u</b>, <b>16a</b>–<b>16c</b>, and <b>21a</b>–<b>21f</b> (yield, 45–91%) as a white or yellow solid.</div></div><div id="sec4_11_10_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> <i>N</i>-(2-Fluoro-5-nitrophenyl)-7-tosyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (<b>7</b>)</h3><div class="NLM_p last">Compound <b>7</b> was prepared according to general procedure A on a 19.0 mmol scale. Purification by column chromatography (4% MeOH/DCM) afforded the title compound (7.57 g, 17.71 mmol, 93% yield). [M + H]<sup>+</sup>: 428.1. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.95 (s, 1H), 8.72 (dd, <i>J</i> = 6.7, 2.8 Hz, 1H), 8.41 (s, 1H), 8.16–8.08 (m, 1H), 8.02 (d, <i>J</i> = 8.2 Hz, 2H), 7.78 (d, <i>J</i> = 4.0 Hz, 1H), 7.62 (t, <i>J</i> = 9.5 Hz, 1H), 7.46 (d, <i>J</i> = 8.2 Hz, 2H), 7.13 (d, <i>J</i> = 4.0 Hz, 1H), 2.37 (s, 3H).</div></div><div id="sec4_11_10_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> <i>N</i><sup>4</sup>-(2-Fluoro-5-nitrophenyl)pyrimidine-2,4-diamine (<b>17a</b>)</h3><div class="NLM_p last">Compound <b>17a</b> was prepared according to general procedure A on a 10.0 mmol scale. Purification by column chromatography (4% MeOH/DCM) afforded the title compound (1.67 g, 6.72 mmol, 67% yield). [M + H]<sup>+</sup>: 250.1. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.57 (d, <i>J</i> = 2.8 Hz, 1H), 8.40 (s, 1H), 7.93 (dd, <i>J</i> = 8.9, 2.8 Hz, 1H), 7.87 (d, <i>J</i> = 5.6 Hz, 1H), 7.20 (d, <i>J</i> = 8.9 Hz, 1H), 6.27–6.11 (m, 3H), 3.74 (t, <i>J</i> = 4.4 Hz, 4H), 3.01 (t, <i>J</i> = 4.5 Hz, 4H).</div></div><div id="sec4_11_10_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> <i>N</i>-(2-Fluoro-5-nitrophenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-4-amine (<b>17b</b>)</h3><div class="NLM_p last">Compound <b>17b</b> was prepared according to general procedure B on a 10 mmol scale. Purification by column chromatography (5% MeOH/DCM) afforded the title compound (2.30 g, 0.275 mmol, 85% yield). [M + H]<sup>+</sup>: 273.0. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.53 (s, 1H), 8.92 (s, 1H), 8.13 (dd, <i>J</i> = 7.1, 2.9 Hz, 1H), 8.04–7.94 (m, 2H), 7.63–7.57 (m, 1H), 7.30–7.28 (m, 1H), 6.55–6.45 (m, 2H).</div></div><div id="sec4_11_10_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> 5-Fluoro-<i>N</i>-(2-fluoro-5-nitrophenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-4-amine (<b>17c</b>)</h3><div class="NLM_p last">Compound <b>17c</b> was prepared according to general procedure B on a 10 mmol scale. Purification by column chromatography (4% MeOH/DCM) afforded the title compound (2.36 g, 8.13 mmol, 81% yield). [M + H]<sup>+</sup>: 291.1. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.71 (s, 1H), 8.98 (s, 1H), 8.15 (d, <i>J</i> = 4.3 Hz, 1H), 7.96–7.90 (m, 1H), 7.84–7.80 (m, 1H), 7.58–7.51 (m, 1H), 7.37 (t, <i>J</i> = 3.0 Hz, 1H), 6.22 (dd, <i>J</i> = 3.5, 1.9 Hz, 1H).</div></div><div id="sec4_11_10_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> 5-Chloro-<i>N</i>-(2-fluoro-5-nitrophenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-4-amine (<b>17d</b>)</h3><div class="NLM_p last">Compound <b>17d</b> was prepared according to general procedure B on a 4.0 mmol scale. Purification by column chromatography (4% MeOH/DCM) afforded the title compound (450.8 mg, 1.47 mmol, 37% yield). [M + H]<sup>+</sup>: 307.7. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.79 (s, 1H), 8.74 (s, 1H), 8.16 (s, 1H), 8.05–7.82 (m, 2H), 7.56 (t, <i>J</i> = 9.7 Hz, 1H), 7.33–7.24 (m, 1H), 5.79 (s, 1H).</div></div><div id="sec4_11_10_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> <i>N</i>-(2-Fluoro-5-nitrophenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine (<b>17e</b>)</h3><div class="NLM_p last">Compound <b>17e</b> was prepared according to general procedure A on a 24.0 mmol scale. Purification by column chromatography (4% MeOH/DCM) afforded the title compound (6.28 g, 22.9 mmol, 95% yield). [M + H]<sup>+</sup>: 275.2. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.79 (s, 1H), 10.27 (s, 1H), 8.94 (dd, <i>J</i> = 6.7, 2.6 Hz, 1H), 8.41 (d, <i>J</i> = 13.0 Hz, 2H), 8.17–8.10 (m, 1H), 7.69–7.61 (m, 1H).</div></div><div id="sec4_11_10_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> <i>N</i>-(2-Fluoro-5-nitrophenyl)thieno[2,3-<i>d</i>]pyrimidin-4-amine (<b>17f</b>)</h3><div class="NLM_p last">Compound <b>17f</b> was prepared according to general procedure A on a 12.3 mmol scale. Purification by column chromatography (4% MeOH/DCM) afforded the title compound (2.39 g, 8.24 mmol, 67% yield). [M + H]<sup>+</sup>: 291.0. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.97 (s, 1H), 8.68 (dd, <i>J</i> = 6.6, 2.9 Hz, 1H), 8.50 (s, 1H), 8.20–8.16 (m, 1H), 7.86 (d, <i>J</i> = 6.0 Hz, 1H), 7.80 (d, <i>J</i> = 6.0 Hz, 1H), 7.65 (t, <i>J</i> = 9.5 Hz, 1H).</div></div><div id="sec4_11_10_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> <i>N</i><sup>1</sup>,<i>N</i><sup>1</sup>-Dimethyl-<i>N</i><sup>2</sup>-(7-tosyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)benzene-1,2,4-triamine (<b>9b</b>)</h3><div class="NLM_p last">Compound <b>9b</b> was prepared according to general procedure D on a 4.68 mmol scale. Purification by column chromatography (2.5% MeOH/DCM) afforded the title compound (1.05 g, 2.49 mmol, 53% yield). [M + H]<sup>+</sup>: 423.2 <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.95 (s, 1H), 8.33 (s, 1H), 8.01 (d, <i>J</i> = 1.8 Hz, 1H), 7.99 (d, <i>J</i> = 1.8 Hz, 1H), 7.64 (d, <i>J</i> = 4.0 Hz, 1H), 7.46 (t, <i>J</i> = 1.2 Hz, 1H), 7.45–7.42 (m, 1H), 7.15 (d, <i>J</i> = 2.6 Hz, 1H), 6.92 (d, <i>J</i> = 8.5 Hz, 1H), 6.71 (d, <i>J</i> = 4.0 Hz, 1H), 6.37 (dd, <i>J</i> = 8.4, 2.6 Hz, 1H), 4.88 (s, 2H), 2.48 (s, 6H), 2.36 (s, 3H).</div></div><div id="sec4_11_10_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> <i>N</i><sup>1</sup>-(Methoxymethyl)-<i>N</i><sup>1</sup>-methyl-<i>N</i><sup>2</sup>-(7-tosyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)benzene-1,2,4-triamine (<b>9c</b>)</h3><div class="NLM_p last">Compound <b>9c</b> was prepared according to general procedure D on a 4.0 mmol scale. Purification by column chromatography (2.5% MeOH/DCM) afforded the title compound (1.13 g, 2.50 mmol, 62% yield). [M + H]<sup>+</sup>: 453.2. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.19 (s, 1H), 8.42 (s, 1H), 8.00 (d, <i>J</i> = 8.1 Hz, 2H), 7.74–7.69 (m, 2H), 7.45 (d, <i>J</i> = 8.1 Hz, 2H), 7.02 (d, <i>J</i> = 8.5 Hz, 1H), 6.73 (d, <i>J</i> = 4.1 Hz, 1H), 6.31 (dd, <i>J</i> = 8.4, 2.6 Hz, 1H), 5.22 (s, 2H), 3.27 (t, <i>J</i> = 5.2 Hz, 2H), 3.06 (s, 3H), 2.85 (t, <i>J</i> = 5.2 Hz, 2H), 2.59 (s, 3H), 2.36 (s, 3H).</div></div><div id="sec4_11_10_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> <i>N</i><sup>1</sup>-((Dimethylamino)methyl)-<i>N</i><sup>1</sup>-methyl-<i>N</i><sup>2</sup>-(7-tosyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)benzene-1,2,4-triamine (<b>9d</b>)</h3><div class="NLM_p last">Compound <b>9d</b> was prepared according to general procedure D on a 4.0 mmol scale. Purification by column chromatography (8.0% MeOH/DCM) afforded the title compound (1.04 g, 2.24 mmol, 56% yield). [M + H]<sup>+</sup>: 466.2. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.24 (s, 1H), 8.31 (s, 1H), 8.06–7.94 (m, 2H), 7.65 (d, <i>J</i> = 4.0 Hz, 1H), 7.45 (d, <i>J</i> = 8.2 Hz, 2H), 7.16–7.07 (m, 2H), 6.95 (d, <i>J</i> = 8.5 Hz, 1H), 6.39 (dd, <i>J</i> = 8.5, 2.6 Hz, 1H), 4.99 (s, 2H), 3.08 (d, <i>J</i> = 7.3 Hz, 2H), 3.03 (d, <i>J</i> = 7.3 Hz, 3H), 2.59 (s, 5H), 2.44 (s, 3H), 2.37 (s, 3H).</div></div><div id="sec4_11_10_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> 6-(Pyrrolidin-1-yl)-<i>N</i><sup>1</sup>-(7-tosyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)benzene-1,3-diamine (<b>9e</b>)</h3><div class="NLM_p last">Compound <b>9e</b> was prepared according to general procedure D on a 2.98 mmol scale. Purification by column chromatography (2.5% MeOH/DCM) afforded the title compound (828.9 mg, 1.85 mmol, 62% yield). [M + H]<sup>+</sup>: 449.1. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.05 (t, <i>J</i> = 5.1 Hz, 1H), 8.25 (t, <i>J</i> = 5.3 Hz, 1H), 7.96 (d, <i>J</i> = 7.9 Hz, 2H), 7.55 (d, <i>J</i> = 5.9 Hz, 1H), 7.45 (d, <i>J</i> = 8.5 Hz, 2H), 6.80–6.72 (m, 2H), 6.45 (d, <i>J</i> = 24.6 Hz, 2H), 4.73 (s, 2H), 2.89 (s, 4H), 2.34 (d, <i>J</i> = 5.6 Hz, 3H), 1.68 (s, 4H).</div></div><div id="sec4_11_10_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> 6-Morpholino-<i>N</i><sup>1</sup>-(7-tosyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)benzene-1,3-diamine (<b>9f</b>)</h3><div class="NLM_p last">Compound <b>9f</b> was prepared according to general procedure D on a 4.0 mmol scale. Purification by column chromatography (2.5% MeOH/DCM) afforded the title compound (1.35 g, 2.90 mmol, 72% yield). [M + H]<sup>+</sup>: 465.2. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.95 (s, 1H), 8.36 (s, 1H), 8.03–7.96 (m, 2H), 7.65 (d, <i>J</i> = 4.0 Hz, 1H), 7.45 (d, <i>J</i> = 8.2 Hz, 2H), 7.30 (d, <i>J</i> = 2.5 Hz, 1H), 6.91 (d, <i>J</i> = 8.4 Hz, 1H), 6.63 (d, <i>J</i> = 4.0 Hz, 1H), 6.35 (dd, <i>J</i> = 8.4, 2.6 Hz, 1H), 4.99 (s, 2H), 3.49 (t, <i>J</i> = 4.3 Hz, 4H), 2.64 (t, <i>J</i> = 4.5 Hz, 4H), 2.36 (s, 3H).</div></div><div id="sec4_11_10_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> 6-(Piperazin-1-yl)-<i>N</i><sup>1</sup>-(7-tosyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)benzene-1,3-diamine (<b>9g</b>)</h3><div class="NLM_p last">Compound <b>9g</b> was prepared according to general procedure D on a 15.8 mmol scale. Purification by column chromatography (10% MeOH/DCM) afforded the title compound (3.45 g, 7.45 mmol, 47% yield). [M + H]<sup>+</sup>: 464.2. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.91 (s, 1H), 8.37 (s, 1H), 8.03–7.97 (m, 2H), 7.65 (d, <i>J</i> = 3.9 Hz, 1H), 7.44 (d, <i>J</i> = 8.3 Hz, 2H), 7.36 (d, <i>J</i> = 2.5 Hz, 1H), 6.90 (d, <i>J</i> = 8.5 Hz, 1H), 6.68 (d, <i>J</i> = 4.1 Hz, 1H), 6.32 (dd, <i>J</i> = 8.4, 2.6 Hz, 1H), 5.01 (s, 2H), 3.25 (s, 4H), 2.60 (t, <i>J</i> = 4.9 Hz, 4H), 2.36 (s, 3H), 1.40 (s, 1H).</div></div><div id="sec4_11_10_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> (<i>R</i>)-6-(3-Methylpiperazin-1-yl)-<i>N</i><sup>1</sup>-(7-tosyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)benzene-1,3-diamine (<b>9h</b>)</h3><div class="NLM_p last">Compound <b>9h</b> was prepared according to general procedure D on a 4.68 mmol scale. Purification by column chromatography (10% MeOH/DCM) afforded the title compound (1.21 g, 2.53 mmol, 54% yield). [M + H]<sup>+</sup>: 478.2. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.80 (s, 1H), 8.58 (s, 1H), 8.28 (s, 1H), 7.73–7.67 (m, 3H), 7.44–7.25 (m, 2H), 6.94 (d, <i>J</i> = 8.4 Hz, 1H), 6.45 (dd, <i>J</i> = 3.5, 1.8 Hz, 1H), 6.26 (dd, <i>J</i> = 8.4, 2.6 Hz, 1H), 4.99 (s, 2H), 4.13 (s, 1H), 3.79 (d, <i>J</i> = 12.9 Hz, 1H), 3.27–3.12 (m, 1H), 2.84–2.72 (m, 3H), 2.62 (dd, <i>J</i> = 11.6, 8.0 Hz, 2H), 2.41 (s, 3H), 1.25 (d, <i>J</i> = 6.7 Hz, 3H).</div></div><div id="sec4_11_10_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> (<i>S</i>)-6-(3-Methylpiperazin-1-yl)-<i>N</i><sup>1</sup>-(7-tosyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)benzene-1,3-diamine (<b>9i</b>)</h3><div class="NLM_p last">Compound <b>9i</b> was prepared according to general procedure D on a 3.37 mmol scale. Purification by column chromatography (10% MeOH/DCM) afforded the title compound (1.21 g, 2.54 mmol, 75% yield). [M + H]<sup>+</sup>: 478.2. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.77 (s, 1H), 8.56 (s, 1H), 8.28 (s, 1H), 7.73–7.67 (m, 3H), 7.44–7.25 (m, 2H), 6.94 (d, <i>J</i> = 8.5 Hz, 1H), 6.44 (dd, <i>J</i> = 3.5, 1.8 Hz, 1H), 6.27 (dd, <i>J</i> = 8.4, 2.6 Hz, 1H), 4.96 (s, 2H), 4.14 (s, 1H), 3.83–3.75 (m, 1H), 3.24–3.15 (m, 1H), 2.84–2.73 (m, 3H), 2.67–2.58 (m, 2H), 2.41 (s, 3H), 1.26 (d, <i>J</i> = 6.7 Hz, 3H).</div></div><div id="sec4_11_10_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> 6-(2,5-Diazabicyclo[2.2.1]heptan-2-yl)-<i>N</i><sup>1</sup>-(7-tosyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)benzene-1,3-diamine (<b>9j</b>)</h3><div class="NLM_p last">Compound <b>9j</b> was prepared according to general procedure D on a 1.58 mmol scale. Purification by column chromatography (10% MeOH/DCM) afforded the title compound (330.3 mg, 0.695 mmol, 44% yield). [M + H]<sup>+</sup>: 476.2. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.05 (s, 1H), 8.23 (s, 1H), 7.98 (d, <i>J</i> = 8.0 Hz, 2H), 7.54 (d, <i>J</i> = 4.0 Hz, 1H), 7.44 (d, <i>J</i> = 8.2 Hz, 2H), 6.71–6.60 (m, 2H), 6.44 (dd, <i>J</i> = 8.6, 2.7 Hz, 2H), 4.71 (s, 2H), 4.15 (d, <i>J</i> = 22.4 Hz, 1H), 3.92 (s, 1H), 3.29–3.20 (m, 1H), 3.17 (d, <i>J</i> = 5.2 Hz, 1H), 3.10 (t, <i>J</i> = 7.2 Hz, 1H), 2.86–2.73 (m, 1H), 2.36 (s, 3H), 1.66 (s, 2H), 1.30 (s, 1H).</div></div><div id="sec4_11_10_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> 6-(4-Methylpiperazin-1-yl)-<i>N</i><sup>1</sup>-(7-tosyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)benzene-1,3-diamine (<b>9k</b>)</h3><div class="NLM_p last">Compound <b>9k</b> was prepared according to general procedure D on a 8.47 mmol scale. Purification by column chromatography (5% MeOH/DCM) afforded the title compound (2.33 g, 4.88 mmol, 58% yield). [M + H]<sup>+</sup>: 478.2. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.80 (s, 1H), 8.37 (s, 1H), 8.08–7.96 (m, 2H), 7.68 (d, <i>J</i> = 4.0 Hz, 1H), 7.46 (d, <i>J</i> = 8.2 Hz, 2H), 7.34 (d, <i>J</i> = 2.6 Hz, 1H), 6.91 (d, <i>J</i> = 8.5 Hz, 1H), 6.75 (d, <i>J</i> = 3.9 Hz, 1H), 6.36 (dd, <i>J</i> = 8.5, 2.6 Hz, 1H), 5.11 (s, 2H), 3.27 (s, 4H), 3.02–2.72 (m, 7H), 2.36 (s, 3H).</div></div><div id="sec4_11_10_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> 6-(4-Ethylpiperazin-1-yl)-<i>N</i><sup>1</sup>-(7-tosyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)benzene-1,3-diamine (<b>9l</b>)</h3><div class="NLM_p last">Compound <b>9l</b> was prepared according to general procedure D on a 1.82 mmol scale. Purification by column chromatography (5% MeOH/DCM) afforded the title compound (476.5 mg, 0.97 mmol, 53% yield). [M + H]<sup>+</sup>: 492.2. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.92 (s, 1H), 8.36 (s, 1H), 8.03–7.97 (m, 2H), 7.65 (d, <i>J</i> = 4.0 Hz, 1H), 7.45 (d, <i>J</i> = 8.2 Hz, 2H), 7.28 (d, <i>J</i> = 2.6 Hz, 1H), 6.89 (d, <i>J</i> = 8.4 Hz, 1H), 6.51 (s, 1H), 6.35 (dd, <i>J</i> = 8.4, 2.6 Hz, 1H), 4.98 (s, 2H), 2.68 (t, <i>J</i> = 4.7 Hz, 4H), 2.36 (s, 3H), 2.32–2.20 (m, 4H), 1.24 (d, <i>J</i> = 3.9 Hz, 2H), 0.97 (t, <i>J</i> = 7.1 Hz, 3H).</div></div><div id="sec4_11_10_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> 6-(4-Morpholinopiperidin-1-yl)-<i>N</i><sup>1</sup>-(7-tosyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)benzene-1,3-diamine (<b>9m</b>)</h3><div class="NLM_p last">Compound <b>9m</b> was prepared according to general procedure D on a 4.72 mmol scale. Purification by column chromatography (1% MeOH/DCM) afforded the title compound (1.16 g, 2.12 mmol, 45% yield). [M + H]<sup>+</sup>: 548.2. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.88 (d, <i>J</i> = 5.9 Hz, 1H), 8.36 (t, <i>J</i> = 5.1 Hz, 1H), 7.98 (d, <i>J</i> = 8.0 Hz, 2H), 7.66 (q, <i>J</i> = 4.0 Hz, 1H), 7.46 (d, <i>J</i> = 7.9 Hz, 2H), 7.28 (d, <i>J</i> = 6.2 Hz, 1H), 6.85 (d, <i>J</i> = 8.4 Hz, 1H), 6.52 (s, 1H), 6.35 (d, <i>J</i> = 7.9 Hz, 1H), 4.95 (s, 2H), 3.55 (s, 4H), 2.81 (s, 2H), 2.51 (s, 2H), 2.43–2.28 (m, 7H), 2.10 (s, 1H), 1.67 (d, <i>J</i> = 9.6 Hz, 2H), 1.25 (s, 2H).</div></div><div id="sec4_11_10_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> 6-(4-Methyl-1,4-diazepan-1-yl)-<i>N</i><sup>1</sup>-(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)benzene-1,3-diamine (<b>9n</b>)</h3><div class="NLM_p last">Compound <b>9n</b> was prepared according to general procedure D on a 3.14 mmol scale. Purification by column chromatography (10% MeOH/DCM) afforded the title compound (219.2 mg, 0.65 mmol, 21% yield). [M + H]<sup>+</sup>: 338.2. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.79 (d, <i>J</i> = 6.5 Hz, 1H), 8.82–8.50 (m, 1H), 8.23 (d, <i>J</i> = 4.3 Hz, 1H), 7.40 (t, <i>J</i> = 4.8 Hz, 1H), 7.29–7.16 (m, 1H), 6.93 (d, <i>J</i> = 8.7 Hz, 1H), 6.71–6.59 (m, 1H), 6.31 (d, <i>J</i> = 8.5 Hz, 1H), 4.97 (s, 2H), 3.31–3.08 (m, 6H), 2.95–2.89 (m, 2H), 2.79–2.60 (m, 3H), 2.17–1.90 (m, 2H).</div></div><div id="sec4_11_10_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> <i>N</i><sup>1</sup>-(7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-6-((tetrahydro-2<i>H</i>-pyran-4-yl)oxy)benzene-1,3-diamine (<b>9o</b>)</h3><div class="NLM_p last">Compound <b>9o</b> was prepared according to general procedure D on a 2.5 mmol scale. Purification by column chromatography (2% MeOH/DCM) afforded the title compound (565.8 mg, 1.74 mmol, 70% yield). [M + H]<sup>+</sup>: 326.2. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.70 (s, 1H), 8.25 (s, 1H), 8.19 (s, 1H), 7.32 (d, <i>J</i> = 2.7 Hz, 1H), 7.19–7.17 (m, 1H), 6.82 (d, <i>J</i> = 8.6 Hz, 1H), 6.46–6.45 (m, 1H), 6.31 (dd, <i>J</i> = 8.6, 2.7 Hz, 1H), 4.81 (s, 2H), 4.21–4.12 (m, 1H), 3.77–3.70 (m, 2H), 1.86–1.78 (m, 2H), 1.60–1.49 (m, 2H), 1.36–1.21 (m, 2H).</div></div><div id="sec4_11_10_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> 6-((1-Methylpiperidin-4-yl)oxy)-<i>N</i><sup>1</sup>-(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)benzene-1,3-diamine (<b>9p</b>)</h3><div class="NLM_p last">Compound <b>9p</b> was prepared according to general procedure D on a 2.5 mmol scale. Purification by column chromatography (8% MeOH/DCM) afforded the title compound (544.5 mg, 1.61 mmol, 64% yield). [M + H]<sup>+</sup>: 339.2. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.09 (s, 1H), 8.24 (s, 1H), 7.99 (s, 1H), 7.57 (d, <i>J</i> = 4.0 Hz, 1H), 7.44 (d, <i>J</i> = 8.2 Hz, 2H), 6.64–6.51 (m, 3H), 6.45 (dd, <i>J</i> = 8.4, 2.4 Hz, 1H), 3.24 (s, 1H), 3.07 (s, 2H), 2.69–2.66 (m, 2H), 2.36 (s, 3H), 1.89 (d, <i>J</i> = 9.5 Hz, 2H), 1.59–1.42 (m, 2H).</div></div><div id="sec4_11_10_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> <i>N</i><sup>4</sup>-(5-Amino-2-morpholinophenyl)pyrimidine-2,4-diamine (<b>19a</b>)</h3><div class="NLM_p last">Compound <b>19a</b> was prepared according to general procedure D on a 5.3 mmol scale. Purification by column chromatography (4% MeOH/DCM) afforded the title compound (1.20 g, 4.18 mmol, 79% yield). [M + H]<sup>+</sup>: 287.2. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.15 (s, 1H), 7.81 (d, <i>J</i> = 6.7 Hz, 1H), 7.31 (s, 2H), 7.06 (d, <i>J</i> = 2.6 Hz, 1H), 6.91 (d, <i>J</i> = 8.5 Hz, 1H), 6.39 (dd, <i>J</i> = 8.5, 2.6 Hz, 1H), 6.25 (d, <i>J</i> = 6.6 Hz, 1H), 4.97 (s, 2H), 3.72–3.57 (m, 4H), 2.68 (t, <i>J</i> = 4.5 Hz, 4H).</div></div><div id="sec4_11_10_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> 6-Morpholino-<i>N</i><sup>1</sup>-(1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-4-yl)benzene-1,3-diamine (<b>19b</b>)</h3><div class="NLM_p last">Compound <b>19b</b> was prepared according to general procedure D on a 3.0 mmol scale. Purification by column chromatography (4% MeOH/DCM) afforded the title compound (745.2 mg, 2.41 mmol, 80% yield). [M + H]<sup>+</sup>: 310.2. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.37 (s, 1H), 7.95–7.83 (m, 2H), 7.54 (s, 1H), 7.36 (d, <i>J</i> = 8.3 Hz, 1H), 7.22–7.20 (m, 1H), 6.87 (d, <i>J</i> = 8.4 Hz, 1H), 6.45 (d, <i>J</i> = 5.4 Hz, 1H), 6.35 (d, <i>J</i> = 3.4 Hz, 1H), 4.96 (s, 2H), 3.53 (s, 4H), 2.81 (s, 4H).</div></div><div id="sec4_11_10_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> <i>N</i><sup>1</sup>-(5-Fluoro-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-4-yl)-6-morpholinobenzene-1,3-diamine (<b>19c</b>)</h3><div class="NLM_p last">Compound <b>19c</b> was prepared according to general procedure D on a 3.0 mmol scale. Purification by column chromatography (4% MeOH/DCM) afforded the title compound (863.5 mg, 2.64 mmol, 88% yield). [M + H]<sup>+</sup>: 328.1. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.39 (s, 1H), 8.03 (d, <i>J</i> = 4.2 Hz, 1H), 7.48 (d, <i>J</i> = 1.9 Hz, 1H), 7.20 (t, <i>J</i> = 3.0 Hz, 1H), 6.82 (d, <i>J</i> = 8.3 Hz, 1H), 6.36–6.22 (m, 2H), 5.96 (dd, <i>J</i> = 3.5, 2.0 Hz, 1H), 4.84 (s, 2H), 3.44 (s, 4H), 2.70 (s, 4H).</div></div><div id="sec4_11_10_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> <i>N</i><sup>1</sup>-(5-Chloro-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-4-yl)-6-morpholinobenzene-1,3-diamine (<b>19d</b>)</h3><div class="NLM_p last">Compound <b>19d</b> was prepared according to general procedure D on a 1.3 mmol scale. Purification by column chromatography (4% MeOH/DCM) afforded the title compound (322.5 mg, 0.935 mmol, 72% yield). [M + H]<sup>+</sup>: 345.1. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.49 (s, 1H), 8.06 (s, 1H), 7.51 (s, 1H), 7.16 (s, 1H), 6.85 (d, <i>J</i> = 8.3 Hz, 1H), 6.42 (s, 1H), 6.34 (d, <i>J</i> = 8.3 Hz, 1H), 5.75 (s, 1H), 4.87 (s, 2H), 3.45 (s, 4H), 2.69 (s, 4H).</div></div><div id="sec4_11_10_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74"> 6-Morpholino-<i>N</i><sup>1</sup>-(1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-yl)benzene-1,3-diamine (<b>19e</b>)</h3><div class="NLM_p last">Compound <b>19e</b> was prepared according to general procedure D on a 3.0 mmol scale. Purification by column chromatography (4% MeOH/DCM) afforded the title compound (462.0 mg, 1.48 mmol, 49% yield). [M + H]<sup>+</sup>: 312.2. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.66–13.41 (m, 1H), 9.19 (s, 1H), 8.33 (s, 1H), 7.81 (s, 1H), 7.28 (s, 1H), 6.94 (d, <i>J</i> = 8.5 Hz, 1H), 6.42 (dd, <i>J</i> = 8.4, 2.6 Hz, 1H), 5.02 (s, 2H), 3.58 (s, <i>J</i> = 4.3 Hz, 4H), 2.70 (t, <i>J</i> = 4.5 Hz, 4H).</div></div><div id="sec4_11_10_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> 6-Morpholino-<i>N</i><sup>1</sup>-(thieno[2,3-<i>d</i>]pyrimidin-4-yl)benzene-1,3-diamine (<b>19f</b>)</h3><div class="NLM_p last">Compound <b>19f</b> was prepared according to general procedure D on a 3.0 mmol scale. Purification by column chromatography (4% MeOH/DCM) afforded the title compound (448.1 mg, 1.37 mmol, 46% yield). [M + H]<sup>+</sup>: 328.1. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.14 (s, 1H), 8.50 (s, 1H), 7.74 (d, <i>J</i> = 6.0 Hz, 1H), 7.58 (d, <i>J</i> = 2.6 Hz, 1H), 7.55 (d, <i>J</i> = 6.0 Hz, 1H), 6.98 (d, <i>J</i> = 8.4 Hz, 1H), 6.35 (dd, <i>J</i> = 8.4, 2.6 Hz, 1H), 5.04 (s, 2H), 3.71–3.63 (m, 4H), 2.75–2.68 (m, 4H).</div></div><div id="sec4_11_10_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i76" class="anchor-spacer"></div><h3 class="article-section__title" id="_i76"> 4-Iodo-<i>N</i><sup>1</sup>,<i>N</i><sup>1</sup>-dimethyl-<i>N</i><sup>2</sup>-(7-tosyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)benzene-1,2-diamine (<b>10b</b>)</h3><div class="NLM_p last">Compound <b>10b</b> was prepared according to general procedure E on a 2.4 mmol scale. Purification by column chromatography (2% MeOH/DCM) afforded the title compound (559.7 mg, 1.05 mmol, 44% yield). [M + H]<sup>+</sup>: 534.1. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.17 (s, 1H), 8.33 (s, 1H), 8.02 (d, <i>J</i> = 8.3 Hz, 2H), 7.92 (d, <i>J</i> = 2.0 Hz, 1H), 7.67 (d, <i>J</i> = 4.0 Hz, 1H), 7.45 (d, <i>J</i> = 8.0 Hz, 3H), 6.93–6.88 (m, 2H), 2.60 (s, 6H), 2.37 (s, 3H).</div></div><div id="sec4_11_10_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i77" class="anchor-spacer"></div><h3 class="article-section__title" id="_i77"> 4-Iodo-<i>N</i><sup>1</sup>-(2-methoxyethyl)-<i>N</i><sup>1</sup>-methyl-<i>N</i><sup>2</sup>-(7-tosyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)benzene-1,2-diamine (<b>10c</b>)</h3><div class="NLM_p last">Compound <b>10c</b> was prepared according to general procedure E on a 0.45 mmol scale. Purification by column chromatography (2% MeOH/DCM) afforded the title compound (179.5 mg, 0.311 mmol, 69% yield). [M + H]<sup>+</sup>: 578.1. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.09 (s, 1H), 8.43 (s, 1H), 8.39 (d, <i>J</i> = 2.1 Hz, 1H), 8.03–7.98 (m, 2H), 7.74 (d, <i>J</i> = 4.0 Hz, 1H), 7.45 (d, <i>J</i> = 8.1 Hz, 2H), 7.42 (dd, <i>J</i> = 8.4, 2.1 Hz, 1H), 7.03 (d, <i>J</i> = 8.5 Hz, 1H), 6.84 (d, <i>J</i> = 4.0 Hz, 1H), 3.35 (t, <i>J</i> = 5.5 Hz, 2H), 3.05 (s, 3H), 2.90 (t, <i>J</i> = 5.5 Hz, 2H), 2.68 (s, 3H), 2.36 (s, 3H).</div></div><div id="sec4_11_10_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i78" class="anchor-spacer"></div><h3 class="article-section__title" id="_i78"> <i>N</i><sup>1</sup>-(2-(Dimethylamino)ethyl)-4-iodo-<i>N</i><sup>1</sup>-methyl-<i>N</i><sup>2</sup>-(7-tosyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)benzene-1,2-diamine (<b>10d</b>)</h3><div class="NLM_p last">Compound <b>10d</b> was prepared according to general procedure E on a 0.70 mmol scale. Purification by column chromatography (6% MeOH/DCM) afforded the title compound (309.8 mg, 0.525 mmol, 75% yield). [M + H]<sup>+</sup>: 591.1. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.47 (s, 1H), 8.35 (s, 1H), 8.09–7.93 (m, 3H), 7.71 (d, <i>J</i> = 4.0 Hz, 1H), 7.50–7.39 (m, 3H), 7.23 (s, 1H), 7.01 (d, <i>J</i> = 8.5 Hz, 1H), 2.76 (t, <i>J</i> = 6.0 Hz, 2H), 2.57 (s, 3H), 2.37 (s, 3H), 2.24 (t, <i>J</i> = 6.0 Hz, 2H), 1.98 (s, 6H).</div></div><div id="sec4_11_10_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i79" class="anchor-spacer"></div><h3 class="article-section__title" id="_i79"> <i>N</i>-(5-Iodo-2-(pyrrolidin-1-yl)phenyl)-7-tosyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (<b>10e</b>)</h3><div class="NLM_p last">Compound <b>10e</b> was prepared according to general procedure E on a 0.56 mmol scale. Purification by column chromatography (2% MeOH/DCM) afforded the title compound (219.7 mg, 0.393 mmol, 70% yield). [M + H]<sup>+</sup>: 560.0. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.33 (d, <i>J</i> = 18.4 Hz, 1H), 8.22 (d, <i>J</i> = 10.8 Hz, 1H), 8.02–7.98 (m, 2H), 7.61–7.54 (m, 1H), 7.46 (s, 1H), 7.43 (s, 1H), 7.41–7.38 (m, 1H), 7.13 (d, <i>J</i> = 8.1 Hz, 1H), 6.85–6.70 (m, 1H), 6.63 (d, <i>J</i> = 9.3 Hz, 1H), 3.16–3.11 (m, 4H), 2.37 (s, 3H), 1.78–1.65 (m, 4H).</div></div><div id="sec4_11_10_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i80" class="anchor-spacer"></div><h3 class="article-section__title" id="_i80"> <i>N</i>-(5-Iodo-2-morpholinophenyl)-7-tosyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (<b>10f</b>)</h3><div class="NLM_p last">Compound <b>10f</b> was prepared according to general procedure E on a 1.60 mmol scale. Purification by column chromatography (2% MeOH/DCM) afforded the title compound (571.1 mg, 0.993 mmol, 62% yield). [M + H]<sup>+</sup>: 576.1. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.05 (s, 1H), 8.39 (s, 1H), 8.18 (d, <i>J</i> = 2.1 Hz, 1H), 8.01 (d, <i>J</i> = 8.0 Hz, 2H), 7.68 (d, <i>J</i> = 4.0 Hz, 1H), 7.57–7.40 (m, 3H), 6.95 (d, <i>J</i> = 8.4 Hz, 1H), 6.78 (d, <i>J</i> = 4.0 Hz, 1H), 3.50 (t, <i>J</i> = 4.3 Hz, 4H), 2.77 (t, <i>J</i> = 4.3 Hz, 4H), 2.36 (s, 3H).</div></div><div id="sec4_11_10_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i81" class="anchor-spacer"></div><h3 class="article-section__title" id="_i81"> <i>N</i>-(5-Iodo-2-(piperazin-1-yl)phenyl)-7-tosyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (<b>10g</b>)</h3><div class="NLM_p last">Compound <b>10g</b> was prepared according to general procedure E on a 7.44 mmol scale. Purification by column chromatography (8% MeOH/DCM) afforded the title compound (2.67 g, 4.65 mmol, 63% yield). [M + H]<sup>+</sup>: 575.1. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.98 (s, 1H), 8.41 (s, 1H), 8.28 (d, <i>J</i> = 2.1 Hz, 1H), 8.05–7.97 (m, 2H), 7.69 (d, <i>J</i> = 4.0 Hz, 1H), 7.48–7.43 (m, 3H), 6.95 (d, <i>J</i> = 8.4 Hz, 1H), 6.84 (d, <i>J</i> = 4.1 Hz, 1H), 3.27 (s, 4H), 2.74 (d, <i>J</i> = 5.4 Hz, 4H), 2.36 (s, 3H), 1.39 (s, 1H).</div></div><div id="sec4_11_10_35" class="NLM_sec NLM_sec_level_2"><div id="ac_i82" class="anchor-spacer"></div><h3 class="article-section__title" id="_i82"> (<i>R</i>)-<i>N</i>-(5-Iodo-2-(3-methylpiperazin-1-yl)phenyl)-7-tosyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (<b>10h</b>)</h3><div class="NLM_p last">Compound <b>10h</b> was prepared according to general procedure E on a 0.92 mmol scale. Purification by column chromatography (8% MeOH/DCM) afforded the title compound (282.3 mg, 0.48 mmol, 52% yield). [M + H]<sup>+</sup>: 589.1. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ10.04 (s, 1H), 8.60–8.53 (m, 2H), 8.30 (s, 1H), 7.53–7.41 (m, 2H), 7.27–7.15 (m, 3H), 7.01 (d, <i>J</i> = 8.4 Hz, 1H), 6.52 (dd, <i>J</i> = 3.5, 1.8 Hz, 1H), 4.12–4.08 (m, 2H), 3.81 (d, <i>J</i> = 13.1 Hz, 1H), 3.17 (t, <i>J</i> = 12.1 Hz, 1H), 2.98 (d, <i>J</i> = 11.1 Hz, 1H), 2.81 (d, <i>J</i> = 11.7 Hz, 1H), 2.71 (dd, <i>J</i> = 11.7, 3.6 Hz, 2H), 2.44 (s, 3H), 1.21 (d, <i>J</i> = 6.8 Hz, 3H).</div></div><div id="sec4_11_10_36" class="NLM_sec NLM_sec_level_2"><div id="ac_i83" class="anchor-spacer"></div><h3 class="article-section__title" id="_i83"> (<i>S</i>)-<i>N</i>-(5-Iodo-2-(3-methylpiperazin-1-yl)phenyl)-7-tosyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (<b>10i</b>)</h3><div class="NLM_p last">Compound <b>10i</b> was prepared according to general procedure E on a 0.82 mmol scale. Purification by column chromatography (8% MeOH/DCM) afforded the title compound (217.6 mg, 0.37 mmol, 45% yield). [M + H]<sup>+</sup>: 589.1. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.04 (s, 1H), 8.58 (d, <i>J</i> = 2.1 Hz, 2H), 8.30 (s, 1H), 7.53–7.41 (m, 2H), 7.27–7.15 (m, 3H), 7.01 (d, <i>J</i> = 8.4 Hz, 1H), 6.52 (dd, <i>J</i> = 3.5, 1.8 Hz, 1H), 4.12–4.08 (m, 2H), 3.80 (d, <i>J</i> = 12.9 Hz, 1H), 3.17 (t, <i>J</i> = 12.4 Hz, 1H), 2.98 (d, <i>J</i> = 11.3 Hz, 1H), 2.81 (d, <i>J</i> = 11.7 Hz, 1H), 2.76–2.66 (m, 2H), 2.44 (s, 3H), 1.23–1.19 (m, 3H).</div></div><div id="sec4_11_10_37" class="NLM_sec NLM_sec_level_2"><div id="ac_i84" class="anchor-spacer"></div><h3 class="article-section__title" id="_i84"> <i>N</i>-(2-(2,5-Diazabicyclo[2.2.1]heptan-2-yl)-5-iodophenyl)-7-tosyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (<b>10j</b>)</h3><div class="NLM_p last">Compound <b>10j</b> was prepared according to general procedure E on a 1.16 mmol scale. Purification by column chromatography (8% MeOH/DCM) afforded the title compound (451.5 mg, 4 0.77 mmol, 66% yield). [M + H]<sup>+</sup>: 587.4. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.95 (s, 1H), 8.12 (s, 1H), 7.98 (d, <i>J</i> = 8.0 Hz, 2H), 7.46 (d, <i>J</i> = 2.3 Hz, 1H), 7.44 (d, <i>J</i> = 8.2 Hz, 2H), 6.71–6.60 (m, 2H), 6.70 (dd, <i>J</i> = 8.6, 2.7 Hz, 2H), 4.35 (d, <i>J</i> = 16.4 Hz, 1H), 4.21 (d, <i>J</i> = 30.3 Hz, 1H), 3.54 (d, <i>J</i> = 9.5 Hz, 1H), 3.38 (d, <i>J</i> = 10.3 Hz, 1H), 3.24–3.14 (m, 1H), 2.88 (d, <i>J</i> = 9.2 Hz, 1H), 2.39 (s, 3H), 1.80 (t, <i>J</i> = 7.0 Hz, 1H), 1.73 (t, <i>J</i> = 7.9 Hz, 2H).</div></div><div id="sec4_11_10_38" class="NLM_sec NLM_sec_level_2"><div id="ac_i85" class="anchor-spacer"></div><h3 class="article-section__title" id="_i85"> <i>N</i>-(5-Iodo-2-(4-methylpiperazin-1-yl)phenyl)-7-tosyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (<b>10k</b>)</h3><div class="NLM_p last">Compound <b>10k</b> was prepared according to general procedure E on a 4.40 mmol scale. Purification by column chromatography (5% MeOH/DCM) afforded the title compound (1.35 g, 2.29 mmol, 52% yield). [M + H]<sup>+</sup>: 589.1. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.02 (s, 1H), 8.38 (s, 1H), 8.12 (d, <i>J</i> = 2.1 Hz, 1H), 8.05–7.97 (m, 2H), 7.67 (d, <i>J</i> = 4.0 Hz, 1H), 7.51–7.41 (m, 3H), 6.92 (d, <i>J</i> = 8.4 Hz, 1H), 6.60 (s, 1H), 2.75 (t, <i>J</i> = 4.8 Hz, 4H), 2.36 (s, 3H), 2.13 (s, 4H), 2.03 (s, 3H).</div></div><div id="sec4_11_10_39" class="NLM_sec NLM_sec_level_2"><div id="ac_i86" class="anchor-spacer"></div><h3 class="article-section__title" id="_i86"> <i>N</i>-(2-(4-Ethylpiperazin-1-yl)-5-iodophenyl)-7-tosyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (<b>10l</b>)</h3><div class="NLM_p last">Compound <b>10l</b> was prepared according to general procedure E on a 1.05 mmol scale. Purification by column chromatography (5% MeOH/DCM) afforded the title compound (273.9 mg, 0.44 mmol, 42% yield). [M + Na]<sup>+</sup>: 625.5. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.00 (s, 1H), 8.40 (s, 1H), 8.22–8.14 (m, 1H), 8.05–7.98 (m, 2H), 7.70 (d, <i>J</i> = 4.0 Hz, 1H), 7.53–7.41 (m, 3H), 6.95 (d, <i>J</i> = 8.4 Hz, 1H), 6.74 (s, 1H), 3.93–3.05 (m, 6H), 2.87 (s, 4H), 2.36 (s, 3H), 1.01 (t, <i>J</i> = 7.2 Hz, 3H).</div></div><div id="sec4_11_10_40" class="NLM_sec NLM_sec_level_2"><div id="ac_i87" class="anchor-spacer"></div><h3 class="article-section__title" id="_i87"> <i>N</i>-(5-Iodo-2-(4-morpholinopiperidin-1-yl)phenyl)-7-tosyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (<b>10m</b>)</h3><div class="NLM_p last">Compound <b>10m</b> was prepared according to general procedure E on a 2.24 mmol scale. Purification by column chromatography (2% MeOH/DCM) afforded the title compound (769.9 mg, 1.17 mmol, 52% yield). [M + H]<sup>+</sup>: 659.1. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.82 (d, <i>J</i> = 5.9 Hz, 1H), 8.66 (t, <i>J</i> = 5.0 Hz, 1H), 8.46 (d, <i>J</i> = 8.2 Hz, 2H), 7.39 (s, 1H), 7.16 (d, <i>J</i> = 8.0 Hz, 2H), 7.03 (d, <i>J</i> = 6.1 Hz, 1H), 6.85 (d, <i>J</i> = 8.4 Hz, 1H), 6.52–6.35 (m, 2H), 3.57 (s, 4H), 3.11 (s, 2H), 3.86–2.69 (m, 7H), 2.60 (s, 2H), 2.52–2.34 (m, 1H), 1.85–1.82 (m, 2H), 1.63 (s, 2H).</div></div><div id="sec4_11_10_41" class="NLM_sec NLM_sec_level_2"><div id="ac_i88" class="anchor-spacer"></div><h3 class="article-section__title" id="_i88"> <i>N</i>-(5-Iodo-2-(4-methyl-1,4-diazepan-1-yl)phenyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (<b>10n</b>)</h3><div class="NLM_p last">Compound <b>10n</b> was prepared according to general procedure E on a 0.65 mmol scale. Purification by column chromatography (8% MeOH/DCM) afforded the title compound (128.6 mg, 0.287 mmol, 44% yield). [M + H]<sup>+</sup>: 449.1. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.83 (s, 1H), 8.26 (s, 1H), 7.52 (d, <i>J</i> = 7.7 Hz, 1H), 7.46–7.41 (m, 1H), 7.27 (t, <i>J</i> = 2.9 Hz, 1H), 7.15 (d, <i>J</i> = 7.8 Hz, 1H), 7.01 (d, <i>J</i> = 8.4 Hz, 1H), 6.57 (d, <i>J</i> = 3.4 Hz, 1H), 3.25–3.17 (m, 4H), 3.15–3.03 (m, 3H), 2.71 (s, 3H), 2.30 (s, 1H), 2.06–1.94 (m, 2H).</div></div><div id="sec4_11_10_42" class="NLM_sec NLM_sec_level_2"><div id="ac_i89" class="anchor-spacer"></div><h3 class="article-section__title" id="_i89"> <i>N</i>-(5-Iodo-2-((tetrahydro-2<i>H</i>-pyran-4-yl)oxy)phenyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (<b>10o</b>)</h3><div class="NLM_p last">Compound <b>10o</b> was prepared according to general procedure E on a 0.56 mmol scale. Purification by column chromatography (2% MeOH/DCM) afforded the title compound (162.2 mg, 0.372 mmol, 67% yield). [M + H]<sup>+</sup>: 437.0. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.34 (s, 1H), 9.15 (d, <i>J</i> = 2.2 Hz, 1H), 8.54 (s, 1H), 8.41 (s, 1H), 7.60 (d, <i>J</i> = 2.4 Hz, 1H), 7.33–7.31 (m, 2H), 7.05 (d, <i>J</i> = 8.7 Hz, 1H), 4.75–4.68 (m, 1H), 3.90 (s, 2H), 3.48–3.43 (m, 2H), 2.06–2.03 (m, 2H), 1.84–1.74 (m, 2H).</div></div><div id="sec4_11_10_43" class="NLM_sec NLM_sec_level_2"><div id="ac_i90" class="anchor-spacer"></div><h3 class="article-section__title" id="_i90"> <i>N</i>-(5-Iodo-2-((1-methylpiperidin-4-yl)oxy)phenyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (<b>10p</b>)</h3><div class="NLM_p last">Compound <b>10p</b> was prepared according to general procedure D on a 0.68 mmol scale. Purification by column chromatography (8% MeOH/DCM) afforded the title compound (170.2 mg, 0.379 mmol, 56% yield). [M + H]<sup>+</sup>: 450.1. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.47 (s, 1H), 8.49 (s, 1H), 8.12 (d, <i>J</i> = 8.3 Hz, 2H), 7.67 (d, <i>J</i> = 2.4 Hz, 1H), 7.54 (d, <i>J</i> = 8.2 Hz, 2H), 6.62–6.59 (m, 1H), 3.35 (s, 1H), 3.22–3.18 (m, 2H), 2.72 (s, 2H), 2.41 (s, 3H), 1.95–1.89 (m, 2H), 1.71–1.64 (m, 2H).</div></div><div id="sec4_11_10_44" class="NLM_sec NLM_sec_level_2"><div id="ac_i91" class="anchor-spacer"></div><h3 class="article-section__title" id="_i91"> <i>N</i><sup>4</sup>-(5-Iodo-2-morpholinophenyl)pyrimidine-2,4-diamine (<b>20a</b>)</h3><div class="NLM_p last">Compound <b>20a</b> was prepared according to general procedure E on a 1.20 mmol scale. Purification by column chromatography (5% MeOH/DCM) afforded the title compound (293.8 mg, 0.740 mmol, 62% yield). [M + H]<sup>+</sup>: 398.0. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.27 (d, <i>J</i> = 2.1 Hz, 1H), 8.11 (s, 1H), 7.83 (d, <i>J</i> = 5.7 Hz, 1H), 7.35 (dd, <i>J</i> = 8.3, 2.1 Hz, 1H), 6.90 (d, <i>J</i> = 8.4 Hz, 1H), 6.22 (s, 2H), 6.15 (d, <i>J</i> = 5.7 Hz, 1H), 3.82–3.66 (m, 4H), 2.88–2.72 (m, 4H).</div></div><div id="sec4_11_10_45" class="NLM_sec NLM_sec_level_2"><div id="ac_i92" class="anchor-spacer"></div><h3 class="article-section__title" id="_i92"> <i>N</i>-(5-Iodo-2-morpholinophenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-4-amine (<b>20b</b>)</h3><div class="NLM_p last">Compound <b>20b</b> was prepared according to general procedure E on a 1.77 mmol scale. Purification by column chromatography (5% MeOH/DCM) afforded the title compound (399.5 mg, 0.951 mmol, 54% yield). [M + H]<sup>+</sup>: 421.1. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.41 (s, 1H), 7.99–7.87 (m, 2H), 7.54 (d, <i>J</i> = 2.0 Hz, 1H), 7.40 (dd, <i>J</i> = 8.3, 2.0 Hz, 1H), 7.22–7.20 (m, 1H), 6.90 (d, <i>J</i> = 8.4 Hz, 1H), 6.50 (d, <i>J</i> = 5.4 Hz, 1H), 6.45 (d, <i>J</i> = 3.4 Hz, 1H), 3.56 (t, <i>J</i> = 4.4 Hz, 4H), 2.85 (t, <i>J</i> = 4.5 Hz, 4H).</div></div><div id="sec4_11_10_46" class="NLM_sec NLM_sec_level_2"><div id="ac_i93" class="anchor-spacer"></div><h3 class="article-section__title" id="_i93"> 5-Fluoro-<i>N</i>-(5-iodo-2-morpholinophenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-4-amine (<b>20c</b>)</h3><div class="NLM_p last">Compound <b>20c</b> was prepared according to general procedure E on a 1.28 mmol scale. Purification by column chromatography (5% MeOH/DCM) afforded the title compound (306.2 mg, 0.699 mmol, 55% yield). [M + H]<sup>+</sup>: 439.0. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.48 (s, 1H), 8.05 (d, <i>J</i> = 4.3 Hz, 1H), 7.95 (d, <i>J</i> = 1.7 Hz, 1H), 7.37 (dd, <i>J</i> = 8.3, 2.1 Hz, 1H), 7.32–7.20 (m, 2H), 6.85 (d, <i>J</i> = 8.4 Hz, 1H), 5.93–5.91 (m, 1H), 3.30 (t, <i>J</i> = 4.3 Hz, 4H), 2.79 (t, <i>J</i> = 4.5 Hz, 4H).</div></div><div id="sec4_11_10_47" class="NLM_sec NLM_sec_level_2"><div id="ac_i94" class="anchor-spacer"></div><h3 class="article-section__title" id="_i94"> 5-Chloro-<i>N</i>-(5-iodo-2-morpholinophenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-4-amine (<b>20d</b>)</h3><div class="NLM_p last">Compound <b>20d</b> was prepared according to general procedure E on a 0.79 mmol scale. Purification by column chromatography (5% MeOH/DCM) afforded the title compound (195.2 mg, 0.43 mmol, 54% yield). [M + H]<sup>+</sup>: 455.0. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.56 (s, 1H), 8.07 (s, 1H), 7.83 (s, 1H), 7.43 (dd, <i>J</i> = 8.3, 2.1 Hz, 1H), 7.39 (d, <i>J</i> = 2.1 Hz, 1H), 7.18 (t, <i>J</i> = 3.0 Hz, 1H), 6.86 (d, <i>J</i> = 8.3 Hz, 1H), 5.53 (dd, <i>J</i> = 3.5, 2.0 Hz, 1H), 3.27 (t, <i>J</i> = 4.5 Hz, 4H), 2.77 (t, <i>J</i> = 4.5 Hz, 4H).</div></div><div id="sec4_11_10_48" class="NLM_sec NLM_sec_level_2"><div id="ac_i95" class="anchor-spacer"></div><h3 class="article-section__title" id="_i95"> <i>N</i>-(5-Iodo-2-morpholinophenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine (<b>20e</b>)</h3><div class="NLM_p last">Compound <b>20e</b> was prepared according to general procedure E on a 1.18 mmol scale. Purification by column chromatography (6% MeOH/DCM) afforded the title compound (227 mg, 0.538 mmol, 46% yield). [M + H]<sup>+</sup>: 423.0. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.62 (s, 1H), 9.35 (s, 1H), 8.36 (s, 1H), 8.20 (s, 1H), 8.02–7.99 (m, 1H), 7.54 (dd, <i>J</i> = 8.4, 2.1 Hz, 1H), 6.98 (d, <i>J</i> = 8.4 Hz, 1H), 3.67–3.50 (m, 4H), 2.83 (t, <i>J</i> = 4.5 Hz, 4H).</div></div><div id="sec4_11_10_49" class="NLM_sec NLM_sec_level_2"><div id="ac_i96" class="anchor-spacer"></div><h3 class="article-section__title" id="_i96"> <i>N</i>-(5-Iodo-2-morpholinophenyl)thieno[2,3-<i>d</i>]pyrimidin-4-amine (<b>20f</b>)</h3><div class="NLM_p last">Compound <b>20f</b> was prepared according to general procedure E on a 2.0 mmol scale. Purification by column chromatography (6% MeOH/DCM) afforded the title compound (326.1 mg, 0.744 mmol, 37% yield). [M + Na]<sup>+</sup>: 461.3. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.13 (s, 1H), 8.52 (s, 1H), 8.38 (d, <i>J</i> = 2.1 Hz, 1H), 7.75 (d, <i>J</i> = 6.0 Hz, 1H), 7.68 (d, <i>J</i> = 6.1 Hz, 1H), 7.50 (dd, <i>J</i> = 8.4, 2.1 Hz, 1H), 7.02 (d, <i>J</i> = 8.4 Hz, 1H), 3.69–3.59 (m, 4H), 2.8–2.78 (m, 4H).</div></div><div id="sec4_11_10_50" class="NLM_sec NLM_sec_level_2"><div id="ac_i97" class="anchor-spacer"></div><h3 class="article-section__title" id="_i97"> 4-Iodo-<i>N</i><sup>1</sup>,<i>N</i><sup>1</sup>-dimethyl-<i>N</i><sup>2</sup>-(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)benzene-1,2-diamine (<b>11b</b>)</h3><div class="NLM_p last">Compound <b>11b</b> was prepared according to general procedure F on a 1.0 mmol scale. Purification by column chromatography (2% MeOH/DCM) afforded the title compound (299.4 mg, 0.790 mmol, 79% yield). [M + H]<sup>+</sup>: 380.0. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.81 (s, 1H), 8.58 (s, 1H), 8.41 (d, <i>J</i> = 2.1 Hz, 1H), 8.28 (s, 1H), 7.39 (dd, <i>J</i> = 8.4, 2.2 Hz, 1H), 7.26–7.24 (m, 1H), 6.96 (d, <i>J</i> = 8.4 Hz, 1H), 6.62–6.60 (m, 1H), 2.65 (s, 6H).</div></div><div id="sec4_11_10_51" class="NLM_sec NLM_sec_level_2"><div id="ac_i98" class="anchor-spacer"></div><h3 class="article-section__title" id="_i98"> 4-Iodo-<i>N</i><sup>1</sup>-(2-methoxyethyl)-<i>N</i><sup>1</sup>-methyl-<i>N</i><sup>2</sup>-(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)benzene-1,2-diamine (<b>11c</b>)</h3><div class="NLM_p last">Compound <b>11c</b> was prepared according to general procedure F on a 0.28 mmol scale. Purification by column chromatography (2% MeOH/DCM) afforded the title compound (72.8 mg, 0.172 mmol, 61% yield). [M + H]<sup>+</sup>: 424.1. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.88 (s, 1H), 8.93 (d, <i>J</i> = 2.1 Hz, 1H), 8.82 (s, 1H), 8.37 (s, 1H), 7.39–7.29 (m, 2H), 7.10 (d, <i>J</i> = 8.3 Hz, 1H), 6.54 (dd, <i>J</i> = 3.5, 1.9 Hz, 1H), 3.42 (t, <i>J</i> = 5.2 Hz, 2H), 3.19 (s, 3H), 2.94 (t, <i>J</i> = 5.3 Hz, 2H), 2.70 (s, 3H).</div></div><div id="sec4_11_10_52" class="NLM_sec NLM_sec_level_2"><div id="ac_i99" class="anchor-spacer"></div><h3 class="article-section__title" id="_i99"> <i>N</i><sup>1</sup>-(2-(Dimethylamino)ethyl)-4-iodo-<i>N</i><sup>1</sup>-methyl-<i>N</i><sup>2</sup>-(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)benzene-1,2-diamine (<b>11d</b>)</h3><div class="NLM_p last">Compound <b>11d</b> was prepared according to general procedure F on a 0.46 mmol scale. Purification by column chromatography (8% MeOH/DCM) afforded the title compound (126.0 mg, 0.289 mmol, 63% yield). [M + H]<sup>+</sup>: 437.1. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.85 (s, 1H), 9.27 (s, 1H), 8.91 (d, <i>J</i> = 2.1 Hz, 1H), 8.34 (s, 1H), 7.35 (dd, <i>J</i> = 8.3, 2.1 Hz, 1H), 7.30 (dd, <i>J</i> = 3.4, 2.4 Hz, 1H), 7.12 (d, <i>J</i> = 8.4 Hz, 1H), 6.52 (dd, <i>J</i> = 3.5, 1.8 Hz, 1H), 2.89 (t, <i>J</i> = 6.0 Hz, 2H), 2.68 (s, 3H), 2.27 (t, <i>J</i> = 6.0 Hz, 2H), 2.03 (s, 6H).</div></div><div id="sec4_11_10_53" class="NLM_sec NLM_sec_level_2"><div id="ac_i100" class="anchor-spacer"></div><h3 class="article-section__title" id="_i100"> <i>N</i>-(5-Iodo-2-(pyrrolidin-1-yl)phenyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (<b>11e</b>)</h3><div class="NLM_p last">Compound <b>11e</b> was prepared according to general procedure F on a 0.45 mmol scale. Purification by column chromatography (3% MeOH/DCM) afforded the title compound (129.3 mg, 0.32 mmol, 71% yield). [M + Na]<sup>+</sup>: 428.2. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.60 (s, 1H), 8.83 (s, 1H), 8.09 (d, <i>J</i> = 9.0 Hz, 1H), 7.54–7.35 (m, 1H), 7.29–7.02 (m, 2H), 6.88–6.73 (m, 1H), 6.27 (d, <i>J</i> = 42.9 Hz, 1H), 3.19 (d, <i>J</i> = 3.7 Hz, 4H), 1.82–1.68 (m, 4H).</div></div><div id="sec4_11_10_54" class="NLM_sec NLM_sec_level_2"><div id="ac_i101" class="anchor-spacer"></div><h3 class="article-section__title" id="_i101"> <i>N</i>-(5-Iodo-2-morpholinophenyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (<b>11f</b>)</h3><div class="NLM_p last">Compound <b>11f</b> was prepared according to general procedure F on a 0.88 mmol scale. Purification by column chromatography (2% MeOH/DCM) afforded the title compound (234.9 mg, 0.558 mmol, 62% yield). [M + H]<sup>+</sup>: 422.0. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.88 (s, 1H), 8.73 (d, <i>J</i> = 2.0 Hz, 1H), 8.56 (s, 1H), 8.33 (s, 1H), 7.40 (dd, <i>J</i> = 8.3, 2.1 Hz, 1H), 7.33–7.28 (m, 1H), 7.03 (d, <i>J</i> = 8.3 Hz, 1H), 6.60–6.58 (m, 1H), 3.79–3.69 (m, 4H), 2.88–2.79 (m, 4H).</div></div><div id="sec4_11_10_55" class="NLM_sec NLM_sec_level_2"><div id="ac_i102" class="anchor-spacer"></div><h3 class="article-section__title" id="_i102"> <i>N</i>-(5-Iodo-2-(piperazin-1-yl)phenyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (<b>11g</b>)</h3><div class="NLM_p last">Compound <b>11g</b> was prepared according to general procedure F on a 3.55 mmol scale. Purification by column chromatography (2% MeOH/DCM) afforded the title compound (1.1 g, 2.62 mmol, 74% yield). [M + Na]<sup>+</sup>: 443.3. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.91 (s, 1H), 8.75 (d, <i>J</i> = 2.1 Hz, 1H), 8.52 (s, 1H), 8.34 (s, 1H), 7.39 (dd, <i>J</i> = 8.3, 2.1 Hz, 1H), 7.33–7.31 (m, 1H), 7.00 (d, <i>J</i> = 8.3 Hz, 1H), 6.60–6.58 (m, 1H), 5.28 (s, 1H), 3.05–2.92 (m, 4H), 2.90–2.76 (m, 4H).</div></div><div id="sec4_11_10_56" class="NLM_sec NLM_sec_level_2"><div id="ac_i103" class="anchor-spacer"></div><h3 class="article-section__title" id="_i103"> (<i>R</i>)-<i>N</i>-(5-Iodo-2-(3-methylpiperazin-1-yl)phenyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (<b>11h</b>)</h3><div class="NLM_p last">Compound <b>11h</b> was prepared according to general procedure F on a 0.88 mmol scale. Purification by column chromatography (2% MeOH/DCM) afforded the title compound (247.6 mg, 0.57 mmol, 65% yield). [M + H]<sup>+</sup>: 435.3. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.91 (s, 1H), 8.73 (d, <i>J</i> = 2.0 Hz, 1H), 8.53 (s, 1H), 8.34 (s, 1H), 7.41 (dd, <i>J</i> = 8.3, 2.1 Hz, 1H), 7.32 (dd, <i>J</i> = 3.5, 2.1 Hz, 1H), 7.00 (d, <i>J</i> = 8.4 Hz, 1H), 6.61 (dd, <i>J</i> = 3.5, 1.6 Hz, 1H), 3.25–3.16 (m, 2H), 3.07 (dd, <i>J</i> = 11.2, 3.1 Hz, 1H), 3.02–2.97 (m, 2H), 2.83–2.76 (m, 1H), 2.61–2.56 (m, 1H), 1.91 (s, 1H), 1.10 (d, <i>J</i> = 6.5 Hz, 3H).</div></div><div id="sec4_11_10_57" class="NLM_sec NLM_sec_level_2"><div id="ac_i104" class="anchor-spacer"></div><h3 class="article-section__title" id="_i104"> (<i>S</i>)-<i>N</i>-(5-Iodo-2-(3-methylpiperazin-1-yl)phenyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (<b>11i</b>)</h3><div class="NLM_p last">Compound <b>11i</b> was prepared according to general procedure F on a 0.94 mmol scale. Purification by column chromatography (2% MeOH/DCM) afforded the title compound (312.7 mg, 0.72 mmol, 76% yield). [M + H]<sup>+</sup>: 435.3. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.91 (s, 1H), 8.74 (d, <i>J</i> = 2.1 Hz, 1H), 8.53 (s, 1H), 8.34 (s, 1H), 7.40 (dd, <i>J</i> = 8.3, 2.1 Hz, 1H), 7.31 (dd, <i>J</i> = 3.5, 2.0 Hz, 1H), 7.00 (d, <i>J</i> = 8.3 Hz, 1H), 6.59 (dd, <i>J</i> = 3.5, 1.5 Hz, 1H), 3.22–3.09 (m, 2H), 3.07–2.90 (m, 3H), 2.82–2.76 (m, 1H), 2.55 (s, 1H), 1.91 (s, 1H), 1.08 (d, <i>J</i> = 6.3 Hz, 3H).</div></div><div id="sec4_11_10_58" class="NLM_sec NLM_sec_level_2"><div id="ac_i105" class="anchor-spacer"></div><h3 class="article-section__title" id="_i105"> <i>N</i>-(2-(2,5-Diazabicyclo[2.2.1]heptan-2-yl)-5-iodophenyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (<b>11j</b>)</h3><div class="NLM_p last">Compound <b>11j</b> was prepared according to general procedure F on a 1.43 mmol scale. Purification by column chromatography (2% MeOH/DCM) afforded the title compound (436.6 mg, 1.01 mmol, 71% yield). [M + H]<sup>+</sup>: 433.3. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.63 (s, 1H), 8.77 (s, 1H), 8.11 (s, 1H), 7.54 (d, <i>J</i> = 2.2 Hz, 1H), 7.37 (dd, <i>J</i> = 8.7, 2.2 Hz, 1H), 7.11 (dd, <i>J</i> = 3.5, 1.8 Hz, 1H), 6.65 (d, <i>J</i> = 8.7 Hz, 1H), 6.42 (s, 1H), 4.21 (s, 1H), 3.58–3.49 (m, 2H), 3.17 (s, 1H), 3.01 (d, <i>J</i> = 10.0 Hz, 1H), 2.87–2.76 (m, 2H), 1.69 (d, <i>J</i> = 9.0 Hz, 1H), 1.59 (d, <i>J</i> = 9.8 Hz, 1H).</div></div><div id="sec4_11_10_59" class="NLM_sec NLM_sec_level_2"><div id="ac_i106" class="anchor-spacer"></div><h3 class="article-section__title" id="_i106"> <i>N</i>-(5-Iodo-2-(4-methylpiperazin-1-yl)phenyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (<b>11k</b>)</h3><div class="NLM_p last">Compound <b>11k</b> was prepared according to general procedure F on a 1.59 mmol scale. Purification by column chromatography (2% MeOH/DCM) afforded the title compound (419.5 mg, 0.966 mmol, 61% yield). [M + H]<sup>+</sup>: 435.1. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.91 (s, 1H), 8.79 (d, <i>J</i> = 2.1 Hz, 1H), 8.48 (s, 1H), 8.35 (s, 1H), 7.41–7.30 (m, 2H), 7.02 (d, <i>J</i> = 8.3 Hz, 1H), 6.52 (dd, <i>J</i> = 3.5, 1.8 Hz, 1H), 3.30 (s, 4H), 2.84 (t, <i>J</i> = 4.7 Hz, 4H), 2.24 (s, 3H).</div></div><div id="sec4_11_10_60" class="NLM_sec NLM_sec_level_2"><div id="ac_i107" class="anchor-spacer"></div><h3 class="article-section__title" id="_i107"> <i>N</i>-(2-(4-Ethylpiperazin-1-yl)-5-iodophenyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (<b>11l</b>)</h3><div class="NLM_p last">Compound <b>11l</b> was prepared according to general procedure F on a 0.44 mmol scale. Purification by column chromatography (2% MeOH/DCM) afforded the title compound (109.6 mg, 0.245 mmol, 56% yield). [M + H]<sup>+</sup>: 449.1. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.91 (s, 1H), 8.79 (d, <i>J</i> = 2.0 Hz, 1H), 8.50 (s, 1H), 8.35 (s, 1H), 7.38 (dd, <i>J</i> = 8.3, 2.1 Hz, 1H), 7.33 (dd, <i>J</i> = 3.5, 2.3 Hz, 1H), 7.03 (d, <i>J</i> = 8.4 Hz, 1H), 6.51 (dd, <i>J</i> = 3.5, 1.8 Hz, 1H), 2.85 (t, <i>J</i> = 4.7 Hz, 4H), 2.54 (d, <i>J</i> = 5.0 Hz, 4H), 2.45–2.34 (m, 2H), 1.02 (t, <i>J</i> = 7.1 Hz, 3H).</div></div><div id="sec4_11_10_61" class="NLM_sec NLM_sec_level_2"><div id="ac_i108" class="anchor-spacer"></div><h3 class="article-section__title" id="_i108"> <i>N</i>-(5-Iodo-2-(4-morpholinopiperidin-1-yl)phenyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (<b>11m</b>)</h3><div class="NLM_p last">Compound <b>11m</b> was prepared according to general procedure F on a 0.60 mmol scale. Purification by column chromatography (2% MeOH/DCM) afforded the title compound (180.4 mg, 0.357 mmol, 60% yield). [M + H]<sup>+</sup>: 505.1. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.90 (s, 1H), 8.72 (d, <i>J</i> = 2.1 Hz, 1H), 8.46 (s, 1H), 8.35 (s, 1H), 7.41–7.30 (m, 2H), 6.99 (d, <i>J</i> = 8.3 Hz, 1H), 6.53 (d, <i>J</i> = 3.4 Hz, 1H), 3.59 (s, 4H), 3.29 (s, 4H), 3.11–3.02 (m, 2H), 2.65 (t, <i>J</i> = 11.4 Hz, 2H), 2.27–2.21 (m, 1H), 1.90–1.85 (m, 2H), 1.62–1.50 (m, 2H).</div></div><div id="sec4_11_10_62" class="NLM_sec NLM_sec_level_2"><div id="ac_i109" class="anchor-spacer"></div><h3 class="article-section__title" id="_i109"> 6-Morpholino-<i>N</i><sup>1</sup>-(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)benzene-1,3-diamine (<b>13</b>)</h3><div class="NLM_p last">Compound <b>13</b> was prepared according to general procedure F on a 2.0 mmol scale. Purification by column chromatography (2% MeOH/DCM) afforded the title compound (452.9 mg, 1.460 mmol, 73% yield). [M + H]<sup>+</sup>: 311.2. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.83 (s, 1H), 8.66 (s, 1H), 8.30 (s, 1H), 7.82 (d, <i>J</i> = 2.5 Hz, 1H), 7.28 (t, <i>J</i> = 2.9 Hz, 1H), 6.96 (d, <i>J</i> = 8.4 Hz, 1H), 6.52–6.50 (m, 1H), 6.25 (dd, <i>J</i> = 8.4, 2.6 Hz, 1H), 4.98 (s, 2H), 3.75 (t, <i>J</i> = 4.3 Hz, 4H), 2.73 (t, <i>J</i> = 4.5 Hz, 4H).</div></div><div id="sec4_11_10_63" class="NLM_sec NLM_sec_level_2"><div id="ac_i110" class="anchor-spacer"></div><h3 class="article-section__title" id="_i110"> <i>N</i>-(3-((7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)-4-morpholinophenyl)cyclopentanecarboxamide (<b>14a</b>)</h3><div class="NLM_p last">Compound <b>14a</b> was prepared according to general procedure G on a 0.25 mmol scale. Purification by column chromatography (4% MeOH/DCM) afforded the title compound (48.7 mg, 0.14 mmol, 28% yield). White solid; mp 284–287 °C. HPLC analysis: retention time, 4.318 min; peak area, 96.80%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.84 (s, 1H), 9.87 (s, 1H), 8.61 (s, 1H), 8.39 (s, 1H), 8.29 (s, 1H), 7.50 (dd, <i>J</i> = 8.6, 2.4 Hz, 1H), 7.28 (t, <i>J</i> = 2.8 Hz, 1H), 7.14 (d, <i>J</i> = 8.7 Hz, 1H), 6.54 (d, <i>J</i> = 3.3 Hz, 1H), 3.71 (d, <i>J</i> = 4.8 Hz, 4H), 2.82–2.78 (m, 4H), 1.88–1.79 (m, 2H), 1.77–1.60 (m, 5H), 1.55 (s, 2H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 174.63, 153.79, 151.40, 151.26, 138.67, 136.39, 134.34, 123.25, 120.65, 114.71, 113.38, 104.17, 98.02, 67.22, 52.46, 45.62, 30.59, 26.21; HRMSEI <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>22</sub>H<sub>26</sub>N<sub>6</sub>O<sub>2</sub>, 407.2194; found, 407.2189.</div></div><div id="sec4_11_10_64" class="NLM_sec NLM_sec_level_2"><div id="ac_i111" class="anchor-spacer"></div><h3 class="article-section__title" id="_i111"> 1-(3-((7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)-4-morpholinophenyl)-3-cyclopentylurea (<b>14b</b>)</h3><div class="NLM_p last">Compound <b>14b</b> was prepared according to general procedure G on a 0.5 mmol scale. Purification by column chromatography (4% MeOH/DCM) afforded the title compound (109.5 mg, 0.26 mmol, 52% yield). White solid; mp 252–254 °C. HPLC analysis: retention time, 4.183 min; peak area, 95.48%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.87 (d, <i>J</i> = 7.5 Hz, 1H), 8.63 (d, <i>J</i> = 7.0 Hz, 1H), 8.26 (d, <i>J</i> = 18.5 Hz, 3H), 7.30 (s, 2H), 7.13 (d, <i>J</i> = 11.1 Hz, 1H), 6.56 (d, <i>J</i> = 6.9 Hz, 1H), 6.10 (s, 1H), 4.00–3.85 (m, 1H), 3.74 (s, 4H), 2.78 (s, 4H), 1.82 (s, 2H), 1.58 (d, <i>J</i> = 23.5 Hz, 4H), 1.35 (s, 2H); <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 155.33, 153.73, 151.36, 151.26, 137.73, 136.57, 134.78, 123.33, 121.09, 112.70, 110.99, 104.27, 97.83, 67.38, 52.75, 51.32, 33.39, 23.61; HRMSEI <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>22</sub>H<sub>27</sub>N<sub>7</sub>O<sub>2</sub>, 422.2290; found, 422.2298.</div></div><div id="sec4_11_10_65" class="NLM_sec NLM_sec_level_2"><div id="ac_i112" class="anchor-spacer"></div><h3 class="article-section__title" id="_i112"> <i>N</i>-(3-((7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)-4-morpholinophenyl)-2-hydroxy-2-(thiazol-2-yl)propanamide (<b>14c</b>)</h3><div class="NLM_p last">Compound <b>14c</b> was prepared according to general procedure G on a 0.5 mmol scale. Purification by column chromatography (4% MeOH/DCM) afforded the title compound (79.1 mg, 0.17 mmol, 34% yield). White solid; mp 292–295 °C. HPLC analysis: retention time, 3.188 min; peak area, 95.05%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.80 (s, 1H), 9.77 (s, 1H), 8.60 (s, 1H), 8.53 (d, <i>J</i> = 2.2 Hz, 1H), 8.28 (s, 1H), 7.77 (d, <i>J</i> = 3.2 Hz, 1H), 7.70 (d, <i>J</i> = 3.2 Hz, 1H), 7.45 (dd, <i>J</i> = 8.6, 2.2 Hz, 1H), 7.27–7.24 (m, 1H), 7.15 (d, <i>J</i> = 9.2 Hz, 2H), 6.53 (s, 1H), 3.70 (s, 4H), 2.80 (s, 4H), 1.83 (s, 3H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 174.62, 170.71, 153.89, 151.42, 151.27, 142.63, 139.85, 134.94, 134.17, 123.16, 121.26, 120.47, 115.81, 114.99, 104.13, 98.13, 76.99, 67.14, 52.29, 40.45, 27.04; HRMSEI <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>22</sub>H<sub>23</sub>N<sub>7</sub>O<sub>3</sub>S, 466.1647; found, 466.1654.</div></div><div id="sec4_11_10_66" class="NLM_sec NLM_sec_level_2"><div id="ac_i113" class="anchor-spacer"></div><h3 class="article-section__title" id="_i113"> 1-(4-(2-((7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)-4-iodophenyl)piperazin-1-yl)ethan-1-one (<b>15a</b>)</h3><div class="NLM_p last">Compound <b>15a</b> was prepared according to general procedure G on a 0.4 mmol scale. Purification by column chromatography (5% MeOH/DCM) afforded the title compound (129.8 mg, 0.281 mmol, 70% yield). [M + H]<sup>+</sup>: 463.1. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.89 (s, 1H), 8.76 (d, <i>J</i> = 2.1 Hz, 1H), 8.57 (s, 1H), 8.35 (s, 1H), 7.39 (dd, <i>J</i> = 8.3, 2.1 Hz, 1H), 7.31–7.29 (m, 1H), 7.00 (d, <i>J</i> = 8.3 Hz, 1H), 6.64–6.63 (m, 1H), 3.59 (q, <i>J</i> = 5.3 Hz, 4H), 2.84–2.81 (m, 4H), 2.03 (s, 3H).</div></div><div id="sec4_11_10_67" class="NLM_sec NLM_sec_level_2"><div id="ac_i114" class="anchor-spacer"></div><h3 class="article-section__title" id="_i114"> <i>N</i>-(2-(4-(Ethylsulfonyl)piperazin-1-yl)-5-iodophenyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (<b>15b</b>)</h3><div class="NLM_p last">Compound <b>15b</b> was prepared according to general procedure G on a 0.4 mmol scale. Purification by column chromatography (5% MeOH/DCM) afforded the title compound (160.3 mg, 0.312 mmol, 78% yield). [M + H]<sup>+</sup>: 513.1. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.91 (s, 1H), 8.79–8.69 (m, 1H), 8.50 (s, 1H), 8.34 (s, 1H), 7.41 (dd, <i>J</i> = 8.3, 2.0 Hz, 1H), 7.34–7.27 (m, 1H), 7.05 (d, <i>J</i> = 8.4 Hz, 1H), 6.70–6.59 (m, 1H), 3.33 (s, 4H), 3.13 (q, <i>J</i> = 7.3 Hz, 2H), 2.98–2.80 (m, 4H), 1.25 (t, <i>J</i> = 7.3 Hz, 3H).</div></div><div id="sec4_11_10_68" class="NLM_sec NLM_sec_level_2"><div id="ac_i115" class="anchor-spacer"></div><h3 class="article-section__title" id="_i115"> <i>N</i>-(2-(4-(Cyclopropylsulfonyl)piperazin-1-yl)-5-iodophenyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (<b>15c</b>)</h3><div class="NLM_p last">Compound <b>15c</b> was prepared according to general procedure G on a 0.4 mmol scale. Purification by column chromatography (5% MeOH/DCM) afforded the title compound (143.9 mg, 0.275 mmol, 69% yield). [M + H]<sup>+</sup>: 525.0. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.88 (s, 1H), 8.67 (d, <i>J</i> = 2.1 Hz, 1H), 8.57 (s, 1H), 8.34 (s, 1H), 7.42 (dd, <i>J</i> = 8.3, 2.1 Hz, 1H), 7.34–7.28 (m, 1H), 7.05 (d, <i>J</i> = 8.3 Hz, 1H), 6.59–6.58 (m, 1H), 3.37–3.34 (m, 4H) 2.95–2.92 (m, 4H), 2.68–2.62 (m, 1H), 1.07–1.00 (m, 2H), 0.99–0.94 (m, 2H).</div></div><div id="sec4_11_10_69" class="NLM_sec NLM_sec_level_2"><div id="ac_i116" class="anchor-spacer"></div><h3 class="article-section__title" id="_i116"> 4-(3-((7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)phenyl)-2-(thiazol-2-yl)but-3-yn-2-ol (<b>12a</b>)</h3><div class="NLM_p last">Compound <b>12a</b> was prepared according to general procedure H on a 0.4 mmol scale. Purification by column chromatography (2% MeOH/DCM) afforded the title compound (121.1 mg, 0.335 mmol, 84% yield). White solid; mp 121–123 °C. HPLC analysis: retention time, 3.560 min; peak area, 97.99%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.82 (s, 1H), 9.36 (s, 1H), 8.33 (s, 1H), 8.08–8.06 (m, 1H), 7.96 (d, <i>J</i> = 8.6, 1H), 7.79 (d, <i>J</i> = 3.2 Hz, 1H), 7.70 (d, <i>J</i> = 3.3 Hz, 1H), 7.35 (t, <i>J</i> = 7.9 Hz, 1H), 7.27 (t, <i>J</i> = 2.8 Hz, 1H), 7.11–7.00 (m, 2H), 6.81–6.80 (m, 1H), 1.89 (s, 3H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 176.48, 153.70, 151.35, 151.14, 143.03, 141.23, 129.45, 125.09, 122.96, 122.73, 122.28, 120.92, 120.74, 104.33, 99.14, 92.50, 83.70, 68.37, 31.99; HRMSEI <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>19</sub>H<sub>15</sub>N<sub>5</sub>OS, 362.1071; found, 362.1068.</div></div><div id="sec4_11_10_70" class="NLM_sec NLM_sec_level_2"><div id="ac_i117" class="anchor-spacer"></div><h3 class="article-section__title" id="_i117"> 4-(3-((7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)-4-(dimethylamino)phenyl)-2-(thiazol-2-yl)but-3-yn-2-ol (<b>12b</b>)</h3><div class="NLM_p last">Compound <b>12b</b> was prepared according to general procedure H on a 0.4 mmol scale. Purification by column chromatography (2% MeOH/DCM) afforded the title compound (86.9 mg, 0.215 mmol, 54% yield). White solid; mp 129–131 °C. HPLC analysis: retention time, 4.135 min; peak area, 95.62%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.77 (s, 1H), 8.59 (s, 1H), 8.24 (s, 1H), 7.93 (d, <i>J</i> = 1.9 Hz, 1H), 7.77 (d, <i>J</i> = 3.2 Hz, 1H), 7.68 (d, <i>J</i> = 3.2 Hz, 1H), 7.22–7.20 (m, 1H), 7.13 (d, <i>J</i> = 2.0 Hz, 1H), 7.09 (d, <i>J</i> = 8.4 Hz, 1H), 7.01 (s, 1H), 2.68 (s, 6H), 1.86 (s, 3H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 176.63, 154.27, 151.51, 151.40, 147.18, 142.98, 132.30, 127.94, 127.90, 122.81, 120.85, 119.26, 115.31, 103.95, 98.78, 91.72, 83.79, 68.36, 43.41, 32.05; HRMSEI <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>21</sub>H<sub>20</sub>N<sub>6</sub>OS, 405.1493; found, 405.1488.</div></div><div id="sec4_11_10_71" class="NLM_sec NLM_sec_level_2"><div id="ac_i118" class="anchor-spacer"></div><h3 class="article-section__title" id="_i118"> 4-(3-((7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)-4-((2-methoxyethyl)(methyl)amino)phenyl)-2-(thiazol-2-yl)but-3-yn-2-ol (<b>12c</b>)</h3><div class="NLM_p last">Compound <b>12c</b> was prepared according to general procedure H on a 0.13 mmol scale. Purification by column chromatography (2% MeOH/DCM) afforded the title compound (36.0 mg, 0.08 mmol, 62% yield). White solid; mp 112–115 °C. HPLC analysis: retention time, 4.409 min; peak area, 96.82%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.82 (s, 1H), 8.76 (s, 1H), 8.45–8.44 (m, 1H), 8.35 (d, <i>J</i> = 1.0 Hz, 1H), 7.78 (d, <i>J</i> = 3.2 Hz, 1H), 7.68 (d, <i>J</i> = 3.2 Hz, 1H), 7.29–7.28 (m, 1H), 7.24 (d, <i>J</i> = 8.3 Hz, 1H), 7.09 (dd, <i>J</i> = 8.2, 2.0 Hz, 1H), 7.00 (s, 1H), 6.54–6.52 (m, 1H), 3.43 (t, <i>J</i> = 5.3 Hz, 2H), 3.18 (s, 3H), 2.98 (t, <i>J</i> = 5.3 Hz, 2H), 2.73 (s, 3H), 1.89 (s, 3H); <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ 176.59, 153.68, 151.38, 151.35, 144.43, 143.01, 134.55, 126.49, 124.13, 123.19, 121.64, 120.89, 117.13, 104.39, 98.30, 91.86, 83.90, 69.85, 68.37, 58.48, 56.52, 41.07, 32.04; HRMSEI <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>23</sub>H<sub>24</sub>N<sub>6</sub>O<sub>2</sub>S, 449.1745; found, 449.1752.</div></div><div id="sec4_11_10_72" class="NLM_sec NLM_sec_level_2"><div id="ac_i119" class="anchor-spacer"></div><h3 class="article-section__title" id="_i119"> 4-(3-((7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)-4-((2(dimethylamino)ethyl)(methyl)amino)phenyl)-2-(thiazol-2-yl)but-3-yn-2-ol (<b>12d</b>)</h3><div class="NLM_p last">Compound <b>12d</b> was prepared according to general procedure H on a 0.16 mmol scale. Purification by column chromatography (8% MeOH/DCM) afforded the title compound (53.1 mg, 0.115 mmol, 72% yield). White solid; mp 109–112 °C. HPLC analysis: retention time, 4.078 min; peak area, 96.14%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.80 (s, 1H), 9.12 (s, 1H), 8.41 (d, <i>J</i> = 2.0 Hz, 1H), 8.33 (s, 1H), 7.78 (d, <i>J</i> = 3.3 Hz, 1H), 7.68 (d, <i>J</i> = 3.2 Hz, 1H), 7.30–7.22 (m, 2H), 7.10 (dd, <i>J</i> = 8.2, 2.0 Hz, 1H), 7.01 (s, 1H), 6.53 (d, 1H), 2.93 (t, <i>J</i> = 6.2 Hz, 2H), 2.70 (s, 3H), 2.31 (t, <i>J</i> = 6.2 Hz, 2H), 2.03 (s, 6H), 1.89 (s, 3H); <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ 176.58, 153.86, 151.41, 151.33, 144.72, 143.00, 135.24, 126.63, 124.68, 123.05, 122.05, 120.89, 117.27, 104.36, 98.38, 91.89, 83.89, 68.37, 57.21, 54.91, 45.57, 42.08, 32.03. HRMSEI <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>24</sub>H<sub>27</sub>N<sub>7</sub>OS, 462.2061; found, 462.2069.</div></div><div id="sec4_11_10_73" class="NLM_sec NLM_sec_level_2"><div id="ac_i120" class="anchor-spacer"></div><h3 class="article-section__title" id="_i120"> 4-(3-((7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)-4-(pyrrolidin-1-yl)phenyl)-2-(thiazol-2-yl)but-3-yn-2-ol (<b>12e</b>)</h3><div class="NLM_p last">Compound <b>12e</b> was prepared according to general procedure H on a 0.16 mmol scale. Purification by column chromatography (2% MeOH/DCM) afforded the title compound (62.3 mg, 0.144 mmol, 90% yield). White solid; mp 143–147 °C. HPLC analysis: retention time, 3.286 min; peak area, 95.11%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.61 (s, 1H), 8.86 (s, 1H), 8.11 (s, 1H), 7.76 (d, <i>J</i> = 3.2 Hz, 1H), 7.66 (d, <i>J</i> = 3.2 Hz, 1H), 7.21 (d, <i>J</i> = 2.0 Hz, 1H), 7.18 (dd, <i>J</i> = 8.5, 2.0 Hz, 1H), 7.11–7.07 (m, 1H), 6.90 (s, 1H), 6.77 (d, <i>J</i> = 8.6 Hz, 1H), 6.28 (s, 1H), 3.28 (t, <i>J</i> = 6.3 Hz, 4H), 1.85 (s, 3H), 1.78 (t, <i>J</i> = 6.4 Hz, 4H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 176.85, 156.05, 151.81, 151.39, 147.04, 142.92, 134.41, 130.43, 125.43, 121.95, 120.76, 115.37, 109.89, 103.19, 99.40, 68.34, 50.05, 32.06, 25.52; HRMSEI <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>23</sub>H<sub>22</sub>N<sub>6</sub>OS, 431.1639; found, 431.1646.</div></div><div id="sec4_11_10_74" class="NLM_sec NLM_sec_level_2"><div id="ac_i121" class="anchor-spacer"></div><h3 class="article-section__title" id="_i121"> 4-(3-((7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)-4-morpholinophenyl)-2-(thiazol-2-yl)but-3-yn-2-ol (<b>12f</b>)</h3><div class="NLM_p last">Compound <b>12f</b> was prepared according to general procedure H on a 0.4 mmol scale. Purification by column chromatography (2% MeOH/DCM) afforded the title compound (137.1 mg, 0.307 mmol, 77% yield). White solid; mp 207–210 °C. HPLC analysis: retention time, 3.220 min; peak area, 98.59%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.83 (s, 1H), 8.53 (s, 1H), 8.33–8.32 (m, 1H), 8.31–8.27 (m, 1H), 7.78 (d, <i>J</i> = 3.2 Hz, 1H), 7.68 (d, <i>J</i> = 3.3 Hz, 1H), 7.29–7.27 (m, 1H), 7.21–7.11 (m, 2H), 7.01 (s, 1H), 6.59–6.57 (m, 1H), 3.82–3.63 (m, 4H), 2.96–2.78 (m, 4H), 1.89 (s, 3H); <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ 176.56, 153.62, 151.41, 151.37, 144.29, 143.01, 133.89, 127.18, 125.42, 123.40, 120.90, 120.67, 117.32, 104.21, 98.18, 92.09, 83.69, 68.38, 66.91, 51.75, 32.04; HRMSEI <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>23</sub>H<sub>22</sub>N<sub>6</sub>O<sub>2</sub>S, 447.1598; found, 447.1604.</div></div><div id="sec4_11_10_75" class="NLM_sec NLM_sec_level_2"><div id="ac_i122" class="anchor-spacer"></div><h3 class="article-section__title" id="_i122"> 4-(3-((7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)-4-(piperazin-1-yl)phenyl)-2-(thiazol-2-yl)but-3-yn-2-ol (<b>12g</b>)</h3><div class="NLM_p last">Compound <b>12g</b> was prepared according to general procedure H on a 0.4 mmol scale. Purification by column chromatography (9% MeOH/DCM) afforded the title compound (138.6 mg, 0.311 mmol, 78% yield). White solid; mp 223–226 °C. HPLC analysis: retention time, 3.385 min; peak area, 96.89%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.89 (s, 1H), 8.49 (s, 1H), 8.41–8.28 (m, 2H), 7.78 (d, <i>J</i> = 3.2 Hz, 1H), 7.69 (d, <i>J</i> = 3.3 Hz, 1H), 7.30–7.29 (m, 1H), 7.19–7.10 (m, 2H), 7.04 (s, 1H), 6.55–6.54 (m, 1H), 2.90–2.83 (m, 4H), 2.79–2.75 (m, 4H), 1.87 (s, 3H); <sup>13</sup>C NMR (75 MHz, DMSO-d6)δ 176.59, 153.48, 151.46, 151.30, 144.64, 143.02, 133.96, 126.90, 124.50, 123.51, 120.90, 120.67, 117.14, 104.20, 97.83, 91.97, 83.81, 68.38, 52.77, 46.50, 32.06. HRMSEI <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>23</sub>H<sub>23</sub>N<sub>7</sub>OS, 446.1748; found, 446.1757.</div></div><div id="sec4_11_10_76" class="NLM_sec NLM_sec_level_2"><div id="ac_i123" class="anchor-spacer"></div><h3 class="article-section__title" id="_i123"> 4-(3-((7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)-4-((<i>R</i>)-3-methylpiperazin-1-yl)phenyl)-2-(thiazol-2-yl)but-3-yn-2-ol (<b>12h</b>)</h3><div class="NLM_p last">Compound <b>12h</b> was prepared according to general procedure H on a 0.25 mmol scale. Purification by column chromatography (9% MeOH/DCM) afforded the title compound (57.7 mg, 0.126 mmol, 50% yield). White solid; mp 130–132 °C. HPLC analysis: retention time, 3.522 min; peak area, 97.79%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.90 (s, 1H), 8.49 (s, 1H), 8.36 (d, <i>J</i> = 13.1 Hz, 2H), 7.78 (d, <i>J</i> = 3.3 Hz, 1H), 7.69 (d, <i>J</i> = 3.3 Hz, 1H), 7.30 (d, <i>J</i> = 3.5 Hz, 1H), 7.22–6.99 (m, 3H), 6.51 (d, <i>J</i> = 3.5 Hz, 1H), 2.87 (d, <i>J</i> = 8.9 Hz, 5H), 2.62 (d, <i>J</i> = 8.2 Hz, 1H), 2.30 (t, <i>J</i> = 10.5 Hz, 1H), 2.18 (s, 1H), 1.88 (s, 3H), 0.93 (d, <i>J</i> = 6.1 Hz, 3H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 176.58, 153.46, 151.44, 151.26, 144.32, 143.00, 133.99, 126.86, 124.33, 123.52, 120.89, 120.76, 117.14, 104.19, 97.73, 91.94, 83.81, 68.37, 59.16, 52.05, 51.19, 46.26, 32.05, 19.75. HRMSEI <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>24</sub>H<sub>25</sub>N<sub>7</sub>OS, 460.1909; found, 460.1916.</div></div><div id="sec4_11_10_77" class="NLM_sec NLM_sec_level_2"><div id="ac_i124" class="anchor-spacer"></div><h3 class="article-section__title" id="_i124"> 4-(3-((7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)-4-((S)-3-methylpiperazin-1-yl)phenyl)-2-(thiazol-2-yl)but-3-yn-2-ol (<b>12i</b>)</h3><div class="NLM_p last">Compound <b>12i</b> was prepared according to general procedure H on a 0.23 mmol scale. Purification by column chromatography (9% MeOH/DCM) afforded the title compound (61.4 mg, 0.134 mmol, 58% yield). White solid; mp 130–133 °C. HPLC analysis: retention time, 3.529 min; peak area, 97.54%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.89 (s, 1H), 8.49 (s, 1H), 8.41–8.31 (m, 2H), 7.78 (d, <i>J</i> = 3.3 Hz, 1H), 7.69 (d, <i>J</i> = 3.3 Hz, 1H), 7.30 (d, <i>J</i> = 3.5 Hz, 1H), 7.18–7.01 (m, 3H), 6.51 (d, <i>J</i> = 3.5 Hz, 1H), 2.95–2.82 (m, 5H), 2.63–2.58 (m, 1H), 2.30 (t, <i>J</i> = 10.8 Hz, 1H), 2.19 (s, 1H), 1.88 (s, 3H), 0.93 (d, <i>J</i> = 6.1 Hz, 3H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 176.57, 153.47, 151.45, 151.27, 144.32, 143.01, 133.98, 126.89, 124.40, 123.51, 120.89, 120.77, 117.15, 104.19, 97.76, 91.95, 83.80, 68.37, 59.05, 51.96, 51.19, 46.19, 32.05, 19.66. HRMSEI <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>24</sub>H<sub>25</sub>N<sub>7</sub>OS, 460.1909; found, 460.1917.</div></div><div id="sec4_11_10_78" class="NLM_sec NLM_sec_level_2"><div id="ac_i125" class="anchor-spacer"></div><h3 class="article-section__title" id="_i125"> 4-(3-((7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)-4-(2,5-diazabicyclo[2.2.1]heptan-2-yl)phenyl)-2-(thiazol-2-yl)but-3-yn-2-ol (<b>12j</b>)</h3><div class="NLM_p last">Compound <b>12j</b> was prepared according to general procedure H on a 0.2 mmol scale. Purification by column chromatography (9% MeOH/DCM) afforded the title compound (56.3 mg, 0.123 mmol, 61% yield). White solid; mp 152–154 °C. HPLC analysis: retention time, 2.873 min; peak area, 96.19%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.63 (s, 1H), 8.73 (s, 1H), 8.09 (s, 1H), 7.74 (d, <i>J</i> = 3.2 Hz, 1H), 7.64 (d, <i>J</i> = 3.2 Hz, 1H), 7.20 (s, 1H), 7.13 (d, <i>J</i> = 8.5 Hz, 1H), 7.08 (d, <i>J</i> = 3.5 Hz, 1H), 6.92 (s, 1H), 6.73 (d, <i>J</i> = 8.6 Hz, 1H), 6.35 (s, 1H), 4.26 (s, 1H), 3.58 (d, <i>J</i> = 8.8 Hz, 1H), 3.39 (s, 1H), 3.17 (s, 1H), 2.92 (d, <i>J</i> = 9.3 Hz, 1H), 2.77 (d, <i>J</i> = 8.2 Hz, 2H), 1.83 (s, 3H), 1.63 (d, <i>J</i> = 7.8 Hz, 1H), 1.52 (d, <i>J</i> = 8.5 Hz, 1H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 176.88, 155.64, 151.74, 151.32, 146.15, 142.91, 134.27, 130.00, 125.91, 121.97, 120.75, 115.98, 109.86, 103.27, 99.39, 90.99, 84.05, 68.33, 61.14, 58.99, 56.31, 49.22, 37.03, 32.06; HRMSEI <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>24</sub>H<sub>25</sub>N<sub>7</sub>OS, 458.1738; found, 458.1745.</div></div><div id="sec4_11_10_79" class="NLM_sec NLM_sec_level_2"><div id="ac_i126" class="anchor-spacer"></div><h3 class="article-section__title" id="_i126"> 4-(3-((7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)-4-(4-methylpiperazin-1-yl)phenyl)-2-(thiazol-2-yl)but-3-yn-2-ol (<b>12k</b>)</h3><div class="NLM_p last">Compound <b>12k</b> was prepared according to general procedure H on a 0.4 mmol scale. Purification by column chromatography (9% MeOH/DCM) afforded the title compound (121.8 mg, 0.265 mmol, 66% yield). White solid; mp 223–225 °C. HPLC analysis: retention time, 3.911 min; peak area, 97.00%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.89 (s, 1H), 8.45 (s, 1H), 8.35–8.33 (m, 2H), 7.78 (d, <i>J</i> = 3.2 Hz, 1H), 7.69 (d, <i>J</i> = 3.2 Hz, 1H), 7.31–7.30 (m, 1H), 7.18 (d, <i>J</i> = 8.2 Hz, 1H), 7.13–7.10 (m, 1H), 7.05 (s, 1H), 6.54–6.52 (m, 1H), 2.87 (t, <i>J</i> = 4.3 Hz, 4H), 2.50–2.44 (m, 4H), 2.23 (s, 3H), 1.87 (s, 3H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 176.56, 153.47, 151.45, 151.32, 144.07, 143.01, 133.94, 126.89, 124.62, 123.54, 120.89, 120.69, 117.27, 104.20, 97.81, 92.01, 83.76, 68.38, 55.54, 51.29, 46.21, 32.06; HRMSEI <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>24</sub>H<sub>25</sub>N<sub>7</sub>OS, 460.1915; found, 460.1921.</div></div><div id="sec4_11_10_80" class="NLM_sec NLM_sec_level_2"><div id="ac_i127" class="anchor-spacer"></div><h3 class="article-section__title" id="_i127"> 4-(3-((7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)-4-(4-ethylpiperazin-1-yl)phenyl)-2-(thiazol-2-yl)but-3-yn-2-ol (<b>12l</b>)</h3><div class="NLM_p last">Compound <b>12l</b> was prepared according to general procedure H on a 0.4 mmol scale. Purification by column chromatography (8% MeOH/DCM) afforded the title compound (114.1 mg, 0.241 mmol, 60% yield). White solid; mp 213-215 °C. HPLC analysis: retention time, 4.097 min; peak area, 96.54%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.87 (s, 1H), 8.46 (s, 1H), 8.36–8.32 (m, 2H), 7.77 (d, <i>J</i> = 3.2 Hz, 1H), 7.68 (d, <i>J</i> = 3.2 Hz, 1H), 7.30 (dd, <i>J</i> = 3.5, 2.3 Hz, 1H), 7.18 (d, <i>J</i> = 8.2 Hz, 1H), 7.14–7.09 (m, 1H), 7.04 (s, 1H), 6.52 (dd, <i>J</i> = 3.5, 1.8 Hz, 1H), 2.87 (t, <i>J</i> = 4.7 Hz, 4H), 2.52 (d, <i>J</i> = 3.8 Hz, 4H), 2.38 (q, <i>J</i> = 7.2 Hz, 2H), 1.87 (s, 3H), 1.01 (t, <i>J</i> = 7.1 Hz, 3H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 176.55, 153.48, 151.44, 151.30, 144.13, 143.00, 133.92, 126.88, 124.63, 123.53, 120.89, 120.64, 117.24, 104.18, 97.80, 91.99, 83.76, 68.37, 53.28, 52.10, 51.43, 32.05, 12.50; HRMSEI <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>25</sub>H<sub>27</sub>N<sub>7</sub>OS, 474.2081; found, 474.2086.</div></div><div id="sec4_11_10_81" class="NLM_sec NLM_sec_level_2"><div id="ac_i128" class="anchor-spacer"></div><h3 class="article-section__title" id="_i128"> 4-(3-((7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)-4-(4-morpholinopiperidin-1-yl)phenyl)-2-(thiazol-2-yl)but-3-yn-2-ol (<b>12m</b>)</h3><div class="NLM_p last">Compound <b>12m</b> was prepared according to general procedure H on a 0.33 mmol scale. Purification by column chromatography (4% MeOH/DCM) afforded the title compound (118.1 mg, 0.223 mmol, 68% yield). White solid; mp 152–156 °C. HPLC analysis: retention time, 4.127 min; peak area, 95.19%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.87 (s, 1H), 8.42–8.29 (m, 3H), 7.77 (d, <i>J</i> = 3.1 Hz, 1H), 7.68 (d, <i>J</i> = 3.2 Hz, 1H), 7.30 (d, <i>J</i> = 3.2 Hz, 1H), 7.16–7.09 (m, 2H), 7.03 (s, 1H), 6.55 (s, 1H), 3.58 (s, 4H), 3.09 (d, <i>J</i> = 10.8 Hz, 2H), 2.65 (t, <i>J</i> = 11.4 Hz, 2H), 2.24 (s, 1H), 1.87–1.84 (m, 5H), 1.61–1.50 (m, 2H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 176.58, 153.50, 144.77, 143.00, 133.76, 126.99, 124.98, 123.49, 120.91, 120.50, 116.93, 97.97, 91.93, 83.79, 79.64, 68.37, 61.41, 51.16, 49.96, 32.04, 28.87; HRMSEI <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>28</sub>H<sub>31</sub>N<sub>7</sub>O<sub>2</sub>S, 530.2333; found, 530.2335.</div></div><div id="sec4_11_10_82" class="NLM_sec NLM_sec_level_2"><div id="ac_i129" class="anchor-spacer"></div><h3 class="article-section__title" id="_i129"> 4-(3-((7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)-4-(4-methyl-1,4-diazepan-1-yl)phenyl)-2-(thiazol-2-yl)but-3-yn-2-ol (<b>12n</b>)</h3><div class="NLM_p last">Compound <b>12n</b> was prepared according to general procedure H on a 0.2 mmol scale. Purification by column chromatography (9% MeOH/DCM) afforded the title compound (49.3 mg, 0.104 mmol, 52% yield). White solid; mp 169–172 °C. HPLC analysis: retention time, 3.454 min; peak area, 95.09%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.29 (s, 1H), 8.42–7.90 (m, 2H), 7.88 (d, <i>J</i> = 1.7 Hz, 1H), 7.77 (d, <i>J</i> = 3.2 Hz, 1H), 7.67 (d, <i>J</i> = 3.2 Hz, 1H), 7.57–7.41 (m, 2H), 6.98 (s, 2H), 3.79 (t, <i>J</i> = 6.8 Hz, 2H), 3.17 (s, 3H), 2.50–2.44 (m, 2H), 2.23 (s, 6H), 1.88 (s, 3H); <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ 176.62, 157.23, 148.67, 142.99, 140.46, 132.05, 128.88, 127.24, 120.98, 120.84, 117.76, 114.54, 109.49, 92.03, 84.20, 68.38, 56.90, 47.42, 45.88, 36.62, 32.03; HRMSEI <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>25</sub>H<sub>27</sub>N<sub>7</sub>OS, 474.1953; found, 474.1961.</div></div><div id="sec4_11_10_83" class="NLM_sec NLM_sec_level_2"><div id="ac_i130" class="anchor-spacer"></div><h3 class="article-section__title" id="_i130"> 4-(3-((7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)-4-((tetrahydro-2<i>H</i>-pyran-4-yl)oxy)phenyl)-2-(thiazol-2-yl)but-3-yn-2-ol (<b>12o</b>)</h3><div class="NLM_p last">Compound <b>12o</b> was prepared according to general procedure H on a 0.23 mmol scale. Purification by column chromatography (5% MeOH/DCM) afforded the title compound (84.9 mg, 0.184 mmol, 80% yield). White solid; mp 184–187 °C. HPLC analysis: retention time, 3.533 min; peak area, 97.96%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.82 (s, 1H), 8.43 (s, 1H), 8.27 (d, <i>J</i> = 1.2 Hz, 1H), 8.14 (s, 1H), 7.77 (dd, <i>J</i> = 3.2, 1.2 Hz, 1H), 7.68 (dd, <i>J</i> = 3.3, 1.2 Hz, 1H), 7.24 (d, <i>J</i> = 3.0 Hz, 1H), 7.16 (s, 2H), 6.99 (s, 1H), 6.59–6.52 (m, 1H), 4.67 (dt, <i>J</i> = 8.3, 4.4 Hz, 1H), 3.80–3.67 (m, 2H), 3.44 (t, <i>J</i> = 8.7 Hz, 2H), 3.22–3.00 (m, 1H), 1.87 (s, 3H), 1.64 (qd, <i>J</i> = 8.9, 6.0, 4.3 Hz, 2H), 1.18 (t, <i>J</i> = 7.2 Hz, 1H); <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ 176.64, 154.00, 151.28, 149.52, 143.00, 129.82, 128.06, 126.87, 123.17, 120.88, 114.60, 114.16, 103.97, 98.73, 91.42, 83.63, 72.82, 68.37, 64.56, 46.11, 32.05, 31.78, 9.05. HRMSEI <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>24</sub>H<sub>23</sub>N<sub>5</sub>O<sub>3</sub>S, 462.1584; found, 462.1595.</div></div><div id="sec4_11_10_84" class="NLM_sec NLM_sec_level_2"><div id="ac_i131" class="anchor-spacer"></div><h3 class="article-section__title" id="_i131"> 4-(3-((7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)-4-((1-methylpiperidin-4-yl)oxy)phenyl)-2-(thiazol-2-yl)but-3-yn-2-ol (<b>12p</b>)</h3><div class="NLM_p last">Compound <b>12p</b> was prepared according to general procedure H on a 0.25 mmol scale. Purification by column chromatography (8% MeOH/DCM) afforded the title compound (70.2 mg, 0.148 mmol, 59% yield). White solid; mp 211–215 °C. HPLC analysis: retention time, 3.577 min; peak area, 96.55%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.80 (s, 1H), 8.28 (s, 2H), 8.22 (s, 1H), 7.77 (d, <i>J</i> = 3.2 Hz, 1H), 7.68 (d, <i>J</i> = 3.2 Hz, 1H), 7.26–7.25 (m, 1H), 7.12 (s, 2H), 7.00 (s, 1H), 6.53–6.52 (m, 1H), 4.51 (s, 1H), 2.40 (s, 2H), 2.22–2.17 (m, 2H), 2.08 (s, 3H), 1.91–1.83 (m, 5H), 1.75–1.66 (m, 2H); <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ 176.66, 154.11, 151.38, 149.24, 143.00, 130.13, 127.75, 126.30, 123.13, 120.88, 114.50, 114.06, 98.38, 91.34, 83.72, 68.37, 52.15, 46.26, 32.06, 30.51. HRMSEI <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>25</sub>H<sub>26</sub>N<sub>6</sub>O<sub>2</sub>S, 475.1901; found, 475.1910.</div></div><div id="sec4_11_10_85" class="NLM_sec NLM_sec_level_2"><div id="ac_i132" class="anchor-spacer"></div><h3 class="article-section__title" id="_i132"> 4-(3-((7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)-4-morpholinophenyl)-2-methylbut-3-yn-2-ol (<b>12q</b>)</h3><div class="NLM_p last">Compound <b>12q</b> was prepared according to general procedure H on a 0.28 mmol scale. Purification by column chromatography (2% MeOH/DCM) afforded the title compound (50.2 mg, 0.133 mmol, 48% yield). White solid; mp 253–255 °C. HPLC analysis: retention time, 4.059 min; peak area, 96.57%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.86 (s, 1H), 8.54 (s, 1H), 8.35–8.23 (m, 2H), 7.29–7.28 (m, 1H), 7.17 (d, <i>J</i> = 8.2 Hz, 1H), 7.11 (dd, <i>J</i> = 8.1, 2.0 Hz, 1H), 6.59–6.58 (m, 1H), 5.76 (s, 1H), 5.47 (s, 1H), 3.74–3.72 (m, 4H), 2.89–2.83 (m, 4H), 1.47 (s, 6H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 153.63, 151.40, 151.34, 143.65, 133.92, 126.92, 125.15, 123.38, 120.61, 118.31, 104.21, 98.12, 95.61, 81.05, 66.96, 64.10, 51.84, 32.16; HRMSEI <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>21</sub>H<sub>23</sub>N<sub>5</sub>O<sub>2</sub>, 378.1915; found, 378.1929.</div></div><div id="sec4_11_10_86" class="NLM_sec NLM_sec_level_2"><div id="ac_i133" class="anchor-spacer"></div><h3 class="article-section__title" id="_i133"> 1-((3-((7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)-4-morpholinophenyl)ethynyl)cyclopentan-1-ol (<b>12r</b>)</h3><div class="NLM_p last">Compound <b>12r</b> was prepared according to general procedure H on a 0.24 mmol scale. Purification by column chromatography (2% MeOH/DCM) afforded the title compound (45.1 mg, 0.112 mmol, 47% yield). White solid; mp 212–214 °C. HPLC analysis: retention time, 4.876 min; peak area, 96.14%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.85 (s, 1H), 8.53 (s, 1H), 8.32–8.28 (m, 2H), 7.29–7.26 (m, 1H), 7.17 (d, <i>J</i> = 8.2 Hz, 1H), 7.11 (dd, <i>J</i> = 8.2, 1.9 Hz, 1H), 6.59–6.57 (m, 1H), 5.32 (s, 1H), 3.75–3.72 (m, 4H), 2.87–2.84 (m, 4H), 1.93–1.84 (m, 4H), 1.76–1.65 (m, 4H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 153.63, 151.40, 151.33, 143.59, 133.94, 126.87, 125.10, 123.38, 120.62, 118.45, 104.22, 98.11, 94.65, 82.02, 79.64, 73.27, 66.96, 51.84, 42.51, 23.54; HRMSEI <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>23</sub>H<sub>25</sub>N<sub>5</sub>O<sub>2</sub>, 404.2082; found, 404.2082.</div></div><div id="sec4_11_10_87" class="NLM_sec NLM_sec_level_2"><div id="ac_i134" class="anchor-spacer"></div><h3 class="article-section__title" id="_i134"> 1-((3-((7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)-4-morpholinophenyl)ethynyl)cyclohexan-1-ol (<b>12s</b>)</h3><div class="NLM_p last">Compound <b>12s</b> was prepared according to general procedure H on a 0.24 mmol scale. Purification by column chromatography (2% MeOH/DCM) afforded the title compound (52.2 mg, 0.125 mmol, 52% yield). White solid; mp 211–213 °C. HPLC analysis: retention time, 5.367 min; peak area, 96.11%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.85 (s, 1H), 8.54 (s, 1H), 8.31 (s, 1H), 8.27 (d, <i>J</i> = 1.7 Hz, 1H), 7.29–7.27 (m, 1H), 7.18–7.10 (m, 2H), 6.59–6.57 (m, 1H), 5.44 (s, 1H), 3.73 (t, <i>J</i> = 4.5 Hz, 4H), 2.86 (t, <i>J</i> = 4.5 Hz, 4H), 1.87–1.79 (m, 2H), 1.66–1.63 (m, 2H), 1.59–1.47 (m, 5H), 1.26–1.23 (m, 1H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 153.64, 151.34, 143.76, 133.91, 127.07, 125.25, 123.39, 120.64, 118.44, 104.21, 98.17, 94.54, 83.33, 67.42, 66.96, 51.84, 25.42, 23.28; HRMSEI <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>24</sub>H<sub>27</sub>N<sub>5</sub>O<sub>2</sub>, 418.2228; found, 418.2235.</div></div><div id="sec4_11_10_88" class="NLM_sec NLM_sec_level_2"><div id="ac_i135" class="anchor-spacer"></div><h3 class="article-section__title" id="_i135"> 4-(3-((7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)-4-morpholinophenyl)-2-cyclopentylbut-3-yn-2ol (<b>12t</b>)</h3><div class="NLM_p last">Compound <b>12t</b> was prepared according to general procedure H on a 0.24 mmol scale. Purification by column chromatography (2% MeOH/DCM) afforded the title compound (46.2 mg, 0.107 mmol, 45% yield). White solid; mp 185–187 °C. HPLC analysis: retention time, 5.931 min; peak area, 97.08%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.82 (s, 1H), 8.52 (s, 1H), 8.29 (d, <i>J</i> = 6.9 Hz, 2H), 7.27 (s, 1H), 7.16 (t, <i>J</i> = 7.6 Hz, 1H), 7.08 (d, <i>J</i> = 8.4 Hz, 1H), 6.57 (s, 1H), 5.24 (s, 1H), 3.73–3.71 (m, 4H), 2.86–2.84 (m, 4H), 2.12–2.02 (m, 1H), 1.71–1.68 (m, 2H), 1.66–1.56 (m, 3H), 1.55–1.50 (m, 3H), 1.42 (s, 3H); <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ 153.69, 151.42, 151.31, 143.67, 134.06, 126.92, 125.22, 123.36, 120.69, 118.58, 104.27, 98.10, 93.93, 82.61, 70.03, 67.00, 51.89, 51.49, 29.71, 28.76, 28.11, 26.27, 26.21; HRMSEI <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>25</sub>H<sub>29</sub>N<sub>5</sub>O<sub>2</sub>, 432.2395; found, 432.2398.</div></div><div id="sec4_11_10_89" class="NLM_sec NLM_sec_level_2"><div id="ac_i136" class="anchor-spacer"></div><h3 class="article-section__title" id="_i136"> 4-(3-((7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)-4-morpholinophenyl)-2-(thiophen-2-yl)but-3-yn-2-ol (<b>12u</b>)</h3><div class="NLM_p last">Compound <b>12u</b> was prepared according to general procedure H on a 0.24 mmol scale. Purification by column chromatography (2% MeOH/DCM) afforded the title compound (54.8 mg, 0.123 mmol, 51% yield). White solid; mp 213-215 °C. HPLC analysis: retention time, 3.880 min; peak area, 97.14%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.85 (s, 1H), 8.55 (s, 1H), 8.31 (s, 2H), 7.43 (dd, <i>J</i> = 5.1, 1.3 Hz, 1H), 7.29–7.27 (m, 1H), 7.18–7.15 (m, 3H), 6.98 (dd, <i>J</i> = 5.1, 3.5 Hz, 1H), 6.60–6.58 (m, 1H), 6.53 (s, 1H), 3.73 (t, <i>J</i> = 4.5 Hz, 4H), 2.87 (t, <i>J</i> = 4.5 Hz, 4H), 1.83 (s, 3H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 153.65, 152.44, 151.40, 151.36, 144.18, 133.93, 127.13, 127.00, 125.41, 125.26, 123.63, 123.38, 120.66, 117.61, 104.22, 98.17, 93.39, 83.12, 66.93, 66.51, 51.77, 34.32; HRMSEI <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>24</sub>H<sub>23</sub>N<sub>5</sub>O<sub>2</sub>S, 446.1636; found, 446.1643.</div></div><div id="sec4_11_10_90" class="NLM_sec NLM_sec_level_2"><div id="ac_i137" class="anchor-spacer"></div><h3 class="article-section__title" id="_i137"> 1-(4-(2-((7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)-4-(3-hydroxy-3-(thiazol-2-yl)but-1-yn-1-yl)phenyl)piperazin-1-yl)ethan-1-one (<b>16a</b>)</h3><div class="NLM_p last">Compound <b>16a</b> was prepared according to general procedure H on a 0.23 mmol scale. Purification by column chromatography (5% MeOH/DCM) afforded the title compound (60.9 mg, 0.125 mmol, 54% yield). White solid; mp 244–247 °C. HPLC analysis: retention time, 3.259 min; peak area, 98.89%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.83 (s, 1H), 8.54 (s, 1H), 8.33–8.32 (m, 2H), 7.78 (d, <i>J</i> = 3.3 Hz, 1H), 7.68 (d, <i>J</i> = 3.2 Hz, 1H), 7.30–7.27 (m, 1H), 7.18–7.12 (m, 2H), 7.01 (s, 1H), 6.63–6.62 (m, 1H), 3.61–3.56 (m, 4H), 2.88–2.81 (m, 4H), 2.02 (s, 3H), 1.89 (s, 3H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 176.53, 168.89, 153.61, 151.40, 151.36, 144.09, 143.01, 133.93, 127.08, 125.31, 123.39, 120.90, 117.45, 104.22, 98.29, 92.11, 83.66, 68.38, 51.69, 51.14, 46.47, 41.60, 32.04, 21.70; HRMSEI <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>25</sub>H<sub>25</sub>N<sub>7</sub>O<sub>2</sub>S, 488.1854; found, 488.1863.</div></div><div id="sec4_11_10_91" class="NLM_sec NLM_sec_level_2"><div id="ac_i138" class="anchor-spacer"></div><h3 class="article-section__title" id="_i138"> 4-(3-((7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)-4-(4-(ethylsulfonyl)piperazin-1-yl)phenyl)-2-(thiazol-2-yl)but-3-yn-2-ol (<b>16b</b>)</h3><div class="NLM_p last">Compound <b>16b</b> was prepared according to general procedure H on a 0.27 mmol scale. Purification by column chromatography (5% MeOH/DCM) afforded the title compound (65.1 mg, 0.121 mmol, 45% yield). White solid; mp 137–139 °C. HPLC analysis: retention time, 3.379 min; peak area, 96.70%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.84 (s, 1H), 8.47 (s, 1H), 8.33–8.31 (m, 2H), 7.78 (d, <i>J</i> = 3.2 Hz, 1H), 7.68 (d, <i>J</i> = 3.3 Hz, 1H), 7.29–7.28 (m, 1H), 7.21 (d, <i>J</i> = 8.2 Hz, 1H), 7.14 (dd, <i>J</i> = 8.2, 2.0 Hz, 1H), 7.01 (s, 1H), 6.63–6.61 (m, 1H), 3.12 (q, <i>J</i> = 7.4 Hz, 2H), 2.96–2.93 (m, 4H), 1.89 (s, 3H), 1.27–1.23 (m, 3H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 176.53, 153.60, 151.38, 143.92, 143.01, 133.93, 127.12, 125.44, 123.41, 121.05, 120.91, 117.55, 98.38, 92.15, 83.62, 68.38, 51.19, 45.97, 43.39, 32.04, 8.06; HRMSEI <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>25</sub>H<sub>27</sub>N<sub>7</sub>O<sub>3</sub>S<sub>2</sub>, 538.1678; found, 538.1691.</div></div><div id="sec4_11_10_92" class="NLM_sec NLM_sec_level_2"><div id="ac_i139" class="anchor-spacer"></div><h3 class="article-section__title" id="_i139"> 4-(3-((7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)-4-(4-(cyclopropylsulfonyl)piperazin-1-yl)phenyl)-2-(thiazol-2-yl)but-3-yn-2-ol (<b>16c</b>)</h3><div class="NLM_p last">Compound <b>16c</b> was prepared according to general procedure H on a 0.24 mmol scale. Purification by column chromatography (4% MeOH/DCM) afforded the title compound (73.1 mg, 0.133 mmol, 55% yield). White solid; mp 132–134 °C. HPLC analysis: retention time, 3.427 min; peak area, 96.25%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.83 (s, 1H), 8.52 (s, 1H), 8.33 (s, 1H), 8.25 (d, <i>J</i> = 2.0 Hz, 1H), 7.78–7.77 (m, 1H), 7.69–7.68 (m, 1H), 7.29–7.28 (m, 1H), 7.20 (d, <i>J</i> = 8.3 Hz, 1H), 7.17–7.14 (m, 1H), 7.01 (s, 1H), 6.57–6.56 (m, 1H), 2.98–2.95 (m, 4H), 2.67–2.60 (m, 1H), 1.89 (s, 3H), 1.06–1.03 (m, 2H), 0.96–0.94 (m, 2H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>)δ 176.53, 153.70, 151.43, 151.39, 144.15, 143.01, 133.91, 127.25, 125.78, 123.34, 121.03, 120.91, 117.49, 104.27, 98.34, 92.16, 83.60, 68.37, 50.84, 46.53, 32.04, 25.49, 4.42; HRMSEI <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>26</sub>H<sub>27</sub>N<sub>7</sub>O<sub>3</sub>S<sub>2</sub>, 550.1680; found, 550.1689.</div></div><div id="sec4_11_10_93" class="NLM_sec NLM_sec_level_2"><div id="ac_i140" class="anchor-spacer"></div><h3 class="article-section__title" id="_i140"> 4-(3-((2-Aminopyrimidin-4-yl)amino)-4-morpholinophenyl)-2-(thiazol-2-yl)but-3-yn-2-ol (<b>21a</b>)</h3><div class="NLM_p last">Compound <b>21a</b> was prepared according to general procedure H on a 0.25 mmol scale. Purification by column chromatography (2% MeOH/DCM) afforded the title compound (63.7 mg, 0.151 mmol, 60% yield). White solid; mp 188–190 °C. HPLC analysis: retention time, 3.633 min; peak area, 96.56%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.09 (s, 1H), 7.84 (d, <i>J</i> = 5.7 Hz, 1H), 7.79–7.78 (m, 2H), 7.69 (d, <i>J</i> = 3.3 Hz, 1H), 7.12 (dd, <i>J</i> = 8.2, 1.9 Hz, 1H), 7.07 (d, <i>J</i> = 8.3 Hz, 1H), 6.96 (s, 1H), 6.14–6.11 (m, 3H), 3.78–3.69 (m, 4H), 2.90–2.82 (m, 4H), 1.89 (s, 3H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 161.37, 152.49, 145.01, 133.38, 127.52, 126.99, 126.60, 125.22, 123.67, 120.06, 117.03, 93.33, 83.08, 66.61, 66.50, 51.38, 34.33; HRMSEI <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>21</sub>H<sub>22</sub>N<sub>6</sub>O<sub>2</sub>S, 423.1598; found, 423.1596.</div></div><div id="sec4_11_10_94" class="NLM_sec NLM_sec_level_2"><div id="ac_i141" class="anchor-spacer"></div><h3 class="article-section__title" id="_i141"> 4-(3-((1<i>H</i>-Pyrrolo[2,3-<i>b</i>]pyridin-4-yl)amino)-4-morpholinophenyl)-2-(thiazol-2-yl)but-3-yn-2-ol (<b>21b</b>)</h3><div class="NLM_p last">Compound <b>21b</b> was prepared according to general procedure H on a 0.24 mmol scale. Purification by column chromatography (4% MeOH/DCM) afforded the title compound (61.8 mg, 0.139 mmol, 58% yield). White solid; mp 198–201 °C. HPLC analysis: retention time, 4.318 min; peak area, 96.80%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.35 (s, 1H), 7.91–7.89 (m, 2H), 7.75 (d, <i>J</i> = 3.2 Hz, 1H), 7.66 (d, <i>J</i> = 3.2 Hz, 1H), 7.24 (d, <i>J</i> = 1.9 Hz, 1H), 7.20–7.13 (m, 2H), 7.06 (d, <i>J</i> = 8.3 Hz, 1H), 6.95 (s, 1H), 6.49–6.39 (m, 2H), 3.55 (t, <i>J</i> = 4.5 Hz, 4H), 2.90 (t, <i>J</i> = 4.5 Hz, 4H), 1.84 (s, 3H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 176.53, 150.04, 146.17, 144.15, 143.64, 142.97, 134.32, 127.86, 126.54, 122.82, 120.86, 120.02, 116.23, 109.22, 100.00, 98.23, 92.12, 83.38, 68.33, 66.60, 50.77, 31.98; HRMSEI <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>24</sub>H<sub>23</sub>N<sub>5</sub>O<sub>2</sub>S, 446.1656; found, 446.1644.</div></div><div id="sec4_11_10_95" class="NLM_sec NLM_sec_level_2"><div id="ac_i142" class="anchor-spacer"></div><h3 class="article-section__title" id="_i142"> 4-(3-((5-Fluoro-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-4-yl)amino)-4-morpholinophenyl)-2-(thiazol-2-yl)but-3-yn-2-ol (<b>21c</b>)</h3><div class="NLM_p last">Compound <b>21c</b> was prepared according to general procedure H on a 0.25 mmol scale. Purification by column chromatography (4% MeOH/DCM) afforded the title compound (105.4 mg, 0.227 mmol, 91% yield). White solid; mp 128–131 °C. HPLC analysis: retention time, 4.077 min; peak area, 97.21%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.42 (s, 1H), 8.03 (d, <i>J</i> = 4.3 Hz, 1H), 7.93 (s, 1H), 7.75 (d, <i>J</i> = 3.2 Hz, 1H), 7.65 (d, <i>J</i> = 3.2 Hz, 1H), 7.21–7.17 (m, 1H), 7.13 (dd, <i>J</i> = 8.3, 1.8 Hz, 1H), 7.02–7.00 (m, 2H), 6.93 (s, 1H), 5.84–5.82 (m, 1H), 3.31–3.28 (m, 4H), 2.86–2.83 (m, 4H), 1.83 (s, 3H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ 176.53, 146.77, 146.01, 142.96, 135.16, 131.44, 131.18, 130.83, 130.72, 127.59, 126.15, 125.13, 120.84, 119.75, 116.05, 99.31, 91.98, 83.42, 68.30, 66.43, 50.56, 31.96; HRMSEI <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>24</sub>H<sub>22</sub>FN<sub>5</sub>O<sub>2</sub>S, 464.1552; found, 464.1548.</div></div><div id="sec4_11_10_96" class="NLM_sec NLM_sec_level_2"><div id="ac_i143" class="anchor-spacer"></div><h3 class="article-section__title" id="_i143"> 4-(3-((5-Chloro-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-4-yl)amino)-4-morpholinophenyl)-2-(thiazol-2-yl)but-3-yn-2-ol (<b>21d</b>)</h3><div class="NLM_p last">Compound <b>21d</b> was prepared according to general procedure H on a 0.20 mmol scale. Purification by column chromatography (4% MeOH/DCM) afforded the title compound (74.2 mg, 0.154 mmol, 76% yield). White solid; mp 128–130 °C. HPLC analysis: retention time, 4.752 min; peak area, 96.23%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.51 (s, 1H), 8.05 (s, 1H), 7.83 (s, 1H), 7.75 (d, <i>J</i> = 3.2 Hz, 1H), 7.66 (d, <i>J</i> = 3.3 Hz, 1H), 7.19 (dd, <i>J</i> = 8.2, 2.0 Hz, 1H), 7.11 (dd, <i>J</i> = 3.7, 2.3 Hz, 2H), 7.01 (d, <i>J</i> = 8.3 Hz, 1H), 6.96 (s, 1H), 5.39 (dd, <i>J</i> = 3.5, 2.0 Hz, 1H), 3.23 (t, <i>J</i> = 4.5 Hz, 4H), 2.81 (t, <i>J</i> = 4.7 Hz, 4H), 1.83 (s, 3H); <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ 176.51, 148.63, 146.62, 142.99, 142.28, 139.77, 134.72, 128.40, 127.50, 124.22, 120.88, 119.97, 116.06, 110.73, 110.30, 99.26, 92.14, 83.31, 68.31, 66.54, 50.50, 31.96; HRMSEI <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>22</sub>H<sub>21</sub>N<sub>7</sub>O<sub>2</sub>S, 480.1216; found, 448.1558.</div></div><div id="sec4_11_10_97" class="NLM_sec NLM_sec_level_2"><div id="ac_i144" class="anchor-spacer"></div><h3 class="article-section__title" id="_i144"> 4-(3-((1<i>H</i>-Pyrazolo[3,4-<i>d</i>]pyrimidin-4-yl)amino)-4-morpholinophenyl)-2-(thiazol-2-yl)but-3-yn-2-ol (<b>21e</b>)</h3><div class="NLM_p last">Compound <b>21e</b> was prepared according to general procedure H on a 0.25 mmol scale. Purification by column chromatography (4% MeOH/DCM) afforded the title compound (86.8 mg, 0.194 mmol, 78% yield). White solid; mp 236–238 °C. HPLC analysis: retention time, 3.287 min; peak area, 98.61%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.59 (s, 1H), 9.37 (s, 1H), 8.35 (s, 1H), 7.94 (s, 1H), 7.80–7.76 (m, 2H), 7.68 (d, <i>J</i> = 3.3 Hz, 1H), 7.27 (dd, <i>J</i> = 8.3, 2.1 Hz, 1H), 7.13 (d, <i>J</i> = 8.4 Hz, 1H), 7.02 (s, 1H), 3.58 (t, <i>J</i> = 4.4 Hz, 4H), 2.87 (t, <i>J</i> = 4.6 Hz, 4H), 1.86 (s, 3H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 176.51, 155.76, 155.37, 146.91, 143.00, 132.03, 129.58, 129.46, 120.89, 120.24, 116.41, 100.99, 92.31, 83.25, 68.36, 66.55, 51.29, 32.00; HRMSEI <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>22</sub>H<sub>21</sub>N<sub>7</sub>O<sub>2</sub>S, 448.1551; found, 448.1558.</div></div><div id="sec4_11_10_98" class="NLM_sec NLM_sec_level_2"><div id="ac_i145" class="anchor-spacer"></div><h3 class="article-section__title" id="_i145"> 4-(4-Morpholino-3-(thieno[2,3-<i>d</i>]pyrimidin-4-ylamino)phenyl)-2-(thiazol-2-yl)but-3-yn-2-ol (<b>21f</b>)</h3><div class="NLM_p last">Compound <b>21f</b> was prepared according to general procedure H on a 0.25 mmol scale. Purification by column chromatography (4% MeOH/DCM) afforded the title compound (101.5 mg, 0.219 mmol, 88% yield). White solid; mp 229–231 °C. HPLC analysis: retention time, 4.197 min; peak area, 98.36%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.11 (s, 1H), 8.50 (s, 1H), 7.97 (d, <i>J</i> = 2.0 Hz, 1H), 7.77 (d, <i>J</i> = 3.2 Hz, 1H), 7.73 (d, <i>J</i> = 6.0 Hz, 1H), 7.71–7.66 (m, 2H), 7.24 (dd, <i>J</i> = 8.3, 2.0 Hz, 1H), 7.16 (d, <i>J</i> = 8.3 Hz, 1H), 7.03 (s, 1H), 3.64 (dd, <i>J</i> = 5.8, 3.2 Hz, 4H), 2.86 (t, <i>J</i> = 4.5 Hz, 4H), 1.88 (s, 3H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 176.53, 167.02, 155.34, 153.82, 146.05, 143.01, 132.58, 128.86, 127.98, 124.75, 120.89, 120.56, 119.26, 117.43, 116.88, 92.29, 83.39, 68.39, 66.75, 51.52, 32.02; HRMSEI <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>23</sub>H<sub>21</sub>N<sub>5</sub>O<sub>2</sub>S2:464.1220; found, 464.1212.</div></div><div id="sec4_11_10_99" class="NLM_sec NLM_sec_level_2"><div id="ac_i146" class="anchor-spacer"></div><h3 class="article-section__title" id="_i146"> (<i>R</i>)-4-(3-((7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)-4-morpholinophenyl)-2-(thiazol-2-yl)but-3-yn-2-ol (<b>22</b>)</h3><div class="NLM_p last">Compound <b>22</b> was resolved from <b>12f</b> on a 0.3 mmol scale (64.6 mg, 0.139 mmol, 46% yield). White solid; mp 195–197 °C. HPLC analysis: retention time, 3.725 min; peak area, 99.43%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.87 (s, 1H), 8.54 (s, 1H), 8.33–8.29 (m, 2H), 7.78–7.68 (m, 2H), 7.29–7.07 (m, 4H), 6.60 (s, 1H), 3.73 (s, 4H), 2.86 (s, 4H), 1.88 (s, 3H); <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ 176.55, 153.62, 151.42, 144.29, 143.02, 133.85, 127.19, 125.44, 123.40, 120.90, 120.64, 117.27, 104.21, 98.19, 92.06, 83.67, 68.38, 66.90, 56.51, 51.72, 32.04, 19.02; HRMSEI <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>23</sub>H<sub>22</sub>N<sub>6</sub>O<sub>2</sub>S, 447.1598; found, 447.1608.</div></div><div id="sec4_11_10_100" class="NLM_sec NLM_sec_level_2"><div id="ac_i147" class="anchor-spacer"></div><h3 class="article-section__title" id="_i147"> (<i>S</i>)-4-(3-((7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)-4-morpholinophenyl)-2-(thiazol-2-yl)but-3-yn-2-ol (<b>23</b>)</h3><div class="NLM_p last">Compound <b>23</b> was resolved from <b>12f</b> on a 0.3 mmol scale (63.2 mg, 0.136 mmol, 45% yield). White solid; mp 132–135 °C. HPLC analysis: retention time, 3.738 min; peak area, 98.56%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.87 (s, 1H), 8.54 (s, 1H), 8.30 (d, <i>J</i> = 10.7 Hz, 2H), 7.78–7.68 (m, 2H), 7.35–7.01 (m, 4H), 6.65–6.55 (m, 1H), 3.95–3.65 (m, 4H), 2.86 (t, <i>J</i> = 4.4 Hz, 4H), 1.88 (s, 3H); <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ 176.54, 153.61, 151.41, 151.33, 144.30, 143.02, 133.84, 127.19, 125.45, 123.39, 120.91, 120.64, 117.26, 104.19, 98.18, 92.05, 83.66, 68.37, 66.89, 56.50, 51.72, 32.04, 19.03; HRMSEI <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>23</sub>H<sub>22</sub>N<sub>6</sub>O<sub>2</sub>S, 447.1598; found, 447.1607.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i148"><a href="/doi/suppl/10.1021/acs.jmedchem.0c00055" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_17743" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_17743" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c00055?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00055</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">% Ctrl of compound <b>12f</b> against the 268 wild-type kinases, IC<sub>50</sub> of compound <b>12f</b> against the selected kianses, reagents and antibodies used for biological evaluation in vitro or in vivo, toxicity screening of selected target compounds on normal T cells, <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra for target compounds, HPLC spectra for target compounds (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00055/suppl_file/jm0c00055_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular modeling information involved in ligand <b>1</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00055/suppl_file/jm0c00055_si_002.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Molecular modeling information involved in the overlapping of ligand <b>12k</b> to <b>1</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00055/suppl_file/jm0c00055_si_003.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Molecular modeling information involved in ligand <b>12f</b>_1 (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00055/suppl_file/jm0c00055_si_004.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Molecular modeling information involved in ligand <b>12f</b>_2 (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00055/suppl_file/jm0c00055_si_005.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Molecular formula strings and some data (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00055/suppl_file/jm0c00055_si_006.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00055/suppl_file/jm0c00055_si_001.pdf">jm0c00055_si_001.pdf (6.63 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00055/suppl_file/jm0c00055_si_002.pdb">jm0c00055_si_002.pdb (747.05 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00055/suppl_file/jm0c00055_si_003.pdb">jm0c00055_si_003.pdb (590.45 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00055/suppl_file/jm0c00055_si_004.pdb">jm0c00055_si_004.pdb (393.08 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00055/suppl_file/jm0c00055_si_005.pdb">jm0c00055_si_005.pdb (403.26 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00055/suppl_file/jm0c00055_si_006.csv">jm0c00055_si_006.csv (3.77 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c00055" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_18458" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_18458" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tao Lu</span> - <span class="hlFld-Affiliation affiliation">School
of Sciences, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Natural Medicines, China
Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, P. R. China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#305c4544515f705340451e5554451e535e"><span class="__cf_email__" data-cfemail="066a737267694665767328636273286568">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yadong Chen</span> - <span class="hlFld-Affiliation affiliation">School
of Sciences, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, P. R. China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2189-9356" title="Orcid link">http://orcid.org/0000-0002-2189-9356</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#88f1ecebe0ede6c8ebf8fda6edecfda6ebe6"><span class="__cf_email__" data-cfemail="1c65787f7479725c7f6c6932797869327f72">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yuqin Zhu</span> - <span class="hlFld-Affiliation affiliation">School
of Sciences, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yuxiang Ma</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Natural Medicines, China
Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Weidong Zu</span> - <span class="hlFld-Affiliation affiliation">School
of Sciences, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jianing Song</span> - <span class="hlFld-Affiliation affiliation">School
of Sciences, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hua Wang</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Natural Medicines, China
Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">You Zhong</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Natural Medicines, China
Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hongmei Li</span> - <span class="hlFld-Affiliation affiliation">School
of Sciences, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yanmin Zhang</span> - <span class="hlFld-Affiliation affiliation">School
of Sciences, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, P. R. China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4075-7556" title="Orcid link">http://orcid.org/0000-0002-4075-7556</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qianqian Gao</span> - <span class="hlFld-Affiliation affiliation">School
of Sciences, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bo Kong</span> - <span class="hlFld-Affiliation affiliation">School
of Sciences, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Junyu Xu</span> - <span class="hlFld-Affiliation affiliation">School
of Sciences, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, P. R. China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4918-0693" title="Orcid link">http://orcid.org/0000-0002-4918-0693</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Fei Jiang</span> - <span class="hlFld-Affiliation affiliation">School
of Sciences, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xinren Wang</span> - <span class="hlFld-Affiliation affiliation">School
of Sciences, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shuwen Li</span> - <span class="hlFld-Affiliation affiliation">School
of Sciences, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chenhe Liu</span> - <span class="hlFld-Affiliation affiliation">School
of Sciences, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Haichun Liu</span> - <span class="hlFld-Affiliation affiliation">School
of Sciences, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, P. R. China</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>Yuqin Zhu and Yuxiang Ma contributed equally to this work. The manuscript was written through contributions of all authors.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><p>The authors declare no competing financial interest.<br /></br></p></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i150">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51068" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51068" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This study was supported by grants from the National Natural Science Foundation of China (Grants 81973182 and 81673301) and “Double First-Class” University Project from China Pharmaceutical University (Program CPU2018GF02). We thank Prof. Lei Qiang, China Pharmaceutical University, for technical assistance of pharmacology.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">NIK</td><td class="NLM_def"><p class="first last">nuclear factor κB inducing kinase</p></td></tr><tr><td class="NLM_term">NF-κB</td><td class="NLM_def"><p class="first last">nuclear factor κ-light-chain-enhancer of activated B cell</p></td></tr><tr><td class="NLM_term">TNFSFR</td><td class="NLM_def"><p class="first last">tumor necrosis factor superfamily receptor</p></td></tr><tr><td class="NLM_term">CD40</td><td class="NLM_def"><p class="first last">cluster of differentiation 40</p></td></tr><tr><td class="NLM_term">CD40L</td><td class="NLM_def"><p class="first last">cluster of differentiation 40 ligand</p></td></tr><tr><td class="NLM_term">TRAF3</td><td class="NLM_def"><p class="first last">tumor necrosis factor receptor-associated factor 3</p></td></tr><tr><td class="NLM_term">BAFF</td><td class="NLM_def"><p class="first last">B-cell activating factor</p></td></tr><tr><td class="NLM_term">BAFF-R</td><td class="NLM_def"><p class="first last">B-cell activating factor receptor</p></td></tr><tr><td class="NLM_term">Fn14 (TWEAK-R or TNFRSF12A)</td><td class="NLM_def"><p class="first last">tumor necrosis factor receptor superfamily member 12A</p></td></tr><tr><td class="NLM_term">TRAF2-cIAP</td><td class="NLM_def"><p class="first last">Tumor necrosis factor receptor (TNFR) associated factor 2 cellular inhibitor of apoptosis proteins</p></td></tr><tr><td class="NLM_term">IKKα</td><td class="NLM_def"><p class="first last">IκB kinase α</p></td></tr><tr><td class="NLM_term">IMQ</td><td class="NLM_def"><p class="first last">imiquimod</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i152">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71884" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71884" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 54 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parisi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Symmons, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffiths, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashcroft, D. M.</span></span> <span> </span><span class="NLM_article-title">Global epidemiology of psoriasis: a systematic review of incidence and prevalence</span>. <i>J. Invest. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>133</i></span>,  <span class="NLM_fpage">377</span>– <span class="NLM_lpage">385</span>, <span class="refDoi"> DOI: 10.1038/jid.2012.339</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.1038%2Fjid.2012.339" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=23014338" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVSltbvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=2013&pages=377-385&author=R.+Parisiauthor=D.+P.+Symmonsauthor=C.+E.+Griffithsauthor=D.+M.+Ashcroft&title=Global+epidemiology+of+psoriasis%3A+a+systematic+review+of+incidence+and+prevalence&doi=10.1038%2Fjid.2012.339"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence</span></div><div class="casAuthors">Parisi, Rosa; Symmons, Deborah P. M.; Griffiths, Christopher E. M.; Ashcroft, Darren M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Investigative Dermatology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">133</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">377-385</span>CODEN:
                <span class="NLM_cas:coden">JIDEAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-202X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The worldwide incidence and prevalence of psoriasis is poorly understood.  To better understand this, we performed a systematic review of published population-based studies on the incidence and prevalence of psoriasis.  Three electronic databases were searched from their inception dates to July 2011.  A total of 385 papers were critically appraised; 53 studies reported on the prevalence and incidence of psoriasis in the general population.  The prevalence in children ranged from 0% (Taiwan) to 2.1% (Italy), and in adults it varied from 0.91% (United States) to 8.5% (Norway).  In children, the incidence est. reported (United States) was 40.8/100,000 person-years.  In adults, it varied from 78.9/100,000 person-years (United States) to 230/100,000 person-years (Italy).  The data indicated that the occurrence of psoriasis varied according to age and geog. region, being more frequent in countries more distant from the equator.  Prevalence ests. also varied in relation to demog. characteristics in that studies confined to adults reported higher ests. of psoriasis compared with those involving all age groups.  Studies on the prevalence and incidence of psoriasis have contributed to a better understanding of the burden of the disease.  However, further research is required to fill existing gaps in understanding the epidemiol. of psoriasis and trends in incidence over time.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpky_n-8Uwdc7Vg90H21EOLACvtfcHk0ljCcjoxPxjyJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVSltbvO&md5=b58ddbb50d844d58af03e7bc5b5b85ca</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fjid.2012.339&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fjid.2012.339%26sid%3Dliteratum%253Aachs%26aulast%3DParisi%26aufirst%3DR.%26aulast%3DSymmons%26aufirst%3DD.%2BP.%26aulast%3DGriffiths%26aufirst%3DC.%2BE.%26aulast%3DAshcroft%26aufirst%3DD.%2BM.%26atitle%3DGlobal%2520epidemiology%2520of%2520psoriasis%253A%2520a%2520systematic%2520review%2520of%2520incidence%2520and%2520prevalence%26jtitle%3DJ.%2520Invest.%2520Dermatol.%26date%3D2013%26volume%3D133%26spage%3D377%26epage%3D385%26doi%3D10.1038%2Fjid.2012.339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gaffen, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garg, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cua, D. J.</span></span> <span> </span><span class="NLM_article-title">The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">585</span>– <span class="NLM_lpage">600</span>, <span class="refDoi"> DOI: 10.1038/nri3707</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.1038%2Fnri3707" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=25145755" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVSit7%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=585-600&author=S.+L.+Gaffenauthor=R.+Jainauthor=A.+V.+Gargauthor=D.+J.+Cua&title=The+IL-23-IL-17+immune+axis%3A+from+mechanisms+to+therapeutic+testing&doi=10.1038%2Fnri3707"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing</span></div><div class="casAuthors">Gaffen, Sarah L.; Jain, Renu; Garg, Abhishek V.; Cua, Daniel J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">585-600</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Following the discovery of T helper 17 (TH17) cells, the past decade has witnessed a major revision of the TH subset paradigm and substantial progress has been made in deciphering the mol. mechanisms of T cell lineage commitment and function.  In this Review, we focus on the recent advances that have been made regarding the transcriptional control of TH17 cell plasticity and stability, as well as the effector functions of TH17 cells, and we highlight the mechanisms of IL-17 signalling in mesenchymal and barrier epithelial tissues.  We also discuss the emerging clin. data showing that IL-17-specific and IL-23-specific antibody treatments are remarkably effective for treating many immune-mediated inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsrf-chGl_n7Vg90H21EOLACvtfcHk0ljCcjoxPxjyJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVSit7%252FL&md5=3b78e054323aae062527ce32ec8e05e2</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnri3707&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri3707%26sid%3Dliteratum%253Aachs%26aulast%3DGaffen%26aufirst%3DS.%2BL.%26aulast%3DJain%26aufirst%3DR.%26aulast%3DGarg%26aufirst%3DA.%2BV.%26aulast%3DCua%26aufirst%3DD.%2BJ.%26atitle%3DThe%2520IL-23-IL-17%2520immune%2520axis%253A%2520from%2520mechanisms%2520to%2520therapeutic%2520testing%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2014%26volume%3D14%26spage%3D585%26epage%3D600%26doi%3D10.1038%2Fnri3707" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Elder, J. T.</span></span> <span> </span><span class="NLM_article-title">Genome-wide association scan yields new insights into the immunopathogenesis of psoriasis</span>. <i>Genes Immun.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">201</span>– <span class="NLM_lpage">209</span>, <span class="refDoi"> DOI: 10.1038/gene.2009.11</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.1038%2Fgene.2009.11" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=19262574" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BD1MXkvVSru7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=201-209&author=J.+T.+Elder&title=Genome-wide+association+scan+yields+new+insights+into+the+immunopathogenesis+of+psoriasis&doi=10.1038%2Fgene.2009.11"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Genome-wide association scan yields new insights into the immunopathogenesis of psoriasis</span></div><div class="casAuthors">Elder, J. T.</div><div class="citationInfo"><span class="NLM_cas:title">Genes and Immunity</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">201-209</span>CODEN:
                <span class="NLM_cas:coden">GEIMA2</span>;
        ISSN:<span class="NLM_cas:issn">1466-4879</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Psoriasis is a common, immunol. mediated, inflammatory and hyperproliferative disease of the skin and joints, with a multifactorial genetic basis.  We earlier mapped PSORS1, the major psoriasis susceptibility gene in the major histocompatibility complex (MHC), to within or very near HLA-Cw6.  In an effort to identify non-MHC psoriasis genes, we carried out a collaborative genome-wide assocn. study.  After the initial follow-up genotyping of 21 single nucleotide polymorphisms from 18 loci, showing strong evidence of assocn. in the initial scan, we confirmed evidence of assocn. at seven loci.  Three of these loci confirm earlier reports of assocn. (HLA-C, IL12B, IL23R) and four identify novel signals located near plausible candidate genes (IL23A, IL4/IL13, TNFAIP3 and TNIP1).  In other work, we have also shown that interferon-γ (IFN-γ) treatment induces interleukin (IL)-23 mRNA and protein in antigen-presenting cells (APC), leading to the proliferation of CD4+ and CD8+ memory T cells expressing IL-17.  Although functional variants remain to be identified, we speculate that genetic variants at the IL4/IL13 locus contribute to the Th1 bias that is characteristic of psoriasis, that Th1-derived IFN-γ supports expansion of IL-17+ T cells through APC-derived IL-23 and that neg. regulation of inflammatory signaling through the NF-κB axis is impaired because of genetic variants of TNFAIP3 and TNIP1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmtd0LLTCOLrVg90H21EOLACvtfcHk0ljd3AGsx8xU5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXkvVSru7w%253D&md5=b17f41edfa84a8f033bf9c7ec45b3b55</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fgene.2009.11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fgene.2009.11%26sid%3Dliteratum%253Aachs%26aulast%3DElder%26aufirst%3DJ.%2BT.%26atitle%3DGenome-wide%2520association%2520scan%2520yields%2520new%2520insights%2520into%2520the%2520immunopathogenesis%2520of%2520psoriasis%26jtitle%3DGenes%2520Immun.%26date%3D2009%26volume%3D10%26spage%3D201%26epage%3D209%26doi%3D10.1038%2Fgene.2009.11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Myers, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottlieb, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mease, P.</span></span> <span> </span><span class="NLM_article-title">Psoriasis and psoriatic arthritis: clinical features and disease mechanisms</span>. <i>Clin. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">438</span>– <span class="NLM_lpage">447</span>, <span class="refDoi"> DOI: 10.1016/j.clindermatol.2006.07.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.1016%2Fj.clindermatol.2006.07.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=16966023" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A280%3ADC%252BD28rktVKqsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2006&pages=438-447&author=W.+A.+Myersauthor=A.+B.+Gottliebauthor=P.+Mease&title=Psoriasis+and+psoriatic+arthritis%3A+clinical+features+and+disease+mechanisms&doi=10.1016%2Fj.clindermatol.2006.07.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Psoriasis and psoriatic arthritis: clinical features and disease mechanisms</span></div><div class="casAuthors">Myers Wendy A; Gottlieb Alice B; Mease Philip</div><div class="citationInfo"><span class="NLM_cas:title">Clinics in dermatology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">438-47</span>
        ISSN:<span class="NLM_cas:issn">0738-081X</span>.
    </div><div class="casAbstract">Psoriasis is a chronic skin disorder affecting approximately 1% to 3% of the world's population.  A considerable proportion of patients with psoriasis will develop a form of inflammatory arthritis known as psoriatic arthritis whose prevalence is poorly defined.  Significant advances have been made in determining the pathophysiology of both of these diseases, with recent findings strongly implicating T cells and inflammatory cytokines such as tumor necrosis factor alpha in their pathogenesis.  There exists an increasing array of therapies to benefit both skin and musculoskeletal manifestations.  Newer therapies, such as the biologics, are providing more targeted approaches with potentially fewer systemic toxicities, providing control of disease symptoms and inhibiting progressive joint damage in those with arthritis, as well as improving long-term function and quality of life.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRpm2gTYu8pnYFEOhA_Im3cfW6udTcc2eayp7G5t5-bsrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28rktVKqsw%253D%253D&md5=1c9ab1b05bc72e8ff43b7bdc5324fb64</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.clindermatol.2006.07.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clindermatol.2006.07.006%26sid%3Dliteratum%253Aachs%26aulast%3DMyers%26aufirst%3DW.%2BA.%26aulast%3DGottlieb%26aufirst%3DA.%2BB.%26aulast%3DMease%26aufirst%3DP.%26atitle%3DPsoriasis%2520and%2520psoriatic%2520arthritis%253A%2520clinical%2520features%2520and%2520disease%2520mechanisms%26jtitle%3DClin.%2520Dermatol.%26date%3D2006%26volume%3D24%26spage%3D438%26epage%3D447%26doi%3D10.1016%2Fj.clindermatol.2006.07.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gudjonsson, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoll, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riblett, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kochkodan, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aphale, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voorhees, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elder, J. T.</span></span> <span> </span><span class="NLM_article-title">Evidence for altered Wnt signaling in psoriatic skin</span>. <i>J. Invest. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>130</i></span>,  <span class="NLM_fpage">1849</span>– <span class="NLM_lpage">1859</span>, <span class="refDoi"> DOI: 10.1038/jid.2010.67</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.1038%2Fjid.2010.67" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=20376066" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC3cXnsVyju7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2010&pages=1849-1859&author=J.+E.+Gudjonssonauthor=A.+Johnstonauthor=S.+W.+Stollauthor=M.+B.+Riblettauthor=X.+Xingauthor=J.+J.+Kochkodanauthor=J.+Dingauthor=R.+P.+Nairauthor=A.+Aphaleauthor=J.+J.+Voorheesauthor=J.+T.+Elder&title=Evidence+for+altered+Wnt+signaling+in+psoriatic+skin&doi=10.1038%2Fjid.2010.67"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Evidence for Altered Wnt Signaling in Psoriatic Skin</span></div><div class="casAuthors">Gudjonsson, Johann E.; Johnston, Andrew; Stoll, Stefan W.; Riblett, Mary B.; Xing, Xianying; Kochkodan, James J.; Ding, Jun; Nair, Rajan P.; Aphale, Abhishek; Voorhees, John J.; Elder, James T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Investigative Dermatology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1849-1859</span>CODEN:
                <span class="NLM_cas:coden">JIDEAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-202X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The Wnt gene family encodes a set of highly conserved secreted signaling proteins that have major roles in embryogenesis and tissue homeostasis.  Yet the expression of this family of important mediators in psoriasis, a disease characterized by marked changes in keratinocyte growth and differentiation, is incompletely understood.  We subjected 58 paired biopsies from lesional and uninvolved psoriatic skin and 64 biopsies from normal skin to global gene expression profiling.  WNT5A transcripts were upregulated fivefold in lesional skin, accompanied by increased Wnt-5a protein levels.  Notably, WNT5A mRNA was markedly induced by IL-1α, tumor necrosis factor-α, IFN-γ, and transforming growth factor-α in cultured keratinocytes.  Frizzled 2 (FZD2) and FZD5, which encode receptors for Wnt5A, were also increased in lesional psoriatic skin.  In contrast, expression of WIF1 mRNA, encoding a secreted antagonist of the Wnt proteins, was downregulated > 10-fold in lesional skin, along with decreased WNT inhibitory factor (WIF)-1 immunostaining.  Interestingly, pathway anal. along with reduced AXIN2 expression and lack of nuclear translocation of β-catenin indicated a suppression of canonical Wnt signaling in lesional skin.  The results of our study suggest a shift away from canonical Wnt signaling toward noncanonical pathways driven by interactions between Wnt-5a and its cognate receptors in psoriasis, accompanied by impaired homeostatic inhibition of Wnt signaling by WIF-1 and dickkopf.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJpPw9adK1_bVg90H21EOLACvtfcHk0liCCTgQHHVazA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXnsVyju7g%253D&md5=4a210b3550954c9a33b61a6cd339c6c1</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fjid.2010.67&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fjid.2010.67%26sid%3Dliteratum%253Aachs%26aulast%3DGudjonsson%26aufirst%3DJ.%2BE.%26aulast%3DJohnston%26aufirst%3DA.%26aulast%3DStoll%26aufirst%3DS.%2BW.%26aulast%3DRiblett%26aufirst%3DM.%2BB.%26aulast%3DXing%26aufirst%3DX.%26aulast%3DKochkodan%26aufirst%3DJ.%2BJ.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DNair%26aufirst%3DR.%2BP.%26aulast%3DAphale%26aufirst%3DA.%26aulast%3DVoorhees%26aufirst%3DJ.%2BJ.%26aulast%3DElder%26aufirst%3DJ.%2BT.%26atitle%3DEvidence%2520for%2520altered%2520Wnt%2520signaling%2520in%2520psoriatic%2520skin%26jtitle%3DJ.%2520Invest.%2520Dermatol.%26date%3D2010%26volume%3D130%26spage%3D1849%26epage%3D1859%26doi%3D10.1038%2Fjid.2010.67" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lowes, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suarez-Farinas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krueger, J. G.</span></span> <span> </span><span class="NLM_article-title">Immunology of psoriasis</span>. <i>Annu. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">227</span>– <span class="NLM_lpage">255</span>, <span class="refDoi"> DOI: 10.1146/annurev-immunol-032713-120225</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.1146%2Fannurev-immunol-032713-120225" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=24655295" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC2cXovVemt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&pages=227-255&author=M.+A.+Lowesauthor=M.+Suarez-Farinasauthor=J.+G.+Krueger&title=Immunology+of+psoriasis&doi=10.1146%2Fannurev-immunol-032713-120225"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Immunology of psoriasis</span></div><div class="casAuthors">Lowes, Michelle A.; Suarez-Farinas, Mayte; Krueger, James G.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Immunology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">227-255</span>CODEN:
                <span class="NLM_cas:coden">ARIMDU</span>;
        ISSN:<span class="NLM_cas:issn">0732-0582</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews</span>)
        </div><div class="casAbstract">A review.  The skin is the front line of defense against insult and injury and contains many epidermal and immune elements that comprise the skin-assocd. lymphoid tissue (SALT).  The reaction of these components to injury allows an effective cutaneous response to restore homeostasis.  Psoriasis vulgaris is the best-understood and most accessible human disease that is mediated by T cells and dendritic cells.  Inflammatory myeloid dendritic cells release IL-23 and IL-12 to activate IL-17-producing T cells, Th1 cells, and Th22 cells to produce abundant psoriatic cytokines IL-17, IFN-γ, TNF, and IL-22.  These cytokines mediate effects on keratinocytes to amplify psoriatic inflammation.  Therapeutic studies with anticytokine antibodies have shown the importance of the key cytokines IL-23, TNF, and IL-17 in this process.  We discuss the genetic background of psoriasis and its relationship to immune function, specifically genetic mutations, key PSORS loci, single nucleotide polymorphisms, and the skin transcriptome.  The assocn. between comorbidities and psoriasis is reviewed by correlating the skin transcriptome and serum proteins.  Psoriasis-related cytokine-response pathways are considered in the context of the transcriptome of different mouse models.  This approach offers a model for other inflammatory skin and autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBy6RETuUVSLVg90H21EOLACvtfcHk0liCCTgQHHVazA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXovVemt74%253D&md5=29efa4155cda7347f884244fa5732eac</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1146%2Fannurev-immunol-032713-120225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-immunol-032713-120225%26sid%3Dliteratum%253Aachs%26aulast%3DLowes%26aufirst%3DM.%2BA.%26aulast%3DSuarez-Farinas%26aufirst%3DM.%26aulast%3DKrueger%26aufirst%3DJ.%2BG.%26atitle%3DImmunology%2520of%2520psoriasis%26jtitle%3DAnnu.%2520Rev.%2520Immunol.%26date%3D2014%26volume%3D32%26spage%3D227%26epage%3D255%26doi%3D10.1146%2Fannurev-immunol-032713-120225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guttman-Yassky, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krueger, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebwohl, M. G.</span></span> <span> </span><span class="NLM_article-title">Systemic immune mechanisms in atopic dermatitis and psoriasis with implications for treatment</span>. <i>Exp. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">409</span>– <span class="NLM_lpage">417</span>, <span class="refDoi"> DOI: 10.1111/exd.13336</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.1111%2Fexd.13336" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=28266782" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A280%3ADC%252BC1czjsFentw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2018&pages=409-417&author=E.+Guttman-Yasskyauthor=J.+G.+Kruegerauthor=M.+G.+Lebwohl&title=Systemic+immune+mechanisms+in+atopic+dermatitis+and+psoriasis+with+implications+for+treatment&doi=10.1111%2Fexd.13336"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Systemic immune mechanisms in atopic dermatitis and psoriasis with implications for treatment</span></div><div class="casAuthors">Guttman-Yassky Emma; Lebwohl Mark G; Guttman-Yassky Emma; Krueger James G; Krueger James G</div><div class="citationInfo"><span class="NLM_cas:title">Experimental dermatology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">409-417</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Atopic dermatitis (AD) and psoriasis are inflammatory skin diseases that negatively affect patients' quality of life.  Although distinctions exist between these diseases, both are characterized by erythematous, thickened epidermal lesions that vary in intensity and affected body surface area.  Early models of aetiology attributed symptoms of both diseases to cutaneous inflammation at lesion sites, but recent studies have established that activated immune mediators in the circulation drive disease severity.  Activation of T helper 2 (Th2) and Th22 cells in the circulation appears to be the principal initiator of acute AD pathology, with the emergence of Th1 and Th17/interleukin (IL)-23 pathway activation marking the transition to a chronic state.  The Th17/IL-23 pathway also has an important role in psoriasis.  The role of systemic inflammation in AD and psoriasis is supported by the occurrence of non-cutaneous comorbidities that affect patients, most of which intensify morbidity and disability associated with lesional skin.  Atopic dermatitis is associated with allergic disorders consisting of the "atopic march," whereas psoriasis is frequently accompanied by psoriatic arthritis.  Patients with both disorders are at significantly higher risk of obesity, metabolic disorders, and cardiovascular diseases, all of which feature inflammatory components in their pathology models.  These insights have led to novel therapeutics aimed at addressing psoriasis by targeting tumor necrosis factor- and Th17-related cytokine pathways.  The success of these agents in psoriasis management is driving new therapeutic approaches for moderate-to-severe AD, including agents targeting the Th2 and Th17/Th22 cytokine pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTgSLfl4b90ICEJCPKhJPuqfW6udTcc2eazIUmaqiZ4W7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1czjsFentw%253D%253D&md5=17517173863e93762bae702b05aa81b6</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1111%2Fexd.13336&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fexd.13336%26sid%3Dliteratum%253Aachs%26aulast%3DGuttman-Yassky%26aufirst%3DE.%26aulast%3DKrueger%26aufirst%3DJ.%2BG.%26aulast%3DLebwohl%26aufirst%3DM.%2BG.%26atitle%3DSystemic%2520immune%2520mechanisms%2520in%2520atopic%2520dermatitis%2520and%2520psoriasis%2520with%2520implications%2520for%2520treatment%26jtitle%3DExp.%2520Dermatol.%26date%3D2018%26volume%3D27%26spage%3D409%26epage%3D417%26doi%3D10.1111%2Fexd.13336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Furumoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadina, M.</span></span> <span> </span><span class="NLM_article-title">The arrival of JAK inhibitors: advancing the treatment of immune and hematologic disorders</span>. <i>BioDrugs</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">431</span>– <span class="NLM_lpage">438</span>, <span class="refDoi"> DOI: 10.1007/s40259-013-0040-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.1007%2Fs40259-013-0040-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=23743669" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsl2nsbzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2013&pages=431-438&author=Y.+Furumotoauthor=M.+Gadina&title=The+arrival+of+JAK+inhibitors%3A+advancing+the+treatment+of+immune+and+hematologic+disorders&doi=10.1007%2Fs40259-013-0040-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The Arrival of JAK Inhibitors: Advancing the Treatment of Immune and Hematologic Disorders</span></div><div class="casAuthors">Furumoto, Yasuko; Gadina, Massimo</div><div class="citationInfo"><span class="NLM_cas:title">BioDrugs</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">431-438</span>CODEN:
                <span class="NLM_cas:coden">BIDRF4</span>;
        ISSN:<span class="NLM_cas:issn">1173-8804</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Altered prodn. of cytokines can result in pathologies ranging from autoimmune diseases to malignancies.  The Janus kinase family is a small group of receptor-assocd. signaling mols. that is essential to the signal cascade originating from type I and type II cytokine receptors.  Inhibition of tyrosine kinase enzymic activity using small mols. has recently become a powerful tool for treatment of several malignancies.  Twenty years after the discovery of these enzymes, two inhibitors for this class of kinases have been approved for clin. use and others are currently in the final stage of development.  Here we review the principles of cytokines signaling, summarize our current knowledge of the approved inhibitors, and briefly introduce some of the inhibitors that are currently under development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQNQJyHX0EDLVg90H21EOLACvtfcHk0ljF_1m1xGWMJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsl2nsbzI&md5=a593c1f01565b3dc3bf3df8c424595a6</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1007%2Fs40259-013-0040-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40259-013-0040-7%26sid%3Dliteratum%253Aachs%26aulast%3DFurumoto%26aufirst%3DY.%26aulast%3DGadina%26aufirst%3DM.%26atitle%3DThe%2520arrival%2520of%2520JAK%2520inhibitors%253A%2520advancing%2520the%2520treatment%2520of%2520immune%2520and%2520hematologic%2520disorders%26jtitle%3DBioDrugs%26date%3D2013%26volume%3D27%26spage%3D431%26epage%3D438%26doi%3D10.1007%2Fs40259-013-0040-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alessi, D. R.</span></span> <span> </span><span class="NLM_article-title">Kinase drug discovery--what’s next in the field?</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">96</span>– <span class="NLM_lpage">104</span>, <span class="refDoi"> DOI: 10.1021/cb300610s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb300610s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjvF2q" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=96-104&author=P.+Cohenauthor=D.+R.+Alessi&title=Kinase+drug+discovery%2D%2Dwhat%E2%80%99s+next+in+the+field%3F&doi=10.1021%2Fcb300610s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase Drug Discovery - What's Next in the Field?</span></div><div class="casAuthors">Cohen, Philip; Alessi, Dario R.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">96-104</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Over the past 15 years protein kinases have become the pharmaceutical industry's most important class of drug target in the field of cancer.  Some 20 drugs that target kinases have been approved for clin. use over the past decade, and hundreds more are undergoing clin. trials.  However, the recent approval of the first protein kinase inhibitors for the treatment of inflammatory diseases, coupled with an enhanced understanding of the signaling networks that control the immune system, suggests that there will be a surge of interest in this area over the next 10 years.  In this connection, we discuss opportunities for targeting protein kinases in the MyD88 signaling network for the development of drugs to treat chronic inflammatory and autoimmune diseases.  Activating mutations in protein kinases underlie many other diseases and conditions, and we also discuss why the protein kinases SPAK/OSR1 and LRRK2 have recently become interesting targets for the treatment of hypertension and Parkinson's disease, resp., and the progress that has been made in developing LRRK2 inhibitors.  Finally we suggest that more focus on the identification of inhibitors of kinase activation, rather than kinase activity, may pay dividends in identifying exquisitely specific inhibitors of signal transduction cascades, and we also highlight "pseudo-kinases" as an attractive and unexplored area for drug development that merits much more attention in the years to come.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9qmfkcqZ3ILVg90H21EOLACvtfcHk0ljF_1m1xGWMJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjvF2q&md5=5bf2ced4163b6ae70e604b2916a6a068</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Fcb300610s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb300610s%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DP.%26aulast%3DAlessi%26aufirst%3DD.%2BR.%26atitle%3DKinase%2520drug%2520discovery--what%25E2%2580%2599s%2520next%2520in%2520the%2520field%253F%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2013%26volume%3D8%26spage%3D96%26epage%3D104%26doi%3D10.1021%2Fcb300610s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mócsai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovács, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gergely, P.</span></span> <span> </span><span class="NLM_article-title">What is the future of targeted therapy in rheumatology: biologics or small molecules?</span>. <i>BMC Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">43</span>, <span class="refDoi"> DOI: 10.1186/1741-7015-12-43</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.1186%2F1741-7015-12-43" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=24620738" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjsVWjtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2014&pages=43&author=A.+M%C3%B3csaiauthor=L.+Kov%C3%A1csauthor=P.+Gergely&title=What+is+the+future+of+targeted+therapy+in+rheumatology%3A+biologics+or+small+molecules%3F&doi=10.1186%2F1741-7015-12-43"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">What is the future of targeted therapy in rheumatology: biologics or small molecules?</span></div><div class="casAuthors">Mocsai, Attila; Kovacs, Laszlo; Gergely, Peter</div><div class="citationInfo"><span class="NLM_cas:title">BMC Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">43/1-43/9, 9</span>CODEN:
                <span class="NLM_cas:coden">BMMECZ</span>;
        ISSN:<span class="NLM_cas:issn">1741-7015</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Until late in the 20th century, the therapy of rheumatic diseases relied on the use of drugs that had been developed through empirical approaches without detailed understanding of the mol. mechanisms involved.  That approach changed with the introduction of biol. therapeutics at the end of the 20th century and by the recent development of small-mol. inhibitors of intracellular signal transduction pathways.  Here we compare and discuss the advantages and disadvantages of those two groups of targeted anti-inflammatory therapeutics.  Discussion: TNF-blocking biol. agents were introduced into the therapy of rheumatoid arthritis and other autoimmune and inflammatory diseases in the late 1990s.  Further biol. agents targeting cytokine networks or specific lymphocyte subsets have since been added to the armamentarium of anti-rheumatic therapy.  During the last few years, another wave of novel discoveries led to the development of a new class of small mol. anti-inflammatory compds. targeting intracellular signal transduction mols., such as tyrosine kinases.  In all those cases, the specific targets of the drugs are well defined and significant knowledge about their role in the disease pathomechanism is available, qualifying them for being targeted therapeutics for inflammatory rheumatic diseases.  While both groups of targeted therapeutics offer significant clin. benefit, they clearly differ in several aspects, such as the localization of their targets, their route of administration and target specificity, as well as tech. details such as manufg. procedures and cost basis.  In this debate paper, we compare the advantages and disadvantages of the two different approaches, aiming to shed light on the possible future of targeted therapies.  Summary: Biol. therapeutics and small-mol. inhibitors both have significant advantages and disadvantages in the therapy of rheumatic diseases.  The future of targeted therapies is one of the most exciting questions of current rheumatol. research and therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTONjip_IttLVg90H21EOLACvtfcHk0ljF_1m1xGWMJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjsVWjtrk%253D&md5=20ede05081b83e736ad5675afcffc21d</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1186%2F1741-7015-12-43&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1741-7015-12-43%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25B3csai%26aufirst%3DA.%26aulast%3DKov%25C3%25A1cs%26aufirst%3DL.%26aulast%3DGergely%26aufirst%3DP.%26atitle%3DWhat%2520is%2520the%2520future%2520of%2520targeted%2520therapy%2520in%2520rheumatology%253A%2520biologics%2520or%2520small%2520molecules%253F%26jtitle%3DBMC%2520Med.%26date%3D2014%26volume%3D12%26spage%3D43%26doi%3D10.1186%2F1741-7015-12-43" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ritchlin, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krueger, J. G.</span></span> <span> </span><span class="NLM_article-title">New therapies for psoriasis and psoriatic arthritis</span>. <i>Curr. Opin. Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">204</span>– <span class="NLM_lpage">210</span>, <span class="refDoi"> DOI: 10.1097/BOR.0000000000000274</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.1097%2FBOR.0000000000000274" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=27022911" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC28Xlt1SqsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2016&pages=204-210&author=C.+T.+Ritchlinauthor=J.+G.+Krueger&title=New+therapies+for+psoriasis+and+psoriatic+arthritis&doi=10.1097%2FBOR.0000000000000274"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">New therapies for psoriasis and psoriatic arthritis</span></div><div class="casAuthors">Ritchlin, Christopher T.; Krueger, James G.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Rheumatology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">204-210</span>CODEN:
                <span class="NLM_cas:coden">CORHES</span>;
        ISSN:<span class="NLM_cas:issn">1040-8711</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose of review: Over the last several years, novel immunol. pathways pivotal in the development of the pathobiol. of psoriasis and psoriatic arthritis (PsA) have been revealed.  These discoveries catalyzed a search for new treatment targets resulting in many new therapies that are now available for patients with psoriatic disease.  Recent findings: Helper T cells that secrete interleukin-17 (TH17) along with CD8+ cells, innate lymphocyte cells, and gamma delta T cells are important in the pathogenesis of psoriasis and PsA.  Recently, agents that target interleukin-17, the interleukin-17 receptor, and interleukin-23 (antip19) have been approved or are in clin. trials.  Apremilast, a new oral agent, was approved for the treatment of psoriasis and PsA.  Summary: Secukinumab, an interleukin-17A antibody, has been approved for treatment of psoriasis and PsA in the United States.  It is effective with a good safety profile.  Ixekizumab, another anti-interleukin-17A antibody, is currently in clin. trials and brodalumab, an interleukin-17 receptor antagonist, was removed from clin. trials because of safety concerns despite demonstrated efficacy in psoriasis and PsA.  Targeting interleukin-23 with antibodies to p19 is another approach with encouraging results in psoriasis.  Apremilast, an oral agent, approved to treat psoriasis and PsA demonstrates moderate efficacy with an excellent safety record.  The role of tofacitinib in psoriatic disease remains to be detd. pending a safety review in psoriasis and completion of PsA trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKQAm4F1wdTbVg90H21EOLACvtfcHk0lgal5ig846dfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xlt1SqsLY%253D&md5=f4a645f44a8d9214eb3679bacabdac9f</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1097%2FBOR.0000000000000274&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FBOR.0000000000000274%26sid%3Dliteratum%253Aachs%26aulast%3DRitchlin%26aufirst%3DC.%2BT.%26aulast%3DKrueger%26aufirst%3DJ.%2BG.%26atitle%3DNew%2520therapies%2520for%2520psoriasis%2520and%2520psoriatic%2520arthritis%26jtitle%3DCurr.%2520Opin.%2520Rheumatol.%26date%3D2016%26volume%3D28%26spage%3D204%26epage%3D210%26doi%3D10.1097%2FBOR.0000000000000274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Behrens, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koehm, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwaneck, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmalzing, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gnann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tony, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burkhardt, H.</span></span> <span> </span><span class="NLM_article-title">Minimal disease activity is a stable measure of therapeutic response in psoriatic arthritis patients receiving treatment with adalimumab</span>. <i>Rheumatology (Oxford, U. K.)</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">1938</span>– <span class="NLM_lpage">1946</span>, <span class="refDoi"> DOI: 10.1093/rheumatology/key203</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.1093%2Frheumatology%2Fkey203" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=30010891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlWksb%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=1938-1946&author=F.+Behrensauthor=M.+Koehmauthor=E.+C.+Schwaneckauthor=M.+Schmalzingauthor=H.+Gnannauthor=G.+Gregerauthor=H.+P.+Tonyauthor=H.+Burkhardt&title=Minimal+disease+activity+is+a+stable+measure+of+therapeutic+response+in+psoriatic+arthritis+patients+receiving+treatment+with+adalimumab&doi=10.1093%2Frheumatology%2Fkey203"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Minimal disease activity is a stable measure of therapeutic response in psoriatic arthritis patients receiving treatment with adalimumab</span></div><div class="casAuthors">Behrens, Frank; Koehm, Michaela; Schwaneck, Eva C.; Schmalzing, Marc; Gnann, Holger; Greger, Gerd; Tony, Hans-Peter; Burkhardt, Harald</div><div class="citationInfo"><span class="NLM_cas:title">Rheumatology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1938-1946</span>CODEN:
                <span class="NLM_cas:coden">RUMAFK</span>;
        ISSN:<span class="NLM_cas:issn">1462-0332</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Objective.  The aim of this study was to evaluate minimal disease activity (MDA) assessments in patients with PsA during routine clin. care.  We used data from a multicentre observational study of patients with active PsA who initiated treatment with adalimumab during routine clin. practice and continued treatment for at least 6 mo to evaluate achievement of MDA, individual MDA criteria (modified to conform to study assessments) and ACR responses during 24 mo of therapy.  Pearson correlation coeffs. were used to evaluate the assocn. between MDA and individual criteria at month 6; regression models were used to det. the influence of baseline MDA criteria on achievement of MDA at month 6.  A total of 1684 patients were included in these analyses; most had long-standing disease.  MDA was achieved by 597 patients (35.5%) at month 6.  This proportion increased to 45.5% at month 24 in patients remaining on therapy.  MDA status was stable over time; >75% of patients with MDA at month 6 recorded MDA at subsequent visits.  Pain was the most difficult individual criterion to achieve, and enthesitis was the least difficult.  Higher functional status and fewer tender joints at baseline predicted achievement of MDA at month 6.  About half of patients (51.5%) with an ACR20 response at month 6 achieved MDA.  Conclusion.  In this observational cohort of patients with long-standing disease, MDA provided a stable and valid assessment of clin. status over 24 mo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogMUGXjLLl3bVg90H21EOLACvtfcHk0lgal5ig846dfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlWksb%252FI&md5=6efbe8a5b9067a638d07cd2ae7954c71</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1093%2Frheumatology%2Fkey203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Frheumatology%252Fkey203%26sid%3Dliteratum%253Aachs%26aulast%3DBehrens%26aufirst%3DF.%26aulast%3DKoehm%26aufirst%3DM.%26aulast%3DSchwaneck%26aufirst%3DE.%2BC.%26aulast%3DSchmalzing%26aufirst%3DM.%26aulast%3DGnann%26aufirst%3DH.%26aulast%3DGreger%26aufirst%3DG.%26aulast%3DTony%26aufirst%3DH.%2BP.%26aulast%3DBurkhardt%26aufirst%3DH.%26atitle%3DMinimal%2520disease%2520activity%2520is%2520a%2520stable%2520measure%2520of%2520therapeutic%2520response%2520in%2520psoriatic%2520arthritis%2520patients%2520receiving%2520treatment%2520with%2520adalimumab%26jtitle%3DRheumatology%2520%2528Oxford%252C%2520U.%2520K.%2529%26date%3D2018%26volume%3D57%26spage%3D1938%26epage%3D1946%26doi%3D10.1093%2Frheumatology%2Fkey203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mease, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Heijde, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landewe, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mpofu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tahir, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singhal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boettcher, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navarra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meiser, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Readie, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pricop, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abrams, K.</span></span> <span> </span><span class="NLM_article-title">Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III future 5 study</span>. <i>Ann. Rheum. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">890</span>– <span class="NLM_lpage">897</span>, <span class="refDoi"> DOI: 10.1136/annrheumdis-2017-212687</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.1136%2Fannrheumdis-2017-212687" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=29550766" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC1MXislSitr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2018&pages=890-897&author=P.+Measeauthor=D.+van+der+Heijdeauthor=R.+Landeweauthor=S.+Mpofuauthor=P.+Rahmanauthor=H.+Tahirauthor=A.+Singhalauthor=E.+Boettcherauthor=S.+Navarraauthor=K.+Meiserauthor=A.+Readieauthor=L.+Pricopauthor=K.+Abrams&title=Secukinumab+improves+active+psoriatic+arthritis+symptoms+and+inhibits+radiographic+progression%3A+primary+results+from+the+randomised%2C+double-blind%2C+phase+III+future+5+study&doi=10.1136%2Fannrheumdis-2017-212687"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study</span></div><div class="casAuthors">Mease, Philip; van der Heijde, Desiree; Landewe, Robert; Mpofu, Shephard; Rahman, Proton; Tahir, Hasan; Singhal, Atul; Boettcher, Elke; Navarra, Sandra; Meiser, Karin; Readie, Aimee; Pricop, Luminita; Abrams, Ken</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the Rheumatic Diseases</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">890-897</span>CODEN:
                <span class="NLM_cas:coden">ARDIAO</span>;
        ISSN:<span class="NLM_cas:issn">0003-4967</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">Objectives T o evaluate the effect of s.c. (s.c.) secukinumab, an interleukin-17A inhibitor, on clin. signs and symptoms and radiog. progression in patients with psoriatic arthritis (PsA).  Methods Adults (n=996) with active PsA were randomised 2:2:2:3 to s.c. secukinumab 300 mg or 150 mg with loading dose (LD), 150 mg without LD or placebo.  All groups received secukinumab or placebo at baseline, weeks 1, 2 and 3 and then every 4 wk from week 4.  The primary endpoint was the proportion of patients achieving an American College of Rheumatol. 20 (ACR20) response at week 16.  Results Significantly more patients achieved an ACR20 response at week 16 with secukinumab 300 mg with LD (62.6%), 150 mg with LD (55.5%) or 150 mg without LD (59.5%) than placebo (27.4%) (p<0.0001 for all; non-responder imputation).  Radiog. progression, as measured by van der Heijde-modified total Sharp score, was significantly inhibited at week 24 in all secukinumab arms vs. placebo (p<0.01 for 300 mg with LD and 150 mg without LD and p<0.05 for 150 mg with LD; linear extrapolation).  Adverse event rates at week 24 were similar across treatment arms: 63.1% (300 mg with LD), 62.7% (150 mg with LD), 61.1% (150 mg without LD) and 62.0% (placebo).  No deaths or new safety signals were reported.  Conclusion S.c. secukinumab 300 mg and 150 mg with and without LD significantly improved clin. signs and symptoms and inhibited radiog. structural progression vs. placebo at week 24 in patients with PsA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYCabo-EbLFLVg90H21EOLACvtfcHk0libLuXkRYswgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXislSitr8%253D&md5=1a06f5f8aa8d7c06b5863a7982978e36</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1136%2Fannrheumdis-2017-212687&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fannrheumdis-2017-212687%26sid%3Dliteratum%253Aachs%26aulast%3DMease%26aufirst%3DP.%26aulast%3Dvan%2Bder%2BHeijde%26aufirst%3DD.%26aulast%3DLandewe%26aufirst%3DR.%26aulast%3DMpofu%26aufirst%3DS.%26aulast%3DRahman%26aufirst%3DP.%26aulast%3DTahir%26aufirst%3DH.%26aulast%3DSinghal%26aufirst%3DA.%26aulast%3DBoettcher%26aufirst%3DE.%26aulast%3DNavarra%26aufirst%3DS.%26aulast%3DMeiser%26aufirst%3DK.%26aulast%3DReadie%26aufirst%3DA.%26aulast%3DPricop%26aufirst%3DL.%26aulast%3DAbrams%26aufirst%3DK.%26atitle%3DSecukinumab%2520improves%2520active%2520psoriatic%2520arthritis%2520symptoms%2520and%2520inhibits%2520radiographic%2520progression%253A%2520primary%2520results%2520from%2520the%2520randomised%252C%2520double-blind%252C%2520phase%2520III%2520future%25205%2520study%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2018%26volume%3D77%26spage%3D890%26epage%3D897%26doi%3D10.1136%2Fannrheumdis-2017-212687" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J. J.</span></span> <span> </span><span class="NLM_article-title">Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases</span>. <i>Nat. Rev. Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">25</span>– <span class="NLM_lpage">36</span>, <span class="refDoi"> DOI: 10.1038/nrrheum.2015.167</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.1038%2Fnrrheum.2015.167" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=26633291" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvF2ks7vJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=25-36&author=D.+M.+Schwartzauthor=M.+Bonelliauthor=M.+Gadinaauthor=J.+J.+O%E2%80%99Shea&title=Type+I%2FII+cytokines%2C+JAKs%2C+and+new+strategies+for+treating+autoimmune+diseases&doi=10.1038%2Fnrrheum.2015.167"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases</span></div><div class="casAuthors">Schwartz, Daniella M.; Bonelli, Michael; Gadina, Massimo; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Rheumatology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">25-36</span>CODEN:
                <span class="NLM_cas:coden">NRRACB</span>;
        ISSN:<span class="NLM_cas:issn">1759-4790</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Cytokines are major drivers of autoimmunity, and biol. agents targeting cytokines have revolutionized the treatment of immune-mediated diseases.  Despite the effectiveness of these drugs, they do not induce complete remission in all patients, prompting the development of alternative strategies - including targeting of intracellular signal transduction pathways downstream of cytokines.  Many cytokines that bind type I and type II cytokine receptors are crit. regulators of immune-mediated diseases and employ the Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathway to exert their effect.  Pharmacol. inhibition of JAKs blocks the actions of type I/II cytokines, and within the past 3 years therapeutic JAK inhibitors, or Jakinibs, have become available to rheumatologists.  Jakinibs have proven effective for the treatment of rheumatoid arthritis and other inflammatory diseases.  Adverse effects of these agents are largely related to their mode of action and include infections and hyperlipidemia.  Jakinibs are currently being investigated for a no. of new indications, and second-generation selective Jakinibs are being developed and tested.  Targeting STATs could be a future avenue for the treatment of rheumatol. diseases, although substantial challenges remain.  Nonetheless, the ability to therapeutically target intracellular signalling pathways has already created a new paradigm for the treatment of rheumatol. disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUdr1Dh92dnLVg90H21EOLACvtfcHk0libLuXkRYswgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvF2ks7vJ&md5=e06f7ab6424f1fbdbf481c75fa9ebd23</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fnrrheum.2015.167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrrheum.2015.167%26sid%3Dliteratum%253Aachs%26aulast%3DSchwartz%26aufirst%3DD.%2BM.%26aulast%3DBonelli%26aufirst%3DM.%26aulast%3DGadina%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DType%2520I%252FII%2520cytokines%252C%2520JAKs%252C%2520and%2520new%2520strategies%2520for%2520treating%2520autoimmune%2520diseases%26jtitle%3DNat.%2520Rev.%2520Rheumatol.%26date%3D2016%26volume%3D12%26spage%3D25%26epage%3D36%26doi%3D10.1038%2Fnrrheum.2015.167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bryan, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajapaksa, N. S.</span></span> <span> </span><span class="NLM_article-title">Kinase inhibitors for the treatment of immunological disorders: recent advances</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">9030</span>– <span class="NLM_lpage">9058</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00667</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00667" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVOmsLzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=9030-9058&author=M.+C.+Bryanauthor=N.+S.+Rajapaksa&title=Kinase+inhibitors+for+the+treatment+of+immunological+disorders%3A+recent+advances&doi=10.1021%2Facs.jmedchem.8b00667"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase Inhibitors for the Treatment of Immunological Disorders: Recent Advances</span></div><div class="casAuthors">Bryan, Marian C.; Rajapaksa, Naomi S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">9030-9058</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Small mol. inhibitors targeting autoimmune and inflammatory processes have been an area of intense focus within academia and industry.  Much of this work has been aimed at key kinases operating as central nodes in inflammatory signaling pathways.  While this focus has led to over 30 FDA-approved small mol. kinase inhibitors, only one is currently approved for autoimmune and inflammatory diseases.  Despite this lack of success, there remains tremendous reason for excitement.  Our growing understanding of the biol. involved in the inflammatory response, the factors that lead to safer small mol. kinase inhibitors, and the availability of selective tool mols. for interrogating specific nodes and pathways are all pushing the field forward.  This article focuses on recent developments requiring novel approaches to create safe and effective small mol. kinase inhibitors and where further work is needed to realize the promise of small mol. kinase inhibitors for patient benefit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVucOE4LCJALVg90H21EOLACvtfcHk0libLuXkRYswgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVOmsLzI&md5=aff62adff54c9152d2b2156b05d67400</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00667%26sid%3Dliteratum%253Aachs%26aulast%3DBryan%26aufirst%3DM.%2BC.%26aulast%3DRajapaksa%26aufirst%3DN.%2BS.%26atitle%3DKinase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520immunological%2520disorders%253A%2520recent%2520advances%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D9030%26epage%3D9058%26doi%3D10.1021%2Facs.jmedchem.8b00667" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levine, R. L.</span></span> <span> </span><span class="NLM_article-title">Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">2051</span>– <span class="NLM_lpage">2059</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-0279</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.1158%2F1078-0432.CCR-13-0279" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=24583800" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtl2ms78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=2051-2059&author=S.+C.+Meyerauthor=R.+L.+Levine&title=Molecular+pathways%3A+molecular+basis+for+sensitivity+and+resistance+to+JAK+kinase+inhibitors&doi=10.1158%2F1078-0432.CCR-13-0279"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Pathways: Molecular Basis for Sensitivity and Resistance to JAK Kinase Inhibitors</span></div><div class="casAuthors">Meyer, Sara C.; Levine, Ross L.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2051-2059</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Janus-activated kinases (JAK) are the mediators of a variety of cytokine signals via their cognate receptors that result in activation of intracellular signaling pathways.  Alterations in JAK1, JAK2, JAK3, and TYK2 signaling contribute to different disease states, and dysregulated JAK-STAT signaling is assocd. with hematol. malignancies, autoimmune disorders, and immune-deficient conditions.  Genetic alterations of JAK2 occur in the majority of patients with myeloproliferative neoplasms and occur in a subset of patients with acute leukemias.  JAK-mediated signaling critically relies on STAT transcription factors, and on activation of the MAPK and PI3K/Akt signaling axes.  Hyperactive JAK at the apex of these potent oncogenic signaling pathways therefore represents an important target for small-mol. kinase inhibitors in different disease states.  The JAK1/2 inhibitor ruxolitinib and the JAK3 inhibitor tofacitinib were recently approved for the treatment of myelofibrosis and rheumatoid arthritis, resp., and addnl. ATP-competitive JAK inhibitors are in clin. development.  Although these agents show clin. activity, the ability of these JAK inhibitors to induce clin./mol. remissions in hematol. malignancies seems limited and resistance upon chronic drug exposure is seen.  Alternative modes of targeting JAK2 such as allosteric kinase inhibition or HSP90 inhibition are under evaluation, as is the use of histone deacetylase inhibitors.  Combination therapy approaches integrating inhibition of STAT, PI3K/Akt, and MAPK pathways with JAK kinase inhibitors might be crit. to overcome malignancies characterized by dysregulated JAK signaling.  Clin Cancer Res; 20(8); 2051-9. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKgmYqhJDI07Vg90H21EOLACvtfcHk0ljaexEvlrvVrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtl2ms78%253D&md5=7c7ad00b5c8020fd660d86c057827eb2</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-0279&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-0279%26sid%3Dliteratum%253Aachs%26aulast%3DMeyer%26aufirst%3DS.%2BC.%26aulast%3DLevine%26aufirst%3DR.%2BL.%26atitle%3DMolecular%2520pathways%253A%2520molecular%2520basis%2520for%2520sensitivity%2520and%2520resistance%2520to%2520JAK%2520kinase%2520inhibitors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26spage%3D2051%26epage%3D2059%26doi%3D10.1158%2F1078-0432.CCR-13-0279" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vannucchi, A. M.</span></span> <span> </span><span class="NLM_article-title">Ruxolitinib: a potent and selective janus kinase 1 and 2 inhibitor in patients with myelofibrosis. an update for clinicians</span>. <i>Ther. Adv. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">341</span>– <span class="NLM_lpage">354</span>, <span class="refDoi"> DOI: 10.1177/2040620712459746</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.1177%2F2040620712459746" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=23606937" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnslWntA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=341-354&author=C.+Harrisonauthor=A.+M.+Vannucchi&title=Ruxolitinib%3A+a+potent+and+selective+janus+kinase+1+and+2+inhibitor+in+patients+with+myelofibrosis.+an+update+for+clinicians&doi=10.1177%2F2040620712459746"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians</span></div><div class="casAuthors">Harrison, Claire; Vannucchi, Alessandro N.</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutic Advances in Hematology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">341-354</span>CODEN:
                <span class="NLM_cas:coden">TAHHAT</span>;
        ISSN:<span class="NLM_cas:issn">2040-6207</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">A review.  Ruxolitinib became the first US Food and Drug Administration approved therapy for myelofibrosis in 2011 and EU approval is anticipated in summer 2012.  Two large phase III trials (known as the COMFORT studies) were the basis for this approval and were published recently.  In this review article we discuss the challenges in managing myelofibrosis, the information to date about ruxolitinib and speculate as to the future direction with this and similar agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-1M-lwEgpCrVg90H21EOLACvtfcHk0ljaexEvlrvVrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnslWntA%253D%253D&md5=6c88ade9fb3df126e6b0188b69a68d3c</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1177%2F2040620712459746&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F2040620712459746%26sid%3Dliteratum%253Aachs%26aulast%3DHarrison%26aufirst%3DC.%26aulast%3DVannucchi%26aufirst%3DA.%2BM.%26atitle%3DRuxolitinib%253A%2520a%2520potent%2520and%2520selective%2520janus%2520kinase%25201%2520and%25202%2520inhibitor%2520in%2520patients%2520with%2520myelofibrosis.%2520an%2520update%2520for%2520clinicians%26jtitle%3DTher.%2520Adv.%2520Hematol.%26date%3D2012%26volume%3D3%26spage%3D341%26epage%3D354%26doi%3D10.1177%2F2040620712459746" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Papp, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menter, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Disch, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlichting, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaich, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macias, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janes, J. M.</span></span> <span> </span><span class="NLM_article-title">A randomized phase 2b trial of baricitinib, an oral janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis</span>. <i>Br. J. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>174</i></span>,  <span class="NLM_fpage">1266</span>– <span class="NLM_lpage">1276</span>, <span class="refDoi"> DOI: 10.1111/bjd.14403</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.1111%2Fbjd.14403" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=26800231" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVSiurfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=174&publication_year=2016&pages=1266-1276&author=K.+A.+Pappauthor=M.+A.+Menterauthor=M.+Ramanauthor=D.+Dischauthor=D.+E.+Schlichtingauthor=C.+Gaichauthor=W.+Maciasauthor=X.+Zhangauthor=J.+M.+Janes&title=A+randomized+phase+2b+trial+of+baricitinib%2C+an+oral+janus+kinase+%28JAK%29+1%2FJAK2+inhibitor%2C+in+patients+with+moderate-to-severe+psoriasis&doi=10.1111%2Fbjd.14403"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis</span></div><div class="casAuthors">Papp, K. A.; Menter, M. A.; Raman, M.; Disch, D.; Schlichting, D. E.; Gaich, C.; Macias, W.; Zhang, X.; Janes, J. M.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Dermatology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">174</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1266-1276</span>CODEN:
                <span class="NLM_cas:coden">BJDEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0007-0963</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : Background : Plaque psoriasis is a chronic and often debilitating skin disorder and proinflammatory cytokines are known to play a key role in the disease process.  Objectives : To evaluate the safety and efficacy of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis in a randomized, double-blind, placebo-controlled, dose-ranging phase 2b study.  Methods : Patients were randomized (n = 271) to receive placebo or oral baricitinib at 2, 4, 8 or 10 mg once daily for 12 wk (Part A).  Dose adjustment for 12 addnl. weeks was based on percentage improvement in the Psoriasis Area and Severity Index (PASI) score.  The primary end point was Psoriasis Area and Severity Index (PASI) 75% (PASI-75) at 12 wk for North American patients (n = 238); secondary end points were safety and efficacy measures in the entire population.  Results : At week 12, more North American patients in the 8-mg (43%) and 10-mg (54%) baricitinib groups than in placebo group (17%; P < 0·05) achieved PASI-75.  All baricitinib-treated groups had greater mean changes from baseline in their PASI scores (P < 0·05) at 12 wk and (except 2 mg) had higher rates of PASI-50 than the placebo group; statistically significant PASI-90 responses were achieved in the 8-mg and 10-mg groups at 8 and 12 wk.  More than 81% of PASI-75 responders maintained their scores through 24 wk.  During Part A, study discontinuations due to adverse events (AEs) were 0%, 0%, 2·8%, 6·3% and 5·8% and treatment-emergent AE rates were 44%, 50%, 47%, 58% and 64% for placebo and 2-, 4-, 8- and 10-mg baricitinib groups, resp.  No opportunistic infections were obsd. in any treatment group.  Dose-dependent changes in lab. values were obsd.  Conclusions : Patients with moderate-to-severe psoriasis treated with baricitinib for 12 wk achieved significant improvements in PASI-75.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqVPv2558vrrVg90H21EOLACvtfcHk0ljaexEvlrvVrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVSiurfN&md5=37df34807683b4742548f192f99654f6</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1111%2Fbjd.14403&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbjd.14403%26sid%3Dliteratum%253Aachs%26aulast%3DPapp%26aufirst%3DK.%2BA.%26aulast%3DMenter%26aufirst%3DM.%2BA.%26aulast%3DRaman%26aufirst%3DM.%26aulast%3DDisch%26aufirst%3DD.%26aulast%3DSchlichting%26aufirst%3DD.%2BE.%26aulast%3DGaich%26aufirst%3DC.%26aulast%3DMacias%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DJanes%26aufirst%3DJ.%2BM.%26atitle%3DA%2520randomized%2520phase%25202b%2520trial%2520of%2520baricitinib%252C%2520an%2520oral%2520janus%2520kinase%2520%2528JAK%2529%25201%252FJAK2%2520inhibitor%252C%2520in%2520patients%2520with%2520moderate-to-severe%2520psoriasis%26jtitle%3DBr.%2520J.%2520Dermatol.%26date%3D2016%26volume%3D174%26spage%3D1266%26epage%3D1276%26doi%3D10.1111%2Fbjd.14403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanno, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villarino, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J. J.</span></span> <span> </span><span class="NLM_article-title">JAK inhibition as a therapeutic strategy for immune and inflammatory diseases</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">843</span>– <span class="NLM_lpage">862</span>, <span class="refDoi"> DOI: 10.1038/nrd.2017.201</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.1038%2Fnrd.2017.201" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=29104284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslGqsLnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=843-862&author=D.+M.+Schwartzauthor=Y.+Kannoauthor=A.+Villarinoauthor=M.+Wardauthor=M.+Gadinaauthor=J.+J.+O%E2%80%99Shea&title=JAK+inhibition+as+a+therapeutic+strategy+for+immune+and+inflammatory+diseases&doi=10.1038%2Fnrd.2017.201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">JAK inhibition as a therapeutic strategy for immune and inflammatory diseases</span></div><div class="casAuthors">Schwartz, Daniella M.; Kanno, Yuka; Villarino, Alejandro; Ward, Michael; Gadina, Massimo; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">843-862</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  The discovery of cytokines as key drivers of immune-mediated diseases has spurred efforts to target their assocd. signalling pathways.  Janus kinases (JAKs) are essential signalling mediators downstream of many pro-inflammatory cytokines, and small-mol. inhibitors of JAKs (jakinibs) have gained traction as safe and efficacious options for the treatment of inflammation-driven pathologies such as rheumatoid arthritis, psoriasis and inflammatory bowel disease.  Building on the clin. success of first-generation jakinibs, second-generation compds. that claim to be more selective are currently undergoing development and proceeding to clin. trials.  However, important questions remain about the advantages and limitations of improved JAK selectivity, optimal routes and dosing regimens and how best to identify patients who will benefit from jakinibs.  This Review discusses the biol. of jakinibs from a translational perspective, focusing on recent insights from clin. trials, the development of novel agents and the use of jakinibs in a spectrum of immune and inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9TNpGT01l8rVg90H21EOLACvtfcHk0lhj80ydVg6IYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslGqsLnO&md5=4607422f83f94c0c7194935d6d460c31</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2017.201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2017.201%26sid%3Dliteratum%253Aachs%26aulast%3DSchwartz%26aufirst%3DD.%2BM.%26aulast%3DKanno%26aufirst%3DY.%26aulast%3DVillarino%26aufirst%3DA.%26aulast%3DWard%26aufirst%3DM.%26aulast%3DGadina%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DJAK%2520inhibition%2520as%2520a%2520therapeutic%2520strategy%2520for%2520immune%2520and%2520inflammatory%2520diseases%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2017%26volume%3D16%26spage%3D843%26epage%3D862%26doi%3D10.1038%2Fnrd.2017.201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wernig, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kharas, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okabe, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leeman, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cullen, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gozo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDowell, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levine, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doukas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mak, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noronha, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, Y. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soll, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tefferi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hood, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilliland, D. G.</span></span> <span> </span><span class="NLM_article-title">Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">311</span>– <span class="NLM_lpage">320</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2008.02.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.1016%2Fj.ccr.2008.02.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=18394554" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BD1cXkslSjtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2008&pages=311-320&author=G.+Wernigauthor=M.+G.+Kharasauthor=R.+Okabeauthor=S.+A.+Mooreauthor=D.+S.+Leemanauthor=D.+E.+Cullenauthor=M.+Gozoauthor=E.+P.+McDowellauthor=R.+L.+Levineauthor=J.+Doukasauthor=C.+C.+Makauthor=G.+Noronhaauthor=M.+Martinauthor=Y.+D.+Koauthor=B.+H.+Leeauthor=R.+M.+Sollauthor=A.+Tefferiauthor=J.+D.+Hoodauthor=D.+G.+Gilliland&title=Efficacy+of+TG101348%2C+a+selective+JAK2+inhibitor%2C+in+treatment+of+a+murine+model+of+JAK2V617F-induced+polycythemia+vera&doi=10.1016%2Fj.ccr.2008.02.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera</span></div><div class="casAuthors">Wernig, Gerlinde; Kharas, Michael G.; Okabe, Rachel; Moore, Sandra A.; Leeman, Dena S.; Cullen, Dana E.; Gozo, Maricel; McDowell, Elizabeth P.; Levine, Ross L.; Doukas, John; Mak, Chi Ching; Noronha, Glenn; Martin, Michael; Ko, Yon D.; Lee, Benjamin H.; Soll, Richard M.; Tefferi, Ayalew; Hood, John D.; Gilliland, D. Gary</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">311-320</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">We report that TG101348, a selective small-mol. inhibitor of JAK2 with an in vitro IC50 of ∼3 nM, shows therapeutic efficacy in a murine model of myeloproliferative disease induced by the JAK2V617F mutation.  In treated animals, there was a statistically significant redn. in hematocrit and leukocyte count, a dose-dependent redn./elimination of extramedullary hematopoiesis, and, at least in some instances, evidence for attenuation of myelofibrosis.  There were no apparent toxicities and no effect on T cell no.  In vivo responses were correlated with surrogate endpoints, including redn./elimination of JAK2V617F disease burden assessed by quant. genomic PCR, suppression of endogenous erythroid colony formation, and in vivo inhibition of JAK-STAT signal transduction as assessed by flow cytometric measurement of phosphorylated Stat5.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSJOc4cS_lO7Vg90H21EOLACvtfcHk0lhj80ydVg6IYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXkslSjtrs%253D&md5=3dd923595cafebb6439dd67f026735be</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2008.02.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2008.02.009%26sid%3Dliteratum%253Aachs%26aulast%3DWernig%26aufirst%3DG.%26aulast%3DKharas%26aufirst%3DM.%2BG.%26aulast%3DOkabe%26aufirst%3DR.%26aulast%3DMoore%26aufirst%3DS.%2BA.%26aulast%3DLeeman%26aufirst%3DD.%2BS.%26aulast%3DCullen%26aufirst%3DD.%2BE.%26aulast%3DGozo%26aufirst%3DM.%26aulast%3DMcDowell%26aufirst%3DE.%2BP.%26aulast%3DLevine%26aufirst%3DR.%2BL.%26aulast%3DDoukas%26aufirst%3DJ.%26aulast%3DMak%26aufirst%3DC.%2BC.%26aulast%3DNoronha%26aufirst%3DG.%26aulast%3DMartin%26aufirst%3DM.%26aulast%3DKo%26aufirst%3DY.%2BD.%26aulast%3DLee%26aufirst%3DB.%2BH.%26aulast%3DSoll%26aufirst%3DR.%2BM.%26aulast%3DTefferi%26aufirst%3DA.%26aulast%3DHood%26aufirst%3DJ.%2BD.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26atitle%3DEfficacy%2520of%2520TG101348%252C%2520a%2520selective%2520JAK2%2520inhibitor%252C%2520in%2520treatment%2520of%2520a%2520murine%2520model%2520of%2520JAK2V617F-induced%2520polycythemia%2520vera%26jtitle%3DCancer%2520Cell%26date%3D2008%26volume%3D13%26spage%3D311%26epage%3D320%26doi%3D10.1016%2Fj.ccr.2008.02.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Papp, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pariser, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catlin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wierz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ball, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akinlade, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeiher, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krueger, J. G.</span></span> <span> </span><span class="NLM_article-title">A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel janus kinase inhibitor, in patients with moderate-to-severe psoriasis</span>. <i>Br. J. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>173</i></span>,  <span class="NLM_fpage">767</span>– <span class="NLM_lpage">776</span>, <span class="refDoi"> DOI: 10.1111/bjd.13745</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.1111%2Fbjd.13745" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=25704750" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsF2rtbnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=173&publication_year=2015&pages=767-776&author=K.+Pappauthor=D.+Pariserauthor=M.+Catlinauthor=G.+Wierzauthor=G.+Ballauthor=B.+Akinladeauthor=B.+Zeiherauthor=J.+G.+Krueger&title=A+phase+2a+randomized%2C+double-blind%2C+placebo-controlled%2C+sequential+dose-escalation+study+to+evaluate+the+efficacy+and+safety+of+ASP015K%2C+a+novel+janus+kinase+inhibitor%2C+in+patients+with+moderate-to-severe+psoriasis&doi=10.1111%2Fbjd.13745"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis</span></div><div class="casAuthors">Papp, K.; Pariser, D.; Catlin, M.; Wierz, G.; Ball, G.; Akinlade, B.; Zeiher, B.; Krueger, J. G.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Dermatology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">173</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">767-776</span>CODEN:
                <span class="NLM_cas:coden">BJDEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0007-0963</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background : Many immune-mediated disorders, including psoriasis, involve cytokine signalling via Janus kinase (JAK) enzymes.  ASP015K (also designated JNJ-54781532), a novel oral JAK inhibitor, has shown moderate selectivity for JAK3 over JAK1 and JAK2 in enzyme assays.  Objectives : The objective of this study was to evaluate the efficacy and safety of escalating, sequentially grouped, doses of ASP015K vs. placebo in patients with moderate-to-severe psoriasis.  Methods : This phase 2a multicentre, double-blind, randomized, placebo-controlled study (NCT01096862) enrolled 124 patients with moderate-to-severe plaque psoriasis.  Five sequential ASP015K cohorts were enrolled, consisting of four twice-daily dosing groups (10, 25, 60, 100 mg) and one once-daily dosing group (50 mg) for 6 wk.  Results : The primary efficacy end point [mean change in Psoriasis Area and Severity Index score from baseline to end of treatment (EOT; day 42)] significantly favored ASP015K (overall treatment effect; P < 0·001) vs. placebo, with greater improvements at higher doses.  By EOT, the secondary end points [Physician Static Global Assessment (PSGA) score, percentage of patients achieving PSGA success, and change in percentage, body surface area (BSA)] also improved with ASP015K vs. placebo (P < 0·001 for PSGA score and BSA;P < 0·01 for PSGA success).  Epidermal thickness and proliferation decreased from baseline with ASP015K vs. placebo.  ASP015K was generally well tolerated, with no serious adverse events (AEs) reported.  Conclusions : In patients with moderate-to-severe psoriasis, ASP015K demonstrated dose-dependent improvements in clin. and histol. measures of severity over 6 wk of treatment.  At all doses, ASP015K was well tolerated, with no reported serious AEs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCwNPtMdSIj7Vg90H21EOLACvtfcHk0lhapaOMBbuHnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsF2rtbnE&md5=a5627c011184412f25b6d26cbc8b40a5</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1111%2Fbjd.13745&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbjd.13745%26sid%3Dliteratum%253Aachs%26aulast%3DPapp%26aufirst%3DK.%26aulast%3DPariser%26aufirst%3DD.%26aulast%3DCatlin%26aufirst%3DM.%26aulast%3DWierz%26aufirst%3DG.%26aulast%3DBall%26aufirst%3DG.%26aulast%3DAkinlade%26aufirst%3DB.%26aulast%3DZeiher%26aufirst%3DB.%26aulast%3DKrueger%26aufirst%3DJ.%2BG.%26atitle%3DA%2520phase%25202a%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%252C%2520sequential%2520dose-escalation%2520study%2520to%2520evaluate%2520the%2520efficacy%2520and%2520safety%2520of%2520ASP015K%252C%2520a%2520novel%2520janus%2520kinase%2520inhibitor%252C%2520in%2520patients%2520with%2520moderate-to-severe%2520psoriasis%26jtitle%3DBr.%2520J.%2520Dermatol.%26date%3D2015%26volume%3D173%26spage%3D767%26epage%3D776%26doi%3D10.1111%2Fbjd.13745" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wrobleski, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moslin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spergel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kempson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokarski, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strnad, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zupa-Fernandez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shuster, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillooly, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heimrich, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruzanov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tredup, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulligan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arienzo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aranibar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiney, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chimalakonda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitts, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, D. S.</span></span> <span> </span><span class="NLM_article-title">Highly selective inhibition of tyrosine kinase 2 (TYK2) for the treatment of autoimmune diseases: discovery of the allosteric inhibitor BMS-986165</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">8973</span>– <span class="NLM_lpage">8995</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00444</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00444" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlyht7%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=8973-8995&author=S.+T.+Wrobleskiauthor=R.+Moslinauthor=S.+Linauthor=Y.+Zhangauthor=S.+Spergelauthor=J.+Kempsonauthor=J.+S.+Tokarskiauthor=J.+Strnadauthor=A.+Zupa-Fernandezauthor=L.+Chengauthor=D.+Shusterauthor=K.+Gilloolyauthor=X.+Yangauthor=E.+Heimrichauthor=K.+W.+McIntyreauthor=C.+Chaudhryauthor=J.+Khanauthor=M.+Ruzanovauthor=J.+Tredupauthor=D.+Mulliganauthor=D.+Xieauthor=H.+Sunauthor=C.+Huangauthor=C.+D%E2%80%99Arienzoauthor=N.+Aranibarauthor=M.+Chineyauthor=A.+Chimalakondaauthor=W.+J.+Pittsauthor=L.+Lombardoauthor=P.+H.+Carterauthor=J.+R.+Burkeauthor=D.+S.+Weinstein&title=Highly+selective+inhibition+of+tyrosine+kinase+2+%28TYK2%29+for+the+treatment+of+autoimmune+diseases%3A+discovery+of+the+allosteric+inhibitor+BMS-986165&doi=10.1021%2Facs.jmedchem.9b00444"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165</span></div><div class="casAuthors">Wrobleski, Stephen T.; Moslin, Ryan; Lin, Shuqun; Zhang, Yanlei; Spergel, Steven; Kempson, James; Tokarski, John S.; Strnad, Joann; Zupa-Fernandez, Adriana; Cheng, Lihong; Shuster, David; Gillooly, Kathleen; Yang, Xiaoxia; Heimrich, Elizabeth; McIntyre, Kim W.; Chaudhry, Charu; Khan, Javed; Ruzanov, Max; Tredup, Jeffrey; Mulligan, Dawn; Xie, Dianlin; Sun, Huadong; Huang, Christine; D'Arienzo, Celia; Aranibar, Nelly; Chiney, Manoj; Chimalakonda, Anjaneya; Pitts, William J.; Lombardo, Louis; Carter, Percy H.; Burke, James R.; Weinstein, David S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8973-8995</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Small mol. JAK inhibitors have emerged as a major therapeutic advancement in treating autoimmune diseases.  The discovery of isoform selective JAK inhibitors that traditionally target the catalytically active site of this kinase family has been a formidable challenge.  Our strategy to achieve high selectivity for TYK2 relies on targeting the TYK2 pseudokinase (JH2) domain.  Herein we report the late stage optimization efforts including a structure-guided design and water displacement strategy that led to the discovery of BMS-986165 (11, I) as a high affinity JH2 ligand and potent allosteric inhibitor of TYK2.  In addn. to unprecedented JAK isoform and kinome selectivity, I shows excellent pharmacokinetic properties with minimal profiling liabilities and is efficacious in several murine models of autoimmune disease.  On the basis of these findings, I appears differentiated from all other reported JAK inhibitors and has been advanced as the first pseudokinase-directed therapeutic in clin. development as an oral treatment for autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmA75TJmytlrVg90H21EOLACvtfcHk0lhapaOMBbuHnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlyht7%252FP&md5=ca161c470df002b0bdd2bf6b19920ada</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00444%26sid%3Dliteratum%253Aachs%26aulast%3DWrobleski%26aufirst%3DS.%2BT.%26aulast%3DMoslin%26aufirst%3DR.%26aulast%3DLin%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DSpergel%26aufirst%3DS.%26aulast%3DKempson%26aufirst%3DJ.%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DStrnad%26aufirst%3DJ.%26aulast%3DZupa-Fernandez%26aufirst%3DA.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DShuster%26aufirst%3DD.%26aulast%3DGillooly%26aufirst%3DK.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DHeimrich%26aufirst%3DE.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DChaudhry%26aufirst%3DC.%26aulast%3DKhan%26aufirst%3DJ.%26aulast%3DRuzanov%26aufirst%3DM.%26aulast%3DTredup%26aufirst%3DJ.%26aulast%3DMulligan%26aufirst%3DD.%26aulast%3DXie%26aufirst%3DD.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DC.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%26aulast%3DAranibar%26aufirst%3DN.%26aulast%3DChiney%26aufirst%3DM.%26aulast%3DChimalakonda%26aufirst%3DA.%26aulast%3DPitts%26aufirst%3DW.%2BJ.%26aulast%3DLombardo%26aufirst%3DL.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DWeinstein%26aufirst%3DD.%2BS.%26atitle%3DHighly%2520selective%2520inhibition%2520of%2520tyrosine%2520kinase%25202%2520%2528TYK2%2529%2520for%2520the%2520treatment%2520of%2520autoimmune%2520diseases%253A%2520discovery%2520of%2520the%2520allosteric%2520inhibitor%2520BMS-986165%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D8973%26epage%3D8995%26doi%3D10.1021%2Facs.jmedchem.9b00444" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Musumeci, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanna, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greco, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giacchello, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fallacara, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amato, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schenone, S.</span></span> <span> </span><span class="NLM_article-title">Pyrrolo[2,3-d]pyrimidines active as BTK inhibitors</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">1305</span>– <span class="NLM_lpage">1318</span>, <span class="refDoi"> DOI: 10.1080/13543776.2017.1355908</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.1080%2F13543776.2017.1355908" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=28705083" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1Sgt7vK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=1305-1318&author=F.+Musumeciauthor=M.+Sannaauthor=C.+Grecoauthor=I.+Giacchelloauthor=A.+L.+Fallacaraauthor=R.+Amatoauthor=S.+Schenone&title=Pyrrolo%5B2%2C3-d%5Dpyrimidines+active+as+BTK+inhibitors&doi=10.1080%2F13543776.2017.1355908"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors</span></div><div class="casAuthors">Musumeci, Francesca; Sanna, Monica; Greco, Chiara; Giacchello, Ilaria; Fallacara, Anna Lucia; Amato, Rosario; Schenone, Silvia</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1305-1318</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Introduction: Btk is a tyrosine kinase dysregulated in several B-cell malignancies and autoimmune diseases, and this has given rise to a search for Btk inhibitors.  Nevertheless, only one Btk inhibitor, ibrutinib, has been approved to date, although other compds. are currently being evaluated in clin. trials or in preclinal stages.  Area covered: This review, after a brief introduction on Btk and its inhibitors already in clin. trials, focusses on pyrrolo[2,3-d]pyrimidine derivs. patented in the last five years as Btk inhibitors.  Indeed, the pyrrolo[2,3-d]pyrimidine scaffold, being a deaza-isostere of adenine, the nitrogenous base of ATP, is an actively pursued target for Btk inhibitors.  The patent literature since 2012 have been extensively investigated, pointing out the general features of the patented compds. and, when it is possible, their mechanism of action.  Expert opinion: The recently patented pyrrolo[2,3-d]pyrimidines, acting as reversible or irreversible inhibitors, showed a very interesting in vitro activity.  For this reason, the development of compds. endowed with this scaffold could afford a significant impact in the search for drug candidates for the treatment of immune diseases or B-cell malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPT0s7eVqXebVg90H21EOLACvtfcHk0lhapaOMBbuHnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1Sgt7vK&md5=294c9b8bcafe6f7831187cb963f2f072</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1080%2F13543776.2017.1355908&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2017.1355908%26sid%3Dliteratum%253Aachs%26aulast%3DMusumeci%26aufirst%3DF.%26aulast%3DSanna%26aufirst%3DM.%26aulast%3DGreco%26aufirst%3DC.%26aulast%3DGiacchello%26aufirst%3DI.%26aulast%3DFallacara%26aufirst%3DA.%2BL.%26aulast%3DAmato%26aufirst%3DR.%26aulast%3DSchenone%26aufirst%3DS.%26atitle%3DPyrrolo%255B2%252C3-d%255Dpyrimidines%2520active%2520as%2520BTK%2520inhibitors%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2017%26volume%3D27%26spage%3D1305%26epage%3D1318%26doi%3D10.1080%2F13543776.2017.1355908" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuglstatter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondru, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, Z. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntosh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Litman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kocer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frauchiger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dewdney, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zecic, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taygerly, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarma, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabriel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, T. D.</span></span> <span> </span><span class="NLM_article-title">Structure-based drug design of RN486, a potent and selective bruton’s tyrosine kinase (BTK) inhibitor, for the treatment of rheumatoid arthritis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">512</span>– <span class="NLM_lpage">516</span>, <span class="refDoi"> DOI: 10.1021/jm500305p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500305p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlsl2qtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=512-516&author=Y.+Louauthor=X.+Hanauthor=A.+Kuglstatterauthor=R.+K.+Kondruauthor=Z.+K.+Sweeneyauthor=M.+Sothauthor=J.+McIntoshauthor=R.+Litmanauthor=J.+Suhauthor=B.+Kocerauthor=D.+Davisauthor=J.+Parkauthor=S.+Frauchigerauthor=N.+Dewdneyauthor=H.+Zecicauthor=J.+P.+Taygerlyauthor=K.+Sarmaauthor=J.+Hongauthor=R.+J.+Hillauthor=T.+Gabrielauthor=D.+M.+Goldsteinauthor=T.+D.+Owens&title=Structure-based+drug+design+of+RN486%2C+a+potent+and+selective+bruton%E2%80%99s+tyrosine+kinase+%28BTK%29+inhibitor%2C+for+the+treatment+of+rheumatoid+arthritis&doi=10.1021%2Fjm500305p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Drug Design of RN486, a Potent and Selective Bruton's Tyrosine Kinase (BTK) Inhibitor, for the Treatment of Rheumatoid Arthritis</span></div><div class="casAuthors">Lou, Yan; Han, Xiaochun; Kuglstatter, Andreas; Kondru, Rama K.; Sweeney, Zachary K.; Soth, Michael; McIntosh, Joel; Litman, Renee; Suh, Judy; Kocer, Buelent; Davis, Dana; Park, Jaehyeon; Frauchiger, Sandra; Dewdney, Nolan; Zecic, Hasim; Taygerly, Joshua P.; Sarma, Keshab; Hong, Junbae; Hill, Ronald J.; Gabriel, Tobias; Goldstein, David M.; Owens, Timothy D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">512-516</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Structure-based drug design was used to guide the optimization of a series of selective BTK inhibitors as potential treatments for Rheumatoid arthritis.  Highlights include the introduction of a benzyl alc. group and a fluorine substitution, each of which resulted in over 10-fold increase in activity.  Concurrent optimization of drug-like properties led to compd. I (RN486) (J. Pharmacol. Exp. Ther. 2012, 341, 90), which was selected for advanced preclin. characterization based on its favorable properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMdHX9-PE5I7Vg90H21EOLACvtfcHk0lh2IPKmrJF6GQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlsl2qtb8%253D&md5=dc3c069b0e876f44846a30e3aa6a894a</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm500305p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500305p%26sid%3Dliteratum%253Aachs%26aulast%3DLou%26aufirst%3DY.%26aulast%3DHan%26aufirst%3DX.%26aulast%3DKuglstatter%26aufirst%3DA.%26aulast%3DKondru%26aufirst%3DR.%2BK.%26aulast%3DSweeney%26aufirst%3DZ.%2BK.%26aulast%3DSoth%26aufirst%3DM.%26aulast%3DMcIntosh%26aufirst%3DJ.%26aulast%3DLitman%26aufirst%3DR.%26aulast%3DSuh%26aufirst%3DJ.%26aulast%3DKocer%26aufirst%3DB.%26aulast%3DDavis%26aufirst%3DD.%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DFrauchiger%26aufirst%3DS.%26aulast%3DDewdney%26aufirst%3DN.%26aulast%3DZecic%26aufirst%3DH.%26aulast%3DTaygerly%26aufirst%3DJ.%2BP.%26aulast%3DSarma%26aufirst%3DK.%26aulast%3DHong%26aufirst%3DJ.%26aulast%3DHill%26aufirst%3DR.%2BJ.%26aulast%3DGabriel%26aufirst%3DT.%26aulast%3DGoldstein%26aufirst%3DD.%2BM.%26aulast%3DOwens%26aufirst%3DT.%2BD.%26atitle%3DStructure-based%2520drug%2520design%2520of%2520RN486%252C%2520a%2520potent%2520and%2520selective%2520bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%2520inhibitor%252C%2520for%2520the%2520treatment%2520of%2520rheumatoid%2520arthritis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D512%26epage%3D516%26doi%3D10.1021%2Fjm500305p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Geahlen, R. L.</span></span> <span> </span><span class="NLM_article-title">Getting SYK: spleen tyrosine kinase as a therapeutic target</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">414</span>– <span class="NLM_lpage">422</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2014.05.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.1016%2Fj.tips.2014.05.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=24975478" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVKhtbvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2014&pages=414-422&author=R.+L.+Geahlen&title=Getting+SYK%3A+spleen+tyrosine+kinase+as+a+therapeutic+target&doi=10.1016%2Fj.tips.2014.05.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Getting Syk: spleen tyrosine kinase as a therapeutic target</span></div><div class="casAuthors">Geahlen, Robert L.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">414-422</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Spleen tyrosine kinase (Syk) is a cytoplasmic protein tyrosine kinase well known for its ability to couple immune cell receptors to intracellular signaling pathways that regulate cellular responses to extracellular antigens and antigen-Ig (Ig) complexes of particular importance to the initiation of inflammatory responses.  Thus, Syk is an attractive target for therapeutic kinase inhibitors designed to ameliorate the symptoms and consequences of acute and chronic inflammation.  Its more recently recognized role as a promoter of cell survival in numerous cancer cell types ranging from leukemia to retinoblastoma has attracted considerable interest as a target for a new generation of anticancer drugs.  This review discusses the biol. processes in which Syk participates that have made this kinase such a compelling drug target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoE5Tut36Cq0LVg90H21EOLACvtfcHk0lh2IPKmrJF6GQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVKhtbvK&md5=8b161de626d96f82c754eff4c5ef078f</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2014.05.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2014.05.007%26sid%3Dliteratum%253Aachs%26aulast%3DGeahlen%26aufirst%3DR.%2BL.%26atitle%3DGetting%2520SYK%253A%2520spleen%2520tyrosine%2520kinase%2520as%2520a%2520therapeutic%2520target%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2014%26volume%3D35%26spage%3D414%26epage%3D422%26doi%3D10.1016%2Fj.tips.2014.05.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manoli, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaw, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frutoz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epstein, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khawli, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theil, F. P.</span></span> <span> </span><span class="NLM_article-title">Unraveling the effect of immunogenicity on the PK/PD, efficacy, and safety of therapeutic proteins</span>. <i>J. Immunol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>2016</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">9</span>, <span class="refDoi"> DOI: 10.1155/2016/2342187</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.1155%2F2016%2F2342187" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2016&publication_year=2016&pages=1-9&author=A.+Smithauthor=H.+Manoliauthor=S.+Jawauthor=K.+Frutozauthor=A.+L.+Epsteinauthor=L.+A.+Khawliauthor=F.+P.+Theil&title=Unraveling+the+effect+of+immunogenicity+on+the+PK%2FPD%2C+efficacy%2C+and+safety+of+therapeutic+proteins&doi=10.1155%2F2016%2F2342187"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1155%2F2016%2F2342187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2016%252F2342187%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DManoli%26aufirst%3DH.%26aulast%3DJaw%26aufirst%3DS.%26aulast%3DFrutoz%26aufirst%3DK.%26aulast%3DEpstein%26aufirst%3DA.%2BL.%26aulast%3DKhawli%26aufirst%3DL.%2BA.%26aulast%3DTheil%26aufirst%3DF.%2BP.%26atitle%3DUnraveling%2520the%2520effect%2520of%2520immunogenicity%2520on%2520the%2520PK%252FPD%252C%2520efficacy%252C%2520and%2520safety%2520of%2520therapeutic%2520proteins%26jtitle%3DJ.%2520Immunol.%2520Res.%26date%3D2016%26volume%3D2016%26spage%3D1%26epage%3D9%26doi%3D10.1155%2F2016%2F2342187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Y.</span></span> <span> </span><span class="NLM_article-title">Peli1 negatively regulates noncanonical NF-kappaB signaling to restrain systemic lupus erythematosus</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1136</span>, <span class="refDoi"> DOI: 10.1038/s41467-018-03530-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.1038%2Fs41467-018-03530-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=29555915" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A280%3ADC%252BC1Mnislyruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=1136&author=J.+Liuauthor=X.+Huangauthor=S.+Haoauthor=Y.+Wangauthor=M.+Liuauthor=J.+Xuauthor=X.+Zhangauthor=T.+Yuauthor=S.+Ganauthor=D.+Daiauthor=X.+Luoauthor=Q.+Luauthor=C.+Maoauthor=Y.+Zhangauthor=N.+Shenauthor=B.+Liauthor=M.+Huangauthor=X.+Zhuauthor=J.+Jinauthor=X.+Chengauthor=S.+C.+Sunauthor=Y.+Xiao&title=Peli1+negatively+regulates+noncanonical+NF-kappaB+signaling+to+restrain+systemic+lupus+erythematosus&doi=10.1038%2Fs41467-018-03530-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Peli1 negatively regulates noncanonical NF-κB signaling to restrain systemic lupus erythematosus</span></div><div class="casAuthors">Liu Junli; Hao Shumeng; Wang Yan; Xu Jing; Zhang Xingli; Yu Tao; Gan Shucheng; Zhang Yanyun; Shen Nan; Xiao Yichuan; Huang Xinfang; Liu Manman; Dai Dongfang; Luo Xuan; Lu Qingyan; Mao Chaoming; Shen Nan; Li Bin; Huang Mingzhu; Zhu Xiaodong; Jin Jin; Cheng Xuhong; Sun Shao-Cong</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1136</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Systemic lupus erythematosus (SLE) is characterized by uncontrolled secretion of autoantibodies by plasma cells.  Although the functional importance of plasma cells and autoantibodies in SLE has been well established, the underlying molecular mechanisms of controlling autoantibody production remain poorly understood.  Here we show that Peli1 has a B cell-intrinsic function to protect against lupus-like autoimmunity in mice.  Peli1 deficiency in B cells induces autoantibody production via noncanonical NF-κB signaling.  Mechanically, Peli1 functions as an E3 ligase to associate with NF-κB inducing kinase (NIK) and mediates NIK Lys48 ubiquitination and degradation.  Overexpression of Peli1 inhibits noncanonical NF-κB activation and alleviates lupus-like disease.  In humans, PELI1 levels negatively correlate with disease severity in SLE patients.  Our findings establish Peli1 as a negative regulator of the noncanonical NF-κB pathway in the context of restraining the pathogenesis of lupus-like disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQqtNFjTmkpcCEJCPKhJPuqfW6udTcc2eZUkh-95xbBlLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mnislyruw%253D%253D&md5=01884e67948a03a898b3bda31788ecc9</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-03530-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-03530-3%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DHao%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DYu%26aufirst%3DT.%26aulast%3DGan%26aufirst%3DS.%26aulast%3DDai%26aufirst%3DD.%26aulast%3DLuo%26aufirst%3DX.%26aulast%3DLu%26aufirst%3DQ.%26aulast%3DMao%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DShen%26aufirst%3DN.%26aulast%3DLi%26aufirst%3DB.%26aulast%3DHuang%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DJin%26aufirst%3DJ.%26aulast%3DCheng%26aufirst%3DX.%26aulast%3DSun%26aufirst%3DS.%2BC.%26aulast%3DXiao%26aufirst%3DY.%26atitle%3DPeli1%2520negatively%2520regulates%2520noncanonical%2520NF-kappaB%2520signaling%2520to%2520restrain%2520systemic%2520lupus%2520erythematosus%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26spage%3D1136%26doi%3D10.1038%2Fs41467-018-03530-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brightbill, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suto, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaquiere, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramamoorthi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sujatha-Bhaskar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gogol, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castanedo, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haller, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesch, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bents, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Everett, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohli, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linge, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christian, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaochico, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berezhkovskiy, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modrusan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veliz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Townsend, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeVoss, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godemann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenzie, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hackney, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staben, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alaoui Ismaili, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghilardi, N.</span></span> <span> </span><span class="NLM_article-title">NF-kappaB inducing kinase is a therapeutic target for systemic lupus erythematosus</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">179</span>, <span class="refDoi"> DOI: 10.1038/s41467-017-02672-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.1038%2Fs41467-017-02672-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=29330524" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A280%3ADC%252BC1Mvgtlylug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=179&author=H.+D.+Brightbillauthor=E.+Sutoauthor=N.+Blaquiereauthor=N.+Ramamoorthiauthor=S.+Sujatha-Bhaskarauthor=E.+B.+Gogolauthor=G.+M.+Castanedoauthor=B.+T.+Jacksonauthor=Y.+C.+Kwonauthor=S.+Hallerauthor=J.+Leschauthor=K.+Bentsauthor=C.+Everettauthor=P.+B.+Kohliauthor=S.+Lingeauthor=L.+Christianauthor=K.+Barrettauthor=A.+Jaochicoauthor=L.+M.+Berezhkovskiyauthor=P.+W.+Fanauthor=Z.+Modrusanauthor=K.+Velizauthor=M.+J.+Townsendauthor=J.+DeVossauthor=A.+R.+Johnsonauthor=R.+Godemannauthor=W.+P.+Leeauthor=C.+D.+Austinauthor=B.+S.+McKenzieauthor=J.+A.+Hackneyauthor=J.+J.+Crawfordauthor=S.+T.+Stabenauthor=M.+H.+Alaoui+Ismailiauthor=L.+C.+Wuauthor=N.+Ghilardi&title=NF-kappaB+inducing+kinase+is+a+therapeutic+target+for+systemic+lupus+erythematosus&doi=10.1038%2Fs41467-017-02672-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">NF-κB inducing kinase is a therapeutic target for systemic lupus erythematosus</span></div><div class="casAuthors">Brightbill Hans D; Sujatha-Bhaskar Swathi; Gogol Emily B; Jackson Benjamin T; Christian Laura; Wu Lawren C; Ghilardi Nico; Suto Eric; Kwon Youngsu C; Lesch Justin; DeVoss Jason; Lee Wyne P; McKenzie Brent S; Blaquiere Nicole; Castanedo Georgette M; Crawford James J; Staben Steven T; Ramamoorthi Nandhini; Townsend Michael J; Haller Susan; Austin Cary D; Bents Karin; Linge Sandra; Godemann Robert; Everett Christine; Kohli Pawan Bir; Barrett Kathy; Johnson Adam R; Alaoui Ismaili Moulay H; Jaochico Allan; Berezhkovskiy Leonid M; Fan Peter W; Modrusan Zora; Veliz Kelli; Hackney Jason A</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">179</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">NF-κB-inducing kinase (NIK) mediates non-canonical NF-κB signaling downstream of multiple TNF family members, including BAFF, TWEAK, CD40, and OX40, which are implicated in the pathogenesis of systemic lupus erythematosus (SLE).  Here, we show that experimental lupus in NZB/W F1 mice can be treated with a highly selective and potent NIK small molecule inhibitor.  Both in vitro as well as in vivo, NIK inhibition recapitulates the pharmacological effects of BAFF blockade, which is clinically efficacious in SLE.  Furthermore, NIK inhibition also affects T cell parameters in the spleen and proinflammatory gene expression in the kidney, which may be attributable to inhibition of OX40 and TWEAK signaling, respectively.  As a consequence, NIK inhibition results in improved survival, reduced renal pathology, and lower proteinuria scores.  Collectively, our data suggest that NIK inhibition is a potential therapeutic approach for SLE.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRSowPmlnIWxaqcneEtCi92fW6udTcc2eZUkh-95xbBlLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mvgtlylug%253D%253D&md5=41a91514e1f4e8b2b44912ba6d6a4788</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Fs41467-017-02672-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-017-02672-0%26sid%3Dliteratum%253Aachs%26aulast%3DBrightbill%26aufirst%3DH.%2BD.%26aulast%3DSuto%26aufirst%3DE.%26aulast%3DBlaquiere%26aufirst%3DN.%26aulast%3DRamamoorthi%26aufirst%3DN.%26aulast%3DSujatha-Bhaskar%26aufirst%3DS.%26aulast%3DGogol%26aufirst%3DE.%2BB.%26aulast%3DCastanedo%26aufirst%3DG.%2BM.%26aulast%3DJackson%26aufirst%3DB.%2BT.%26aulast%3DKwon%26aufirst%3DY.%2BC.%26aulast%3DHaller%26aufirst%3DS.%26aulast%3DLesch%26aufirst%3DJ.%26aulast%3DBents%26aufirst%3DK.%26aulast%3DEverett%26aufirst%3DC.%26aulast%3DKohli%26aufirst%3DP.%2BB.%26aulast%3DLinge%26aufirst%3DS.%26aulast%3DChristian%26aufirst%3DL.%26aulast%3DBarrett%26aufirst%3DK.%26aulast%3DJaochico%26aufirst%3DA.%26aulast%3DBerezhkovskiy%26aufirst%3DL.%2BM.%26aulast%3DFan%26aufirst%3DP.%2BW.%26aulast%3DModrusan%26aufirst%3DZ.%26aulast%3DVeliz%26aufirst%3DK.%26aulast%3DTownsend%26aufirst%3DM.%2BJ.%26aulast%3DDeVoss%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DGodemann%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DW.%2BP.%26aulast%3DAustin%26aufirst%3DC.%2BD.%26aulast%3DMcKenzie%26aufirst%3DB.%2BS.%26aulast%3DHackney%26aufirst%3DJ.%2BA.%26aulast%3DCrawford%26aufirst%3DJ.%2BJ.%26aulast%3DStaben%26aufirst%3DS.%2BT.%26aulast%3DAlaoui%2BIsmaili%26aufirst%3DM.%2BH.%26aulast%3DWu%26aufirst%3DL.%2BC.%26aulast%3DGhilardi%26aufirst%3DN.%26atitle%3DNF-kappaB%2520inducing%2520kinase%2520is%2520a%2520therapeutic%2520target%2520for%2520systemic%2520lupus%2520erythematosus%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26spage%3D179%26doi%3D10.1038%2Fs41467-017-02672-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Castanedo, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaquiere, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beresini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bravo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brightbill, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Everett, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godemann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gogol, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hymowitz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kayagaki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohli, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knuppel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraemer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loke, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McEwan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montalbetti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinbacher, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sujatha-Bhaskar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staben, S. T.</span></span> <span> </span><span class="NLM_article-title">Structure-based design of tricyclic NF-kappaB inducing kinase (NIK) inhibitors that have high selectivity over phosphoinositide-3-kinase (PI3K)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">627</span>– <span class="NLM_lpage">640</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01363</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01363" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFCgs7bK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=627-640&author=G.+M.+Castanedoauthor=N.+Blaquiereauthor=M.+Beresiniauthor=B.+Bravoauthor=H.+Brightbillauthor=J.+Chenauthor=H.+F.+Cuiauthor=C.+Eigenbrotauthor=C.+Everettauthor=J.+Fengauthor=R.+Godemannauthor=E.+Gogolauthor=S.+Hymowitzauthor=A.+Johnsonauthor=N.+Kayagakiauthor=P.+B.+Kohliauthor=K.+Knuppelauthor=J.+Kraemerauthor=S.+Krugerauthor=P.+Lokeauthor=P.+McEwanauthor=C.+Montalbettiauthor=D.+A.+Robertsauthor=M.+Smithauthor=S.+Steinbacherauthor=S.+Sujatha-Bhaskarauthor=R.+Takahashiauthor=X.+Wangauthor=L.+C.+Wuauthor=Y.+Zhangauthor=S.+T.+Staben&title=Structure-based+design+of+tricyclic+NF-kappaB+inducing+kinase+%28NIK%29+inhibitors+that+have+high+selectivity+over+phosphoinositide-3-kinase+%28PI3K%29&doi=10.1021%2Facs.jmedchem.6b01363"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Design of Tricyclic NF-κB Inducing Kinase (NIK) Inhibitors That Have High Selectivity over Phosphoinositide-3-kinase (PI3K)</span></div><div class="casAuthors">Castanedo, Georgette M.; Blaquiere, Nicole; Beresini, Maureen; Bravo, Brandon; Brightbill, Hans; Chen, Jacob; Cui, Hai-Feng; Eigenbrot, Charles; Everett, Christine; Feng, Jianwen; Godemann, Robert; Gogol, Emily; Hymowitz, Sarah; Johnson, Adam; Kayagaki, Nobuhiko; Kohli, Pawan Bir; Knuppel, Kathleen; Kraemer, Joachim; Kruger, Susan; Loke, Pui; McEwan, Paul; Montalbetti, Christian; Roberts, David A.; Smith, Myron; Steinbacher, Stefan; Sujatha-Bhaskar, Swathi; Takahashi, Ryan; Wang, Xiaolu; Wu, Lawren C.; Zhang, Yamin; Staben, Steven T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">627-640</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The authors report a structure-guided optimization of a novel series of NF-κB inducing kinase (NIK) inhibitors.  Starting from a modestly potent, low mol. wt. lead, activity was improved by designing a type I1/2 binding mode that accessed a back pocket past the methionine-471 gatekeeper.  Divergent binding modes in NIK and PI3K were used to dampen PI3K-inhibition while maintaining NIK inhibition within these series.  Potent compds. were discovered that selectively inhibit the nuclear translocation of NF-kB2 (p52/REL-B) but not canonical NF-kB1 (REL-A/p50).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrws-sPXJiSfLVg90H21EOLACvtfcHk0lj4ilIWbaPOHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFCgs7bK&md5=316b70f51a5b800ba810082d0b3862da</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01363&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01363%26sid%3Dliteratum%253Aachs%26aulast%3DCastanedo%26aufirst%3DG.%2BM.%26aulast%3DBlaquiere%26aufirst%3DN.%26aulast%3DBeresini%26aufirst%3DM.%26aulast%3DBravo%26aufirst%3DB.%26aulast%3DBrightbill%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DCui%26aufirst%3DH.%2BF.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DEverett%26aufirst%3DC.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DGodemann%26aufirst%3DR.%26aulast%3DGogol%26aufirst%3DE.%26aulast%3DHymowitz%26aufirst%3DS.%26aulast%3DJohnson%26aufirst%3DA.%26aulast%3DKayagaki%26aufirst%3DN.%26aulast%3DKohli%26aufirst%3DP.%2BB.%26aulast%3DKnuppel%26aufirst%3DK.%26aulast%3DKraemer%26aufirst%3DJ.%26aulast%3DKruger%26aufirst%3DS.%26aulast%3DLoke%26aufirst%3DP.%26aulast%3DMcEwan%26aufirst%3DP.%26aulast%3DMontalbetti%26aufirst%3DC.%26aulast%3DRoberts%26aufirst%3DD.%2BA.%26aulast%3DSmith%26aufirst%3DM.%26aulast%3DSteinbacher%26aufirst%3DS.%26aulast%3DSujatha-Bhaskar%26aufirst%3DS.%26aulast%3DTakahashi%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DL.%2BC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DStaben%26aufirst%3DS.%2BT.%26atitle%3DStructure-based%2520design%2520of%2520tricyclic%2520NF-kappaB%2520inducing%2520kinase%2520%2528NIK%2529%2520inhibitors%2520that%2520have%2520high%2520selectivity%2520over%2520phosphoinositide-3-kinase%2520%2528PI3K%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D627%26epage%3D640%26doi%3D10.1021%2Facs.jmedchem.6b01363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blaquiere, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castanedo, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burch, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berezhkovskiy, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brightbill, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghilardi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godemann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gogol, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grabbe, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hole, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hymowitz, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alaoui
Ismaili, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McEwan, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenzie, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvestre, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suto, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sujatha-Bhaskar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staben, S. T.</span></span> <span> </span><span class="NLM_article-title">Scaffold-hopping approach to discover potent, selective, and efficacious inhibitors of NF-kappaB inducing kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">6801</span>– <span class="NLM_lpage">6813</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00678</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00678" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1Snu73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=6801-6813&author=N.+Blaquiereauthor=G.+M.+Castanedoauthor=J.+D.+Burchauthor=L.+M.+Berezhkovskiyauthor=H.+Brightbillauthor=S.+Brownauthor=C.+Chanauthor=P.+C.+Chiangauthor=J.+J.+Crawfordauthor=T.+Dongauthor=P.+Fanauthor=J.+Fengauthor=N.+Ghilardiauthor=R.+Godemannauthor=E.+Gogolauthor=A.+Grabbeauthor=A.+J.+Holeauthor=B.+Huauthor=S.+G.+Hymowitzauthor=M.+H.+Alaoui%0AIsmailiauthor=H.+Leauthor=P.+Leeauthor=W.+Leeauthor=X.+Linauthor=N.+Liuauthor=P.+A.+McEwanauthor=B.+McKenzieauthor=H.+L.+Silvestreauthor=E.+Sutoauthor=S.+Sujatha-Bhaskarauthor=G.+Wuauthor=L.+C.+Wuauthor=Y.+Zhangauthor=Z.+Zhongauthor=S.+T.+Staben&title=Scaffold-hopping+approach+to+discover+potent%2C+selective%2C+and+efficacious+inhibitors+of+NF-kappaB+inducing+kinase&doi=10.1021%2Facs.jmedchem.8b00678"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Scaffold-Hopping Approach To Discover Potent, Selective, and Efficacious Inhibitors of NF-κB Inducing Kinase</span></div><div class="casAuthors">Blaquiere, Nicole; Castanedo, Georgette M.; Burch, Jason D.; Berezhkovskiy, Leonid M.; Brightbill, Hans; Brown, Suzanne; Chan, Connie; Chiang, Po-Chang; Crawford, James J.; Dong, Teresa; Fan, Peter; Feng, Jianwen; Ghilardi, Nico; Godemann, Robert; Gogol, Emily; Grabbe, Alice; Hole, Alison J.; Hu, Baihua; Hymowitz, Sarah G.; Alaoui Ismaili, Moulay Hicham; Le, Hoa; Lee, Patrick; Lee, Wyne; Lin, Xingyu; Liu, Ning; McEwan, Paul A.; McKenzie, Brent; Silvestre, Hernani L.; Suto, Eric; Sujatha-Bhaskar, Swathi; Wu, Guosheng; Wu, Lawren C.; Zhang, Yamin; Zhong, Zoe; Staben, Steven T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6801-6813</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">NF-κB-inducing kinase (NIK) is a protein kinase central to the noncanonical NF-κB pathway downstream from multiple TNF receptor family members, including BAFF, which has been assocd. with B cell survival and maturation, dendritic cell activation, secondary lymphoid organ development, and bone metab.  We report herein the discovery of lead chem. series of NIK inhibitors that were identified through a scaffold-hopping strategy using structure-based design.  Electronic and steric properties of lead compds. were modified to address glutathione conjugation and amide hydrolysis.  These highly potent compds. exhibited selective inhibition of LTβR-dependent p52 translocation and transcription of NF-κB2 related genes.  Compd. 4f is shown to have a favorable pharmacokinetic profile across species and to inhibit BAFF-induced B cell survival in vitro and reduce splenic marginal zone B cells in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5FXb6VJDRqbVg90H21EOLACvtfcHk0lj4ilIWbaPOHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1Snu73P&md5=5ff01b23d827b3d96078a17fff885aea</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00678&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00678%26sid%3Dliteratum%253Aachs%26aulast%3DBlaquiere%26aufirst%3DN.%26aulast%3DCastanedo%26aufirst%3DG.%2BM.%26aulast%3DBurch%26aufirst%3DJ.%2BD.%26aulast%3DBerezhkovskiy%26aufirst%3DL.%2BM.%26aulast%3DBrightbill%26aufirst%3DH.%26aulast%3DBrown%26aufirst%3DS.%26aulast%3DChan%26aufirst%3DC.%26aulast%3DChiang%26aufirst%3DP.%2BC.%26aulast%3DCrawford%26aufirst%3DJ.%2BJ.%26aulast%3DDong%26aufirst%3DT.%26aulast%3DFan%26aufirst%3DP.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DGhilardi%26aufirst%3DN.%26aulast%3DGodemann%26aufirst%3DR.%26aulast%3DGogol%26aufirst%3DE.%26aulast%3DGrabbe%26aufirst%3DA.%26aulast%3DHole%26aufirst%3DA.%2BJ.%26aulast%3DHu%26aufirst%3DB.%26aulast%3DHymowitz%26aufirst%3DS.%2BG.%26aulast%3DAlaoui%2BIsmaili%26aufirst%3DM.%2BH.%26aulast%3DLe%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DP.%26aulast%3DLee%26aufirst%3DW.%26aulast%3DLin%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DN.%26aulast%3DMcEwan%26aufirst%3DP.%2BA.%26aulast%3DMcKenzie%26aufirst%3DB.%26aulast%3DSilvestre%26aufirst%3DH.%2BL.%26aulast%3DSuto%26aufirst%3DE.%26aulast%3DSujatha-Bhaskar%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DWu%26aufirst%3DL.%2BC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZhong%26aufirst%3DZ.%26aulast%3DStaben%26aufirst%3DS.%2BT.%26atitle%3DScaffold-hopping%2520approach%2520to%2520discover%2520potent%252C%2520selective%252C%2520and%2520efficacious%2520inhibitors%2520of%2520NF-kappaB%2520inducing%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D6801%26epage%3D6813%26doi%3D10.1021%2Facs.jmedchem.8b00678" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Willmann, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sacco, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martins, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garncarz, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krolo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boztug, K.</span></span> <span> </span><span class="NLM_article-title">Expanding the interactome of the noncanonical NF-kappaB signaling pathway</span>. <i>J. Proteome Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">2900</span>– <span class="NLM_lpage">2909</span>, <span class="refDoi"> DOI: 10.1021/acs.jproteome.5b01004</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jproteome.5b01004" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFKksrvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=2900-2909&author=K.+L.+Willmannauthor=R.+Saccoauthor=R.+Martinsauthor=W.+Garncarzauthor=A.+Kroloauthor=S.+Knappauthor=K.+L.+Bennettauthor=K.+Boztug&title=Expanding+the+interactome+of+the+noncanonical+NF-kappaB+signaling+pathway&doi=10.1021%2Facs.jproteome.5b01004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Expanding the Interactome of the Noncanonical NF-κB Signaling Pathway</span></div><div class="casAuthors">Willmann, Katharina L.; Sacco, Roberto; Martins, Rui; Garncarz, Wojciech; Krolo, Ana; Knapp, Sylvia; Bennett, Keiryn L.; Boztug, Kaan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Proteome Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2900-2909</span>CODEN:
                <span class="NLM_cas:coden">JPROBS</span>;
        ISSN:<span class="NLM_cas:issn">1535-3893</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">NF-κB signaling is a central pathway of immunity and integrates signal transduction upon a wide array of inflammatory stimuli.  Noncanonical NF-κB signaling is activated by a small subset of TNF family receptors and characterized by NF-κB2/p52 transcriptional activity.  The medical relevance of this pathway has recently re-emerged from the discovery of primary immunodeficiency patients that have loss-of-function mutations in the MAP3K14 gene encoding NIK.  Nevertheless, knowledge of protein interactions that regulate noncanonical NF-κB signaling is sparse.  Here we report a detailed state-of-the-art mass spectrometry-based protein-protein interaction network including the noncanonical NF-κB signaling nodes TRAF2, TRAF3, IKKα, NIK, and NF-κB2/p100.  The value of the data set was confirmed by the identification of interactions already known to regulate this pathway.  In addn., a remarkable no. of novel interactors were identified.  We provide validation of the novel NIK and IKKα interactor FKBP8, which may regulate processes downstream of noncanonical NF-κB signaling.  To understand perturbed noncanonical NF-κB signaling in the context of misregulated NIK in disease, we also provide a differential interactome of NIK mutants that cause immunodeficiency.  Altogether, this data set not only provides crit. insight into how protein-protein interactions can regulate immune signaling but also offers a novel resource on noncanonical NF-κB signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPK89IMi9DnbVg90H21EOLACvtfcHk0lh5SgoSyVVQWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFKksrvP&md5=d81f8e0ca9fb8b7cd5ab57980d4ab36e</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Facs.jproteome.5b01004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jproteome.5b01004%26sid%3Dliteratum%253Aachs%26aulast%3DWillmann%26aufirst%3DK.%2BL.%26aulast%3DSacco%26aufirst%3DR.%26aulast%3DMartins%26aufirst%3DR.%26aulast%3DGarncarz%26aufirst%3DW.%26aulast%3DKrolo%26aufirst%3DA.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DBennett%26aufirst%3DK.%2BL.%26aulast%3DBoztug%26aufirst%3DK.%26atitle%3DExpanding%2520the%2520interactome%2520of%2520the%2520noncanonical%2520NF-kappaB%2520signaling%2520pathway%26jtitle%3DJ.%2520Proteome%2520Res.%26date%3D2016%26volume%3D15%26spage%3D2900%26epage%3D2909%26doi%3D10.1021%2Facs.jproteome.5b01004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Noort, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Zoest, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weijers, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koolwijk, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maracle, C. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novack, D. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siemerink, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlingemann, R. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tak, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tas, S. W.</span></span> <span> </span><span class="NLM_article-title">NF-kappaB-inducing kinase is a key regulator of inflammation-induced and tumour-associated angiogenesis</span>. <i>J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>234</i></span>,  <span class="NLM_fpage">375</span>– <span class="NLM_lpage">385</span>, <span class="refDoi"> DOI: 10.1002/path.4403</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.1002%2Fpath.4403" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=25043127" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslCqtrnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=234&publication_year=2014&pages=375-385&author=A.+R.+Noortauthor=K.+P.+van+Zoestauthor=E.+M.+Weijersauthor=P.+Koolwijkauthor=C.+X.+Maracleauthor=D.+V.+Novackauthor=M.+J.+Siemerinkauthor=R.+O.+Schlingemannauthor=P.+P.+Takauthor=S.+W.+Tas&title=NF-kappaB-inducing+kinase+is+a+key+regulator+of+inflammation-induced+and+tumour-associated+angiogenesis&doi=10.1002%2Fpath.4403"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">NF-κB-inducing kinase is a key regulator of inflammation-induced and tumour-associated angiogenesis</span></div><div class="casAuthors">Noort, Ae R.; van Zoest, Katinka PM; Weijers, Ester M.; Koolwijk, Pieter; Maracle, Chrissta X.; Novack, Deborah V.; Siemerink, Martin J.; Schlingemann, Reinier O.; Tak, Paul P.; Tas, Sander W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pathology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">234</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">375-385</span>CODEN:
                <span class="NLM_cas:coden">JPTLAS</span>;
        ISSN:<span class="NLM_cas:issn">1096-9896</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Angiogenesis is essential during development and in pathol. conditions such as chronic inflammation and cancer progression.  Inhibition of angiogenesis by targeting vascular endothelial growth factor (VEGF) blocks disease progression, but most patients eventually develop resistance which may result from compensatory signalling pathways.  In endothelial cells (ECs), expression of the pro-angiogenic chemokine CXCL12 is regulated by non-canonical nuclear factor (NF)-κB signalling.  Here, we report that NF-κB-inducing kinase (NIK) and subsequent non-canonical NF-κB signalling regulate both inflammation-induced and tumor-assocd. angiogenesis.  NIK is highly expressed in endothelial cells (ECs) in tumor tissues and inflamed rheumatoid arthritis synovial tissue.  Furthermore, non-canonical NF-κB signalling in human microvascular ECs significantly enhanced vascular tube formation, which was completely blocked by siRNA targeting NIK.  Interestingly, Nik-/- mice exhibited normal angiogenesis during development and unaltered TNFα- or VEGF-induced angiogenic responses, whereas angiogenesis induced by non-canonical NF-κB stimuli was significantly reduced.  In addn., angiogenesis in exptl. arthritis and a murine tumor model was severely impaired in these mice.  These studies provide evidence for a role of non-canonical NF-κB signalling in pathol. angiogenesis, and identify NIK as a potential therapeutic target in chronic inflammatory diseases and tumor neoangiogenesis. © 2014 The Authors.  The Journal of Pathol. published by John Wiley & Sons Ltd on behalf of Pathol. Society of Great Britain and Ireland.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGmctnhHR1SrVg90H21EOLACvtfcHk0lh5SgoSyVVQWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslCqtrnE&md5=94bdaa642c3246981d16f79958dbc5d9</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1002%2Fpath.4403&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpath.4403%26sid%3Dliteratum%253Aachs%26aulast%3DNoort%26aufirst%3DA.%2BR.%26aulast%3Dvan%2BZoest%26aufirst%3DK.%2BP.%26aulast%3DWeijers%26aufirst%3DE.%2BM.%26aulast%3DKoolwijk%26aufirst%3DP.%26aulast%3DMaracle%26aufirst%3DC.%2BX.%26aulast%3DNovack%26aufirst%3DD.%2BV.%26aulast%3DSiemerink%26aufirst%3DM.%2BJ.%26aulast%3DSchlingemann%26aufirst%3DR.%2BO.%26aulast%3DTak%26aufirst%3DP.%2BP.%26aulast%3DTas%26aufirst%3DS.%2BW.%26atitle%3DNF-kappaB-inducing%2520kinase%2520is%2520a%2520key%2520regulator%2520of%2520inflammation-induced%2520and%2520tumour-associated%2520angiogenesis%26jtitle%3DJ.%2520Pathol.%26date%3D2014%26volume%3D234%26spage%3D375%26epage%3D385%26doi%3D10.1002%2Fpath.4403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Janda, A.</span>; <span class="NLM_string-name">Rizzi, M.</span></span> <span> </span><span class="NLM_article-title">Humoral primary immunodeficiency and autoimmune and inflammatory manifestations</span>.  <i>Humoral Primary Immunodeficiencies</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Elios, M. M.</span>, <span class="NLM_string-name">Rizzi, M.</span></span>, Eds.; <span class="NLM_publisher-name">Springer International Publishing</span>: <span class="NLM_publisher-loc">Cham, Switzerland</span>, <span class="NLM_year">2019</span>; pp  <span class="NLM_fpage">325</span>– <span class="NLM_lpage">346</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.1007%2F978-3-319-91785-6_24" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&pages=325-346&author=A.+Janda&author=M.+Rizziauthor=M.+M.+D%E2%80%99Elios&author=M.+Rizzi&title=Humoral+Primary+Immunodeficiencies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1007%2F978-3-319-91785-6_24&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-3-319-91785-6_24%26sid%3Dliteratum%253Aachs%26aulast%3DJanda%26aufirst%3DA.%26atitle%3DHumoral%2520primary%2520immunodeficiency%2520and%2520autoimmune%2520and%2520inflammatory%2520manifestations%26btitle%3DHumoral%2520Primary%2520Immunodeficiencies%26aulast%3DD%25E2%2580%2599Elios%26aufirst%3DM.%2BM.%26pub%3DSpringer%2520International%2520Publishing%26date%3D2019%26spage%3D325%26epage%3D346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Valino-Rivas, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaquero, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sucunza, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutierrez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanz, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fresno, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortiz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Nino, M. D.</span></span> <span> </span><span class="NLM_article-title">NIK as a druggable mediator of tissue injury</span>. <i>Trends Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">341</span>– <span class="NLM_lpage">360</span>, <span class="refDoi"> DOI: 10.1016/j.molmed.2019.02.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.1016%2Fj.molmed.2019.02.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=30926358" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC1MXltVeru7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2019&pages=341-360&author=L.+Valino-Rivasauthor=J.+J.+Vaqueroauthor=D.+Sucunzaauthor=S.+Gutierrezauthor=A.+B.+Sanzauthor=M.+Fresnoauthor=A.+Ortizauthor=M.+D.+Sanchez-Nino&title=NIK+as+a+druggable+mediator+of+tissue+injury&doi=10.1016%2Fj.molmed.2019.02.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">NIK as a Druggable Mediator of Tissue Injury</span></div><div class="casAuthors">Valino-Rivas, Lara; Vaquero, Juan Jose; Sucunza, David; Gutierrez, Sara; Sanz, Ana B.; Fresno, Manuel; Ortiz, Alberto; Sanchez-Nino, Maria Dolores</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Molecular Medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">341-360</span>CODEN:
                <span class="NLM_cas:coden">TMMRCY</span>;
        ISSN:<span class="NLM_cas:issn">1471-4914</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">NF-κB-inducing kinase (NIK, MAP3K14) is best known as the apical kinase that triggers non-canonical NF-κB activation and by its role in the immune system.  Recent data indicate a role for NIK expressed by non-lymphoid cells in cancer, kidney disease, liver injury, glucose homeostasis, osteosarcopenia, vascular calcification, hematopoiesis, and endothelial function.  The spectrum of NIK-assocd. disease now ranges from immunodeficiency (when NIK is defective) to autoimmunity, cancer, sterile inflammation, fibrosis, and metabolic disease when NIK is overactive.  The development of novel small-mol. NIK inhibitors has paved the way to test NIK targeting to treat disease in vivo, and may eventually lead to NIK targeting in the clinic.  In addn., NIK activators are being explored for specific conditions such as myeloid leukemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpM16Ar9Bc8fbVg90H21EOLACvtfcHk0lj2U6ZKrIQHGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXltVeru7o%253D&md5=e47fa848ac97b68c83c390aba8d99027</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.molmed.2019.02.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molmed.2019.02.005%26sid%3Dliteratum%253Aachs%26aulast%3DValino-Rivas%26aufirst%3DL.%26aulast%3DVaquero%26aufirst%3DJ.%2BJ.%26aulast%3DSucunza%26aufirst%3DD.%26aulast%3DGutierrez%26aufirst%3DS.%26aulast%3DSanz%26aufirst%3DA.%2BB.%26aulast%3DFresno%26aufirst%3DM.%26aulast%3DOrtiz%26aufirst%3DA.%26aulast%3DSanchez-Nino%26aufirst%3DM.%2BD.%26atitle%3DNIK%2520as%2520a%2520druggable%2520mediator%2520of%2520tissue%2520injury%26jtitle%3DTrends%2520Mol.%2520Med.%26date%3D2019%26volume%3D25%26spage%3D341%26epage%3D360%26doi%3D10.1016%2Fj.molmed.2019.02.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omary, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rui, L.</span></span> <span> </span><span class="NLM_article-title">Mouse hepatocyte overexpression of NF-kappaB-inducing kinase (NIK) triggers fatal macrophage-dependent liver injury and fibrosis</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">2065</span>– <span class="NLM_lpage">2076</span>, <span class="refDoi"> DOI: 10.1002/hep.27348</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.1002%2Fhep.27348" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=25088600" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVCis73L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2014&pages=2065-2076&author=H.+Shenauthor=L.+Shengauthor=Z.+Chenauthor=L.+Jiangauthor=H.+Suauthor=L.+Yinauthor=M.+B.+Omaryauthor=L.+Rui&title=Mouse+hepatocyte+overexpression+of+NF-kappaB-inducing+kinase+%28NIK%29+triggers+fatal+macrophage-dependent+liver+injury+and+fibrosis&doi=10.1002%2Fhep.27348"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Mouse hepatocyte overexpression of NF-κB-inducing kinase (NIK) triggers fatal macrophage-dependent liver injury and fibrosis</span></div><div class="casAuthors">Shen, Hong; Sheng, Liang; Chen, Zheng; Jiang, Lin; Su, Haoran; Yin, Lei; Omary, M. Bishr; Rui, Liangyou</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2065-2076</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Damaged, necrotic, or apoptotic hepatocytes release damage-assocd. mol. patterns that initiate sterile inflammation, and liver inflammation drives liver injury and fibrosis.  Here we identified hepatic nuclear factor kappa B (NF-κB)-inducing kinase (NIK), a Ser/Thr kinase, as a novel trigger of fatal liver inflammation.  NIK is activated by a broad spectrum of stimuli.  It was up-regulated in injured livers in both mice and humans.  In primary mouse hepatocytes, NIK overexpression stimulated, independently of cell injury and death, release of numerous chemokines and cytokines that activated bone marrow-derived macrophages (BMDMs).  BMDMs in turn secreted proapoptotic mols. that stimulated hepatocyte apoptosis.  Hepatocyte-specific expression of the NIK transgene triggered massive liver inflammation, oxidative stress, hepatocyte apoptosis, and liver fibrosis, leading to wt. loss, hypoglycemia, and death.  Depletion of Kupffer cells/macrophages reversed NIK-induced liver destruction and death.  Conclusion: the hepatocyte NIK-liver immune cell axis promotes liver inflammation, injury, and fibrosis, thus driving liver disease progression. (Hepatol. 2014;60:2064-2075).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgV39v_Rc3ObVg90H21EOLACvtfcHk0lj2U6ZKrIQHGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVCis73L&md5=7aeccfee609708edca22548eab6eb6b0</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1002%2Fhep.27348&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.27348%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DH.%26aulast%3DSheng%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DJiang%26aufirst%3DL.%26aulast%3DSu%26aufirst%3DH.%26aulast%3DYin%26aufirst%3DL.%26aulast%3DOmary%26aufirst%3DM.%2BB.%26aulast%3DRui%26aufirst%3DL.%26atitle%3DMouse%2520hepatocyte%2520overexpression%2520of%2520NF-kappaB-inducing%2520kinase%2520%2528NIK%2529%2520triggers%2520fatal%2520macrophage-dependent%2520liver%2520injury%2520and%2520fibrosis%26jtitle%3DHepatology%26date%3D2014%26volume%3D60%26spage%3D2065%26epage%3D2076%26doi%3D10.1002%2Fhep.27348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ren, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rui, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span> <span> </span><span class="NLM_article-title">A small-molecule inhibitor of NF-kappaB-inducing kinase (NIK) protects liver from toxin-induced inflammation, oxidative stress, and injury</span>. <i>FASEB J.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">711</span>– <span class="NLM_lpage">718</span>, <span class="refDoi"> DOI: 10.1096/fj.201600840R</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.1096%2Ffj.201600840R" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=27871061" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpsleit78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2017&pages=711-718&author=X.+Renauthor=X.+Liauthor=L.+Jiaauthor=D.+Chenauthor=H.+Houauthor=L.+Ruiauthor=Y.+Zhaoauthor=Z.+Chen&title=A+small-molecule+inhibitor+of+NF-kappaB-inducing+kinase+%28NIK%29+protects+liver+from+toxin-induced+inflammation%2C+oxidative+stress%2C+and+injury&doi=10.1096%2Ffj.201600840R"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">A small-molecule inhibitor of NF-κB-inducing kinase (NIK) protects liver from toxin-induced inflammation, oxidative stress, and injury</span></div><div class="casAuthors">Ren, Xiaomeng; Li, Xinzhi; Jia, Linna; Chen, Deheng; Hou, Hai; Rui, Liangyou; Zhao, Yujun; Chen, Zheng</div><div class="citationInfo"><span class="NLM_cas:title">FASEB Journal</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">711-718</span>CODEN:
                <span class="NLM_cas:coden">FAJOEC</span>;
        ISSN:<span class="NLM_cas:issn">0892-6638</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">Potent and selective chem. probes are valuable tools for discovery of novel treatments for human diseases.  NF-κB-inducing kinase (NIK) is a key trigger in the development of liver injury and fibrosis.  Whether inhibition of NIK activity by chem. probes ameliorates liver inflammation and injury is largely unknown.  In this study, a small-mol. inhibitor of NIK, B022, was found to be a potent and selective chem. probe for liver inflammation and injury.  B022 inhibited the NIK signaling pathway, including NIK-induced p100-to-p52 processing and inflammatory gene expression, both in vitro and in vivo.  Furthermore, in vivo administration of B022 protected against not only NIK but also CCl4-induced liver inflammation and injury.  Our data suggest that inhibition of NIK is a novel strategy for treatment of liver inflammation, oxidative stress, and injury.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAtVxDU8yQibVg90H21EOLACvtfcHk0lj2U6ZKrIQHGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpsleit78%253D&md5=84f05fa8fdf2fcfe79d167827ceea738</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1096%2Ffj.201600840R&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1096%252Ffj.201600840R%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DJia%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DHou%26aufirst%3DH.%26aulast%3DRui%26aufirst%3DL.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DZ.%26atitle%3DA%2520small-molecule%2520inhibitor%2520of%2520NF-kappaB-inducing%2520kinase%2520%2528NIK%2529%2520protects%2520liver%2520from%2520toxin-induced%2520inflammation%252C%2520oxidative%2520stress%252C%2520and%2520injury%26jtitle%3DFASEB%2520J.%26date%3D2017%26volume%3D31%26spage%3D711%26epage%3D718%26doi%3D10.1096%2Ffj.201600840R" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Etemadi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chopin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderton, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanzer, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rickard, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abeysekera, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spall, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hla, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitson, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonder, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ernst, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smyth, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaux, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nutt, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nachbur, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silke, J.</span></span> <span> </span><span class="NLM_article-title">TRAF2 regulates TNF and NF-kappaB signalling to suppress apoptosis and skin inflammation independently of sphingosine kinase 1</span>. <i>eLife</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>4</i></span>, <span class="NLM_elocation-id">e10592</span> <span class="refDoi"> DOI: 10.7554/eLife.10592</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.7554%2FeLife.10592" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=26701909" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlvVClsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2015&author=N.+Etemadiauthor=M.+Chopinauthor=H.+Andertonauthor=M.+C.+Tanzerauthor=J.+A.+Rickardauthor=W.+Abeysekeraauthor=C.+Hallauthor=S.+K.+Spallauthor=B.+Wangauthor=Y.+Xiongauthor=T.+Hlaauthor=S.+M.+Pitsonauthor=C.+S.+Bonderauthor=W.+W.+Wongauthor=M.+Ernstauthor=G.+K.+Smythauthor=D.+L.+Vauxauthor=S.+L.+Nuttauthor=U.+Nachburauthor=J.+Silke&title=TRAF2+regulates+TNF+and+NF-kappaB+signalling+to+suppress+apoptosis+and+skin+inflammation+independently+of+sphingosine+kinase+1&doi=10.7554%2FeLife.10592"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">TRAF2 regulates TNF and NF-κB signalling to suppress apoptosis and skin inflammation independently of sphingosine kinase-1</span></div><div class="casAuthors">Etemadi, Nima; Chopin, Michael; Anderton, Holly; Tanzer, Maria C.; Rickard, James A.; Abeysekera, Waruni; Hall, Cathrine; Spall, Sukhdeep K.; Wang, Bing; Xiong, Yuquan; Hla, Timothy; Pitson, Stuart M.; Bonder, Claudine S.; Wei-Lynn Wong, Wendy; Ernst, Matthias; Smyth, Gordon; Vaux, David L.; Nutt, Stephen L.; Nachbur, Ueli; Silke, John</div><div class="citationInfo"><span class="NLM_cas:title">eLife</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">e10592/1-e10592/27</span>CODEN:
                <span class="NLM_cas:coden">ELIFA8</span>;
        ISSN:<span class="NLM_cas:issn">2050-084X</span>.
    
            (<span class="NLM_cas:orgname">eLife Sciences Publications Ltd.</span>)
        </div><div class="casAbstract">TRAF2 is a component of TNF superfamily signalling complexes and plays an essential role in the regulation and homeostasis of immune cells.  TRAF2 deficient mice die around birth, therefore its role in adult tissues is not well-explored.  Furthermore, the role of the TRAF2 RING is controversial.  It has been claimed that the atypical TRAF2 RING cannot function as a ubiquitin E3 ligase but counterclaimed that TRAF2 RING requires a co-factor, sphingosine-1-phosphate, that is generated by the enzyme sphingosine kinase 1, to function as an E3 ligase.  Keratinocyte-specific deletion of Traf2, but not Sphk1 deficiency, disrupted TNF mediated NF- κB and MAP kinase signalling and caused epidermal hyperplasia and psoriatic skin inflammation.  This inflammation was driven by TNF, cell death, non-canonical NF- κB and the adaptive immune system, and might therefore represent a clin. relevant model of psoriasis.  TRAF2 therefore has essential tissue specific functions that do not overlap with those of Sphk1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4GaudWa3VhLVg90H21EOLACvtfcHk0lhMQ7KBhkU1Eg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlvVClsrc%253D&md5=b82e9922ad3b437dc71151876bf1921c</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.7554%2FeLife.10592&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7554%252FeLife.10592%26sid%3Dliteratum%253Aachs%26aulast%3DEtemadi%26aufirst%3DN.%26aulast%3DChopin%26aufirst%3DM.%26aulast%3DAnderton%26aufirst%3DH.%26aulast%3DTanzer%26aufirst%3DM.%2BC.%26aulast%3DRickard%26aufirst%3DJ.%2BA.%26aulast%3DAbeysekera%26aufirst%3DW.%26aulast%3DHall%26aufirst%3DC.%26aulast%3DSpall%26aufirst%3DS.%2BK.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DXiong%26aufirst%3DY.%26aulast%3DHla%26aufirst%3DT.%26aulast%3DPitson%26aufirst%3DS.%2BM.%26aulast%3DBonder%26aufirst%3DC.%2BS.%26aulast%3DWong%26aufirst%3DW.%2BW.%26aulast%3DErnst%26aufirst%3DM.%26aulast%3DSmyth%26aufirst%3DG.%2BK.%26aulast%3DVaux%26aufirst%3DD.%2BL.%26aulast%3DNutt%26aufirst%3DS.%2BL.%26aulast%3DNachbur%26aufirst%3DU.%26aulast%3DSilke%26aufirst%3DJ.%26atitle%3DTRAF2%2520regulates%2520TNF%2520and%2520NF-kappaB%2520signalling%2520to%2520suppress%2520apoptosis%2520and%2520skin%2520inflammation%2520independently%2520of%2520sphingosine%2520kinase%25201%26jtitle%3DeLife%26date%3D2015%26volume%3D4%26doi%3D10.7554%2FeLife.10592" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mair, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joller, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoeppli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onder, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hahn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludewig, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waisman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becher, B.</span></span> <span> </span><span class="NLM_article-title">The NF-kappaB-inducing kinase is essential for the developmental programming of skin-resident and IL-17-producing gammadelta T cells</span>. <i>eLife</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>4</i></span>, <span class="NLM_elocation-id">e10087</span> <span class="refDoi"> DOI: 10.7554/eLife.10087</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.7554%2FeLife.10087" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=26637788" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlvVCntbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2015&author=F.+Mairauthor=S.+Jollerauthor=R.+Hoeppliauthor=L.+Onderauthor=M.+Hahnauthor=B.+Ludewigauthor=A.+Waismanauthor=B.+Becher&title=The+NF-kappaB-inducing+kinase+is+essential+for+the+developmental+programming+of+skin-resident+and+IL-17-producing+gammadelta+T+cells&doi=10.7554%2FeLife.10087"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">The NFκB-inducing kinase is essential for the developmental programming of skin-resident and IL-17-producing γδ T cells</span></div><div class="casAuthors">Mair, Florian; Joller, Stefanie; Hoeppli, Romy; Onder, Lucas; Hahn, Matthias; Ludewig, Burkhard; Waisman, Ari; Becher, Burkhard</div><div class="citationInfo"><span class="NLM_cas:title">eLife</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">e10087/1-e10087/16</span>CODEN:
                <span class="NLM_cas:coden">ELIFA8</span>;
        ISSN:<span class="NLM_cas:issn">2050-084X</span>.
    
            (<span class="NLM_cas:orgname">eLife Sciences Publications Ltd.</span>)
        </div><div class="casAbstract">& amp; #x03B3; & amp; #x03B4; T cells contribute to first line immune defense, particularly through their ability for rapid prodn. of proinflammatory cytokines.  The cytokine profile of & amp; #x03B3; & amp; #x03B4; T cells is hard-wired already during thymic development.  Yet, the mol. pathways underlying this phenomenon are incompletely understood.  Here we show that signaling via the NF & amp; #x03BA;B-inducing kinase (NIK) is essential for the formation of a fully functional & amp; #x03B3; & amp; #x03B4; T cell compartment.  In the absence of NIK, development of V & amp; #x03B3;5+ dendritic epidermal T cells (DETCs) was halted in the embryonic thymus, and impaired NIK function caused a selective loss of IL-17 expression by & amp; #x03B3; & amp; #x03B4; T cells.  Using a novel conditional mutant of NIK, we could show in vivo that NIK signaling in thymic epithelial cells is essential for the thymic hardwiring of & amp; #x03B3; & amp; #x03B4; T cell cytokine prodn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpT0H7VbjtfJbVg90H21EOLACvtfcHk0lhMQ7KBhkU1Eg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlvVCntbo%253D&md5=793ba613f113d2da3ea55401e52587d3</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.7554%2FeLife.10087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7554%252FeLife.10087%26sid%3Dliteratum%253Aachs%26aulast%3DMair%26aufirst%3DF.%26aulast%3DJoller%26aufirst%3DS.%26aulast%3DHoeppli%26aufirst%3DR.%26aulast%3DOnder%26aufirst%3DL.%26aulast%3DHahn%26aufirst%3DM.%26aulast%3DLudewig%26aufirst%3DB.%26aulast%3DWaisman%26aufirst%3DA.%26aulast%3DBecher%26aufirst%3DB.%26atitle%3DThe%2520NF-kappaB-inducing%2520kinase%2520is%2520essential%2520for%2520the%2520developmental%2520programming%2520of%2520skin-resident%2520and%2520IL-17-producing%2520gammadelta%2520T%2520cells%26jtitle%3DeLife%26date%3D2015%26volume%3D4%26doi%3D10.7554%2FeLife.10087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eshima, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okabe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kajiura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noma, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinohara, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwabuchi, K.</span></span> <span> </span><span class="NLM_article-title">Significant involvement of nuclear factor-kappaB-inducing kinase in proper differentiation of alphabeta and gammadelta T cells</span>. <i>Immunology</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>141</i></span>,  <span class="NLM_fpage">222</span>– <span class="NLM_lpage">232</span>, <span class="refDoi"> DOI: 10.1111/imm.12186</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.1111%2Fimm.12186" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=24117043" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC2cXktFahtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2014&pages=222-232&author=K.+Eshimaauthor=M.+Okabeauthor=S.+Kajiuraauthor=H.+Nomaauthor=N.+Shinoharaauthor=K.+Iwabuchi&title=Significant+involvement+of+nuclear+factor-kappaB-inducing+kinase+in+proper+differentiation+of+alphabeta+and+gammadelta+T+cells&doi=10.1111%2Fimm.12186"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Significant involvement of nuclear factor-κB-inducing kinase in proper differentiation of αβ and γδ T cells</span></div><div class="casAuthors">Eshima, Koji; Okabe, Motohito; Kajiura, Satoshi; Noma, Haruka; Shinohara, Nobukata; Iwabuchi, Kazuya</div><div class="citationInfo"><span class="NLM_cas:title">Immunology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">222-232</span>CODEN:
                <span class="NLM_cas:coden">IMMUAM</span>;
        ISSN:<span class="NLM_cas:issn">0019-2805</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Nuclear factor-κB-inducing kinase (NIK) is known to play a crit. role in maintaining proper immune function.  This is exemplified in the spontaneous mutant mouse lacking functional NIK, alymphoplasia (aly), which is simultaneously immune-compromised and autoimmune-prone.  To investigate the role of NIK in αβ T-cell repertoire formation, we analyzed T-cell development in aly/aly mice bearing a transgenic T-cell receptor (TCR).  Although there were no apparent abnormalities in the mature αβ T cells of non-transgenic aly/aly mice, the maturation efficiency of idiotypehigh+ T cells in the TCR-transgenic mice was lower in aly/aly mice compared with those found in aly/+ mice, suggesting that the mature αβ T-cell repertoire could be altered by the absence of functional NIK.  In one strain of TCR-transgenic aly/aly mice with a neg. selecting H-2 background, the proportion of CD8low+ idiotypehigh+ cells, which are thought to potentially represent the γδ lineage of T cells, was markedly decreased.  When the γδ T cells in non-transgenic aly/aly mice were investigated, the proportion of γδ T cells in the peripheral organs of aly/aly mice was found to be one-half to one-fifth of those in aly/+ mice.  Analyses of bone marrow chimera mice indicated that NIK in host cells, rather than in donor cells was important for generating a normal no. of peripheral γδ T cells.  Collectively, these results suggest that NIK could be involved in thymic pos. selection of some αβ T cells and that NIK in non-haematopoietic cells is important for the optimal development and/or maintenance of γδ T cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruwpl2eiDwarVg90H21EOLACvtfcHk0lheAc9kRjoziQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXktFahtg%253D%253D&md5=cd4e578e3494e115e066f06736a65ef1</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1111%2Fimm.12186&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fimm.12186%26sid%3Dliteratum%253Aachs%26aulast%3DEshima%26aufirst%3DK.%26aulast%3DOkabe%26aufirst%3DM.%26aulast%3DKajiura%26aufirst%3DS.%26aulast%3DNoma%26aufirst%3DH.%26aulast%3DShinohara%26aufirst%3DN.%26aulast%3DIwabuchi%26aufirst%3DK.%26atitle%3DSignificant%2520involvement%2520of%2520nuclear%2520factor-kappaB-inducing%2520kinase%2520in%2520proper%2520differentiation%2520of%2520alphabeta%2520and%2520gammadelta%2520T%2520cells%26jtitle%3DImmunology%26date%3D2014%26volume%3D141%26spage%3D222%26epage%3D232%26doi%3D10.1111%2Fimm.12186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">El
Malki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karbach, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huppert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zayoud, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reissig, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuler, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolaev, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karram, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munzel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhlmann, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luhmann, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Stebut, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wortge, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurschus, F. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waisman, A.</span></span> <span> </span><span class="NLM_article-title">An alternative pathway of imiquimod-induced psoriasis-like skin inflammation in the absence of interleukin-17 receptor a signaling</span>. <i>J. Invest. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>133</i></span>,  <span class="NLM_fpage">441</span>– <span class="NLM_lpage">451</span>, <span class="refDoi"> DOI: 10.1038/jid.2012.318</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.1038%2Fjid.2012.318" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=22951726" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlWns73J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=2013&pages=441-451&author=K.+El%0AMalkiauthor=S.+H.+Karbachauthor=J.+Huppertauthor=M.+Zayoudauthor=S.+Reissigauthor=R.+Schulerauthor=A.+Nikolaevauthor=K.+Karramauthor=T.+Munzelauthor=C.+R.+Kuhlmannauthor=H.+J.+Luhmannauthor=E.+von+Stebutauthor=S.+Wortgeauthor=F.+C.+Kurschusauthor=A.+Waisman&title=An+alternative+pathway+of+imiquimod-induced+psoriasis-like+skin+inflammation+in+the+absence+of+interleukin-17+receptor+a+signaling&doi=10.1038%2Fjid.2012.318"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">An Alternative Pathway of Imiquimod-Induced Psoriasis-Like Skin Inflammation in the Absence of Interleukin-17 Receptor A Signaling</span></div><div class="casAuthors">El Malki, Khalifa; Karbach, Susanne H.; Huppert, Jula; Zayoud, Morad; Reissig, Sonja; Schueler, Rebecca; Nikolaev, Alexej; Karram, Khalad; Muenzel, Thomas; Kuhlmann, Christoph R. W.; Luhmann, Heiko J.; von Stebut, Esther; Woertge, Simone; Kurschus, Florian C.; Waisman, Ari</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Investigative Dermatology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">133</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">441-451</span>CODEN:
                <span class="NLM_cas:coden">JIDEAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-202X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Topical application of imiquimod (IMQ) on the skin of mice induces inflammation with common features found in psoriatic skin.  Recently, it was postulated that IL-17 has an important role both in psoriasis and in the IMQ model.  To further investigate the impact of IL-17RA signaling in psoriasis, we generated IL-17 receptor A (IL-17RA)-deficient mice (IL-17RAdel) and challenged these mice with IMQ.  Interestingly, the disease was only partially reduced and delayed but not abolished when compared with controls.  In the absence of IL-17RA, we found persisting signs of inflammation such as neutrophil and macrophage infiltration within the skin.  Surprisingly, already in the naive state, the skin of IL-17RAdel mice contained significantly elevated nos. of Th17- and IL-17-producing γδ T cells, assuming that IL-17RA signaling regulates the population size of Th17 and γδ T cells.  Upon IMQ treatment of IL-17RAdel mice, these cells secreted elevated amts. of tumor necrosis factor-α, IL-6, and IL-22, accompanied by increased levels of the chemokine CXCL2, suggesting an alternative pathway of neutrophil and macrophage skin infiltration.  Hence, our findings have major implications in the potential long-term treatment of psoriasis by IL-17-targeting drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlZh_TcBKGGbVg90H21EOLACvtfcHk0lheAc9kRjoziQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlWns73J&md5=69b76e9109adad0c2e92c44e522daed4</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1038%2Fjid.2012.318&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fjid.2012.318%26sid%3Dliteratum%253Aachs%26aulast%3DEl%2BMalki%26aufirst%3DK.%26aulast%3DKarbach%26aufirst%3DS.%2BH.%26aulast%3DHuppert%26aufirst%3DJ.%26aulast%3DZayoud%26aufirst%3DM.%26aulast%3DReissig%26aufirst%3DS.%26aulast%3DSchuler%26aufirst%3DR.%26aulast%3DNikolaev%26aufirst%3DA.%26aulast%3DKarram%26aufirst%3DK.%26aulast%3DMunzel%26aufirst%3DT.%26aulast%3DKuhlmann%26aufirst%3DC.%2BR.%26aulast%3DLuhmann%26aufirst%3DH.%2BJ.%26aulast%3Dvon%2BStebut%26aufirst%3DE.%26aulast%3DWortge%26aufirst%3DS.%26aulast%3DKurschus%26aufirst%3DF.%2BC.%26aulast%3DWaisman%26aufirst%3DA.%26atitle%3DAn%2520alternative%2520pathway%2520of%2520imiquimod-induced%2520psoriasis-like%2520skin%2520inflammation%2520in%2520the%2520absence%2520of%2520interleukin-17%2520receptor%2520a%2520signaling%26jtitle%3DJ.%2520Invest.%2520Dermatol.%26date%3D2013%26volume%3D133%26spage%3D441%26epage%3D451%26doi%3D10.1038%2Fjid.2012.318" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chio, I. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brustle, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mak, T. W.</span></span> <span> </span><span class="NLM_article-title">Crucial role for TNF receptor-associated factor 2 (TRAF2) in regulating NFkappaB2 signaling that contributes to autoimmunity</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">18354</span>– <span class="NLM_lpage">18359</span>, <span class="refDoi"> DOI: 10.1073/pnas.1109427108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.1073%2Fpnas.1109427108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=22042853" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsF2itrvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=18354-18359&author=W.+J.+Linauthor=Y.+W.+Suauthor=Y.+C.+Luauthor=Z.+Haoauthor=I.+I.+Chioauthor=N.+J.+Chenauthor=A.+Brustleauthor=W.+Y.+Liauthor=T.+W.+Mak&title=Crucial+role+for+TNF+receptor-associated+factor+2+%28TRAF2%29+in+regulating+NFkappaB2+signaling+that+contributes+to+autoimmunity&doi=10.1073%2Fpnas.1109427108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Crucial role for TNF receptor-associated factor 2 (TRAF2) in regulating NFκB2 signaling that contributes to autoimmunity</span></div><div class="casAuthors">Lin, Wen-Jye; Su, Yu-Wen; Lu, Yong-Chen; Hao, Zhenyue; Chio, Iok In Christine; Chen, Nien-Jung; Brustle, Anne; Li, Wanda Y.; Mak, Tak Wah</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">18354-18359, S18354/1-S18354/7</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">TNF receptor-assocd. factor 2 (TRAF2) is a key intracellular signaling mediator that acts downstream of not only TNFα but also various members of the TNFa superfamily.  Here, we report that, despite their lack of TNFa signaling, TRAF2-/-TNFα-/- mice develop an inflammatory disorder characterized by autoantibody accumulation and organ infiltration by T cells with the phenotypes of activated, effector, and memory cells.  RAG1-/- mice reconstituted with TRAF2-/-TNFα-/- bone marrow cells showed increased nos. of hyperactive T cells and rapidly developed progressive and eventually lethal inflammation.  No inflammation was obsd. in RAG1-/- mice reconstituted with TRAF2-/-TNFα-/-T-cell receptor β-/- or TRAF2-/-TNFα-/-NFκB-induced kinase+/- bone marrow cells.  The pathogenic TRAF2-/-TNFα-/- T cells showed constitutive NFκB2p52 activation and produced elevated levels of T-helper 1 and T-helper 17 cytokines.  Our. results suggest that a regulatory circuit consisting of TRAF2-NFκB-induced kinase-NFκB2p52 is essential for the proper control of effector T-cell polarization and that loss of T-cell TRAF2 function induces constitutive NFκB2p52 activity that drives fatal autoimmune inflammation independently of TNFα signaling.  The involvement of this regulatory circuit in controlling autoimmune responses highlights the delicate balance required to avoid paradoxical adverse events when implementing new targeted anti-inflammatory therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGox81gak_2xvbVg90H21EOLACvtfcHk0lheAc9kRjoziQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsF2itrvN&md5=4e7c755d7db1e9fac89b556342ffa39d</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1109427108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1109427108%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DW.%2BJ.%26aulast%3DSu%26aufirst%3DY.%2BW.%26aulast%3DLu%26aufirst%3DY.%2BC.%26aulast%3DHao%26aufirst%3DZ.%26aulast%3DChio%26aufirst%3DI.%2BI.%26aulast%3DChen%26aufirst%3DN.%2BJ.%26aulast%3DBrustle%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DW.%2BY.%26aulast%3DMak%26aufirst%3DT.%2BW.%26atitle%3DCrucial%2520role%2520for%2520TNF%2520receptor-associated%2520factor%25202%2520%2528TRAF2%2529%2520in%2520regulating%2520NFkappaB2%2520signaling%2520that%2520contributes%2520to%2520autoimmunity%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2011%26volume%3D108%26spage%3D18354%26epage%3D18359%26doi%3D10.1073%2Fpnas.1109427108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, H.</span></span> <span> </span><span class="NLM_article-title">Rutaecarpine inhibited imiquimod-induced psoriasis-like dermatitis via inhibiting the NF-kappaB and TLR7 pathways in mice</span>. <i>Biomed. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">1876</span>– <span class="NLM_lpage">1883</span>, <span class="refDoi"> DOI: 10.1016/j.biopha.2018.10.062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.1016%2Fj.biopha.2018.10.062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=30551443" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlGgtL7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2019&pages=1876-1883&author=Y.+Liauthor=G.+Zhangauthor=M.+Chenauthor=M.+Tongauthor=M.+Zhaoauthor=F.+Tangauthor=R.+Xiaoauthor=H.+Wen&title=Rutaecarpine+inhibited+imiquimod-induced+psoriasis-like+dermatitis+via+inhibiting+the+NF-kappaB+and+TLR7+pathways+in+mice&doi=10.1016%2Fj.biopha.2018.10.062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Rutaecarpine inhibited imiquimod-induced psoriasis-like dermatitis via inhibiting the NF-κB and TLR7 pathways in mice</span></div><div class="casAuthors">Li, Yongjian; Zhang, Guiying; Chen, Mingliang; Tong, Min; Zhao, Ming; Tang, Fang; Xiao, Rong; Wen, Haiquan</div><div class="citationInfo"><span class="NLM_cas:title">Biomedicine & Pharmacotherapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1876-1883</span>CODEN:
                <span class="NLM_cas:coden">BIPHEX</span>;
        ISSN:<span class="NLM_cas:issn">0753-3322</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Psoriasis is a chronic, immune-mediated inflammatory skin disease.  As psoriasis rarely occurs in nonhuman animals, the lack of an ideal animal model reflecting the histopathol. and mol. immunol. characteristics of psoriasis remains an urgent issue.  In the present study, an imiquimod-induced psoriasis-like dermatitis mouse model was constructed under natural immune conditions and verified by evaluations of the Psoriasis Area and Severity Index (PASI) score and Baker score, H&E staining, immunohistochem. examn. of the CD3 and Gr1 levels, measurement of plasmacytoid dendritic cell- (pDC) and Th17-assocd. cytokine levels, and evaluation of p65 phosphorylation and TLR7 expression.  Moreover, rutaecarpine (RUT), the main active ingredient in the traditional Chinese medicine Wu-Zhu-Yu, could improve psoriasis-like dermatitis through effects on pDC- and Th17-assocd. cytokines through NF-κB and toll-like receptor 7 (TLR7) signaling.  Taken together, the imiquimod-induced psoriasis-like dermatitis mouse model can be regarded as an ideal model for evaluating psoriasis pathogenesis and antipsoriatic drugs.  We provided theor. and exptl. evidence for the clin. application of RUT in psoriasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYzmOHp7vLqbVg90H21EOLACvtfcHk0lgQrLlGN0T0aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlGgtL7I&md5=5076a975933814d69d25f8997c4791b1</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.biopha.2018.10.062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopha.2018.10.062%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DTong%26aufirst%3DM.%26aulast%3DZhao%26aufirst%3DM.%26aulast%3DTang%26aufirst%3DF.%26aulast%3DXiao%26aufirst%3DR.%26aulast%3DWen%26aufirst%3DH.%26atitle%3DRutaecarpine%2520inhibited%2520imiquimod-induced%2520psoriasis-like%2520dermatitis%2520via%2520inhibiting%2520the%2520NF-kappaB%2520and%2520TLR7%2520pathways%2520in%2520mice%26jtitle%3DBiomed.%2520Pharmacother.%26date%3D2019%26volume%3D109%26spage%3D1876%26epage%3D1883%26doi%3D10.1016%2Fj.biopha.2018.10.062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGee, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sudom, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubenstein, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anwer, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cushing, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayres, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eksterowicz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faulder, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waszkowycz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plotnikova, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrelly, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span> <span> </span><span class="NLM_article-title">Inhibiting NF-kappaB-inducing kinase (NIK): discovery, structure-based design, synthesis, structure-activity relationship, and co-crystal structures</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1238</span>– <span class="NLM_lpage">1244</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.01.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.1016%2Fj.bmcl.2013.01.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=23374866" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVGmt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=1238-1244&author=K.+Liauthor=L.+R.+McGeeauthor=B.+Fisherauthor=A.+Sudomauthor=J.+Liuauthor=S.+M.+Rubensteinauthor=M.+K.+Anwerauthor=T.+D.+Cushingauthor=Y.+Shinauthor=M.+Ayresauthor=F.+Leeauthor=J.+Eksterowiczauthor=P.+Faulderauthor=B.+Waszkowyczauthor=O.+Plotnikovaauthor=E.+Farrellyauthor=S.+H.+Xiaoauthor=G.+Chenauthor=Z.+Wang&title=Inhibiting+NF-kappaB-inducing+kinase+%28NIK%29%3A+discovery%2C+structure-based+design%2C+synthesis%2C+structure-activity+relationship%2C+and+co-crystal+structures&doi=10.1016%2Fj.bmcl.2013.01.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibiting NF-κB-inducing kinase (NIK): Discovery, structure-based design, synthesis, structure-activity relationship, and co-crystal structures</span></div><div class="casAuthors">Li, Kexue; McGee, Lawrence R.; Fisher, Ben; Sudom, Athena; Liu, Jinsong; Rubenstein, Steven M.; Anwer, Mohmed K.; Cushing, Timothy D.; Shin, Youngsook; Ayres, Merrill; Lee, Fei; Eksterowicz, John; Faulder, Paul; Waszkowycz, Bohdan; Plotnikova, Olga; Farrelly, Ellyn; Xiao, Shou-Hua; Chen, Guoqing; Wang, Zhulun</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1238-1244</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The discovery, structure-based design, synthesis, and optimization of NIK inhibitors are described.  Our work began with an HTS hit, imidazopyridinyl pyrimidinamine I.  We utilized homol. modeling and conformational anal. to optimize the indole scaffold leading to the discovery of novel and potent conformationally constrained inhibitors such as compds. II [R1 = Br, C≡CCMe2OH].  Compds. II [R1 = Br] and III were co-crystd. with NIK kinase domain to provide structural insights.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpm5WqvTIrBqrVg90H21EOLACvtfcHk0lgQrLlGN0T0aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVGmt7s%253D&md5=a382078cf3bf84a41749783be33a5988</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.01.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.01.012%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DK.%26aulast%3DMcGee%26aufirst%3DL.%2BR.%26aulast%3DFisher%26aufirst%3DB.%26aulast%3DSudom%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DRubenstein%26aufirst%3DS.%2BM.%26aulast%3DAnwer%26aufirst%3DM.%2BK.%26aulast%3DCushing%26aufirst%3DT.%2BD.%26aulast%3DShin%26aufirst%3DY.%26aulast%3DAyres%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DF.%26aulast%3DEksterowicz%26aufirst%3DJ.%26aulast%3DFaulder%26aufirst%3DP.%26aulast%3DWaszkowycz%26aufirst%3DB.%26aulast%3DPlotnikova%26aufirst%3DO.%26aulast%3DFarrelly%26aufirst%3DE.%26aulast%3DXiao%26aufirst%3DS.%2BH.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DZ.%26atitle%3DInhibiting%2520NF-kappaB-inducing%2520kinase%2520%2528NIK%2529%253A%2520discovery%252C%2520structure-based%2520design%252C%2520synthesis%252C%2520structure-activity%2520relationship%252C%2520and%2520co-crystal%2520structures%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D1238%26epage%3D1244%26doi%3D10.1016%2Fj.bmcl.2013.01.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Songyang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, X.</span></span> <span> </span><span class="NLM_article-title">Gain-of-function mutation of card14 leads to spontaneous psoriasis-like skin inflammation through enhanced keratinocyte response to IL-17A</span>. <i>Immunity</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">66</span>– <span class="NLM_lpage">79</span>, <span class="refDoi"> DOI: 10.1016/j.immuni.2018.05.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.1016%2Fj.immuni.2018.05.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=29980436" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1GjsLbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2018&pages=66-79&author=M.+Wangauthor=S.+Zhangauthor=G.+Zhengauthor=J.+Huangauthor=Z.+Songyangauthor=X.+Zhaoauthor=X.+Lin&title=Gain-of-function+mutation+of+card14+leads+to+spontaneous+psoriasis-like+skin+inflammation+through+enhanced+keratinocyte+response+to+IL-17A&doi=10.1016%2Fj.immuni.2018.05.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Gain-of-Function Mutation of Card14 Leads to Spontaneous Psoriasis-like Skin Inflammation through Enhanced Keratinocyte Response to IL-17A</span></div><div class="casAuthors">Wang, Mingchao; Zhang, Shanshan; Zheng, Guoxing; Huang, Junjiu; Zhou, Songyang; Zhao, Xueqiang; Lin, Xin</div><div class="citationInfo"><span class="NLM_cas:title">Immunity</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">66-79.e5</span>CODEN:
                <span class="NLM_cas:coden">IUNIEH</span>;
        ISSN:<span class="NLM_cas:issn">1074-7613</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Genetic mutations of CARD14 (encoding CARMA2) are obsd. in psoriasis patients.  Here we showed that Card14E138A/+ and Card14ΔQ136/+ mice developed spontaneous psoriasis-like skin inflammation, which resulted from constitutively activated CARMA2 via self-aggregation leading to the enhanced activation of the IL-23-IL-17A cytokine axis.  Card14-/- mice displayed attenuated skin inflammation in the imiquimod-induced psoriasis model due to impaired IL-17A signaling in keratinocytes.  CARMA2, mainly expressed in keratinocytes, assocs. with the ACT1-TRAF6 signaling complex and mediates IL-17A-induced NF-κB and MAPK signaling pathway activation, which leads to expression of pro-inflammatory factors.  Thus, CARMA2 serves as a key mediator of IL-17A signaling and its constitutive activation in keratinocytes leads to the onset of psoriasis, which indicates an important role of NF-κB activation in keratinocytes in psoriatic initiation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjgNs_LJtXvbVg90H21EOLACvtfcHk0liPB7UYcOEKyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1GjsLbF&md5=7ebbcf845656a0852f4a82f1b0e7d4ca</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.immuni.2018.05.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.immuni.2018.05.012%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DZheng%26aufirst%3DG.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DSongyang%26aufirst%3DZ.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DLin%26aufirst%3DX.%26atitle%3DGain-of-function%2520mutation%2520of%2520card14%2520leads%2520to%2520spontaneous%2520psoriasis-like%2520skin%2520inflammation%2520through%2520enhanced%2520keratinocyte%2520response%2520to%2520IL-17A%26jtitle%3DImmunity%26date%3D2018%26volume%3D49%26spage%3D66%26epage%3D79%26doi%3D10.1016%2Fj.immuni.2018.05.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Klimov, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tretiakov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gapanovich, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kokaeva, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soboleva, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakaniya, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korsunskaya, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sobolev, V.</span></span> <span> </span><span class="NLM_article-title">Assessment of the role of NO synthase genes polymorphisms in the pathogenesis of psoriasis</span>. <i>J. Adv. Med. Med. Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">6</span>, <span class="refDoi"> DOI: 10.9734/JAMMR/2018/41039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.9734%2FJAMMR%2F2018%2F41039" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2018&pages=1-6&author=E.+Klimovauthor=A.+Tretiakovauthor=E.+Gapanovichauthor=Z.+Kokaevaauthor=A.+Sobolevaauthor=L.+Sakaniyaauthor=I.+Korsunskayaauthor=V.+Sobolev&title=Assessment+of+the+role+of+NO+synthase+genes+polymorphisms+in+the+pathogenesis+of+psoriasis&doi=10.9734%2FJAMMR%2F2018%2F41039"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.9734%2FJAMMR%2F2018%2F41039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.9734%252FJAMMR%252F2018%252F41039%26sid%3Dliteratum%253Aachs%26aulast%3DKlimov%26aufirst%3DE.%26aulast%3DTretiakov%26aufirst%3DA.%26aulast%3DGapanovich%26aufirst%3DE.%26aulast%3DKokaeva%26aufirst%3DZ.%26aulast%3DSoboleva%26aufirst%3DA.%26aulast%3DSakaniya%26aufirst%3DL.%26aulast%3DKorsunskaya%26aufirst%3DI.%26aulast%3DSobolev%26aufirst%3DV.%26atitle%3DAssessment%2520of%2520the%2520role%2520of%2520NO%2520synthase%2520genes%2520polymorphisms%2520in%2520the%2520pathogenesis%2520of%2520psoriasis%26jtitle%3DJ.%2520Adv.%2520Med.%2520Med.%2520Res.%26date%3D2018%26volume%3D26%26spage%3D1%26epage%3D6%26doi%3D10.9734%2FJAMMR%2F2018%2F41039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scholz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yau, A. C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hüffmeier, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burkhardt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmdahl, R.</span></span> <span> </span><span class="NLM_article-title">Mannan-induced NOS2 in macrophages enhances IL-17-driven psoriatic arthritis by innate lymphocytes</span>. <i>Sci. Adv.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>4</i></span>, <span class="NLM_elocation-id">eaas9864</span> <span class="refDoi"> DOI: 10.1126/sciadv.aas9864</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.1126%2Fsciadv.aas9864" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=29774240" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2018&author=J.+Zhongauthor=T.+Scholzauthor=A.+C.+Y.+Yauauthor=S.+Guerardauthor=U.+H%C3%BCffmeierauthor=H.+Burkhardtauthor=R.+Holmdahl&title=Mannan-induced+NOS2+in+macrophages+enhances+IL-17-driven+psoriatic+arthritis+by+innate+lymphocytes&doi=10.1126%2Fsciadv.aas9864"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1126%2Fsciadv.aas9864&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fsciadv.aas9864%26sid%3Dliteratum%253Aachs%26aulast%3DZhong%26aufirst%3DJ.%26aulast%3DScholz%26aufirst%3DT.%26aulast%3DYau%26aufirst%3DA.%2BC.%2BY.%26aulast%3DGuerard%26aufirst%3DS.%26aulast%3DH%25C3%25BCffmeier%26aufirst%3DU.%26aulast%3DBurkhardt%26aufirst%3DH.%26aulast%3DHolmdahl%26aufirst%3DR.%26atitle%3DMannan-induced%2520NOS2%2520in%2520macrophages%2520enhances%2520IL-17-driven%2520psoriatic%2520arthritis%2520by%2520innate%2520lymphocytes%26jtitle%3DSci.%2520Adv.%26date%3D2018%26volume%3D4%26doi%3D10.1126%2Fsciadv.aas9864" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, W.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of bis-aryl ureas and amides based on 2-amino-3-purinylpyridine scaffold as DFG-out B-Raf kinase inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">581</span>– <span class="NLM_lpage">596</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2014.10.039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.1016%2Fj.ejmech.2014.10.039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=25462267" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslOjtL7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2015&pages=581-596&author=W.+Yangauthor=Y.+Chenauthor=X.+Zhouauthor=Y.+Guauthor=W.+Qianauthor=F.+Zhangauthor=W.+Hanauthor=T.+Luauthor=W.+Tang&title=Design%2C+synthesis+and+biological+evaluation+of+bis-aryl+ureas+and+amides+based+on+2-amino-3-purinylpyridine+scaffold+as+DFG-out+B-Raf+kinase+inhibitors&doi=10.1016%2Fj.ejmech.2014.10.039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of bis-aryl ureas and amides based on 2-amino-3-purinylpyridine scaffold as DFG-out B-Raf kinase inhibitors</span></div><div class="casAuthors">Yang, Weimin; Chen, Yadong; Zhou, Xiang; Gu, Yazhou; Qian, Wenqi; Zhang, Fan; Han, Wei; Lu, Tao; Tang, Weifang</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">581-596</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">By combining the scaffolds of UI-125 and Sorafenib, a series of bis-aryl ureas and amides based on 2-amino-3-purinylpyridine moiety were designed and synthesized as novel DFG-out B-RafV600E inhibitors.  Several of these compds. displayed potent antiproliferative activities against melanoma A375 (B-RafV600E) cell lines with IC50 values of 3.190, 2.276, 1.856, 1.632 μM and 1.839 μM, resp., comparable with the pos. control Vemurafenib (IC50 = 3.32 μM).  Selected compds. were tested for the ERK inhibition in human melanoma A375 (B-RafV600E) and SK-MEL-2 (B-RafWT) cell lines by Western blot.  The results revealed that our compds. inhibited the proliferation of melanoma A375 cells (B-RafV600E) through ERK pathway, without paradoxical activation of ERK in melanoma SK-MEL-2 cells (B-RafWT).  Eventually, two compds. were selected to confirm their inhibitory effects on tumor growth in A375 xenograft models in mice.  Compd. I exhibited equiv. antitumor efficacy in vivo (T/C = 44.37%), compared to Sorafenib (T/C = 37.35%), by 23-day repetitive administration of a single dose of 50 mg/kg without significant body wt. loss.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq84bBDYugz1bVg90H21EOLACvtfcHk0liPB7UYcOEKyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslOjtL7I&md5=6a65e09b0121c8f2f32facbfeae8f86b</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.10.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.10.039%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DGu%26aufirst%3DY.%26aulast%3DQian%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DF.%26aulast%3DHan%26aufirst%3DW.%26aulast%3DLu%26aufirst%3DT.%26aulast%3DTang%26aufirst%3DW.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520bis-aryl%2520ureas%2520and%2520amides%2520based%2520on%25202-amino-3-purinylpyridine%2520scaffold%2520as%2520DFG-out%2520B-Raf%2520kinase%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D89%26spage%3D581%26epage%3D596%26doi%3D10.1016%2Fj.ejmech.2014.10.039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Toledo, C. E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Souza, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraga, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribeiro, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferreira, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitral, R. W. F.</span></span> <span> </span><span class="NLM_article-title">Cellular viability and nitric oxide (NO) production by J774 macrophages in the presence of orthodontic archwires</span>. <i>J. Biomed. Sci. Eng.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">255</span>– <span class="NLM_lpage">262</span>, <span class="refDoi"> DOI: 10.4236/jbise.2012.55032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.4236%2Fjbise.2012.55032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFChurbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2012&pages=255-262&author=C.+E.+P.+Toledoauthor=M.+A.+Souzaauthor=M.+R.+Fragaauthor=L.+C.+Ribeiroauthor=A.+P.+Ferreiraauthor=R.+W.+F.+Vitral&title=Cellular+viability+and+nitric+oxide+%28NO%29+production+by+J774+macrophages+in+the+presence+of+orthodontic+archwires&doi=10.4236%2Fjbise.2012.55032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Cellular viability and nitric oxide (NO) production by J774 macrophages in the presence of orthodontic archwires</span></div><div class="casAuthors">Toledo, Carlos E. P.; Souza, Maria A.; Fraga, Marcelo R.; Ribeiro, Luiz C.; Ferreira, Ana P.; Vitral, Robert W. F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomedical Science and Engineering</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">255-262</span>CODEN:
                <span class="NLM_cas:coden">JBSEC8</span>;
        ISSN:<span class="NLM_cas:issn">1937-6871</span>.
    
            (<span class="NLM_cas:orgname">Scientific Research Publishing, Inc.</span>)
        </div><div class="casAbstract">To assess, in vitro, the cellular viability in a murine macrophage cell line J774 with 9 different orthodontic wires and to evaluate the effects of its NO prodn.  To assess cellular viability by MTT: 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl tetrazolium bromide assay in the cell line J774 with 9 different orthodontic wires and quantify NO prodn. by these macrophages.  Cell cultures were evaluated at 24, 48 and 72 h.  There was no significant difference of the means of cellular viability between the control and the group of wires in the resp. time intervals.  In the comparison with the control group, there was significant difference in the NO prodn. in groups 1, 6, and 9 at 24 h interval.  Group 8 showed significant difference in relation to the control group at final time interval.  Cellular viability in all groups was higher at the final time interval than at the initial time interval.  This increase was significant in the control group.  In the material groups, the final mean of cellular viability at 72 h showed no significant difference when compared with the control group.  NO prodn. in all groups was higher at the final time interval than at the initial time interval.  This increase was significant in the control group.  In the material groups, the final mean of NO prodn. at 72 h was only significant in group 8 (beta-titanium) when compared with the control group.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA3yScnd8EW7Vg90H21EOLACvtfcHk0lhRIHhV6pABbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFChurbF&md5=2b987fd34c729311fe912320a28a725b</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.4236%2Fjbise.2012.55032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4236%252Fjbise.2012.55032%26sid%3Dliteratum%253Aachs%26aulast%3DToledo%26aufirst%3DC.%2BE.%2BP.%26aulast%3DSouza%26aufirst%3DM.%2BA.%26aulast%3DFraga%26aufirst%3DM.%2BR.%26aulast%3DRibeiro%26aufirst%3DL.%2BC.%26aulast%3DFerreira%26aufirst%3DA.%2BP.%26aulast%3DVitral%26aufirst%3DR.%2BW.%2BF.%26atitle%3DCellular%2520viability%2520and%2520nitric%2520oxide%2520%2528NO%2529%2520production%2520by%2520J774%2520macrophages%2520in%2520the%2520presence%2520of%2520orthodontic%2520archwires%26jtitle%3DJ.%2520Biomed.%2520Sci.%2520Eng.%26date%3D2012%26volume%3D5%26spage%3D255%26epage%3D262%26doi%3D10.4236%2Fjbise.2012.55032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vlessidis, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evmiridis, N. P.</span></span> <span> </span><span class="NLM_article-title">Determination of nitric oxide in biological samples</span>. <i>Microchim. Acta</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>147</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">21</span>, <span class="refDoi"> DOI: 10.1007/s00604-004-0212-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.1007%2Fs00604-004-0212-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BD2cXkvF2ltro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=147&publication_year=2004&pages=1-21&author=D.+Yaoauthor=A.+G.+Vlessidisauthor=N.+P.+Evmiridis&title=Determination+of+nitric+oxide+in+biological+samples&doi=10.1007%2Fs00604-004-0212-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Determination of Nitric Oxide in Biological Samples</span></div><div class="casAuthors">Yao, Dachun; Vlessidis, Athanasios G.; Evmiridis, Nicholaos P.</div><div class="citationInfo"><span class="NLM_cas:title">Microchimica Acta</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">147</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">1-20</span>CODEN:
                <span class="NLM_cas:coden">MIACAQ</span>;
        ISSN:<span class="NLM_cas:issn">0026-3672</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag Wien</span>)
        </div><div class="casAbstract">A review.  NO plays an important role in the regulation of physiol. and pathophysiol. mechanisms, and quite a lot of studies were focused on this kind of special mol.  It is difficult to achieve reliable ex vivo NO measurements with the existing anal. methods, and developing a reliable in vivo monitoring method for NO is still an urgent task.  In this review, the techniques used for the detn. of endogenous NO formed by enzymic action and its reactions with other biol. substances found in living organisms are discussed with respect to applications both in vivo or in vitro.  Various NO (micro)sensors and trap probes based on different principles are presented with their resp. advantages and limitations.  Finally, an NO monitoring system based on the combination of microdialysis sampling and chemiluminescence is introduced which is considered to be a prospective method for in vivo monitoring.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrErxIf0VULrVg90H21EOLACvtfcHk0lhRIHhV6pABbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXkvF2ltro%253D&md5=25ecb4f809c2e0ad93eee515f6b09bd7</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1007%2Fs00604-004-0212-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00604-004-0212-8%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DD.%26aulast%3DVlessidis%26aufirst%3DA.%2BG.%26aulast%3DEvmiridis%26aufirst%3DN.%2BP.%26atitle%3DDetermination%2520of%2520nitric%2520oxide%2520in%2520biological%2520samples%26jtitle%3DMicrochim.%2520Acta%26date%3D2004%26volume%3D147%26spage%3D1%26epage%3D21%26doi%3D10.1007%2Fs00604-004-0212-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, X. G.</span></span> <span> </span><span class="NLM_article-title">Protective effects of specific cannabinoid receptor 2 agonist GW405833 on concanavalin A-induced acute liver injury in mice</span>. <i>Acta Pharmacol. Sin.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">1404</span>– <span class="NLM_lpage">1411</span>, <span class="refDoi"> DOI: 10.1038/s41401-019-0213-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.1038%2Fs41401-019-0213-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=30918343" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmslKrs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2019&pages=1404-1411&author=Z.+B.+Huangauthor=Y.+X.+Zhengauthor=N.+Liauthor=S.+L.+Caiauthor=Y.+Huangauthor=J.+Wangauthor=X.+W.+Huauthor=Y.+Wangauthor=J.+Wuauthor=X.+G.+Fan&title=Protective+effects+of+specific+cannabinoid+receptor+2+agonist+GW405833+on+concanavalin+A-induced+acute+liver+injury+in+mice&doi=10.1038%2Fs41401-019-0213-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Protective effects of specific cannabinoid receptor 2 agonist GW405833 on concanavalin A-induced acute liver injury in mice</span></div><div class="casAuthors">Huang, Ze-bing; Zheng, Yi-xiang; Li, Ning; Cai, Sheng-lan; Huang, Yan; Wang, Juan; Hu, Xing-wang; Wang, Yang; Wu, Jie; Fan, Xue-gong</div><div class="citationInfo"><span class="NLM_cas:title">Acta Pharmacologica Sinica</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1404-1411</span>CODEN:
                <span class="NLM_cas:coden">APSCG5</span>;
        ISSN:<span class="NLM_cas:issn">1671-4083</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Cannabinoid receptor 2 (CB2R) is highly expressed in immune cells and plays an important role in regulating immune responses.  In the current study, we investigated the effects of GW405833 (GW), a specific CB2R agonist, on acute liver injury induced by Con A (Con A).  In animal expts., acute liver injury was induced in mice by injection of Con A (20 mg/kg, i.v.).  The mice were treated with GW (20 mg/kg, i.p., 30 min after Con A injection) or GW plus the selective CB2R antagonist AM630 (2 mg/kg, i.p., 15 min after Con A injection).  We found that Con A caused severe acute liver injury evidenced by significantly increased serum aminotransferase levels, massive hepatocyte apoptosis, and necrosis, as well as lymphocyte infiltration in liver tissues.  Treatment with GW significantly ameliorated Con A-induced pathol. injury in liver tissue, decreased serum aminotransferase levels, and decreased hepatocyte apoptosis.  The therapeutic effects of GW were prevented by AM630.  In cell expts., we showed that CB2Rs were highly expressed in Jurkat T cells, but little expression in L02 liver cells.  Treatment with GW (10-40 μg/mL) dose-dependently decreased the viability of Jurkat T cells and induced cell apoptosis, which was reversed by AM630.  In the coculture of Jurkat T cells with L02 liver cells, GW dose-dependently protected L02 cells from apoptosis induced by Con A (5 μg/mL).  The protective effect of GW was reversed by AM630 (1 μg/mL).  Our results suggest that GW protects against Con A-induced acute liver injury in mice by inhibiting Jurkat T-cell proliferation through the CB2Rs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiBN1WxVxipLVg90H21EOLACvtfcHk0lhRIHhV6pABbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmslKrs74%253D&md5=1dc9a0008e43ff2710fe779a4253910b</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1038%2Fs41401-019-0213-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41401-019-0213-0%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DZ.%2BB.%26aulast%3DZheng%26aufirst%3DY.%2BX.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DCai%26aufirst%3DS.%2BL.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DX.%2BW.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DFan%26aufirst%3DX.%2BG.%26atitle%3DProtective%2520effects%2520of%2520specific%2520cannabinoid%2520receptor%25202%2520agonist%2520GW405833%2520on%2520concanavalin%2520A-induced%2520acute%2520liver%2520injury%2520in%2520mice%26jtitle%3DActa%2520Pharmacol.%2520Sin.%26date%3D2019%26volume%3D40%26spage%3D1404%26epage%3D1411%26doi%3D10.1038%2Fs41401-019-0213-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, T.</span></span> <span> </span><span class="NLM_article-title">Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-kinase inhibitor with potentially high efficiency against acute myelocytic leukemia</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">1499</span>– <span class="NLM_lpage">1518</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01261</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01261" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlyqurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=1499-1518&author=Y.+Wangauthor=Y.+Zhiauthor=Q.+Jinauthor=S.+Luauthor=G.+Linauthor=H.+Yuanauthor=T.+Yangauthor=Z.+Wangauthor=C.+Yaoauthor=J.+Lingauthor=H.+Guoauthor=T.+Liauthor=J.+Jinauthor=B.+Liauthor=L.+Zhangauthor=Y.+Chenauthor=T.+Lu&title=Discovery+of+4-%28%287H-Pyrrolo%5B2%2C3-d%5Dpyrimidin-4-yl%29amino%29-N-%284-%28%284-methylpiperazin-1-yl%29methyl%29phenyl%29-1H-pyrazole-3-carboxamide+%28FN-1501%29%2C+an+FLT3-+and+CDK-kinase+inhibitor+with+potentially+high+efficiency+against+acute+myelocytic+leukemia&doi=10.1021%2Facs.jmedchem.7b01261"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia</span></div><div class="casAuthors">Wang, Yue; Zhi, Yanle; Jin, Qiaomei; Lu, Shuai; Lin, Guowu; Yuan, Haoliang; Yang, Taotao; Wang, Zhanwei; Yao, Chao; Ling, Jun; Guo, Hao; Li, Tonghui; Jin, Jianlin; Li, Baoquan; Zhang, Li; Chen, Yadong; Lu, Tao</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1499-1518</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of 1-H-pyrazole-3-carboxamide derivs. have been designed and synthesized that exhibit excellent FLT3 and CDK inhibition and antiproliferative activities.  A structure-activity-relationship study illustrates that the incorporation of a pyrimidine-fused heterocycle at position 4 of the pyrazole is crit. for FLT3 and CDK inhibition.  Compd. 50 (FN-1501), which possesses potent inhibitory activities against FLT3, CDK2, CDK4, and CDK6 with IC50 values in the nanomolar range, shows antiproliferative activities against MV4-11 cells (IC50: 0.008 μM), which correlates with the suppression of retinoblastoma phosphorylation, FLT3, ERK, AKT, and STAT5 and the onset of apoptosis.  Acute-toxicity studies in mice show that compd. I (LD50: 186 mg/kg) is safer than AT7519 (32 mg/kg).  In MV4-11 xenografts in a nude-mouse model, compd. I can induce tumor regression at the dose of 15 mg/kg, which is more efficient than cytarabine (50 mg/kg).  Taken together, these results demonstrate the potential of this unique compd. for further development into a drug applied in acute-myeloid-leukemia (AML) therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfX9S4QkGccbVg90H21EOLACvtfcHk0ljLUtvZLdWCRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlyqurg%253D&md5=2757ad7559e655c5d96f0a8af8c74aa5</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01261%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhi%26aufirst%3DY.%26aulast%3DJin%26aufirst%3DQ.%26aulast%3DLu%26aufirst%3DS.%26aulast%3DLin%26aufirst%3DG.%26aulast%3DYuan%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DYao%26aufirst%3DC.%26aulast%3DLing%26aufirst%3DJ.%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DT.%26aulast%3DJin%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DT.%26atitle%3DDiscovery%2520of%25204-%2528%25287H-Pyrrolo%255B2%252C3-d%255Dpyrimidin-4-yl%2529amino%2529-N-%25284-%2528%25284-methylpiperazin-1-yl%2529methyl%2529phenyl%2529-1H-pyrazole-3-carboxamide%2520%2528FN-1501%2529%252C%2520an%2520FLT3-%2520and%2520CDK-kinase%2520inhibitor%2520with%2520potentially%2520high%2520efficiency%2520against%2520acute%2520myelocytic%2520leukemia%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D1499%26epage%3D1518%26doi%3D10.1021%2Facs.jmedchem.7b01261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of benzo[cd]indol-2(1H)-ones and pyrrolo[4,3,2-de]quinolin-2(1H)-ones as bromodomain and extra-terminal domain (BET) inhibitors with selectivity for the first bromodomain with potential high efficiency against acute gouty arthritis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">11080</span>– <span class="NLM_lpage">11107</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01010</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01010" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit1yqur7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=11080-11107&author=F.+Jiangauthor=Q.+Huauthor=Z.+Zhangauthor=H.+Liauthor=H.+Liauthor=D.+Zhangauthor=H.+Liauthor=Y.+Maauthor=J.+Xuauthor=H.+Chenauthor=Y.+Cuiauthor=Y.+Zhiauthor=Y.+Zhangauthor=J.+Xuauthor=J.+Zhuauthor=T.+Luauthor=Y.+Chen&title=Discovery+of+benzo%5Bcd%5Dindol-2%281H%29-ones+and+pyrrolo%5B4%2C3%2C2-de%5Dquinolin-2%281H%29-ones+as+bromodomain+and+extra-terminal+domain+%28BET%29+inhibitors+with+selectivity+for+the+first+bromodomain+with+potential+high+efficiency+against+acute+gouty+arthritis&doi=10.1021%2Facs.jmedchem.9b01010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Benzo[cd]indol-2(1H)-ones and Pyrrolo[4,3,2-de]quinolin-2(1H)-ones as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the First Bromodomain with Potential High Efficiency against Acute Gouty Arthritis</span></div><div class="casAuthors">Jiang, Fei; Hu, Qinghua; Zhang, Zhimin; Li, Hongmei; Li, Huili; Zhang, Dewei; Li, Hanwen; Ma, Yu; Xu, Jingjing; Chen, Haifang; Cui, Yong; Zhi, Yanle; Zhang, Yanmin; Xu, Junyu; Zhu, Jiapeng; Lu, Tao; Chen, Yadong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">11080-11107</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The bromodomain and extra-terminal domain (BET) family of proteins are readers which specifically recognize histone-acetylated lysine residues.  Each BET bromodomain protein contains two highly homologous domains: the first bromodomain (BD1) and the second bromodomain (BD2).  Pan-BET bromodomain inhibition is a potential therapy for various cancers and immune-inflammatory diseases, but only few reported inhibitors show selectivity within the BET family.  Herein, we identified a series of benzo[cd]indol-2(1H)-ones and pyrrolo[4,3,2-de]quinolin-2(1H)-ones with good selectivity for BET BD1.  Through structure-based optimization, highly active and selective compds. are ultimately obtained.  The representative compds. are the first reported inhibitors with selectivity more than 100-fold for BRD4(1) over BRD4(2).  Among them, we further show that 68 (LT052) mediates BRD4/NF-κB/NLRP3 signaling inflammatory pathways with comparable protein expression and significantly improves symptoms of gout arthritis in a rat model.  Therefore, selective pharmacol. modulation of individual bromodomains could represent a strategy for the treatment of acute gouty arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrav2e3P7XQ1LVg90H21EOLACvtfcHk0ljLUtvZLdWCRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit1yqur7E&md5=5cce669e137812d20f8ba2a9785f4666</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01010%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DF.%26aulast%3DHu%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DMa%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DCui%26aufirst%3DY.%26aulast%3DZhi%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520benzo%255Bcd%255Dindol-2%25281H%2529-ones%2520and%2520pyrrolo%255B4%252C3%252C2-de%255Dquinolin-2%25281H%2529-ones%2520as%2520bromodomain%2520and%2520extra-terminal%2520domain%2520%2528BET%2529%2520inhibitors%2520with%2520selectivity%2520for%2520the%2520first%2520bromodomain%2520with%2520potential%2520high%2520efficiency%2520against%2520acute%2520gouty%2520arthritis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D11080%26epage%3D11107%26doi%3D10.1021%2Facs.jmedchem.9b01010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">van
der Fits, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mourits, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voerman, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kant, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laman, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornelissen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mus, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Florencia, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prens, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubberts, E.</span></span> <span> </span><span class="NLM_article-title">Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>182</i></span>,  <span class="NLM_fpage">5836</span>– <span class="NLM_lpage">5845</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.0802999</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.4049%2Fjimmunol.0802999" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=19380832" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BD1MXkslKhtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=182&publication_year=2009&pages=5836-5845&author=L.+van%0Ader+Fitsauthor=S.+Mouritsauthor=J.+S.+Voermanauthor=M.+Kantauthor=L.+Boonauthor=J.+D.+Lamanauthor=F.+Cornelissenauthor=A.+M.+Musauthor=E.+Florenciaauthor=E.+P.+Prensauthor=E.+Lubberts&title=Imiquimod-induced+psoriasis-like+skin+inflammation+in+mice+is+mediated+via+the+IL-23%2FIL-17+axis&doi=10.4049%2Fjimmunol.0802999"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice Is Mediated via the IL-23/IL-17 Axis</span></div><div class="casAuthors">van der Fits, Leslie; Mourits, Sabine; Voerman, Jane S. A.; Kant, Marius; Boon, Louis; Laman, Jon D.; Cornelissen, Ferry; Mus, Anne-Marie; Florencia, Edwin; Prens, Errol P.; Lubberts, Erik</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">182</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">5836-5845</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Topical application of imiquimod (IMQ), a TLR7/8 ligand and potent immune activator, can induce and exacerbate psoriasis, a chronic inflammatory skin disorder.  Recently, a crucial role was proposed for the IL-23/IL-17 axis in psoriasis.  The authors hypothesized that IMQ-induced dermatitis in mice can serve as a model for the anal. of pathogenic mechanisms in psoriasis-like dermatitis and assessed its IL-23/IL-17 axis dependency.  Daily application of IMQ on mouse back skin induced inflamed scaly skin lesions resembling plaque type psoriasis.  These lesions showed increased epidermal proliferation, abnormal differentiation, epidermal accumulation of neutrophils in microabcesses, neoangiogenesis, and infiltrates consisting of CD4+ T cells, CD11c+ dendritic cells, and plasmacytoid dendritic cells.  IMQ induced epidermal expression of IL-23, IL-17A, and IL-17F, as well as an increase in splenic Th17 cells.  IMQ-induced dermatitis was partially dependent on the presence of T cells, whereas disease development was almost completely blocked in mice deficient for IL-23 or the IL-17 receptor, demonstrating a pivotal role of the IL-23/IL-17 axis.  In conclusion, the sole application of the innate TLR7/8 ligand IMQ rapidly induces a dermatitis closely resembling human psoriasis, critically dependent on the IL-23/IL-17 axis.  This rapid and convenient model allows further elucidation of pathogenic mechanisms and evaluation of new therapies in psoriasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWu9yN1SM3ibVg90H21EOLACvtfcHk0ljLUtvZLdWCRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXkslKhtrs%253D&md5=3e895f11e5cbfd9ee20a83ad34a4f419</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.0802999&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.0802999%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2Bder%2BFits%26aufirst%3DL.%26aulast%3DMourits%26aufirst%3DS.%26aulast%3DVoerman%26aufirst%3DJ.%2BS.%26aulast%3DKant%26aufirst%3DM.%26aulast%3DBoon%26aufirst%3DL.%26aulast%3DLaman%26aufirst%3DJ.%2BD.%26aulast%3DCornelissen%26aufirst%3DF.%26aulast%3DMus%26aufirst%3DA.%2BM.%26aulast%3DFlorencia%26aufirst%3DE.%26aulast%3DPrens%26aufirst%3DE.%2BP.%26aulast%3DLubberts%26aufirst%3DE.%26atitle%3DImiquimod-induced%2520psoriasis-like%2520skin%2520inflammation%2520in%2520mice%2520is%2520mediated%2520via%2520the%2520IL-23%252FIL-17%2520axis%26jtitle%3DJ.%2520Immunol.%26date%3D2009%26volume%3D182%26spage%3D5836%26epage%3D5845%26doi%3D10.4049%2Fjimmunol.0802999" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, L.</span></span> <span> </span><span class="NLM_article-title">One-pot synthesis of polysubstituted spirofluorene-indene via Ru(II)-catalyzed [3 + 2] annulation and intramolecular friedel-crafts cyclization</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">9973</span>– <span class="NLM_lpage">9979</span>, <span class="refDoi"> DOI: 10.1021/acs.joc.5b01517</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.joc.5b01517" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFKqsrbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2015&pages=9973-9979&author=Y.+Q.+Zhuauthor=L.+Dong&title=One-pot+synthesis+of+polysubstituted+spirofluorene-indene+via+Ru%28II%29-catalyzed+%5B3+%2B+2%5D+annulation+and+intramolecular+friedel-crafts+cyclization&doi=10.1021%2Facs.joc.5b01517"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">One-Pot Synthesis of Polysubstituted Spirofluorene-Indene via Ru(II)-Catalyzed [3 + 2] Annulation and Intramolecular Friedel-Crafts Cyclization</span></div><div class="casAuthors">Zhu, Yu-Qin; Dong, Lin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">9973-9979</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Ru(II)-catalyzed one-pot synthesis of polysubstituted spirofluorene-indenes via [3+2] annulation and then intramol. Friedel-Crafts alkylation has been achieved.  The simple method provides a broad scope of aryl ketones and internal alkynes, achieving PAHs skeletons in moderate to good yields.  E.g., in presence of [RuCl2(p-cymene)]2, AgBF4, Cu(acac)2, and pivalic acid, annulation and Friedel-Crafts alkylation of aryl ketone I with diphenylacetylene gave 80% II.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcIlhk51SFbLVg90H21EOLACvtfcHk0liFigQocHZmQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFKqsrbL&md5=b0d19f74a69840d028730088d1b8c1fc</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Facs.joc.5b01517&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.joc.5b01517%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DY.%2BQ.%26aulast%3DDong%26aufirst%3DL.%26atitle%3DOne-pot%2520synthesis%2520of%2520polysubstituted%2520spirofluorene-indene%2520via%2520Ru%2528II%2529-catalyzed%2520%255B3%2520%252B%25202%255D%2520annulation%2520and%2520intramolecular%2520friedel-crafts%2520cyclization%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2015%26volume%3D80%26spage%3D9973%26epage%3D9979%26doi%3D10.1021%2Facs.joc.5b01517" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 5 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Zhouling Xie, Xiaoxiao Yang, Yajun Duan, Jihong Han, <span class="NLM_string-name hlFld-ContribAuthor">Chenzhong Liao</span>. </span><span class="cited-content_cbyCitation_article-title">Small-Molecule Kinase Inhibitors for the Treatment of Nononcologic Diseases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (3)
                                     , 1283-1345. <a href="https://doi.org/10.1021/acs.jmedchem.0c01511" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01511</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01511&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01511%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSmall-Molecule%252BKinase%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BNononcologic%252BDiseases%26aulast%3DXie%26aufirst%3DZhouling%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D29082020%26date%3D22012021%26volume%3D64%26issue%3D3%26spage%3D1283%26epage%3D1345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jing  Cheng</span>, <span class="hlFld-ContribAuthor ">Xuexin  Feng</span>, <span class="hlFld-ContribAuthor ">Zhiqiang  Li</span>, <span class="hlFld-ContribAuthor ">Feilong  Zhou</span>, <span class="hlFld-ContribAuthor ">Jin-Ming  Yang</span>, <span class="hlFld-ContribAuthor ">Yujun  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmacological inhibition of NF-κB-inducing kinase (NIK) with small molecules for the treatment of human diseases. </span><span class="cited-content_cbyCitation_journal-name">RSC Medicinal Chemistry</span><span> <strong>2021,</strong> <em>12 </em>
                                    (4)
                                     , 552-565. <a href="https://doi.org/10.1039/D0MD00361A" title="DOI URL">https://doi.org/10.1039/D0MD00361A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0MD00361A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0MD00361A%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Medicinal%2520Chemistry%26atitle%3DPharmacological%252Binhibition%252Bof%252BNF-%2525CE%2525BAB-inducing%252Bkinase%252B%252528NIK%252529%252Bwith%252Bsmall%252Bmolecules%252Bfor%252Bthe%252Btreatment%252Bof%252Bhuman%252Bdiseases%26aulast%3DCheng%26aufirst%3DJing%26date%3D2021%26date%3D2021%26volume%3D12%26issue%3D4%26spage%3D552%26epage%3D565" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiamin  Zheng</span>, <span class="hlFld-ContribAuthor ">Jun  Wu</span>, <span class="hlFld-ContribAuthor ">Xiao  Ding</span>, <span class="hlFld-ContribAuthor ">Hong C.  Shen</span>, <span class="hlFld-ContribAuthor ">Ge  Zou</span>. </span><span class="cited-content_cbyCitation_article-title">Small molecule approaches to treat autoimmune and inflammatory diseases (Part I): Kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>38 </em>, 127862. <a href="https://doi.org/10.1016/j.bmcl.2021.127862" title="DOI URL">https://doi.org/10.1016/j.bmcl.2021.127862</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2021.127862&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2021.127862%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSmall%252Bmolecule%252Bapproaches%252Bto%252Btreat%252Bautoimmune%252Band%252Binflammatory%252Bdiseases%252B%252528Part%252BI%252529%25253A%252BKinase%252Binhibitors%26aulast%3DZheng%26aufirst%3DJiamin%26date%3D2021%26volume%3D38%26spage%3D127862" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anastasiya V.  Agafonova</span>, <span class="hlFld-ContribAuthor ">Liya D.  Funt</span>, <span class="hlFld-ContribAuthor ">Mikhail S.  Novikov</span>, <span class="hlFld-ContribAuthor ">Alexander F.  Khlebnikov</span>. </span><span class="cited-content_cbyCitation_article-title">An isoxazole strategy for the synthesis of alkyl 5-amino-4-cyano-1
              H
              -pyrrole-2-carboxylates – versatile building blocks for assembling pyrrolo-fused heterocycles. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2021,</strong> <em>19 </em>
                                    (9)
                                     , 1976-1984. <a href="https://doi.org/10.1039/D1OB00053E" title="DOI URL">https://doi.org/10.1039/D1OB00053E</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1OB00053E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1OB00053E%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DAn%252Bisoxazole%252Bstrategy%252Bfor%252Bthe%252Bsynthesis%252Bof%252Balkyl%252B5-amino-4-cyano-1%252BH%252B-pyrrole-2-carboxylates%252B%2525E2%252580%252593%252Bversatile%252Bbuilding%252Bblocks%252Bfor%252Bassembling%252Bpyrrolo-fused%252Bheterocycles%26aulast%3DAgafonova%26aufirst%3DAnastasiya%2BV.%26date%3D2021%26date%3D2021%26volume%3D19%26issue%3D9%26spage%3D1976%26epage%3D1984" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jianing  Song</span>, <span class="hlFld-ContribAuthor ">Yuqin  Zhu</span>, <span class="hlFld-ContribAuthor ">Weidong  Zu</span>, <span class="hlFld-ContribAuthor ">Chunqi  Duan</span>, <span class="hlFld-ContribAuthor ">Junyu  Xu</span>, <span class="hlFld-ContribAuthor ">Fei  Jiang</span>, <span class="hlFld-ContribAuthor ">Xinren  Wang</span>, <span class="hlFld-ContribAuthor ">Shuwen  Li</span>, <span class="hlFld-ContribAuthor ">Chenhe  Liu</span>, <span class="hlFld-ContribAuthor ">Qianqian  Gao</span>, <span class="hlFld-ContribAuthor ">Hongmei  Li</span>, <span class="hlFld-ContribAuthor ">Yanmin  Zhang</span>, <span class="hlFld-ContribAuthor ">Weifang  Tang</span>, <span class="hlFld-ContribAuthor ">Tao  Lu</span>, <span class="hlFld-ContribAuthor ">Yadong  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">The discovery of quinoline derivatives, as NF-κB inducing kinase (NIK) inhibitors with anti-inflammatory effects in vitro, low toxicities against T cell growth. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2021,</strong> <em>29 </em>, 115856. <a href="https://doi.org/10.1016/j.bmc.2020.115856" title="DOI URL">https://doi.org/10.1016/j.bmc.2020.115856</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2020.115856&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2020.115856%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DThe%252Bdiscovery%252Bof%252Bquinoline%252Bderivatives%25252C%252Bas%252BNF-%2525CE%2525BAB%252Binducing%252Bkinase%252B%252528NIK%252529%252Binhibitors%252Bwith%252Banti-inflammatory%252Beffects%252Bin%252Bvitro%25252C%252Blow%252Btoxicities%252Bagainst%252BT%252Bcell%252Bgrowth%26aulast%3DSong%26aufirst%3DJianing%26date%3D2021%26volume%3D29%26spage%3D115856" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/medium/jm0c00055_0019.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/large/jm0c00055_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00055&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/medium/jm0c00055_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/large/jm0c00055_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Representative NIK inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/large/jm0c00055_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00055&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/medium/jm0c00055_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/large/jm0c00055_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Binding mode of ligand <b>1</b> with NIK and the assumptions of design strategies. (B) Design strategy from compound <b>1</b> to compound <b>12k</b>. The corresponding NIK inhibitory activities were displayed. (C) Overlay of compound <b>12k</b> to ligand <b>1</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4G3E">4G3E</a>). Only the hydrogen bonding interaction between <b>12k</b> and NIK is presented.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/large/jm0c00055_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00055&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/medium/jm0c00055_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/large/jm0c00055_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of <i>N</i>-Phenyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine Analogs<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/large/jm0c00055_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00055&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) TsCl, NaH, THF, 0 °C; (b) AgOTf, dioxane, 130 °C; (c) corresponding amine, K<sub>2</sub>CO<sub>3</sub>, DMF, 90 °C or relative alcohol, NaH, DMF, 0 °C; (d) Fe, NH<sub>4</sub>Cl, 75% EtOH; (e) NaNO<sub>2</sub>, KI, <i>p</i>-TsOH, CH<sub>3</sub>CN/H<sub>2</sub>O, 0 °C to rt; (f) NaOH, 95% EtOH, 40 °C; (g) PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub>, CuI, Et<sub>3</sub>N/THF = 1:3; (h) appropriate acyl chloride or isocyanate, Et<sub>3</sub>N, DMF, 0 °C; (i) appropriate sulfonyl chloride or acetyl chloride, Et<sub>3</sub>N, DMF, 0 °C.</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/medium/jm0c00055_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/large/jm0c00055_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compounds <b>21a</b>–<b>21f</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/large/jm0c00055_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00055&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) when X = Cl, AgOTf, dioxane, 130 °C or when X = Br, Pd<sub>2</sub>(dba)<sub>3</sub>, K<sub>2</sub>CO<sub>3</sub>, <i>t</i>-BuOH, 100 °C; (b) morpholine, K<sub>2</sub>CO<sub>3</sub>, DMF, 90 °C; (c) Fe, NH<sub>4</sub>Cl, 75% EtOH; (d) NaNO<sub>2</sub>, KI, <i>p</i>-TsOH, CH<sub>3</sub>CN/H<sub>2</sub>O, 0 °C to room temperature; (e) PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub>, CuI, THF/Et<sub>3</sub>N = 3:1, 40 °C.</p></p></figure><figure data-id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/medium/jm0c00055_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/large/jm0c00055_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Binding mode analysis of compound <b>12f</b> to NIK protein. The solvent accessible region of NIK protein occupied by hydrophilic fragment of the ligand is particularly highlighted. (A) Compound <b>12f</b> docked into NIK (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4G3E">4G3E</a>). (B) Compound <b>12f</b> docked into NIK (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6G4Y">6G4Y</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/large/jm0c00055_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00055&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/medium/jm0c00055_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/large/jm0c00055_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) A wild-type screening (Reaction Biology Corp.) was performed to investigate the selectivity of <b>12f</b> against 268 kinases in a single-dose duplicate mode at a concentration of 1 μM. The 10 μM ATP concentration was conducted. Staurosporine served as a positive control, where % Ctrl = [(test compound signal – positive control signal)/(negative control signal – positive control signal)] × 100. (B) Further inhibitory activity of compound <b>12f</b> against selected kinases using the P<sup>33</sup>-radiolabeled assay. The values are the mean from two independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/large/jm0c00055_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00055&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/medium/jm0c00055_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/large/jm0c00055_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Compound <b>12f</b> Enantiomeric Resolution and Determination of the Dominant Configuration<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/large/jm0c00055_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00055&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p><span class="fn-label"><sup>a</sup></span>Enantiomeric resolution of compound <b>12f</b> was preformed. Mobile phase: hexane/EtOH = 50:50, v/v.</p><p><span class="fn-label"><sup>b</sup></span>Using Griess reagents method, NO inhibition rate % = [(model group NO concentration – compound group NO concentration)/(model group NO concentration – control group NO concentration)] × 100. The values are the mean ± SD from three independent experiments, n = 3.</p><p class="last"><span class="fn-label"><sup>c</sup></span>Con A-induced primary T cell proliferation was investigated under the treatment of selected compounds. Proliferation-inhibitory rate (%) = [(test hole absorbance – blank hole absorbance)/(control hole absorbance – blank hole absorbance)] × 100. The values are the mean ± SD from three independent experiments, n = 3.</p></p></figure><figure data-id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/medium/jm0c00055_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/large/jm0c00055_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Toxicity comparison between <b>12f</b> and its enantiomers (<b>22</b>, <b>23</b>) against normal growth of T cells at 10 μM concentration. Proliferation-inhibitory rate (%) = [(test hole absorbance – blank hole absorbance)/(control hole absorbance – blank hole absorbance)] × 100. The values are the mean ± SD from three independent experiments, <i>n</i> = 3.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/large/jm0c00055_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00055&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/medium/jm0c00055_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/large/jm0c00055_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (A) The culture supernatant IL-6 levels in LPS-induced BEAS-2B cells were analyzed and quantified by ELISA. (B) Quantitative PCR analysis of the mRNA levels of exocrine inflammatory factors (TNFα, IL-6, IL-23, IL-1β), chemokine (CCL3), and cytokine (NOS2) in LPS-stimulated J774 cells. <i>P</i> values are determined by two-tailed Student’s <i>t</i> test: between the normal and model group, <sup>#</sup><i>P</i> < 0.05, <sup>##</sup><i>P</i> < 0.005,<sup>###</sup><i>P</i> < 0.0005; between model and <b>12f</b> treatment groups, n.s. (not significant), *<i>P</i> < 0.05, **<i>P</i> < 0.005, ***<i>P</i> < 0.0005. Data are represented as the mean ± SD from two (A) and three (B) biological replicates.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/large/jm0c00055_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00055&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/medium/jm0c00055_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/large/jm0c00055_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. (A) Representative images of dorsal back from wild-type C57 mice untreated or treated with IMQ or <b>12f</b> for 7 or 4 days. (B) Hematoxylin and eosin (H&E) staining of skin sections from the dorsal back (normal group, IMQ and <b>12f</b> were untreated; model group, only IMQ treatment; 12f-I/12f-II, at 60 mg/kg or 120 mg/kg doses of <b>12f</b> treatment, along with IMQ induction). Scale bar, 50 μm. (C) Epidermal thickness was measured in six randomly chosen fields. (D) The weight of the mouse spleen was counted, and each point represents the value of the spleen weight of a mouse. (E) TNF-α and IL-17A in the mouse serum were analyzed and quantified by ELISA. Data are shown as the mean ± SEM based on three independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/large/jm0c00055_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00055&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/medium/jm0c00055_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/large/jm0c00055_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. (A) Representative skin sections from the back of the mice, which were stained with Ki67 antibody (normal group, IMQ and <b>12f</b> were untreated; model group, only IMQ treatment; 12f-I/12f-II, at 60 mg/kg or 120 mg/kg doses of <b>12f</b> treatment, respectively, along with IMQ induction). Scale bar, 50 μm. (B) The percentage of Ki67<sup>+</sup> cells in the total cells was analyzed by ImageJ software. (C) F4/80 immunofluorescence staining revealed the recruitment of macrophages in the back skin tissue of C57 mice. <i>P</i> values are determined by two-tailed Student’s <i>t</i> test: compared with normal group, <sup>#</sup><i>P</i> < 0.05, <sup>##</sup><i>P</i> < 0.005,<sup>###</sup><i>P</i> < 0.0005; compared with model group, *<i>P</i> < 0.05, **<i>P</i> < 0.005, ***<i>P</i> < 0.0005. Data are represented as the mean ± SD.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/large/jm0c00055_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00055&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/medium/jm0c00055_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/large/jm0c00055_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. (A) After oral administration of compound <b>12f</b> (12f-I, 60 mg/kg; 12f-II, 120 mg/kg), the levels of NF-κB2 signaling pathway-related proteins (p100 and p52) were monitored. Quantitative analysis was normalized to GAPDH. (B) The relative optical densities of specific proteins were recorded. (C) Quantitative analysis of mRNA levels in the skin of the back of mice (TNFα, IL-6, IL-10, IL-12) to investigate the effect of high and low doses of <b>12f</b> treatment on the expression of immune regulation-related genes induced by IMQ in mice. (D) Pathological signal response to the treatment of <b>12f</b> as the NIK inhibitor was depicted. <i>P</i> values are determined by two-tailed Student’s <i>t</i> test: between normal and model group, <sup>#</sup><i>P</i> < 0.05, <sup>##</sup><i>P</i> < 0.005,<sup>###</sup><i>P</i> < 0.0005; between model and <b>12f</b> treatment groups, n.s. (not significant), *<i>P</i> < 0.05, **<i>P</i> < 0.005, ***<i>P</i> < 0.0005. Data are presented as the mean ± SD of three independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00055/20200701/images/large/jm0c00055_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00055&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i152">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_53525" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_53525" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 54 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parisi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Symmons, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffiths, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashcroft, D. M.</span></span> <span> </span><span class="NLM_article-title">Global epidemiology of psoriasis: a systematic review of incidence and prevalence</span>. <i>J. Invest. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>133</i></span>,  <span class="NLM_fpage">377</span>– <span class="NLM_lpage">385</span>, <span class="refDoi"> DOI: 10.1038/jid.2012.339</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.1038%2Fjid.2012.339" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=23014338" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVSltbvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=2013&pages=377-385&author=R.+Parisiauthor=D.+P.+Symmonsauthor=C.+E.+Griffithsauthor=D.+M.+Ashcroft&title=Global+epidemiology+of+psoriasis%3A+a+systematic+review+of+incidence+and+prevalence&doi=10.1038%2Fjid.2012.339"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence</span></div><div class="casAuthors">Parisi, Rosa; Symmons, Deborah P. M.; Griffiths, Christopher E. M.; Ashcroft, Darren M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Investigative Dermatology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">133</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">377-385</span>CODEN:
                <span class="NLM_cas:coden">JIDEAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-202X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The worldwide incidence and prevalence of psoriasis is poorly understood.  To better understand this, we performed a systematic review of published population-based studies on the incidence and prevalence of psoriasis.  Three electronic databases were searched from their inception dates to July 2011.  A total of 385 papers were critically appraised; 53 studies reported on the prevalence and incidence of psoriasis in the general population.  The prevalence in children ranged from 0% (Taiwan) to 2.1% (Italy), and in adults it varied from 0.91% (United States) to 8.5% (Norway).  In children, the incidence est. reported (United States) was 40.8/100,000 person-years.  In adults, it varied from 78.9/100,000 person-years (United States) to 230/100,000 person-years (Italy).  The data indicated that the occurrence of psoriasis varied according to age and geog. region, being more frequent in countries more distant from the equator.  Prevalence ests. also varied in relation to demog. characteristics in that studies confined to adults reported higher ests. of psoriasis compared with those involving all age groups.  Studies on the prevalence and incidence of psoriasis have contributed to a better understanding of the burden of the disease.  However, further research is required to fill existing gaps in understanding the epidemiol. of psoriasis and trends in incidence over time.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpky_n-8Uwdc7Vg90H21EOLACvtfcHk0li4edmUszKdjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVSltbvO&md5=b58ddbb50d844d58af03e7bc5b5b85ca</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fjid.2012.339&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fjid.2012.339%26sid%3Dliteratum%253Aachs%26aulast%3DParisi%26aufirst%3DR.%26aulast%3DSymmons%26aufirst%3DD.%2BP.%26aulast%3DGriffiths%26aufirst%3DC.%2BE.%26aulast%3DAshcroft%26aufirst%3DD.%2BM.%26atitle%3DGlobal%2520epidemiology%2520of%2520psoriasis%253A%2520a%2520systematic%2520review%2520of%2520incidence%2520and%2520prevalence%26jtitle%3DJ.%2520Invest.%2520Dermatol.%26date%3D2013%26volume%3D133%26spage%3D377%26epage%3D385%26doi%3D10.1038%2Fjid.2012.339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gaffen, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garg, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cua, D. J.</span></span> <span> </span><span class="NLM_article-title">The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">585</span>– <span class="NLM_lpage">600</span>, <span class="refDoi"> DOI: 10.1038/nri3707</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.1038%2Fnri3707" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=25145755" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVSit7%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=585-600&author=S.+L.+Gaffenauthor=R.+Jainauthor=A.+V.+Gargauthor=D.+J.+Cua&title=The+IL-23-IL-17+immune+axis%3A+from+mechanisms+to+therapeutic+testing&doi=10.1038%2Fnri3707"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing</span></div><div class="casAuthors">Gaffen, Sarah L.; Jain, Renu; Garg, Abhishek V.; Cua, Daniel J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">585-600</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Following the discovery of T helper 17 (TH17) cells, the past decade has witnessed a major revision of the TH subset paradigm and substantial progress has been made in deciphering the mol. mechanisms of T cell lineage commitment and function.  In this Review, we focus on the recent advances that have been made regarding the transcriptional control of TH17 cell plasticity and stability, as well as the effector functions of TH17 cells, and we highlight the mechanisms of IL-17 signalling in mesenchymal and barrier epithelial tissues.  We also discuss the emerging clin. data showing that IL-17-specific and IL-23-specific antibody treatments are remarkably effective for treating many immune-mediated inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsrf-chGl_n7Vg90H21EOLACvtfcHk0li4edmUszKdjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVSit7%252FL&md5=3b78e054323aae062527ce32ec8e05e2</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnri3707&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri3707%26sid%3Dliteratum%253Aachs%26aulast%3DGaffen%26aufirst%3DS.%2BL.%26aulast%3DJain%26aufirst%3DR.%26aulast%3DGarg%26aufirst%3DA.%2BV.%26aulast%3DCua%26aufirst%3DD.%2BJ.%26atitle%3DThe%2520IL-23-IL-17%2520immune%2520axis%253A%2520from%2520mechanisms%2520to%2520therapeutic%2520testing%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2014%26volume%3D14%26spage%3D585%26epage%3D600%26doi%3D10.1038%2Fnri3707" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Elder, J. T.</span></span> <span> </span><span class="NLM_article-title">Genome-wide association scan yields new insights into the immunopathogenesis of psoriasis</span>. <i>Genes Immun.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">201</span>– <span class="NLM_lpage">209</span>, <span class="refDoi"> DOI: 10.1038/gene.2009.11</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.1038%2Fgene.2009.11" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=19262574" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BD1MXkvVSru7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=201-209&author=J.+T.+Elder&title=Genome-wide+association+scan+yields+new+insights+into+the+immunopathogenesis+of+psoriasis&doi=10.1038%2Fgene.2009.11"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Genome-wide association scan yields new insights into the immunopathogenesis of psoriasis</span></div><div class="casAuthors">Elder, J. T.</div><div class="citationInfo"><span class="NLM_cas:title">Genes and Immunity</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">201-209</span>CODEN:
                <span class="NLM_cas:coden">GEIMA2</span>;
        ISSN:<span class="NLM_cas:issn">1466-4879</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Psoriasis is a common, immunol. mediated, inflammatory and hyperproliferative disease of the skin and joints, with a multifactorial genetic basis.  We earlier mapped PSORS1, the major psoriasis susceptibility gene in the major histocompatibility complex (MHC), to within or very near HLA-Cw6.  In an effort to identify non-MHC psoriasis genes, we carried out a collaborative genome-wide assocn. study.  After the initial follow-up genotyping of 21 single nucleotide polymorphisms from 18 loci, showing strong evidence of assocn. in the initial scan, we confirmed evidence of assocn. at seven loci.  Three of these loci confirm earlier reports of assocn. (HLA-C, IL12B, IL23R) and four identify novel signals located near plausible candidate genes (IL23A, IL4/IL13, TNFAIP3 and TNIP1).  In other work, we have also shown that interferon-γ (IFN-γ) treatment induces interleukin (IL)-23 mRNA and protein in antigen-presenting cells (APC), leading to the proliferation of CD4+ and CD8+ memory T cells expressing IL-17.  Although functional variants remain to be identified, we speculate that genetic variants at the IL4/IL13 locus contribute to the Th1 bias that is characteristic of psoriasis, that Th1-derived IFN-γ supports expansion of IL-17+ T cells through APC-derived IL-23 and that neg. regulation of inflammatory signaling through the NF-κB axis is impaired because of genetic variants of TNFAIP3 and TNIP1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmtd0LLTCOLrVg90H21EOLACvtfcHk0lj5x4BRQDVg3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXkvVSru7w%253D&md5=b17f41edfa84a8f033bf9c7ec45b3b55</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fgene.2009.11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fgene.2009.11%26sid%3Dliteratum%253Aachs%26aulast%3DElder%26aufirst%3DJ.%2BT.%26atitle%3DGenome-wide%2520association%2520scan%2520yields%2520new%2520insights%2520into%2520the%2520immunopathogenesis%2520of%2520psoriasis%26jtitle%3DGenes%2520Immun.%26date%3D2009%26volume%3D10%26spage%3D201%26epage%3D209%26doi%3D10.1038%2Fgene.2009.11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Myers, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottlieb, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mease, P.</span></span> <span> </span><span class="NLM_article-title">Psoriasis and psoriatic arthritis: clinical features and disease mechanisms</span>. <i>Clin. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">438</span>– <span class="NLM_lpage">447</span>, <span class="refDoi"> DOI: 10.1016/j.clindermatol.2006.07.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.1016%2Fj.clindermatol.2006.07.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=16966023" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A280%3ADC%252BD28rktVKqsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2006&pages=438-447&author=W.+A.+Myersauthor=A.+B.+Gottliebauthor=P.+Mease&title=Psoriasis+and+psoriatic+arthritis%3A+clinical+features+and+disease+mechanisms&doi=10.1016%2Fj.clindermatol.2006.07.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Psoriasis and psoriatic arthritis: clinical features and disease mechanisms</span></div><div class="casAuthors">Myers Wendy A; Gottlieb Alice B; Mease Philip</div><div class="citationInfo"><span class="NLM_cas:title">Clinics in dermatology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">438-47</span>
        ISSN:<span class="NLM_cas:issn">0738-081X</span>.
    </div><div class="casAbstract">Psoriasis is a chronic skin disorder affecting approximately 1% to 3% of the world's population.  A considerable proportion of patients with psoriasis will develop a form of inflammatory arthritis known as psoriatic arthritis whose prevalence is poorly defined.  Significant advances have been made in determining the pathophysiology of both of these diseases, with recent findings strongly implicating T cells and inflammatory cytokines such as tumor necrosis factor alpha in their pathogenesis.  There exists an increasing array of therapies to benefit both skin and musculoskeletal manifestations.  Newer therapies, such as the biologics, are providing more targeted approaches with potentially fewer systemic toxicities, providing control of disease symptoms and inhibiting progressive joint damage in those with arthritis, as well as improving long-term function and quality of life.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRpm2gTYu8pnYFEOhA_Im3cfW6udTcc2eaTQFPidYWZZbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28rktVKqsw%253D%253D&md5=1c9ab1b05bc72e8ff43b7bdc5324fb64</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.clindermatol.2006.07.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clindermatol.2006.07.006%26sid%3Dliteratum%253Aachs%26aulast%3DMyers%26aufirst%3DW.%2BA.%26aulast%3DGottlieb%26aufirst%3DA.%2BB.%26aulast%3DMease%26aufirst%3DP.%26atitle%3DPsoriasis%2520and%2520psoriatic%2520arthritis%253A%2520clinical%2520features%2520and%2520disease%2520mechanisms%26jtitle%3DClin.%2520Dermatol.%26date%3D2006%26volume%3D24%26spage%3D438%26epage%3D447%26doi%3D10.1016%2Fj.clindermatol.2006.07.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gudjonsson, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoll, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riblett, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kochkodan, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aphale, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voorhees, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elder, J. T.</span></span> <span> </span><span class="NLM_article-title">Evidence for altered Wnt signaling in psoriatic skin</span>. <i>J. Invest. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>130</i></span>,  <span class="NLM_fpage">1849</span>– <span class="NLM_lpage">1859</span>, <span class="refDoi"> DOI: 10.1038/jid.2010.67</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.1038%2Fjid.2010.67" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=20376066" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC3cXnsVyju7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2010&pages=1849-1859&author=J.+E.+Gudjonssonauthor=A.+Johnstonauthor=S.+W.+Stollauthor=M.+B.+Riblettauthor=X.+Xingauthor=J.+J.+Kochkodanauthor=J.+Dingauthor=R.+P.+Nairauthor=A.+Aphaleauthor=J.+J.+Voorheesauthor=J.+T.+Elder&title=Evidence+for+altered+Wnt+signaling+in+psoriatic+skin&doi=10.1038%2Fjid.2010.67"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Evidence for Altered Wnt Signaling in Psoriatic Skin</span></div><div class="casAuthors">Gudjonsson, Johann E.; Johnston, Andrew; Stoll, Stefan W.; Riblett, Mary B.; Xing, Xianying; Kochkodan, James J.; Ding, Jun; Nair, Rajan P.; Aphale, Abhishek; Voorhees, John J.; Elder, James T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Investigative Dermatology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1849-1859</span>CODEN:
                <span class="NLM_cas:coden">JIDEAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-202X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The Wnt gene family encodes a set of highly conserved secreted signaling proteins that have major roles in embryogenesis and tissue homeostasis.  Yet the expression of this family of important mediators in psoriasis, a disease characterized by marked changes in keratinocyte growth and differentiation, is incompletely understood.  We subjected 58 paired biopsies from lesional and uninvolved psoriatic skin and 64 biopsies from normal skin to global gene expression profiling.  WNT5A transcripts were upregulated fivefold in lesional skin, accompanied by increased Wnt-5a protein levels.  Notably, WNT5A mRNA was markedly induced by IL-1α, tumor necrosis factor-α, IFN-γ, and transforming growth factor-α in cultured keratinocytes.  Frizzled 2 (FZD2) and FZD5, which encode receptors for Wnt5A, were also increased in lesional psoriatic skin.  In contrast, expression of WIF1 mRNA, encoding a secreted antagonist of the Wnt proteins, was downregulated > 10-fold in lesional skin, along with decreased WNT inhibitory factor (WIF)-1 immunostaining.  Interestingly, pathway anal. along with reduced AXIN2 expression and lack of nuclear translocation of β-catenin indicated a suppression of canonical Wnt signaling in lesional skin.  The results of our study suggest a shift away from canonical Wnt signaling toward noncanonical pathways driven by interactions between Wnt-5a and its cognate receptors in psoriasis, accompanied by impaired homeostatic inhibition of Wnt signaling by WIF-1 and dickkopf.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJpPw9adK1_bVg90H21EOLACvtfcHk0lj5x4BRQDVg3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXnsVyju7g%253D&md5=4a210b3550954c9a33b61a6cd339c6c1</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fjid.2010.67&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fjid.2010.67%26sid%3Dliteratum%253Aachs%26aulast%3DGudjonsson%26aufirst%3DJ.%2BE.%26aulast%3DJohnston%26aufirst%3DA.%26aulast%3DStoll%26aufirst%3DS.%2BW.%26aulast%3DRiblett%26aufirst%3DM.%2BB.%26aulast%3DXing%26aufirst%3DX.%26aulast%3DKochkodan%26aufirst%3DJ.%2BJ.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DNair%26aufirst%3DR.%2BP.%26aulast%3DAphale%26aufirst%3DA.%26aulast%3DVoorhees%26aufirst%3DJ.%2BJ.%26aulast%3DElder%26aufirst%3DJ.%2BT.%26atitle%3DEvidence%2520for%2520altered%2520Wnt%2520signaling%2520in%2520psoriatic%2520skin%26jtitle%3DJ.%2520Invest.%2520Dermatol.%26date%3D2010%26volume%3D130%26spage%3D1849%26epage%3D1859%26doi%3D10.1038%2Fjid.2010.67" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lowes, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suarez-Farinas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krueger, J. G.</span></span> <span> </span><span class="NLM_article-title">Immunology of psoriasis</span>. <i>Annu. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">227</span>– <span class="NLM_lpage">255</span>, <span class="refDoi"> DOI: 10.1146/annurev-immunol-032713-120225</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.1146%2Fannurev-immunol-032713-120225" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=24655295" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC2cXovVemt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&pages=227-255&author=M.+A.+Lowesauthor=M.+Suarez-Farinasauthor=J.+G.+Krueger&title=Immunology+of+psoriasis&doi=10.1146%2Fannurev-immunol-032713-120225"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Immunology of psoriasis</span></div><div class="casAuthors">Lowes, Michelle A.; Suarez-Farinas, Mayte; Krueger, James G.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Immunology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">227-255</span>CODEN:
                <span class="NLM_cas:coden">ARIMDU</span>;
        ISSN:<span class="NLM_cas:issn">0732-0582</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews</span>)
        </div><div class="casAbstract">A review.  The skin is the front line of defense against insult and injury and contains many epidermal and immune elements that comprise the skin-assocd. lymphoid tissue (SALT).  The reaction of these components to injury allows an effective cutaneous response to restore homeostasis.  Psoriasis vulgaris is the best-understood and most accessible human disease that is mediated by T cells and dendritic cells.  Inflammatory myeloid dendritic cells release IL-23 and IL-12 to activate IL-17-producing T cells, Th1 cells, and Th22 cells to produce abundant psoriatic cytokines IL-17, IFN-γ, TNF, and IL-22.  These cytokines mediate effects on keratinocytes to amplify psoriatic inflammation.  Therapeutic studies with anticytokine antibodies have shown the importance of the key cytokines IL-23, TNF, and IL-17 in this process.  We discuss the genetic background of psoriasis and its relationship to immune function, specifically genetic mutations, key PSORS loci, single nucleotide polymorphisms, and the skin transcriptome.  The assocn. between comorbidities and psoriasis is reviewed by correlating the skin transcriptome and serum proteins.  Psoriasis-related cytokine-response pathways are considered in the context of the transcriptome of different mouse models.  This approach offers a model for other inflammatory skin and autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBy6RETuUVSLVg90H21EOLACvtfcHk0ljS9jJjzghlDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXovVemt74%253D&md5=29efa4155cda7347f884244fa5732eac</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1146%2Fannurev-immunol-032713-120225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-immunol-032713-120225%26sid%3Dliteratum%253Aachs%26aulast%3DLowes%26aufirst%3DM.%2BA.%26aulast%3DSuarez-Farinas%26aufirst%3DM.%26aulast%3DKrueger%26aufirst%3DJ.%2BG.%26atitle%3DImmunology%2520of%2520psoriasis%26jtitle%3DAnnu.%2520Rev.%2520Immunol.%26date%3D2014%26volume%3D32%26spage%3D227%26epage%3D255%26doi%3D10.1146%2Fannurev-immunol-032713-120225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guttman-Yassky, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krueger, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebwohl, M. G.</span></span> <span> </span><span class="NLM_article-title">Systemic immune mechanisms in atopic dermatitis and psoriasis with implications for treatment</span>. <i>Exp. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">409</span>– <span class="NLM_lpage">417</span>, <span class="refDoi"> DOI: 10.1111/exd.13336</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.1111%2Fexd.13336" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=28266782" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A280%3ADC%252BC1czjsFentw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2018&pages=409-417&author=E.+Guttman-Yasskyauthor=J.+G.+Kruegerauthor=M.+G.+Lebwohl&title=Systemic+immune+mechanisms+in+atopic+dermatitis+and+psoriasis+with+implications+for+treatment&doi=10.1111%2Fexd.13336"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Systemic immune mechanisms in atopic dermatitis and psoriasis with implications for treatment</span></div><div class="casAuthors">Guttman-Yassky Emma; Lebwohl Mark G; Guttman-Yassky Emma; Krueger James G; Krueger James G</div><div class="citationInfo"><span class="NLM_cas:title">Experimental dermatology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">409-417</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Atopic dermatitis (AD) and psoriasis are inflammatory skin diseases that negatively affect patients' quality of life.  Although distinctions exist between these diseases, both are characterized by erythematous, thickened epidermal lesions that vary in intensity and affected body surface area.  Early models of aetiology attributed symptoms of both diseases to cutaneous inflammation at lesion sites, but recent studies have established that activated immune mediators in the circulation drive disease severity.  Activation of T helper 2 (Th2) and Th22 cells in the circulation appears to be the principal initiator of acute AD pathology, with the emergence of Th1 and Th17/interleukin (IL)-23 pathway activation marking the transition to a chronic state.  The Th17/IL-23 pathway also has an important role in psoriasis.  The role of systemic inflammation in AD and psoriasis is supported by the occurrence of non-cutaneous comorbidities that affect patients, most of which intensify morbidity and disability associated with lesional skin.  Atopic dermatitis is associated with allergic disorders consisting of the "atopic march," whereas psoriasis is frequently accompanied by psoriatic arthritis.  Patients with both disorders are at significantly higher risk of obesity, metabolic disorders, and cardiovascular diseases, all of which feature inflammatory components in their pathology models.  These insights have led to novel therapeutics aimed at addressing psoriasis by targeting tumor necrosis factor- and Th17-related cytokine pathways.  The success of these agents in psoriasis management is driving new therapeutic approaches for moderate-to-severe AD, including agents targeting the Th2 and Th17/Th22 cytokine pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTgSLfl4b90ICEJCPKhJPuqfW6udTcc2eYBa524NOZs-Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1czjsFentw%253D%253D&md5=17517173863e93762bae702b05aa81b6</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1111%2Fexd.13336&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fexd.13336%26sid%3Dliteratum%253Aachs%26aulast%3DGuttman-Yassky%26aufirst%3DE.%26aulast%3DKrueger%26aufirst%3DJ.%2BG.%26aulast%3DLebwohl%26aufirst%3DM.%2BG.%26atitle%3DSystemic%2520immune%2520mechanisms%2520in%2520atopic%2520dermatitis%2520and%2520psoriasis%2520with%2520implications%2520for%2520treatment%26jtitle%3DExp.%2520Dermatol.%26date%3D2018%26volume%3D27%26spage%3D409%26epage%3D417%26doi%3D10.1111%2Fexd.13336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Furumoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadina, M.</span></span> <span> </span><span class="NLM_article-title">The arrival of JAK inhibitors: advancing the treatment of immune and hematologic disorders</span>. <i>BioDrugs</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">431</span>– <span class="NLM_lpage">438</span>, <span class="refDoi"> DOI: 10.1007/s40259-013-0040-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.1007%2Fs40259-013-0040-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=23743669" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsl2nsbzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2013&pages=431-438&author=Y.+Furumotoauthor=M.+Gadina&title=The+arrival+of+JAK+inhibitors%3A+advancing+the+treatment+of+immune+and+hematologic+disorders&doi=10.1007%2Fs40259-013-0040-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The Arrival of JAK Inhibitors: Advancing the Treatment of Immune and Hematologic Disorders</span></div><div class="casAuthors">Furumoto, Yasuko; Gadina, Massimo</div><div class="citationInfo"><span class="NLM_cas:title">BioDrugs</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">431-438</span>CODEN:
                <span class="NLM_cas:coden">BIDRF4</span>;
        ISSN:<span class="NLM_cas:issn">1173-8804</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Altered prodn. of cytokines can result in pathologies ranging from autoimmune diseases to malignancies.  The Janus kinase family is a small group of receptor-assocd. signaling mols. that is essential to the signal cascade originating from type I and type II cytokine receptors.  Inhibition of tyrosine kinase enzymic activity using small mols. has recently become a powerful tool for treatment of several malignancies.  Twenty years after the discovery of these enzymes, two inhibitors for this class of kinases have been approved for clin. use and others are currently in the final stage of development.  Here we review the principles of cytokines signaling, summarize our current knowledge of the approved inhibitors, and briefly introduce some of the inhibitors that are currently under development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQNQJyHX0EDLVg90H21EOLACvtfcHk0ljS9jJjzghlDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsl2nsbzI&md5=a593c1f01565b3dc3bf3df8c424595a6</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1007%2Fs40259-013-0040-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40259-013-0040-7%26sid%3Dliteratum%253Aachs%26aulast%3DFurumoto%26aufirst%3DY.%26aulast%3DGadina%26aufirst%3DM.%26atitle%3DThe%2520arrival%2520of%2520JAK%2520inhibitors%253A%2520advancing%2520the%2520treatment%2520of%2520immune%2520and%2520hematologic%2520disorders%26jtitle%3DBioDrugs%26date%3D2013%26volume%3D27%26spage%3D431%26epage%3D438%26doi%3D10.1007%2Fs40259-013-0040-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alessi, D. R.</span></span> <span> </span><span class="NLM_article-title">Kinase drug discovery--what’s next in the field?</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">96</span>– <span class="NLM_lpage">104</span>, <span class="refDoi"> DOI: 10.1021/cb300610s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb300610s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjvF2q" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=96-104&author=P.+Cohenauthor=D.+R.+Alessi&title=Kinase+drug+discovery%2D%2Dwhat%E2%80%99s+next+in+the+field%3F&doi=10.1021%2Fcb300610s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase Drug Discovery - What's Next in the Field?</span></div><div class="casAuthors">Cohen, Philip; Alessi, Dario R.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">96-104</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Over the past 15 years protein kinases have become the pharmaceutical industry's most important class of drug target in the field of cancer.  Some 20 drugs that target kinases have been approved for clin. use over the past decade, and hundreds more are undergoing clin. trials.  However, the recent approval of the first protein kinase inhibitors for the treatment of inflammatory diseases, coupled with an enhanced understanding of the signaling networks that control the immune system, suggests that there will be a surge of interest in this area over the next 10 years.  In this connection, we discuss opportunities for targeting protein kinases in the MyD88 signaling network for the development of drugs to treat chronic inflammatory and autoimmune diseases.  Activating mutations in protein kinases underlie many other diseases and conditions, and we also discuss why the protein kinases SPAK/OSR1 and LRRK2 have recently become interesting targets for the treatment of hypertension and Parkinson's disease, resp., and the progress that has been made in developing LRRK2 inhibitors.  Finally we suggest that more focus on the identification of inhibitors of kinase activation, rather than kinase activity, may pay dividends in identifying exquisitely specific inhibitors of signal transduction cascades, and we also highlight "pseudo-kinases" as an attractive and unexplored area for drug development that merits much more attention in the years to come.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9qmfkcqZ3ILVg90H21EOLACvtfcHk0lj_xXCDHvYhcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjvF2q&md5=5bf2ced4163b6ae70e604b2916a6a068</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Fcb300610s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb300610s%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DP.%26aulast%3DAlessi%26aufirst%3DD.%2BR.%26atitle%3DKinase%2520drug%2520discovery--what%25E2%2580%2599s%2520next%2520in%2520the%2520field%253F%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2013%26volume%3D8%26spage%3D96%26epage%3D104%26doi%3D10.1021%2Fcb300610s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mócsai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovács, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gergely, P.</span></span> <span> </span><span class="NLM_article-title">What is the future of targeted therapy in rheumatology: biologics or small molecules?</span>. <i>BMC Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">43</span>, <span class="refDoi"> DOI: 10.1186/1741-7015-12-43</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.1186%2F1741-7015-12-43" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=24620738" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjsVWjtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2014&pages=43&author=A.+M%C3%B3csaiauthor=L.+Kov%C3%A1csauthor=P.+Gergely&title=What+is+the+future+of+targeted+therapy+in+rheumatology%3A+biologics+or+small+molecules%3F&doi=10.1186%2F1741-7015-12-43"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">What is the future of targeted therapy in rheumatology: biologics or small molecules?</span></div><div class="casAuthors">Mocsai, Attila; Kovacs, Laszlo; Gergely, Peter</div><div class="citationInfo"><span class="NLM_cas:title">BMC Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">43/1-43/9, 9</span>CODEN:
                <span class="NLM_cas:coden">BMMECZ</span>;
        ISSN:<span class="NLM_cas:issn">1741-7015</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Until late in the 20th century, the therapy of rheumatic diseases relied on the use of drugs that had been developed through empirical approaches without detailed understanding of the mol. mechanisms involved.  That approach changed with the introduction of biol. therapeutics at the end of the 20th century and by the recent development of small-mol. inhibitors of intracellular signal transduction pathways.  Here we compare and discuss the advantages and disadvantages of those two groups of targeted anti-inflammatory therapeutics.  Discussion: TNF-blocking biol. agents were introduced into the therapy of rheumatoid arthritis and other autoimmune and inflammatory diseases in the late 1990s.  Further biol. agents targeting cytokine networks or specific lymphocyte subsets have since been added to the armamentarium of anti-rheumatic therapy.  During the last few years, another wave of novel discoveries led to the development of a new class of small mol. anti-inflammatory compds. targeting intracellular signal transduction mols., such as tyrosine kinases.  In all those cases, the specific targets of the drugs are well defined and significant knowledge about their role in the disease pathomechanism is available, qualifying them for being targeted therapeutics for inflammatory rheumatic diseases.  While both groups of targeted therapeutics offer significant clin. benefit, they clearly differ in several aspects, such as the localization of their targets, their route of administration and target specificity, as well as tech. details such as manufg. procedures and cost basis.  In this debate paper, we compare the advantages and disadvantages of the two different approaches, aiming to shed light on the possible future of targeted therapies.  Summary: Biol. therapeutics and small-mol. inhibitors both have significant advantages and disadvantages in the therapy of rheumatic diseases.  The future of targeted therapies is one of the most exciting questions of current rheumatol. research and therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTONjip_IttLVg90H21EOLACvtfcHk0lj_xXCDHvYhcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjsVWjtrk%253D&md5=20ede05081b83e736ad5675afcffc21d</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1186%2F1741-7015-12-43&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1741-7015-12-43%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25B3csai%26aufirst%3DA.%26aulast%3DKov%25C3%25A1cs%26aufirst%3DL.%26aulast%3DGergely%26aufirst%3DP.%26atitle%3DWhat%2520is%2520the%2520future%2520of%2520targeted%2520therapy%2520in%2520rheumatology%253A%2520biologics%2520or%2520small%2520molecules%253F%26jtitle%3DBMC%2520Med.%26date%3D2014%26volume%3D12%26spage%3D43%26doi%3D10.1186%2F1741-7015-12-43" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ritchlin, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krueger, J. G.</span></span> <span> </span><span class="NLM_article-title">New therapies for psoriasis and psoriatic arthritis</span>. <i>Curr. Opin. Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">204</span>– <span class="NLM_lpage">210</span>, <span class="refDoi"> DOI: 10.1097/BOR.0000000000000274</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.1097%2FBOR.0000000000000274" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=27022911" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC28Xlt1SqsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2016&pages=204-210&author=C.+T.+Ritchlinauthor=J.+G.+Krueger&title=New+therapies+for+psoriasis+and+psoriatic+arthritis&doi=10.1097%2FBOR.0000000000000274"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">New therapies for psoriasis and psoriatic arthritis</span></div><div class="casAuthors">Ritchlin, Christopher T.; Krueger, James G.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Rheumatology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">204-210</span>CODEN:
                <span class="NLM_cas:coden">CORHES</span>;
        ISSN:<span class="NLM_cas:issn">1040-8711</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose of review: Over the last several years, novel immunol. pathways pivotal in the development of the pathobiol. of psoriasis and psoriatic arthritis (PsA) have been revealed.  These discoveries catalyzed a search for new treatment targets resulting in many new therapies that are now available for patients with psoriatic disease.  Recent findings: Helper T cells that secrete interleukin-17 (TH17) along with CD8+ cells, innate lymphocyte cells, and gamma delta T cells are important in the pathogenesis of psoriasis and PsA.  Recently, agents that target interleukin-17, the interleukin-17 receptor, and interleukin-23 (antip19) have been approved or are in clin. trials.  Apremilast, a new oral agent, was approved for the treatment of psoriasis and PsA.  Summary: Secukinumab, an interleukin-17A antibody, has been approved for treatment of psoriasis and PsA in the United States.  It is effective with a good safety profile.  Ixekizumab, another anti-interleukin-17A antibody, is currently in clin. trials and brodalumab, an interleukin-17 receptor antagonist, was removed from clin. trials because of safety concerns despite demonstrated efficacy in psoriasis and PsA.  Targeting interleukin-23 with antibodies to p19 is another approach with encouraging results in psoriasis.  Apremilast, an oral agent, approved to treat psoriasis and PsA demonstrates moderate efficacy with an excellent safety record.  The role of tofacitinib in psoriatic disease remains to be detd. pending a safety review in psoriasis and completion of PsA trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKQAm4F1wdTbVg90H21EOLACvtfcHk0lj_xXCDHvYhcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xlt1SqsLY%253D&md5=f4a645f44a8d9214eb3679bacabdac9f</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1097%2FBOR.0000000000000274&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FBOR.0000000000000274%26sid%3Dliteratum%253Aachs%26aulast%3DRitchlin%26aufirst%3DC.%2BT.%26aulast%3DKrueger%26aufirst%3DJ.%2BG.%26atitle%3DNew%2520therapies%2520for%2520psoriasis%2520and%2520psoriatic%2520arthritis%26jtitle%3DCurr.%2520Opin.%2520Rheumatol.%26date%3D2016%26volume%3D28%26spage%3D204%26epage%3D210%26doi%3D10.1097%2FBOR.0000000000000274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Behrens, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koehm, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwaneck, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmalzing, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gnann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tony, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burkhardt, H.</span></span> <span> </span><span class="NLM_article-title">Minimal disease activity is a stable measure of therapeutic response in psoriatic arthritis patients receiving treatment with adalimumab</span>. <i>Rheumatology (Oxford, U. K.)</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">1938</span>– <span class="NLM_lpage">1946</span>, <span class="refDoi"> DOI: 10.1093/rheumatology/key203</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.1093%2Frheumatology%2Fkey203" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=30010891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlWksb%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=1938-1946&author=F.+Behrensauthor=M.+Koehmauthor=E.+C.+Schwaneckauthor=M.+Schmalzingauthor=H.+Gnannauthor=G.+Gregerauthor=H.+P.+Tonyauthor=H.+Burkhardt&title=Minimal+disease+activity+is+a+stable+measure+of+therapeutic+response+in+psoriatic+arthritis+patients+receiving+treatment+with+adalimumab&doi=10.1093%2Frheumatology%2Fkey203"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Minimal disease activity is a stable measure of therapeutic response in psoriatic arthritis patients receiving treatment with adalimumab</span></div><div class="casAuthors">Behrens, Frank; Koehm, Michaela; Schwaneck, Eva C.; Schmalzing, Marc; Gnann, Holger; Greger, Gerd; Tony, Hans-Peter; Burkhardt, Harald</div><div class="citationInfo"><span class="NLM_cas:title">Rheumatology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1938-1946</span>CODEN:
                <span class="NLM_cas:coden">RUMAFK</span>;
        ISSN:<span class="NLM_cas:issn">1462-0332</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Objective.  The aim of this study was to evaluate minimal disease activity (MDA) assessments in patients with PsA during routine clin. care.  We used data from a multicentre observational study of patients with active PsA who initiated treatment with adalimumab during routine clin. practice and continued treatment for at least 6 mo to evaluate achievement of MDA, individual MDA criteria (modified to conform to study assessments) and ACR responses during 24 mo of therapy.  Pearson correlation coeffs. were used to evaluate the assocn. between MDA and individual criteria at month 6; regression models were used to det. the influence of baseline MDA criteria on achievement of MDA at month 6.  A total of 1684 patients were included in these analyses; most had long-standing disease.  MDA was achieved by 597 patients (35.5%) at month 6.  This proportion increased to 45.5% at month 24 in patients remaining on therapy.  MDA status was stable over time; >75% of patients with MDA at month 6 recorded MDA at subsequent visits.  Pain was the most difficult individual criterion to achieve, and enthesitis was the least difficult.  Higher functional status and fewer tender joints at baseline predicted achievement of MDA at month 6.  About half of patients (51.5%) with an ACR20 response at month 6 achieved MDA.  Conclusion.  In this observational cohort of patients with long-standing disease, MDA provided a stable and valid assessment of clin. status over 24 mo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogMUGXjLLl3bVg90H21EOLACvtfcHk0ljkFMMYSW0YOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlWksb%252FI&md5=6efbe8a5b9067a638d07cd2ae7954c71</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1093%2Frheumatology%2Fkey203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Frheumatology%252Fkey203%26sid%3Dliteratum%253Aachs%26aulast%3DBehrens%26aufirst%3DF.%26aulast%3DKoehm%26aufirst%3DM.%26aulast%3DSchwaneck%26aufirst%3DE.%2BC.%26aulast%3DSchmalzing%26aufirst%3DM.%26aulast%3DGnann%26aufirst%3DH.%26aulast%3DGreger%26aufirst%3DG.%26aulast%3DTony%26aufirst%3DH.%2BP.%26aulast%3DBurkhardt%26aufirst%3DH.%26atitle%3DMinimal%2520disease%2520activity%2520is%2520a%2520stable%2520measure%2520of%2520therapeutic%2520response%2520in%2520psoriatic%2520arthritis%2520patients%2520receiving%2520treatment%2520with%2520adalimumab%26jtitle%3DRheumatology%2520%2528Oxford%252C%2520U.%2520K.%2529%26date%3D2018%26volume%3D57%26spage%3D1938%26epage%3D1946%26doi%3D10.1093%2Frheumatology%2Fkey203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mease, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Heijde, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landewe, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mpofu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tahir, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singhal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boettcher, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navarra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meiser, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Readie, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pricop, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abrams, K.</span></span> <span> </span><span class="NLM_article-title">Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III future 5 study</span>. <i>Ann. Rheum. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">890</span>– <span class="NLM_lpage">897</span>, <span class="refDoi"> DOI: 10.1136/annrheumdis-2017-212687</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.1136%2Fannrheumdis-2017-212687" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=29550766" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC1MXislSitr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2018&pages=890-897&author=P.+Measeauthor=D.+van+der+Heijdeauthor=R.+Landeweauthor=S.+Mpofuauthor=P.+Rahmanauthor=H.+Tahirauthor=A.+Singhalauthor=E.+Boettcherauthor=S.+Navarraauthor=K.+Meiserauthor=A.+Readieauthor=L.+Pricopauthor=K.+Abrams&title=Secukinumab+improves+active+psoriatic+arthritis+symptoms+and+inhibits+radiographic+progression%3A+primary+results+from+the+randomised%2C+double-blind%2C+phase+III+future+5+study&doi=10.1136%2Fannrheumdis-2017-212687"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study</span></div><div class="casAuthors">Mease, Philip; van der Heijde, Desiree; Landewe, Robert; Mpofu, Shephard; Rahman, Proton; Tahir, Hasan; Singhal, Atul; Boettcher, Elke; Navarra, Sandra; Meiser, Karin; Readie, Aimee; Pricop, Luminita; Abrams, Ken</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the Rheumatic Diseases</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">890-897</span>CODEN:
                <span class="NLM_cas:coden">ARDIAO</span>;
        ISSN:<span class="NLM_cas:issn">0003-4967</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">Objectives T o evaluate the effect of s.c. (s.c.) secukinumab, an interleukin-17A inhibitor, on clin. signs and symptoms and radiog. progression in patients with psoriatic arthritis (PsA).  Methods Adults (n=996) with active PsA were randomised 2:2:2:3 to s.c. secukinumab 300 mg or 150 mg with loading dose (LD), 150 mg without LD or placebo.  All groups received secukinumab or placebo at baseline, weeks 1, 2 and 3 and then every 4 wk from week 4.  The primary endpoint was the proportion of patients achieving an American College of Rheumatol. 20 (ACR20) response at week 16.  Results Significantly more patients achieved an ACR20 response at week 16 with secukinumab 300 mg with LD (62.6%), 150 mg with LD (55.5%) or 150 mg without LD (59.5%) than placebo (27.4%) (p<0.0001 for all; non-responder imputation).  Radiog. progression, as measured by van der Heijde-modified total Sharp score, was significantly inhibited at week 24 in all secukinumab arms vs. placebo (p<0.01 for 300 mg with LD and 150 mg without LD and p<0.05 for 150 mg with LD; linear extrapolation).  Adverse event rates at week 24 were similar across treatment arms: 63.1% (300 mg with LD), 62.7% (150 mg with LD), 61.1% (150 mg without LD) and 62.0% (placebo).  No deaths or new safety signals were reported.  Conclusion S.c. secukinumab 300 mg and 150 mg with and without LD significantly improved clin. signs and symptoms and inhibited radiog. structural progression vs. placebo at week 24 in patients with PsA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYCabo-EbLFLVg90H21EOLACvtfcHk0ljkFMMYSW0YOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXislSitr8%253D&md5=1a06f5f8aa8d7c06b5863a7982978e36</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1136%2Fannrheumdis-2017-212687&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fannrheumdis-2017-212687%26sid%3Dliteratum%253Aachs%26aulast%3DMease%26aufirst%3DP.%26aulast%3Dvan%2Bder%2BHeijde%26aufirst%3DD.%26aulast%3DLandewe%26aufirst%3DR.%26aulast%3DMpofu%26aufirst%3DS.%26aulast%3DRahman%26aufirst%3DP.%26aulast%3DTahir%26aufirst%3DH.%26aulast%3DSinghal%26aufirst%3DA.%26aulast%3DBoettcher%26aufirst%3DE.%26aulast%3DNavarra%26aufirst%3DS.%26aulast%3DMeiser%26aufirst%3DK.%26aulast%3DReadie%26aufirst%3DA.%26aulast%3DPricop%26aufirst%3DL.%26aulast%3DAbrams%26aufirst%3DK.%26atitle%3DSecukinumab%2520improves%2520active%2520psoriatic%2520arthritis%2520symptoms%2520and%2520inhibits%2520radiographic%2520progression%253A%2520primary%2520results%2520from%2520the%2520randomised%252C%2520double-blind%252C%2520phase%2520III%2520future%25205%2520study%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2018%26volume%3D77%26spage%3D890%26epage%3D897%26doi%3D10.1136%2Fannrheumdis-2017-212687" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J. J.</span></span> <span> </span><span class="NLM_article-title">Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases</span>. <i>Nat. Rev. Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">25</span>– <span class="NLM_lpage">36</span>, <span class="refDoi"> DOI: 10.1038/nrrheum.2015.167</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.1038%2Fnrrheum.2015.167" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=26633291" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvF2ks7vJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=25-36&author=D.+M.+Schwartzauthor=M.+Bonelliauthor=M.+Gadinaauthor=J.+J.+O%E2%80%99Shea&title=Type+I%2FII+cytokines%2C+JAKs%2C+and+new+strategies+for+treating+autoimmune+diseases&doi=10.1038%2Fnrrheum.2015.167"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases</span></div><div class="casAuthors">Schwartz, Daniella M.; Bonelli, Michael; Gadina, Massimo; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Rheumatology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">25-36</span>CODEN:
                <span class="NLM_cas:coden">NRRACB</span>;
        ISSN:<span class="NLM_cas:issn">1759-4790</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Cytokines are major drivers of autoimmunity, and biol. agents targeting cytokines have revolutionized the treatment of immune-mediated diseases.  Despite the effectiveness of these drugs, they do not induce complete remission in all patients, prompting the development of alternative strategies - including targeting of intracellular signal transduction pathways downstream of cytokines.  Many cytokines that bind type I and type II cytokine receptors are crit. regulators of immune-mediated diseases and employ the Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathway to exert their effect.  Pharmacol. inhibition of JAKs blocks the actions of type I/II cytokines, and within the past 3 years therapeutic JAK inhibitors, or Jakinibs, have become available to rheumatologists.  Jakinibs have proven effective for the treatment of rheumatoid arthritis and other inflammatory diseases.  Adverse effects of these agents are largely related to their mode of action and include infections and hyperlipidemia.  Jakinibs are currently being investigated for a no. of new indications, and second-generation selective Jakinibs are being developed and tested.  Targeting STATs could be a future avenue for the treatment of rheumatol. diseases, although substantial challenges remain.  Nonetheless, the ability to therapeutically target intracellular signalling pathways has already created a new paradigm for the treatment of rheumatol. disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUdr1Dh92dnLVg90H21EOLACvtfcHk0ljXxGl-SNaU2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvF2ks7vJ&md5=e06f7ab6424f1fbdbf481c75fa9ebd23</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fnrrheum.2015.167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrrheum.2015.167%26sid%3Dliteratum%253Aachs%26aulast%3DSchwartz%26aufirst%3DD.%2BM.%26aulast%3DBonelli%26aufirst%3DM.%26aulast%3DGadina%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DType%2520I%252FII%2520cytokines%252C%2520JAKs%252C%2520and%2520new%2520strategies%2520for%2520treating%2520autoimmune%2520diseases%26jtitle%3DNat.%2520Rev.%2520Rheumatol.%26date%3D2016%26volume%3D12%26spage%3D25%26epage%3D36%26doi%3D10.1038%2Fnrrheum.2015.167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bryan, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajapaksa, N. S.</span></span> <span> </span><span class="NLM_article-title">Kinase inhibitors for the treatment of immunological disorders: recent advances</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">9030</span>– <span class="NLM_lpage">9058</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00667</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00667" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVOmsLzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=9030-9058&author=M.+C.+Bryanauthor=N.+S.+Rajapaksa&title=Kinase+inhibitors+for+the+treatment+of+immunological+disorders%3A+recent+advances&doi=10.1021%2Facs.jmedchem.8b00667"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase Inhibitors for the Treatment of Immunological Disorders: Recent Advances</span></div><div class="casAuthors">Bryan, Marian C.; Rajapaksa, Naomi S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">9030-9058</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Small mol. inhibitors targeting autoimmune and inflammatory processes have been an area of intense focus within academia and industry.  Much of this work has been aimed at key kinases operating as central nodes in inflammatory signaling pathways.  While this focus has led to over 30 FDA-approved small mol. kinase inhibitors, only one is currently approved for autoimmune and inflammatory diseases.  Despite this lack of success, there remains tremendous reason for excitement.  Our growing understanding of the biol. involved in the inflammatory response, the factors that lead to safer small mol. kinase inhibitors, and the availability of selective tool mols. for interrogating specific nodes and pathways are all pushing the field forward.  This article focuses on recent developments requiring novel approaches to create safe and effective small mol. kinase inhibitors and where further work is needed to realize the promise of small mol. kinase inhibitors for patient benefit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVucOE4LCJALVg90H21EOLACvtfcHk0ljXxGl-SNaU2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVOmsLzI&md5=aff62adff54c9152d2b2156b05d67400</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00667%26sid%3Dliteratum%253Aachs%26aulast%3DBryan%26aufirst%3DM.%2BC.%26aulast%3DRajapaksa%26aufirst%3DN.%2BS.%26atitle%3DKinase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520immunological%2520disorders%253A%2520recent%2520advances%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D9030%26epage%3D9058%26doi%3D10.1021%2Facs.jmedchem.8b00667" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levine, R. L.</span></span> <span> </span><span class="NLM_article-title">Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">2051</span>– <span class="NLM_lpage">2059</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-0279</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.1158%2F1078-0432.CCR-13-0279" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=24583800" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtl2ms78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=2051-2059&author=S.+C.+Meyerauthor=R.+L.+Levine&title=Molecular+pathways%3A+molecular+basis+for+sensitivity+and+resistance+to+JAK+kinase+inhibitors&doi=10.1158%2F1078-0432.CCR-13-0279"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Pathways: Molecular Basis for Sensitivity and Resistance to JAK Kinase Inhibitors</span></div><div class="casAuthors">Meyer, Sara C.; Levine, Ross L.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2051-2059</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Janus-activated kinases (JAK) are the mediators of a variety of cytokine signals via their cognate receptors that result in activation of intracellular signaling pathways.  Alterations in JAK1, JAK2, JAK3, and TYK2 signaling contribute to different disease states, and dysregulated JAK-STAT signaling is assocd. with hematol. malignancies, autoimmune disorders, and immune-deficient conditions.  Genetic alterations of JAK2 occur in the majority of patients with myeloproliferative neoplasms and occur in a subset of patients with acute leukemias.  JAK-mediated signaling critically relies on STAT transcription factors, and on activation of the MAPK and PI3K/Akt signaling axes.  Hyperactive JAK at the apex of these potent oncogenic signaling pathways therefore represents an important target for small-mol. kinase inhibitors in different disease states.  The JAK1/2 inhibitor ruxolitinib and the JAK3 inhibitor tofacitinib were recently approved for the treatment of myelofibrosis and rheumatoid arthritis, resp., and addnl. ATP-competitive JAK inhibitors are in clin. development.  Although these agents show clin. activity, the ability of these JAK inhibitors to induce clin./mol. remissions in hematol. malignancies seems limited and resistance upon chronic drug exposure is seen.  Alternative modes of targeting JAK2 such as allosteric kinase inhibition or HSP90 inhibition are under evaluation, as is the use of histone deacetylase inhibitors.  Combination therapy approaches integrating inhibition of STAT, PI3K/Akt, and MAPK pathways with JAK kinase inhibitors might be crit. to overcome malignancies characterized by dysregulated JAK signaling.  Clin Cancer Res; 20(8); 2051-9. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKgmYqhJDI07Vg90H21EOLACvtfcHk0ljXxGl-SNaU2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtl2ms78%253D&md5=7c7ad00b5c8020fd660d86c057827eb2</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-0279&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-0279%26sid%3Dliteratum%253Aachs%26aulast%3DMeyer%26aufirst%3DS.%2BC.%26aulast%3DLevine%26aufirst%3DR.%2BL.%26atitle%3DMolecular%2520pathways%253A%2520molecular%2520basis%2520for%2520sensitivity%2520and%2520resistance%2520to%2520JAK%2520kinase%2520inhibitors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26spage%3D2051%26epage%3D2059%26doi%3D10.1158%2F1078-0432.CCR-13-0279" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vannucchi, A. M.</span></span> <span> </span><span class="NLM_article-title">Ruxolitinib: a potent and selective janus kinase 1 and 2 inhibitor in patients with myelofibrosis. an update for clinicians</span>. <i>Ther. Adv. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">341</span>– <span class="NLM_lpage">354</span>, <span class="refDoi"> DOI: 10.1177/2040620712459746</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.1177%2F2040620712459746" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=23606937" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnslWntA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=341-354&author=C.+Harrisonauthor=A.+M.+Vannucchi&title=Ruxolitinib%3A+a+potent+and+selective+janus+kinase+1+and+2+inhibitor+in+patients+with+myelofibrosis.+an+update+for+clinicians&doi=10.1177%2F2040620712459746"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians</span></div><div class="casAuthors">Harrison, Claire; Vannucchi, Alessandro N.</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutic Advances in Hematology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">341-354</span>CODEN:
                <span class="NLM_cas:coden">TAHHAT</span>;
        ISSN:<span class="NLM_cas:issn">2040-6207</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">A review.  Ruxolitinib became the first US Food and Drug Administration approved therapy for myelofibrosis in 2011 and EU approval is anticipated in summer 2012.  Two large phase III trials (known as the COMFORT studies) were the basis for this approval and were published recently.  In this review article we discuss the challenges in managing myelofibrosis, the information to date about ruxolitinib and speculate as to the future direction with this and similar agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-1M-lwEgpCrVg90H21EOLACvtfcHk0lhhZlbmwuz21w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnslWntA%253D%253D&md5=6c88ade9fb3df126e6b0188b69a68d3c</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1177%2F2040620712459746&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F2040620712459746%26sid%3Dliteratum%253Aachs%26aulast%3DHarrison%26aufirst%3DC.%26aulast%3DVannucchi%26aufirst%3DA.%2BM.%26atitle%3DRuxolitinib%253A%2520a%2520potent%2520and%2520selective%2520janus%2520kinase%25201%2520and%25202%2520inhibitor%2520in%2520patients%2520with%2520myelofibrosis.%2520an%2520update%2520for%2520clinicians%26jtitle%3DTher.%2520Adv.%2520Hematol.%26date%3D2012%26volume%3D3%26spage%3D341%26epage%3D354%26doi%3D10.1177%2F2040620712459746" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Papp, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menter, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Disch, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlichting, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaich, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macias, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janes, J. M.</span></span> <span> </span><span class="NLM_article-title">A randomized phase 2b trial of baricitinib, an oral janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis</span>. <i>Br. J. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>174</i></span>,  <span class="NLM_fpage">1266</span>– <span class="NLM_lpage">1276</span>, <span class="refDoi"> DOI: 10.1111/bjd.14403</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.1111%2Fbjd.14403" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=26800231" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVSiurfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=174&publication_year=2016&pages=1266-1276&author=K.+A.+Pappauthor=M.+A.+Menterauthor=M.+Ramanauthor=D.+Dischauthor=D.+E.+Schlichtingauthor=C.+Gaichauthor=W.+Maciasauthor=X.+Zhangauthor=J.+M.+Janes&title=A+randomized+phase+2b+trial+of+baricitinib%2C+an+oral+janus+kinase+%28JAK%29+1%2FJAK2+inhibitor%2C+in+patients+with+moderate-to-severe+psoriasis&doi=10.1111%2Fbjd.14403"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis</span></div><div class="casAuthors">Papp, K. A.; Menter, M. A.; Raman, M.; Disch, D.; Schlichting, D. E.; Gaich, C.; Macias, W.; Zhang, X.; Janes, J. M.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Dermatology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">174</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1266-1276</span>CODEN:
                <span class="NLM_cas:coden">BJDEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0007-0963</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : Background : Plaque psoriasis is a chronic and often debilitating skin disorder and proinflammatory cytokines are known to play a key role in the disease process.  Objectives : To evaluate the safety and efficacy of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis in a randomized, double-blind, placebo-controlled, dose-ranging phase 2b study.  Methods : Patients were randomized (n = 271) to receive placebo or oral baricitinib at 2, 4, 8 or 10 mg once daily for 12 wk (Part A).  Dose adjustment for 12 addnl. weeks was based on percentage improvement in the Psoriasis Area and Severity Index (PASI) score.  The primary end point was Psoriasis Area and Severity Index (PASI) 75% (PASI-75) at 12 wk for North American patients (n = 238); secondary end points were safety and efficacy measures in the entire population.  Results : At week 12, more North American patients in the 8-mg (43%) and 10-mg (54%) baricitinib groups than in placebo group (17%; P < 0·05) achieved PASI-75.  All baricitinib-treated groups had greater mean changes from baseline in their PASI scores (P < 0·05) at 12 wk and (except 2 mg) had higher rates of PASI-50 than the placebo group; statistically significant PASI-90 responses were achieved in the 8-mg and 10-mg groups at 8 and 12 wk.  More than 81% of PASI-75 responders maintained their scores through 24 wk.  During Part A, study discontinuations due to adverse events (AEs) were 0%, 0%, 2·8%, 6·3% and 5·8% and treatment-emergent AE rates were 44%, 50%, 47%, 58% and 64% for placebo and 2-, 4-, 8- and 10-mg baricitinib groups, resp.  No opportunistic infections were obsd. in any treatment group.  Dose-dependent changes in lab. values were obsd.  Conclusions : Patients with moderate-to-severe psoriasis treated with baricitinib for 12 wk achieved significant improvements in PASI-75.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqVPv2558vrrVg90H21EOLACvtfcHk0lhhZlbmwuz21w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVSiurfN&md5=37df34807683b4742548f192f99654f6</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1111%2Fbjd.14403&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbjd.14403%26sid%3Dliteratum%253Aachs%26aulast%3DPapp%26aufirst%3DK.%2BA.%26aulast%3DMenter%26aufirst%3DM.%2BA.%26aulast%3DRaman%26aufirst%3DM.%26aulast%3DDisch%26aufirst%3DD.%26aulast%3DSchlichting%26aufirst%3DD.%2BE.%26aulast%3DGaich%26aufirst%3DC.%26aulast%3DMacias%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DJanes%26aufirst%3DJ.%2BM.%26atitle%3DA%2520randomized%2520phase%25202b%2520trial%2520of%2520baricitinib%252C%2520an%2520oral%2520janus%2520kinase%2520%2528JAK%2529%25201%252FJAK2%2520inhibitor%252C%2520in%2520patients%2520with%2520moderate-to-severe%2520psoriasis%26jtitle%3DBr.%2520J.%2520Dermatol.%26date%3D2016%26volume%3D174%26spage%3D1266%26epage%3D1276%26doi%3D10.1111%2Fbjd.14403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanno, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villarino, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J. J.</span></span> <span> </span><span class="NLM_article-title">JAK inhibition as a therapeutic strategy for immune and inflammatory diseases</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">843</span>– <span class="NLM_lpage">862</span>, <span class="refDoi"> DOI: 10.1038/nrd.2017.201</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.1038%2Fnrd.2017.201" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=29104284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslGqsLnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=843-862&author=D.+M.+Schwartzauthor=Y.+Kannoauthor=A.+Villarinoauthor=M.+Wardauthor=M.+Gadinaauthor=J.+J.+O%E2%80%99Shea&title=JAK+inhibition+as+a+therapeutic+strategy+for+immune+and+inflammatory+diseases&doi=10.1038%2Fnrd.2017.201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">JAK inhibition as a therapeutic strategy for immune and inflammatory diseases</span></div><div class="casAuthors">Schwartz, Daniella M.; Kanno, Yuka; Villarino, Alejandro; Ward, Michael; Gadina, Massimo; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">843-862</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  The discovery of cytokines as key drivers of immune-mediated diseases has spurred efforts to target their assocd. signalling pathways.  Janus kinases (JAKs) are essential signalling mediators downstream of many pro-inflammatory cytokines, and small-mol. inhibitors of JAKs (jakinibs) have gained traction as safe and efficacious options for the treatment of inflammation-driven pathologies such as rheumatoid arthritis, psoriasis and inflammatory bowel disease.  Building on the clin. success of first-generation jakinibs, second-generation compds. that claim to be more selective are currently undergoing development and proceeding to clin. trials.  However, important questions remain about the advantages and limitations of improved JAK selectivity, optimal routes and dosing regimens and how best to identify patients who will benefit from jakinibs.  This Review discusses the biol. of jakinibs from a translational perspective, focusing on recent insights from clin. trials, the development of novel agents and the use of jakinibs in a spectrum of immune and inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9TNpGT01l8rVg90H21EOLACvtfcHk0lhhZlbmwuz21w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslGqsLnO&md5=4607422f83f94c0c7194935d6d460c31</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2017.201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2017.201%26sid%3Dliteratum%253Aachs%26aulast%3DSchwartz%26aufirst%3DD.%2BM.%26aulast%3DKanno%26aufirst%3DY.%26aulast%3DVillarino%26aufirst%3DA.%26aulast%3DWard%26aufirst%3DM.%26aulast%3DGadina%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DJAK%2520inhibition%2520as%2520a%2520therapeutic%2520strategy%2520for%2520immune%2520and%2520inflammatory%2520diseases%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2017%26volume%3D16%26spage%3D843%26epage%3D862%26doi%3D10.1038%2Fnrd.2017.201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wernig, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kharas, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okabe, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leeman, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cullen, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gozo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDowell, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levine, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doukas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mak, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noronha, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, Y. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soll, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tefferi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hood, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilliland, D. G.</span></span> <span> </span><span class="NLM_article-title">Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">311</span>– <span class="NLM_lpage">320</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2008.02.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.1016%2Fj.ccr.2008.02.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=18394554" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BD1cXkslSjtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2008&pages=311-320&author=G.+Wernigauthor=M.+G.+Kharasauthor=R.+Okabeauthor=S.+A.+Mooreauthor=D.+S.+Leemanauthor=D.+E.+Cullenauthor=M.+Gozoauthor=E.+P.+McDowellauthor=R.+L.+Levineauthor=J.+Doukasauthor=C.+C.+Makauthor=G.+Noronhaauthor=M.+Martinauthor=Y.+D.+Koauthor=B.+H.+Leeauthor=R.+M.+Sollauthor=A.+Tefferiauthor=J.+D.+Hoodauthor=D.+G.+Gilliland&title=Efficacy+of+TG101348%2C+a+selective+JAK2+inhibitor%2C+in+treatment+of+a+murine+model+of+JAK2V617F-induced+polycythemia+vera&doi=10.1016%2Fj.ccr.2008.02.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera</span></div><div class="casAuthors">Wernig, Gerlinde; Kharas, Michael G.; Okabe, Rachel; Moore, Sandra A.; Leeman, Dena S.; Cullen, Dana E.; Gozo, Maricel; McDowell, Elizabeth P.; Levine, Ross L.; Doukas, John; Mak, Chi Ching; Noronha, Glenn; Martin, Michael; Ko, Yon D.; Lee, Benjamin H.; Soll, Richard M.; Tefferi, Ayalew; Hood, John D.; Gilliland, D. Gary</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">311-320</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">We report that TG101348, a selective small-mol. inhibitor of JAK2 with an in vitro IC50 of ∼3 nM, shows therapeutic efficacy in a murine model of myeloproliferative disease induced by the JAK2V617F mutation.  In treated animals, there was a statistically significant redn. in hematocrit and leukocyte count, a dose-dependent redn./elimination of extramedullary hematopoiesis, and, at least in some instances, evidence for attenuation of myelofibrosis.  There were no apparent toxicities and no effect on T cell no.  In vivo responses were correlated with surrogate endpoints, including redn./elimination of JAK2V617F disease burden assessed by quant. genomic PCR, suppression of endogenous erythroid colony formation, and in vivo inhibition of JAK-STAT signal transduction as assessed by flow cytometric measurement of phosphorylated Stat5.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSJOc4cS_lO7Vg90H21EOLACvtfcHk0lgmrVwkYqP90Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXkslSjtrs%253D&md5=3dd923595cafebb6439dd67f026735be</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2008.02.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2008.02.009%26sid%3Dliteratum%253Aachs%26aulast%3DWernig%26aufirst%3DG.%26aulast%3DKharas%26aufirst%3DM.%2BG.%26aulast%3DOkabe%26aufirst%3DR.%26aulast%3DMoore%26aufirst%3DS.%2BA.%26aulast%3DLeeman%26aufirst%3DD.%2BS.%26aulast%3DCullen%26aufirst%3DD.%2BE.%26aulast%3DGozo%26aufirst%3DM.%26aulast%3DMcDowell%26aufirst%3DE.%2BP.%26aulast%3DLevine%26aufirst%3DR.%2BL.%26aulast%3DDoukas%26aufirst%3DJ.%26aulast%3DMak%26aufirst%3DC.%2BC.%26aulast%3DNoronha%26aufirst%3DG.%26aulast%3DMartin%26aufirst%3DM.%26aulast%3DKo%26aufirst%3DY.%2BD.%26aulast%3DLee%26aufirst%3DB.%2BH.%26aulast%3DSoll%26aufirst%3DR.%2BM.%26aulast%3DTefferi%26aufirst%3DA.%26aulast%3DHood%26aufirst%3DJ.%2BD.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26atitle%3DEfficacy%2520of%2520TG101348%252C%2520a%2520selective%2520JAK2%2520inhibitor%252C%2520in%2520treatment%2520of%2520a%2520murine%2520model%2520of%2520JAK2V617F-induced%2520polycythemia%2520vera%26jtitle%3DCancer%2520Cell%26date%3D2008%26volume%3D13%26spage%3D311%26epage%3D320%26doi%3D10.1016%2Fj.ccr.2008.02.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Papp, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pariser, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catlin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wierz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ball, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akinlade, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeiher, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krueger, J. G.</span></span> <span> </span><span class="NLM_article-title">A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel janus kinase inhibitor, in patients with moderate-to-severe psoriasis</span>. <i>Br. J. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>173</i></span>,  <span class="NLM_fpage">767</span>– <span class="NLM_lpage">776</span>, <span class="refDoi"> DOI: 10.1111/bjd.13745</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.1111%2Fbjd.13745" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=25704750" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsF2rtbnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=173&publication_year=2015&pages=767-776&author=K.+Pappauthor=D.+Pariserauthor=M.+Catlinauthor=G.+Wierzauthor=G.+Ballauthor=B.+Akinladeauthor=B.+Zeiherauthor=J.+G.+Krueger&title=A+phase+2a+randomized%2C+double-blind%2C+placebo-controlled%2C+sequential+dose-escalation+study+to+evaluate+the+efficacy+and+safety+of+ASP015K%2C+a+novel+janus+kinase+inhibitor%2C+in+patients+with+moderate-to-severe+psoriasis&doi=10.1111%2Fbjd.13745"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis</span></div><div class="casAuthors">Papp, K.; Pariser, D.; Catlin, M.; Wierz, G.; Ball, G.; Akinlade, B.; Zeiher, B.; Krueger, J. G.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Dermatology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">173</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">767-776</span>CODEN:
                <span class="NLM_cas:coden">BJDEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0007-0963</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background : Many immune-mediated disorders, including psoriasis, involve cytokine signalling via Janus kinase (JAK) enzymes.  ASP015K (also designated JNJ-54781532), a novel oral JAK inhibitor, has shown moderate selectivity for JAK3 over JAK1 and JAK2 in enzyme assays.  Objectives : The objective of this study was to evaluate the efficacy and safety of escalating, sequentially grouped, doses of ASP015K vs. placebo in patients with moderate-to-severe psoriasis.  Methods : This phase 2a multicentre, double-blind, randomized, placebo-controlled study (NCT01096862) enrolled 124 patients with moderate-to-severe plaque psoriasis.  Five sequential ASP015K cohorts were enrolled, consisting of four twice-daily dosing groups (10, 25, 60, 100 mg) and one once-daily dosing group (50 mg) for 6 wk.  Results : The primary efficacy end point [mean change in Psoriasis Area and Severity Index score from baseline to end of treatment (EOT; day 42)] significantly favored ASP015K (overall treatment effect; P < 0·001) vs. placebo, with greater improvements at higher doses.  By EOT, the secondary end points [Physician Static Global Assessment (PSGA) score, percentage of patients achieving PSGA success, and change in percentage, body surface area (BSA)] also improved with ASP015K vs. placebo (P < 0·001 for PSGA score and BSA;P < 0·01 for PSGA success).  Epidermal thickness and proliferation decreased from baseline with ASP015K vs. placebo.  ASP015K was generally well tolerated, with no serious adverse events (AEs) reported.  Conclusions : In patients with moderate-to-severe psoriasis, ASP015K demonstrated dose-dependent improvements in clin. and histol. measures of severity over 6 wk of treatment.  At all doses, ASP015K was well tolerated, with no reported serious AEs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCwNPtMdSIj7Vg90H21EOLACvtfcHk0lgmrVwkYqP90Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsF2rtbnE&md5=a5627c011184412f25b6d26cbc8b40a5</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1111%2Fbjd.13745&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbjd.13745%26sid%3Dliteratum%253Aachs%26aulast%3DPapp%26aufirst%3DK.%26aulast%3DPariser%26aufirst%3DD.%26aulast%3DCatlin%26aufirst%3DM.%26aulast%3DWierz%26aufirst%3DG.%26aulast%3DBall%26aufirst%3DG.%26aulast%3DAkinlade%26aufirst%3DB.%26aulast%3DZeiher%26aufirst%3DB.%26aulast%3DKrueger%26aufirst%3DJ.%2BG.%26atitle%3DA%2520phase%25202a%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%252C%2520sequential%2520dose-escalation%2520study%2520to%2520evaluate%2520the%2520efficacy%2520and%2520safety%2520of%2520ASP015K%252C%2520a%2520novel%2520janus%2520kinase%2520inhibitor%252C%2520in%2520patients%2520with%2520moderate-to-severe%2520psoriasis%26jtitle%3DBr.%2520J.%2520Dermatol.%26date%3D2015%26volume%3D173%26spage%3D767%26epage%3D776%26doi%3D10.1111%2Fbjd.13745" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wrobleski, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moslin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spergel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kempson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokarski, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strnad, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zupa-Fernandez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shuster, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillooly, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heimrich, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruzanov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tredup, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulligan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arienzo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aranibar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiney, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chimalakonda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitts, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, D. S.</span></span> <span> </span><span class="NLM_article-title">Highly selective inhibition of tyrosine kinase 2 (TYK2) for the treatment of autoimmune diseases: discovery of the allosteric inhibitor BMS-986165</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">8973</span>– <span class="NLM_lpage">8995</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00444</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00444" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlyht7%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=8973-8995&author=S.+T.+Wrobleskiauthor=R.+Moslinauthor=S.+Linauthor=Y.+Zhangauthor=S.+Spergelauthor=J.+Kempsonauthor=J.+S.+Tokarskiauthor=J.+Strnadauthor=A.+Zupa-Fernandezauthor=L.+Chengauthor=D.+Shusterauthor=K.+Gilloolyauthor=X.+Yangauthor=E.+Heimrichauthor=K.+W.+McIntyreauthor=C.+Chaudhryauthor=J.+Khanauthor=M.+Ruzanovauthor=J.+Tredupauthor=D.+Mulliganauthor=D.+Xieauthor=H.+Sunauthor=C.+Huangauthor=C.+D%E2%80%99Arienzoauthor=N.+Aranibarauthor=M.+Chineyauthor=A.+Chimalakondaauthor=W.+J.+Pittsauthor=L.+Lombardoauthor=P.+H.+Carterauthor=J.+R.+Burkeauthor=D.+S.+Weinstein&title=Highly+selective+inhibition+of+tyrosine+kinase+2+%28TYK2%29+for+the+treatment+of+autoimmune+diseases%3A+discovery+of+the+allosteric+inhibitor+BMS-986165&doi=10.1021%2Facs.jmedchem.9b00444"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165</span></div><div class="casAuthors">Wrobleski, Stephen T.; Moslin, Ryan; Lin, Shuqun; Zhang, Yanlei; Spergel, Steven; Kempson, James; Tokarski, John S.; Strnad, Joann; Zupa-Fernandez, Adriana; Cheng, Lihong; Shuster, David; Gillooly, Kathleen; Yang, Xiaoxia; Heimrich, Elizabeth; McIntyre, Kim W.; Chaudhry, Charu; Khan, Javed; Ruzanov, Max; Tredup, Jeffrey; Mulligan, Dawn; Xie, Dianlin; Sun, Huadong; Huang, Christine; D'Arienzo, Celia; Aranibar, Nelly; Chiney, Manoj; Chimalakonda, Anjaneya; Pitts, William J.; Lombardo, Louis; Carter, Percy H.; Burke, James R.; Weinstein, David S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8973-8995</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Small mol. JAK inhibitors have emerged as a major therapeutic advancement in treating autoimmune diseases.  The discovery of isoform selective JAK inhibitors that traditionally target the catalytically active site of this kinase family has been a formidable challenge.  Our strategy to achieve high selectivity for TYK2 relies on targeting the TYK2 pseudokinase (JH2) domain.  Herein we report the late stage optimization efforts including a structure-guided design and water displacement strategy that led to the discovery of BMS-986165 (11, I) as a high affinity JH2 ligand and potent allosteric inhibitor of TYK2.  In addn. to unprecedented JAK isoform and kinome selectivity, I shows excellent pharmacokinetic properties with minimal profiling liabilities and is efficacious in several murine models of autoimmune disease.  On the basis of these findings, I appears differentiated from all other reported JAK inhibitors and has been advanced as the first pseudokinase-directed therapeutic in clin. development as an oral treatment for autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmA75TJmytlrVg90H21EOLACvtfcHk0ljAfzpn5C9gWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlyht7%252FP&md5=ca161c470df002b0bdd2bf6b19920ada</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00444%26sid%3Dliteratum%253Aachs%26aulast%3DWrobleski%26aufirst%3DS.%2BT.%26aulast%3DMoslin%26aufirst%3DR.%26aulast%3DLin%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DSpergel%26aufirst%3DS.%26aulast%3DKempson%26aufirst%3DJ.%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DStrnad%26aufirst%3DJ.%26aulast%3DZupa-Fernandez%26aufirst%3DA.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DShuster%26aufirst%3DD.%26aulast%3DGillooly%26aufirst%3DK.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DHeimrich%26aufirst%3DE.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DChaudhry%26aufirst%3DC.%26aulast%3DKhan%26aufirst%3DJ.%26aulast%3DRuzanov%26aufirst%3DM.%26aulast%3DTredup%26aufirst%3DJ.%26aulast%3DMulligan%26aufirst%3DD.%26aulast%3DXie%26aufirst%3DD.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DC.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%26aulast%3DAranibar%26aufirst%3DN.%26aulast%3DChiney%26aufirst%3DM.%26aulast%3DChimalakonda%26aufirst%3DA.%26aulast%3DPitts%26aufirst%3DW.%2BJ.%26aulast%3DLombardo%26aufirst%3DL.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DWeinstein%26aufirst%3DD.%2BS.%26atitle%3DHighly%2520selective%2520inhibition%2520of%2520tyrosine%2520kinase%25202%2520%2528TYK2%2529%2520for%2520the%2520treatment%2520of%2520autoimmune%2520diseases%253A%2520discovery%2520of%2520the%2520allosteric%2520inhibitor%2520BMS-986165%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D8973%26epage%3D8995%26doi%3D10.1021%2Facs.jmedchem.9b00444" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Musumeci, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanna, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greco, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giacchello, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fallacara, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amato, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schenone, S.</span></span> <span> </span><span class="NLM_article-title">Pyrrolo[2,3-d]pyrimidines active as BTK inhibitors</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">1305</span>– <span class="NLM_lpage">1318</span>, <span class="refDoi"> DOI: 10.1080/13543776.2017.1355908</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.1080%2F13543776.2017.1355908" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=28705083" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1Sgt7vK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=1305-1318&author=F.+Musumeciauthor=M.+Sannaauthor=C.+Grecoauthor=I.+Giacchelloauthor=A.+L.+Fallacaraauthor=R.+Amatoauthor=S.+Schenone&title=Pyrrolo%5B2%2C3-d%5Dpyrimidines+active+as+BTK+inhibitors&doi=10.1080%2F13543776.2017.1355908"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors</span></div><div class="casAuthors">Musumeci, Francesca; Sanna, Monica; Greco, Chiara; Giacchello, Ilaria; Fallacara, Anna Lucia; Amato, Rosario; Schenone, Silvia</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1305-1318</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Introduction: Btk is a tyrosine kinase dysregulated in several B-cell malignancies and autoimmune diseases, and this has given rise to a search for Btk inhibitors.  Nevertheless, only one Btk inhibitor, ibrutinib, has been approved to date, although other compds. are currently being evaluated in clin. trials or in preclinal stages.  Area covered: This review, after a brief introduction on Btk and its inhibitors already in clin. trials, focusses on pyrrolo[2,3-d]pyrimidine derivs. patented in the last five years as Btk inhibitors.  Indeed, the pyrrolo[2,3-d]pyrimidine scaffold, being a deaza-isostere of adenine, the nitrogenous base of ATP, is an actively pursued target for Btk inhibitors.  The patent literature since 2012 have been extensively investigated, pointing out the general features of the patented compds. and, when it is possible, their mechanism of action.  Expert opinion: The recently patented pyrrolo[2,3-d]pyrimidines, acting as reversible or irreversible inhibitors, showed a very interesting in vitro activity.  For this reason, the development of compds. endowed with this scaffold could afford a significant impact in the search for drug candidates for the treatment of immune diseases or B-cell malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPT0s7eVqXebVg90H21EOLACvtfcHk0ljAfzpn5C9gWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1Sgt7vK&md5=294c9b8bcafe6f7831187cb963f2f072</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1080%2F13543776.2017.1355908&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2017.1355908%26sid%3Dliteratum%253Aachs%26aulast%3DMusumeci%26aufirst%3DF.%26aulast%3DSanna%26aufirst%3DM.%26aulast%3DGreco%26aufirst%3DC.%26aulast%3DGiacchello%26aufirst%3DI.%26aulast%3DFallacara%26aufirst%3DA.%2BL.%26aulast%3DAmato%26aufirst%3DR.%26aulast%3DSchenone%26aufirst%3DS.%26atitle%3DPyrrolo%255B2%252C3-d%255Dpyrimidines%2520active%2520as%2520BTK%2520inhibitors%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2017%26volume%3D27%26spage%3D1305%26epage%3D1318%26doi%3D10.1080%2F13543776.2017.1355908" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuglstatter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondru, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, Z. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntosh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Litman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kocer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frauchiger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dewdney, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zecic, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taygerly, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarma, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabriel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, T. D.</span></span> <span> </span><span class="NLM_article-title">Structure-based drug design of RN486, a potent and selective bruton’s tyrosine kinase (BTK) inhibitor, for the treatment of rheumatoid arthritis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">512</span>– <span class="NLM_lpage">516</span>, <span class="refDoi"> DOI: 10.1021/jm500305p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500305p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlsl2qtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=512-516&author=Y.+Louauthor=X.+Hanauthor=A.+Kuglstatterauthor=R.+K.+Kondruauthor=Z.+K.+Sweeneyauthor=M.+Sothauthor=J.+McIntoshauthor=R.+Litmanauthor=J.+Suhauthor=B.+Kocerauthor=D.+Davisauthor=J.+Parkauthor=S.+Frauchigerauthor=N.+Dewdneyauthor=H.+Zecicauthor=J.+P.+Taygerlyauthor=K.+Sarmaauthor=J.+Hongauthor=R.+J.+Hillauthor=T.+Gabrielauthor=D.+M.+Goldsteinauthor=T.+D.+Owens&title=Structure-based+drug+design+of+RN486%2C+a+potent+and+selective+bruton%E2%80%99s+tyrosine+kinase+%28BTK%29+inhibitor%2C+for+the+treatment+of+rheumatoid+arthritis&doi=10.1021%2Fjm500305p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Drug Design of RN486, a Potent and Selective Bruton's Tyrosine Kinase (BTK) Inhibitor, for the Treatment of Rheumatoid Arthritis</span></div><div class="casAuthors">Lou, Yan; Han, Xiaochun; Kuglstatter, Andreas; Kondru, Rama K.; Sweeney, Zachary K.; Soth, Michael; McIntosh, Joel; Litman, Renee; Suh, Judy; Kocer, Buelent; Davis, Dana; Park, Jaehyeon; Frauchiger, Sandra; Dewdney, Nolan; Zecic, Hasim; Taygerly, Joshua P.; Sarma, Keshab; Hong, Junbae; Hill, Ronald J.; Gabriel, Tobias; Goldstein, David M.; Owens, Timothy D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">512-516</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Structure-based drug design was used to guide the optimization of a series of selective BTK inhibitors as potential treatments for Rheumatoid arthritis.  Highlights include the introduction of a benzyl alc. group and a fluorine substitution, each of which resulted in over 10-fold increase in activity.  Concurrent optimization of drug-like properties led to compd. I (RN486) (J. Pharmacol. Exp. Ther. 2012, 341, 90), which was selected for advanced preclin. characterization based on its favorable properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMdHX9-PE5I7Vg90H21EOLACvtfcHk0li7neUN-BZv2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlsl2qtb8%253D&md5=dc3c069b0e876f44846a30e3aa6a894a</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm500305p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500305p%26sid%3Dliteratum%253Aachs%26aulast%3DLou%26aufirst%3DY.%26aulast%3DHan%26aufirst%3DX.%26aulast%3DKuglstatter%26aufirst%3DA.%26aulast%3DKondru%26aufirst%3DR.%2BK.%26aulast%3DSweeney%26aufirst%3DZ.%2BK.%26aulast%3DSoth%26aufirst%3DM.%26aulast%3DMcIntosh%26aufirst%3DJ.%26aulast%3DLitman%26aufirst%3DR.%26aulast%3DSuh%26aufirst%3DJ.%26aulast%3DKocer%26aufirst%3DB.%26aulast%3DDavis%26aufirst%3DD.%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DFrauchiger%26aufirst%3DS.%26aulast%3DDewdney%26aufirst%3DN.%26aulast%3DZecic%26aufirst%3DH.%26aulast%3DTaygerly%26aufirst%3DJ.%2BP.%26aulast%3DSarma%26aufirst%3DK.%26aulast%3DHong%26aufirst%3DJ.%26aulast%3DHill%26aufirst%3DR.%2BJ.%26aulast%3DGabriel%26aufirst%3DT.%26aulast%3DGoldstein%26aufirst%3DD.%2BM.%26aulast%3DOwens%26aufirst%3DT.%2BD.%26atitle%3DStructure-based%2520drug%2520design%2520of%2520RN486%252C%2520a%2520potent%2520and%2520selective%2520bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%2520inhibitor%252C%2520for%2520the%2520treatment%2520of%2520rheumatoid%2520arthritis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D512%26epage%3D516%26doi%3D10.1021%2Fjm500305p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Geahlen, R. L.</span></span> <span> </span><span class="NLM_article-title">Getting SYK: spleen tyrosine kinase as a therapeutic target</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">414</span>– <span class="NLM_lpage">422</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2014.05.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.1016%2Fj.tips.2014.05.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=24975478" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVKhtbvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2014&pages=414-422&author=R.+L.+Geahlen&title=Getting+SYK%3A+spleen+tyrosine+kinase+as+a+therapeutic+target&doi=10.1016%2Fj.tips.2014.05.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Getting Syk: spleen tyrosine kinase as a therapeutic target</span></div><div class="casAuthors">Geahlen, Robert L.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">414-422</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Spleen tyrosine kinase (Syk) is a cytoplasmic protein tyrosine kinase well known for its ability to couple immune cell receptors to intracellular signaling pathways that regulate cellular responses to extracellular antigens and antigen-Ig (Ig) complexes of particular importance to the initiation of inflammatory responses.  Thus, Syk is an attractive target for therapeutic kinase inhibitors designed to ameliorate the symptoms and consequences of acute and chronic inflammation.  Its more recently recognized role as a promoter of cell survival in numerous cancer cell types ranging from leukemia to retinoblastoma has attracted considerable interest as a target for a new generation of anticancer drugs.  This review discusses the biol. processes in which Syk participates that have made this kinase such a compelling drug target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoE5Tut36Cq0LVg90H21EOLACvtfcHk0li7neUN-BZv2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVKhtbvK&md5=8b161de626d96f82c754eff4c5ef078f</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2014.05.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2014.05.007%26sid%3Dliteratum%253Aachs%26aulast%3DGeahlen%26aufirst%3DR.%2BL.%26atitle%3DGetting%2520SYK%253A%2520spleen%2520tyrosine%2520kinase%2520as%2520a%2520therapeutic%2520target%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2014%26volume%3D35%26spage%3D414%26epage%3D422%26doi%3D10.1016%2Fj.tips.2014.05.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manoli, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaw, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frutoz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epstein, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khawli, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theil, F. P.</span></span> <span> </span><span class="NLM_article-title">Unraveling the effect of immunogenicity on the PK/PD, efficacy, and safety of therapeutic proteins</span>. <i>J. Immunol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>2016</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">9</span>, <span class="refDoi"> DOI: 10.1155/2016/2342187</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.1155%2F2016%2F2342187" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2016&publication_year=2016&pages=1-9&author=A.+Smithauthor=H.+Manoliauthor=S.+Jawauthor=K.+Frutozauthor=A.+L.+Epsteinauthor=L.+A.+Khawliauthor=F.+P.+Theil&title=Unraveling+the+effect+of+immunogenicity+on+the+PK%2FPD%2C+efficacy%2C+and+safety+of+therapeutic+proteins&doi=10.1155%2F2016%2F2342187"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1155%2F2016%2F2342187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2016%252F2342187%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DManoli%26aufirst%3DH.%26aulast%3DJaw%26aufirst%3DS.%26aulast%3DFrutoz%26aufirst%3DK.%26aulast%3DEpstein%26aufirst%3DA.%2BL.%26aulast%3DKhawli%26aufirst%3DL.%2BA.%26aulast%3DTheil%26aufirst%3DF.%2BP.%26atitle%3DUnraveling%2520the%2520effect%2520of%2520immunogenicity%2520on%2520the%2520PK%252FPD%252C%2520efficacy%252C%2520and%2520safety%2520of%2520therapeutic%2520proteins%26jtitle%3DJ.%2520Immunol.%2520Res.%26date%3D2016%26volume%3D2016%26spage%3D1%26epage%3D9%26doi%3D10.1155%2F2016%2F2342187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Y.</span></span> <span> </span><span class="NLM_article-title">Peli1 negatively regulates noncanonical NF-kappaB signaling to restrain systemic lupus erythematosus</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1136</span>, <span class="refDoi"> DOI: 10.1038/s41467-018-03530-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.1038%2Fs41467-018-03530-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=29555915" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A280%3ADC%252BC1Mnislyruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=1136&author=J.+Liuauthor=X.+Huangauthor=S.+Haoauthor=Y.+Wangauthor=M.+Liuauthor=J.+Xuauthor=X.+Zhangauthor=T.+Yuauthor=S.+Ganauthor=D.+Daiauthor=X.+Luoauthor=Q.+Luauthor=C.+Maoauthor=Y.+Zhangauthor=N.+Shenauthor=B.+Liauthor=M.+Huangauthor=X.+Zhuauthor=J.+Jinauthor=X.+Chengauthor=S.+C.+Sunauthor=Y.+Xiao&title=Peli1+negatively+regulates+noncanonical+NF-kappaB+signaling+to+restrain+systemic+lupus+erythematosus&doi=10.1038%2Fs41467-018-03530-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Peli1 negatively regulates noncanonical NF-κB signaling to restrain systemic lupus erythematosus</span></div><div class="casAuthors">Liu Junli; Hao Shumeng; Wang Yan; Xu Jing; Zhang Xingli; Yu Tao; Gan Shucheng; Zhang Yanyun; Shen Nan; Xiao Yichuan; Huang Xinfang; Liu Manman; Dai Dongfang; Luo Xuan; Lu Qingyan; Mao Chaoming; Shen Nan; Li Bin; Huang Mingzhu; Zhu Xiaodong; Jin Jin; Cheng Xuhong; Sun Shao-Cong</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1136</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Systemic lupus erythematosus (SLE) is characterized by uncontrolled secretion of autoantibodies by plasma cells.  Although the functional importance of plasma cells and autoantibodies in SLE has been well established, the underlying molecular mechanisms of controlling autoantibody production remain poorly understood.  Here we show that Peli1 has a B cell-intrinsic function to protect against lupus-like autoimmunity in mice.  Peli1 deficiency in B cells induces autoantibody production via noncanonical NF-κB signaling.  Mechanically, Peli1 functions as an E3 ligase to associate with NF-κB inducing kinase (NIK) and mediates NIK Lys48 ubiquitination and degradation.  Overexpression of Peli1 inhibits noncanonical NF-κB activation and alleviates lupus-like disease.  In humans, PELI1 levels negatively correlate with disease severity in SLE patients.  Our findings establish Peli1 as a negative regulator of the noncanonical NF-κB pathway in the context of restraining the pathogenesis of lupus-like disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQqtNFjTmkpcCEJCPKhJPuqfW6udTcc2eaaAjz97DHI27ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mnislyruw%253D%253D&md5=01884e67948a03a898b3bda31788ecc9</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-03530-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-03530-3%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DHao%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DYu%26aufirst%3DT.%26aulast%3DGan%26aufirst%3DS.%26aulast%3DDai%26aufirst%3DD.%26aulast%3DLuo%26aufirst%3DX.%26aulast%3DLu%26aufirst%3DQ.%26aulast%3DMao%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DShen%26aufirst%3DN.%26aulast%3DLi%26aufirst%3DB.%26aulast%3DHuang%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DJin%26aufirst%3DJ.%26aulast%3DCheng%26aufirst%3DX.%26aulast%3DSun%26aufirst%3DS.%2BC.%26aulast%3DXiao%26aufirst%3DY.%26atitle%3DPeli1%2520negatively%2520regulates%2520noncanonical%2520NF-kappaB%2520signaling%2520to%2520restrain%2520systemic%2520lupus%2520erythematosus%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26spage%3D1136%26doi%3D10.1038%2Fs41467-018-03530-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brightbill, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suto, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaquiere, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramamoorthi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sujatha-Bhaskar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gogol, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castanedo, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haller, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesch, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bents, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Everett, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohli, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linge, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christian, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaochico, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berezhkovskiy, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modrusan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veliz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Townsend, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeVoss, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godemann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenzie, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hackney, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staben, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alaoui Ismaili, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghilardi, N.</span></span> <span> </span><span class="NLM_article-title">NF-kappaB inducing kinase is a therapeutic target for systemic lupus erythematosus</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">179</span>, <span class="refDoi"> DOI: 10.1038/s41467-017-02672-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.1038%2Fs41467-017-02672-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=29330524" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A280%3ADC%252BC1Mvgtlylug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=179&author=H.+D.+Brightbillauthor=E.+Sutoauthor=N.+Blaquiereauthor=N.+Ramamoorthiauthor=S.+Sujatha-Bhaskarauthor=E.+B.+Gogolauthor=G.+M.+Castanedoauthor=B.+T.+Jacksonauthor=Y.+C.+Kwonauthor=S.+Hallerauthor=J.+Leschauthor=K.+Bentsauthor=C.+Everettauthor=P.+B.+Kohliauthor=S.+Lingeauthor=L.+Christianauthor=K.+Barrettauthor=A.+Jaochicoauthor=L.+M.+Berezhkovskiyauthor=P.+W.+Fanauthor=Z.+Modrusanauthor=K.+Velizauthor=M.+J.+Townsendauthor=J.+DeVossauthor=A.+R.+Johnsonauthor=R.+Godemannauthor=W.+P.+Leeauthor=C.+D.+Austinauthor=B.+S.+McKenzieauthor=J.+A.+Hackneyauthor=J.+J.+Crawfordauthor=S.+T.+Stabenauthor=M.+H.+Alaoui+Ismailiauthor=L.+C.+Wuauthor=N.+Ghilardi&title=NF-kappaB+inducing+kinase+is+a+therapeutic+target+for+systemic+lupus+erythematosus&doi=10.1038%2Fs41467-017-02672-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">NF-κB inducing kinase is a therapeutic target for systemic lupus erythematosus</span></div><div class="casAuthors">Brightbill Hans D; Sujatha-Bhaskar Swathi; Gogol Emily B; Jackson Benjamin T; Christian Laura; Wu Lawren C; Ghilardi Nico; Suto Eric; Kwon Youngsu C; Lesch Justin; DeVoss Jason; Lee Wyne P; McKenzie Brent S; Blaquiere Nicole; Castanedo Georgette M; Crawford James J; Staben Steven T; Ramamoorthi Nandhini; Townsend Michael J; Haller Susan; Austin Cary D; Bents Karin; Linge Sandra; Godemann Robert; Everett Christine; Kohli Pawan Bir; Barrett Kathy; Johnson Adam R; Alaoui Ismaili Moulay H; Jaochico Allan; Berezhkovskiy Leonid M; Fan Peter W; Modrusan Zora; Veliz Kelli; Hackney Jason A</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">179</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">NF-κB-inducing kinase (NIK) mediates non-canonical NF-κB signaling downstream of multiple TNF family members, including BAFF, TWEAK, CD40, and OX40, which are implicated in the pathogenesis of systemic lupus erythematosus (SLE).  Here, we show that experimental lupus in NZB/W F1 mice can be treated with a highly selective and potent NIK small molecule inhibitor.  Both in vitro as well as in vivo, NIK inhibition recapitulates the pharmacological effects of BAFF blockade, which is clinically efficacious in SLE.  Furthermore, NIK inhibition also affects T cell parameters in the spleen and proinflammatory gene expression in the kidney, which may be attributable to inhibition of OX40 and TWEAK signaling, respectively.  As a consequence, NIK inhibition results in improved survival, reduced renal pathology, and lower proteinuria scores.  Collectively, our data suggest that NIK inhibition is a potential therapeutic approach for SLE.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRSowPmlnIWxaqcneEtCi92fW6udTcc2eaaAjz97DHI27ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mvgtlylug%253D%253D&md5=41a91514e1f4e8b2b44912ba6d6a4788</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Fs41467-017-02672-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-017-02672-0%26sid%3Dliteratum%253Aachs%26aulast%3DBrightbill%26aufirst%3DH.%2BD.%26aulast%3DSuto%26aufirst%3DE.%26aulast%3DBlaquiere%26aufirst%3DN.%26aulast%3DRamamoorthi%26aufirst%3DN.%26aulast%3DSujatha-Bhaskar%26aufirst%3DS.%26aulast%3DGogol%26aufirst%3DE.%2BB.%26aulast%3DCastanedo%26aufirst%3DG.%2BM.%26aulast%3DJackson%26aufirst%3DB.%2BT.%26aulast%3DKwon%26aufirst%3DY.%2BC.%26aulast%3DHaller%26aufirst%3DS.%26aulast%3DLesch%26aufirst%3DJ.%26aulast%3DBents%26aufirst%3DK.%26aulast%3DEverett%26aufirst%3DC.%26aulast%3DKohli%26aufirst%3DP.%2BB.%26aulast%3DLinge%26aufirst%3DS.%26aulast%3DChristian%26aufirst%3DL.%26aulast%3DBarrett%26aufirst%3DK.%26aulast%3DJaochico%26aufirst%3DA.%26aulast%3DBerezhkovskiy%26aufirst%3DL.%2BM.%26aulast%3DFan%26aufirst%3DP.%2BW.%26aulast%3DModrusan%26aufirst%3DZ.%26aulast%3DVeliz%26aufirst%3DK.%26aulast%3DTownsend%26aufirst%3DM.%2BJ.%26aulast%3DDeVoss%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DGodemann%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DW.%2BP.%26aulast%3DAustin%26aufirst%3DC.%2BD.%26aulast%3DMcKenzie%26aufirst%3DB.%2BS.%26aulast%3DHackney%26aufirst%3DJ.%2BA.%26aulast%3DCrawford%26aufirst%3DJ.%2BJ.%26aulast%3DStaben%26aufirst%3DS.%2BT.%26aulast%3DAlaoui%2BIsmaili%26aufirst%3DM.%2BH.%26aulast%3DWu%26aufirst%3DL.%2BC.%26aulast%3DGhilardi%26aufirst%3DN.%26atitle%3DNF-kappaB%2520inducing%2520kinase%2520is%2520a%2520therapeutic%2520target%2520for%2520systemic%2520lupus%2520erythematosus%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26spage%3D179%26doi%3D10.1038%2Fs41467-017-02672-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Castanedo, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaquiere, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beresini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bravo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brightbill, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Everett, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godemann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gogol, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hymowitz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kayagaki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohli, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knuppel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraemer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loke, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McEwan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montalbetti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinbacher, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sujatha-Bhaskar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staben, S. T.</span></span> <span> </span><span class="NLM_article-title">Structure-based design of tricyclic NF-kappaB inducing kinase (NIK) inhibitors that have high selectivity over phosphoinositide-3-kinase (PI3K)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">627</span>– <span class="NLM_lpage">640</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01363</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01363" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFCgs7bK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=627-640&author=G.+M.+Castanedoauthor=N.+Blaquiereauthor=M.+Beresiniauthor=B.+Bravoauthor=H.+Brightbillauthor=J.+Chenauthor=H.+F.+Cuiauthor=C.+Eigenbrotauthor=C.+Everettauthor=J.+Fengauthor=R.+Godemannauthor=E.+Gogolauthor=S.+Hymowitzauthor=A.+Johnsonauthor=N.+Kayagakiauthor=P.+B.+Kohliauthor=K.+Knuppelauthor=J.+Kraemerauthor=S.+Krugerauthor=P.+Lokeauthor=P.+McEwanauthor=C.+Montalbettiauthor=D.+A.+Robertsauthor=M.+Smithauthor=S.+Steinbacherauthor=S.+Sujatha-Bhaskarauthor=R.+Takahashiauthor=X.+Wangauthor=L.+C.+Wuauthor=Y.+Zhangauthor=S.+T.+Staben&title=Structure-based+design+of+tricyclic+NF-kappaB+inducing+kinase+%28NIK%29+inhibitors+that+have+high+selectivity+over+phosphoinositide-3-kinase+%28PI3K%29&doi=10.1021%2Facs.jmedchem.6b01363"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Design of Tricyclic NF-κB Inducing Kinase (NIK) Inhibitors That Have High Selectivity over Phosphoinositide-3-kinase (PI3K)</span></div><div class="casAuthors">Castanedo, Georgette M.; Blaquiere, Nicole; Beresini, Maureen; Bravo, Brandon; Brightbill, Hans; Chen, Jacob; Cui, Hai-Feng; Eigenbrot, Charles; Everett, Christine; Feng, Jianwen; Godemann, Robert; Gogol, Emily; Hymowitz, Sarah; Johnson, Adam; Kayagaki, Nobuhiko; Kohli, Pawan Bir; Knuppel, Kathleen; Kraemer, Joachim; Kruger, Susan; Loke, Pui; McEwan, Paul; Montalbetti, Christian; Roberts, David A.; Smith, Myron; Steinbacher, Stefan; Sujatha-Bhaskar, Swathi; Takahashi, Ryan; Wang, Xiaolu; Wu, Lawren C.; Zhang, Yamin; Staben, Steven T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">627-640</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The authors report a structure-guided optimization of a novel series of NF-κB inducing kinase (NIK) inhibitors.  Starting from a modestly potent, low mol. wt. lead, activity was improved by designing a type I1/2 binding mode that accessed a back pocket past the methionine-471 gatekeeper.  Divergent binding modes in NIK and PI3K were used to dampen PI3K-inhibition while maintaining NIK inhibition within these series.  Potent compds. were discovered that selectively inhibit the nuclear translocation of NF-kB2 (p52/REL-B) but not canonical NF-kB1 (REL-A/p50).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrws-sPXJiSfLVg90H21EOLACvtfcHk0lhbQp3E_MhsxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFCgs7bK&md5=316b70f51a5b800ba810082d0b3862da</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01363&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01363%26sid%3Dliteratum%253Aachs%26aulast%3DCastanedo%26aufirst%3DG.%2BM.%26aulast%3DBlaquiere%26aufirst%3DN.%26aulast%3DBeresini%26aufirst%3DM.%26aulast%3DBravo%26aufirst%3DB.%26aulast%3DBrightbill%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DCui%26aufirst%3DH.%2BF.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DEverett%26aufirst%3DC.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DGodemann%26aufirst%3DR.%26aulast%3DGogol%26aufirst%3DE.%26aulast%3DHymowitz%26aufirst%3DS.%26aulast%3DJohnson%26aufirst%3DA.%26aulast%3DKayagaki%26aufirst%3DN.%26aulast%3DKohli%26aufirst%3DP.%2BB.%26aulast%3DKnuppel%26aufirst%3DK.%26aulast%3DKraemer%26aufirst%3DJ.%26aulast%3DKruger%26aufirst%3DS.%26aulast%3DLoke%26aufirst%3DP.%26aulast%3DMcEwan%26aufirst%3DP.%26aulast%3DMontalbetti%26aufirst%3DC.%26aulast%3DRoberts%26aufirst%3DD.%2BA.%26aulast%3DSmith%26aufirst%3DM.%26aulast%3DSteinbacher%26aufirst%3DS.%26aulast%3DSujatha-Bhaskar%26aufirst%3DS.%26aulast%3DTakahashi%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DL.%2BC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DStaben%26aufirst%3DS.%2BT.%26atitle%3DStructure-based%2520design%2520of%2520tricyclic%2520NF-kappaB%2520inducing%2520kinase%2520%2528NIK%2529%2520inhibitors%2520that%2520have%2520high%2520selectivity%2520over%2520phosphoinositide-3-kinase%2520%2528PI3K%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D627%26epage%3D640%26doi%3D10.1021%2Facs.jmedchem.6b01363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blaquiere, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castanedo, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burch, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berezhkovskiy, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brightbill, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghilardi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godemann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gogol, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grabbe, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hole, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hymowitz, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alaoui
Ismaili, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McEwan, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenzie, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvestre, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suto, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sujatha-Bhaskar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staben, S. T.</span></span> <span> </span><span class="NLM_article-title">Scaffold-hopping approach to discover potent, selective, and efficacious inhibitors of NF-kappaB inducing kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">6801</span>– <span class="NLM_lpage">6813</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00678</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00678" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1Snu73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=6801-6813&author=N.+Blaquiereauthor=G.+M.+Castanedoauthor=J.+D.+Burchauthor=L.+M.+Berezhkovskiyauthor=H.+Brightbillauthor=S.+Brownauthor=C.+Chanauthor=P.+C.+Chiangauthor=J.+J.+Crawfordauthor=T.+Dongauthor=P.+Fanauthor=J.+Fengauthor=N.+Ghilardiauthor=R.+Godemannauthor=E.+Gogolauthor=A.+Grabbeauthor=A.+J.+Holeauthor=B.+Huauthor=S.+G.+Hymowitzauthor=M.+H.+Alaoui%0AIsmailiauthor=H.+Leauthor=P.+Leeauthor=W.+Leeauthor=X.+Linauthor=N.+Liuauthor=P.+A.+McEwanauthor=B.+McKenzieauthor=H.+L.+Silvestreauthor=E.+Sutoauthor=S.+Sujatha-Bhaskarauthor=G.+Wuauthor=L.+C.+Wuauthor=Y.+Zhangauthor=Z.+Zhongauthor=S.+T.+Staben&title=Scaffold-hopping+approach+to+discover+potent%2C+selective%2C+and+efficacious+inhibitors+of+NF-kappaB+inducing+kinase&doi=10.1021%2Facs.jmedchem.8b00678"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Scaffold-Hopping Approach To Discover Potent, Selective, and Efficacious Inhibitors of NF-κB Inducing Kinase</span></div><div class="casAuthors">Blaquiere, Nicole; Castanedo, Georgette M.; Burch, Jason D.; Berezhkovskiy, Leonid M.; Brightbill, Hans; Brown, Suzanne; Chan, Connie; Chiang, Po-Chang; Crawford, James J.; Dong, Teresa; Fan, Peter; Feng, Jianwen; Ghilardi, Nico; Godemann, Robert; Gogol, Emily; Grabbe, Alice; Hole, Alison J.; Hu, Baihua; Hymowitz, Sarah G.; Alaoui Ismaili, Moulay Hicham; Le, Hoa; Lee, Patrick; Lee, Wyne; Lin, Xingyu; Liu, Ning; McEwan, Paul A.; McKenzie, Brent; Silvestre, Hernani L.; Suto, Eric; Sujatha-Bhaskar, Swathi; Wu, Guosheng; Wu, Lawren C.; Zhang, Yamin; Zhong, Zoe; Staben, Steven T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6801-6813</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">NF-κB-inducing kinase (NIK) is a protein kinase central to the noncanonical NF-κB pathway downstream from multiple TNF receptor family members, including BAFF, which has been assocd. with B cell survival and maturation, dendritic cell activation, secondary lymphoid organ development, and bone metab.  We report herein the discovery of lead chem. series of NIK inhibitors that were identified through a scaffold-hopping strategy using structure-based design.  Electronic and steric properties of lead compds. were modified to address glutathione conjugation and amide hydrolysis.  These highly potent compds. exhibited selective inhibition of LTβR-dependent p52 translocation and transcription of NF-κB2 related genes.  Compd. 4f is shown to have a favorable pharmacokinetic profile across species and to inhibit BAFF-induced B cell survival in vitro and reduce splenic marginal zone B cells in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5FXb6VJDRqbVg90H21EOLACvtfcHk0lgwwA2ZllVSwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1Snu73P&md5=5ff01b23d827b3d96078a17fff885aea</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00678&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00678%26sid%3Dliteratum%253Aachs%26aulast%3DBlaquiere%26aufirst%3DN.%26aulast%3DCastanedo%26aufirst%3DG.%2BM.%26aulast%3DBurch%26aufirst%3DJ.%2BD.%26aulast%3DBerezhkovskiy%26aufirst%3DL.%2BM.%26aulast%3DBrightbill%26aufirst%3DH.%26aulast%3DBrown%26aufirst%3DS.%26aulast%3DChan%26aufirst%3DC.%26aulast%3DChiang%26aufirst%3DP.%2BC.%26aulast%3DCrawford%26aufirst%3DJ.%2BJ.%26aulast%3DDong%26aufirst%3DT.%26aulast%3DFan%26aufirst%3DP.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DGhilardi%26aufirst%3DN.%26aulast%3DGodemann%26aufirst%3DR.%26aulast%3DGogol%26aufirst%3DE.%26aulast%3DGrabbe%26aufirst%3DA.%26aulast%3DHole%26aufirst%3DA.%2BJ.%26aulast%3DHu%26aufirst%3DB.%26aulast%3DHymowitz%26aufirst%3DS.%2BG.%26aulast%3DAlaoui%2BIsmaili%26aufirst%3DM.%2BH.%26aulast%3DLe%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DP.%26aulast%3DLee%26aufirst%3DW.%26aulast%3DLin%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DN.%26aulast%3DMcEwan%26aufirst%3DP.%2BA.%26aulast%3DMcKenzie%26aufirst%3DB.%26aulast%3DSilvestre%26aufirst%3DH.%2BL.%26aulast%3DSuto%26aufirst%3DE.%26aulast%3DSujatha-Bhaskar%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DWu%26aufirst%3DL.%2BC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZhong%26aufirst%3DZ.%26aulast%3DStaben%26aufirst%3DS.%2BT.%26atitle%3DScaffold-hopping%2520approach%2520to%2520discover%2520potent%252C%2520selective%252C%2520and%2520efficacious%2520inhibitors%2520of%2520NF-kappaB%2520inducing%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D6801%26epage%3D6813%26doi%3D10.1021%2Facs.jmedchem.8b00678" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Willmann, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sacco, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martins, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garncarz, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krolo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boztug, K.</span></span> <span> </span><span class="NLM_article-title">Expanding the interactome of the noncanonical NF-kappaB signaling pathway</span>. <i>J. Proteome Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">2900</span>– <span class="NLM_lpage">2909</span>, <span class="refDoi"> DOI: 10.1021/acs.jproteome.5b01004</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jproteome.5b01004" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFKksrvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=2900-2909&author=K.+L.+Willmannauthor=R.+Saccoauthor=R.+Martinsauthor=W.+Garncarzauthor=A.+Kroloauthor=S.+Knappauthor=K.+L.+Bennettauthor=K.+Boztug&title=Expanding+the+interactome+of+the+noncanonical+NF-kappaB+signaling+pathway&doi=10.1021%2Facs.jproteome.5b01004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Expanding the Interactome of the Noncanonical NF-κB Signaling Pathway</span></div><div class="casAuthors">Willmann, Katharina L.; Sacco, Roberto; Martins, Rui; Garncarz, Wojciech; Krolo, Ana; Knapp, Sylvia; Bennett, Keiryn L.; Boztug, Kaan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Proteome Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2900-2909</span>CODEN:
                <span class="NLM_cas:coden">JPROBS</span>;
        ISSN:<span class="NLM_cas:issn">1535-3893</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">NF-κB signaling is a central pathway of immunity and integrates signal transduction upon a wide array of inflammatory stimuli.  Noncanonical NF-κB signaling is activated by a small subset of TNF family receptors and characterized by NF-κB2/p52 transcriptional activity.  The medical relevance of this pathway has recently re-emerged from the discovery of primary immunodeficiency patients that have loss-of-function mutations in the MAP3K14 gene encoding NIK.  Nevertheless, knowledge of protein interactions that regulate noncanonical NF-κB signaling is sparse.  Here we report a detailed state-of-the-art mass spectrometry-based protein-protein interaction network including the noncanonical NF-κB signaling nodes TRAF2, TRAF3, IKKα, NIK, and NF-κB2/p100.  The value of the data set was confirmed by the identification of interactions already known to regulate this pathway.  In addn., a remarkable no. of novel interactors were identified.  We provide validation of the novel NIK and IKKα interactor FKBP8, which may regulate processes downstream of noncanonical NF-κB signaling.  To understand perturbed noncanonical NF-κB signaling in the context of misregulated NIK in disease, we also provide a differential interactome of NIK mutants that cause immunodeficiency.  Altogether, this data set not only provides crit. insight into how protein-protein interactions can regulate immune signaling but also offers a novel resource on noncanonical NF-κB signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPK89IMi9DnbVg90H21EOLACvtfcHk0lgwwA2ZllVSwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFKksrvP&md5=d81f8e0ca9fb8b7cd5ab57980d4ab36e</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Facs.jproteome.5b01004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jproteome.5b01004%26sid%3Dliteratum%253Aachs%26aulast%3DWillmann%26aufirst%3DK.%2BL.%26aulast%3DSacco%26aufirst%3DR.%26aulast%3DMartins%26aufirst%3DR.%26aulast%3DGarncarz%26aufirst%3DW.%26aulast%3DKrolo%26aufirst%3DA.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DBennett%26aufirst%3DK.%2BL.%26aulast%3DBoztug%26aufirst%3DK.%26atitle%3DExpanding%2520the%2520interactome%2520of%2520the%2520noncanonical%2520NF-kappaB%2520signaling%2520pathway%26jtitle%3DJ.%2520Proteome%2520Res.%26date%3D2016%26volume%3D15%26spage%3D2900%26epage%3D2909%26doi%3D10.1021%2Facs.jproteome.5b01004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Noort, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Zoest, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weijers, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koolwijk, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maracle, C. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novack, D. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siemerink, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlingemann, R. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tak, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tas, S. W.</span></span> <span> </span><span class="NLM_article-title">NF-kappaB-inducing kinase is a key regulator of inflammation-induced and tumour-associated angiogenesis</span>. <i>J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>234</i></span>,  <span class="NLM_fpage">375</span>– <span class="NLM_lpage">385</span>, <span class="refDoi"> DOI: 10.1002/path.4403</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.1002%2Fpath.4403" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=25043127" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslCqtrnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=234&publication_year=2014&pages=375-385&author=A.+R.+Noortauthor=K.+P.+van+Zoestauthor=E.+M.+Weijersauthor=P.+Koolwijkauthor=C.+X.+Maracleauthor=D.+V.+Novackauthor=M.+J.+Siemerinkauthor=R.+O.+Schlingemannauthor=P.+P.+Takauthor=S.+W.+Tas&title=NF-kappaB-inducing+kinase+is+a+key+regulator+of+inflammation-induced+and+tumour-associated+angiogenesis&doi=10.1002%2Fpath.4403"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">NF-κB-inducing kinase is a key regulator of inflammation-induced and tumour-associated angiogenesis</span></div><div class="casAuthors">Noort, Ae R.; van Zoest, Katinka PM; Weijers, Ester M.; Koolwijk, Pieter; Maracle, Chrissta X.; Novack, Deborah V.; Siemerink, Martin J.; Schlingemann, Reinier O.; Tak, Paul P.; Tas, Sander W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pathology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">234</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">375-385</span>CODEN:
                <span class="NLM_cas:coden">JPTLAS</span>;
        ISSN:<span class="NLM_cas:issn">1096-9896</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Angiogenesis is essential during development and in pathol. conditions such as chronic inflammation and cancer progression.  Inhibition of angiogenesis by targeting vascular endothelial growth factor (VEGF) blocks disease progression, but most patients eventually develop resistance which may result from compensatory signalling pathways.  In endothelial cells (ECs), expression of the pro-angiogenic chemokine CXCL12 is regulated by non-canonical nuclear factor (NF)-κB signalling.  Here, we report that NF-κB-inducing kinase (NIK) and subsequent non-canonical NF-κB signalling regulate both inflammation-induced and tumor-assocd. angiogenesis.  NIK is highly expressed in endothelial cells (ECs) in tumor tissues and inflamed rheumatoid arthritis synovial tissue.  Furthermore, non-canonical NF-κB signalling in human microvascular ECs significantly enhanced vascular tube formation, which was completely blocked by siRNA targeting NIK.  Interestingly, Nik-/- mice exhibited normal angiogenesis during development and unaltered TNFα- or VEGF-induced angiogenic responses, whereas angiogenesis induced by non-canonical NF-κB stimuli was significantly reduced.  In addn., angiogenesis in exptl. arthritis and a murine tumor model was severely impaired in these mice.  These studies provide evidence for a role of non-canonical NF-κB signalling in pathol. angiogenesis, and identify NIK as a potential therapeutic target in chronic inflammatory diseases and tumor neoangiogenesis. © 2014 The Authors.  The Journal of Pathol. published by John Wiley & Sons Ltd on behalf of Pathol. Society of Great Britain and Ireland.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGmctnhHR1SrVg90H21EOLACvtfcHk0lj-pot7edJRng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslCqtrnE&md5=94bdaa642c3246981d16f79958dbc5d9</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1002%2Fpath.4403&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpath.4403%26sid%3Dliteratum%253Aachs%26aulast%3DNoort%26aufirst%3DA.%2BR.%26aulast%3Dvan%2BZoest%26aufirst%3DK.%2BP.%26aulast%3DWeijers%26aufirst%3DE.%2BM.%26aulast%3DKoolwijk%26aufirst%3DP.%26aulast%3DMaracle%26aufirst%3DC.%2BX.%26aulast%3DNovack%26aufirst%3DD.%2BV.%26aulast%3DSiemerink%26aufirst%3DM.%2BJ.%26aulast%3DSchlingemann%26aufirst%3DR.%2BO.%26aulast%3DTak%26aufirst%3DP.%2BP.%26aulast%3DTas%26aufirst%3DS.%2BW.%26atitle%3DNF-kappaB-inducing%2520kinase%2520is%2520a%2520key%2520regulator%2520of%2520inflammation-induced%2520and%2520tumour-associated%2520angiogenesis%26jtitle%3DJ.%2520Pathol.%26date%3D2014%26volume%3D234%26spage%3D375%26epage%3D385%26doi%3D10.1002%2Fpath.4403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Janda, A.</span>; <span class="NLM_string-name">Rizzi, M.</span></span> <span> </span><span class="NLM_article-title">Humoral primary immunodeficiency and autoimmune and inflammatory manifestations</span>.  <i>Humoral Primary Immunodeficiencies</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Elios, M. M.</span>, <span class="NLM_string-name">Rizzi, M.</span></span>, Eds.; <span class="NLM_publisher-name">Springer International Publishing</span>: <span class="NLM_publisher-loc">Cham, Switzerland</span>, <span class="NLM_year">2019</span>; pp  <span class="NLM_fpage">325</span>– <span class="NLM_lpage">346</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.1007%2F978-3-319-91785-6_24" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&pages=325-346&author=A.+Janda&author=M.+Rizziauthor=M.+M.+D%E2%80%99Elios&author=M.+Rizzi&title=Humoral+Primary+Immunodeficiencies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1007%2F978-3-319-91785-6_24&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-3-319-91785-6_24%26sid%3Dliteratum%253Aachs%26aulast%3DJanda%26aufirst%3DA.%26atitle%3DHumoral%2520primary%2520immunodeficiency%2520and%2520autoimmune%2520and%2520inflammatory%2520manifestations%26btitle%3DHumoral%2520Primary%2520Immunodeficiencies%26aulast%3DD%25E2%2580%2599Elios%26aufirst%3DM.%2BM.%26pub%3DSpringer%2520International%2520Publishing%26date%3D2019%26spage%3D325%26epage%3D346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Valino-Rivas, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaquero, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sucunza, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutierrez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanz, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fresno, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortiz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Nino, M. D.</span></span> <span> </span><span class="NLM_article-title">NIK as a druggable mediator of tissue injury</span>. <i>Trends Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">341</span>– <span class="NLM_lpage">360</span>, <span class="refDoi"> DOI: 10.1016/j.molmed.2019.02.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.1016%2Fj.molmed.2019.02.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=30926358" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC1MXltVeru7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2019&pages=341-360&author=L.+Valino-Rivasauthor=J.+J.+Vaqueroauthor=D.+Sucunzaauthor=S.+Gutierrezauthor=A.+B.+Sanzauthor=M.+Fresnoauthor=A.+Ortizauthor=M.+D.+Sanchez-Nino&title=NIK+as+a+druggable+mediator+of+tissue+injury&doi=10.1016%2Fj.molmed.2019.02.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">NIK as a Druggable Mediator of Tissue Injury</span></div><div class="casAuthors">Valino-Rivas, Lara; Vaquero, Juan Jose; Sucunza, David; Gutierrez, Sara; Sanz, Ana B.; Fresno, Manuel; Ortiz, Alberto; Sanchez-Nino, Maria Dolores</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Molecular Medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">341-360</span>CODEN:
                <span class="NLM_cas:coden">TMMRCY</span>;
        ISSN:<span class="NLM_cas:issn">1471-4914</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">NF-κB-inducing kinase (NIK, MAP3K14) is best known as the apical kinase that triggers non-canonical NF-κB activation and by its role in the immune system.  Recent data indicate a role for NIK expressed by non-lymphoid cells in cancer, kidney disease, liver injury, glucose homeostasis, osteosarcopenia, vascular calcification, hematopoiesis, and endothelial function.  The spectrum of NIK-assocd. disease now ranges from immunodeficiency (when NIK is defective) to autoimmunity, cancer, sterile inflammation, fibrosis, and metabolic disease when NIK is overactive.  The development of novel small-mol. NIK inhibitors has paved the way to test NIK targeting to treat disease in vivo, and may eventually lead to NIK targeting in the clinic.  In addn., NIK activators are being explored for specific conditions such as myeloid leukemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpM16Ar9Bc8fbVg90H21EOLACvtfcHk0lht3hYerEGGwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXltVeru7o%253D&md5=e47fa848ac97b68c83c390aba8d99027</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.molmed.2019.02.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molmed.2019.02.005%26sid%3Dliteratum%253Aachs%26aulast%3DValino-Rivas%26aufirst%3DL.%26aulast%3DVaquero%26aufirst%3DJ.%2BJ.%26aulast%3DSucunza%26aufirst%3DD.%26aulast%3DGutierrez%26aufirst%3DS.%26aulast%3DSanz%26aufirst%3DA.%2BB.%26aulast%3DFresno%26aufirst%3DM.%26aulast%3DOrtiz%26aufirst%3DA.%26aulast%3DSanchez-Nino%26aufirst%3DM.%2BD.%26atitle%3DNIK%2520as%2520a%2520druggable%2520mediator%2520of%2520tissue%2520injury%26jtitle%3DTrends%2520Mol.%2520Med.%26date%3D2019%26volume%3D25%26spage%3D341%26epage%3D360%26doi%3D10.1016%2Fj.molmed.2019.02.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omary, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rui, L.</span></span> <span> </span><span class="NLM_article-title">Mouse hepatocyte overexpression of NF-kappaB-inducing kinase (NIK) triggers fatal macrophage-dependent liver injury and fibrosis</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">2065</span>– <span class="NLM_lpage">2076</span>, <span class="refDoi"> DOI: 10.1002/hep.27348</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.1002%2Fhep.27348" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=25088600" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVCis73L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2014&pages=2065-2076&author=H.+Shenauthor=L.+Shengauthor=Z.+Chenauthor=L.+Jiangauthor=H.+Suauthor=L.+Yinauthor=M.+B.+Omaryauthor=L.+Rui&title=Mouse+hepatocyte+overexpression+of+NF-kappaB-inducing+kinase+%28NIK%29+triggers+fatal+macrophage-dependent+liver+injury+and+fibrosis&doi=10.1002%2Fhep.27348"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Mouse hepatocyte overexpression of NF-κB-inducing kinase (NIK) triggers fatal macrophage-dependent liver injury and fibrosis</span></div><div class="casAuthors">Shen, Hong; Sheng, Liang; Chen, Zheng; Jiang, Lin; Su, Haoran; Yin, Lei; Omary, M. Bishr; Rui, Liangyou</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2065-2076</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Damaged, necrotic, or apoptotic hepatocytes release damage-assocd. mol. patterns that initiate sterile inflammation, and liver inflammation drives liver injury and fibrosis.  Here we identified hepatic nuclear factor kappa B (NF-κB)-inducing kinase (NIK), a Ser/Thr kinase, as a novel trigger of fatal liver inflammation.  NIK is activated by a broad spectrum of stimuli.  It was up-regulated in injured livers in both mice and humans.  In primary mouse hepatocytes, NIK overexpression stimulated, independently of cell injury and death, release of numerous chemokines and cytokines that activated bone marrow-derived macrophages (BMDMs).  BMDMs in turn secreted proapoptotic mols. that stimulated hepatocyte apoptosis.  Hepatocyte-specific expression of the NIK transgene triggered massive liver inflammation, oxidative stress, hepatocyte apoptosis, and liver fibrosis, leading to wt. loss, hypoglycemia, and death.  Depletion of Kupffer cells/macrophages reversed NIK-induced liver destruction and death.  Conclusion: the hepatocyte NIK-liver immune cell axis promotes liver inflammation, injury, and fibrosis, thus driving liver disease progression. (Hepatol. 2014;60:2064-2075).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgV39v_Rc3ObVg90H21EOLACvtfcHk0lht3hYerEGGwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVCis73L&md5=7aeccfee609708edca22548eab6eb6b0</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1002%2Fhep.27348&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.27348%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DH.%26aulast%3DSheng%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DJiang%26aufirst%3DL.%26aulast%3DSu%26aufirst%3DH.%26aulast%3DYin%26aufirst%3DL.%26aulast%3DOmary%26aufirst%3DM.%2BB.%26aulast%3DRui%26aufirst%3DL.%26atitle%3DMouse%2520hepatocyte%2520overexpression%2520of%2520NF-kappaB-inducing%2520kinase%2520%2528NIK%2529%2520triggers%2520fatal%2520macrophage-dependent%2520liver%2520injury%2520and%2520fibrosis%26jtitle%3DHepatology%26date%3D2014%26volume%3D60%26spage%3D2065%26epage%3D2076%26doi%3D10.1002%2Fhep.27348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ren, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rui, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span> <span> </span><span class="NLM_article-title">A small-molecule inhibitor of NF-kappaB-inducing kinase (NIK) protects liver from toxin-induced inflammation, oxidative stress, and injury</span>. <i>FASEB J.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">711</span>– <span class="NLM_lpage">718</span>, <span class="refDoi"> DOI: 10.1096/fj.201600840R</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.1096%2Ffj.201600840R" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=27871061" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpsleit78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2017&pages=711-718&author=X.+Renauthor=X.+Liauthor=L.+Jiaauthor=D.+Chenauthor=H.+Houauthor=L.+Ruiauthor=Y.+Zhaoauthor=Z.+Chen&title=A+small-molecule+inhibitor+of+NF-kappaB-inducing+kinase+%28NIK%29+protects+liver+from+toxin-induced+inflammation%2C+oxidative+stress%2C+and+injury&doi=10.1096%2Ffj.201600840R"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">A small-molecule inhibitor of NF-κB-inducing kinase (NIK) protects liver from toxin-induced inflammation, oxidative stress, and injury</span></div><div class="casAuthors">Ren, Xiaomeng; Li, Xinzhi; Jia, Linna; Chen, Deheng; Hou, Hai; Rui, Liangyou; Zhao, Yujun; Chen, Zheng</div><div class="citationInfo"><span class="NLM_cas:title">FASEB Journal</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">711-718</span>CODEN:
                <span class="NLM_cas:coden">FAJOEC</span>;
        ISSN:<span class="NLM_cas:issn">0892-6638</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">Potent and selective chem. probes are valuable tools for discovery of novel treatments for human diseases.  NF-κB-inducing kinase (NIK) is a key trigger in the development of liver injury and fibrosis.  Whether inhibition of NIK activity by chem. probes ameliorates liver inflammation and injury is largely unknown.  In this study, a small-mol. inhibitor of NIK, B022, was found to be a potent and selective chem. probe for liver inflammation and injury.  B022 inhibited the NIK signaling pathway, including NIK-induced p100-to-p52 processing and inflammatory gene expression, both in vitro and in vivo.  Furthermore, in vivo administration of B022 protected against not only NIK but also CCl4-induced liver inflammation and injury.  Our data suggest that inhibition of NIK is a novel strategy for treatment of liver inflammation, oxidative stress, and injury.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAtVxDU8yQibVg90H21EOLACvtfcHk0lhiLc7zDtSTSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpsleit78%253D&md5=84f05fa8fdf2fcfe79d167827ceea738</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1096%2Ffj.201600840R&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1096%252Ffj.201600840R%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DJia%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DHou%26aufirst%3DH.%26aulast%3DRui%26aufirst%3DL.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DZ.%26atitle%3DA%2520small-molecule%2520inhibitor%2520of%2520NF-kappaB-inducing%2520kinase%2520%2528NIK%2529%2520protects%2520liver%2520from%2520toxin-induced%2520inflammation%252C%2520oxidative%2520stress%252C%2520and%2520injury%26jtitle%3DFASEB%2520J.%26date%3D2017%26volume%3D31%26spage%3D711%26epage%3D718%26doi%3D10.1096%2Ffj.201600840R" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Etemadi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chopin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderton, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanzer, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rickard, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abeysekera, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spall, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hla, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitson, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonder, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ernst, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smyth, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaux, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nutt, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nachbur, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silke, J.</span></span> <span> </span><span class="NLM_article-title">TRAF2 regulates TNF and NF-kappaB signalling to suppress apoptosis and skin inflammation independently of sphingosine kinase 1</span>. <i>eLife</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>4</i></span>, <span class="NLM_elocation-id">e10592</span> <span class="refDoi"> DOI: 10.7554/eLife.10592</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.7554%2FeLife.10592" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=26701909" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlvVClsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2015&author=N.+Etemadiauthor=M.+Chopinauthor=H.+Andertonauthor=M.+C.+Tanzerauthor=J.+A.+Rickardauthor=W.+Abeysekeraauthor=C.+Hallauthor=S.+K.+Spallauthor=B.+Wangauthor=Y.+Xiongauthor=T.+Hlaauthor=S.+M.+Pitsonauthor=C.+S.+Bonderauthor=W.+W.+Wongauthor=M.+Ernstauthor=G.+K.+Smythauthor=D.+L.+Vauxauthor=S.+L.+Nuttauthor=U.+Nachburauthor=J.+Silke&title=TRAF2+regulates+TNF+and+NF-kappaB+signalling+to+suppress+apoptosis+and+skin+inflammation+independently+of+sphingosine+kinase+1&doi=10.7554%2FeLife.10592"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">TRAF2 regulates TNF and NF-κB signalling to suppress apoptosis and skin inflammation independently of sphingosine kinase-1</span></div><div class="casAuthors">Etemadi, Nima; Chopin, Michael; Anderton, Holly; Tanzer, Maria C.; Rickard, James A.; Abeysekera, Waruni; Hall, Cathrine; Spall, Sukhdeep K.; Wang, Bing; Xiong, Yuquan; Hla, Timothy; Pitson, Stuart M.; Bonder, Claudine S.; Wei-Lynn Wong, Wendy; Ernst, Matthias; Smyth, Gordon; Vaux, David L.; Nutt, Stephen L.; Nachbur, Ueli; Silke, John</div><div class="citationInfo"><span class="NLM_cas:title">eLife</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">e10592/1-e10592/27</span>CODEN:
                <span class="NLM_cas:coden">ELIFA8</span>;
        ISSN:<span class="NLM_cas:issn">2050-084X</span>.
    
            (<span class="NLM_cas:orgname">eLife Sciences Publications Ltd.</span>)
        </div><div class="casAbstract">TRAF2 is a component of TNF superfamily signalling complexes and plays an essential role in the regulation and homeostasis of immune cells.  TRAF2 deficient mice die around birth, therefore its role in adult tissues is not well-explored.  Furthermore, the role of the TRAF2 RING is controversial.  It has been claimed that the atypical TRAF2 RING cannot function as a ubiquitin E3 ligase but counterclaimed that TRAF2 RING requires a co-factor, sphingosine-1-phosphate, that is generated by the enzyme sphingosine kinase 1, to function as an E3 ligase.  Keratinocyte-specific deletion of Traf2, but not Sphk1 deficiency, disrupted TNF mediated NF- κB and MAP kinase signalling and caused epidermal hyperplasia and psoriatic skin inflammation.  This inflammation was driven by TNF, cell death, non-canonical NF- κB and the adaptive immune system, and might therefore represent a clin. relevant model of psoriasis.  TRAF2 therefore has essential tissue specific functions that do not overlap with those of Sphk1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4GaudWa3VhLVg90H21EOLACvtfcHk0ljeeUEgO4fqMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlvVClsrc%253D&md5=b82e9922ad3b437dc71151876bf1921c</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.7554%2FeLife.10592&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7554%252FeLife.10592%26sid%3Dliteratum%253Aachs%26aulast%3DEtemadi%26aufirst%3DN.%26aulast%3DChopin%26aufirst%3DM.%26aulast%3DAnderton%26aufirst%3DH.%26aulast%3DTanzer%26aufirst%3DM.%2BC.%26aulast%3DRickard%26aufirst%3DJ.%2BA.%26aulast%3DAbeysekera%26aufirst%3DW.%26aulast%3DHall%26aufirst%3DC.%26aulast%3DSpall%26aufirst%3DS.%2BK.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DXiong%26aufirst%3DY.%26aulast%3DHla%26aufirst%3DT.%26aulast%3DPitson%26aufirst%3DS.%2BM.%26aulast%3DBonder%26aufirst%3DC.%2BS.%26aulast%3DWong%26aufirst%3DW.%2BW.%26aulast%3DErnst%26aufirst%3DM.%26aulast%3DSmyth%26aufirst%3DG.%2BK.%26aulast%3DVaux%26aufirst%3DD.%2BL.%26aulast%3DNutt%26aufirst%3DS.%2BL.%26aulast%3DNachbur%26aufirst%3DU.%26aulast%3DSilke%26aufirst%3DJ.%26atitle%3DTRAF2%2520regulates%2520TNF%2520and%2520NF-kappaB%2520signalling%2520to%2520suppress%2520apoptosis%2520and%2520skin%2520inflammation%2520independently%2520of%2520sphingosine%2520kinase%25201%26jtitle%3DeLife%26date%3D2015%26volume%3D4%26doi%3D10.7554%2FeLife.10592" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mair, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joller, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoeppli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onder, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hahn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludewig, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waisman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becher, B.</span></span> <span> </span><span class="NLM_article-title">The NF-kappaB-inducing kinase is essential for the developmental programming of skin-resident and IL-17-producing gammadelta T cells</span>. <i>eLife</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>4</i></span>, <span class="NLM_elocation-id">e10087</span> <span class="refDoi"> DOI: 10.7554/eLife.10087</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.7554%2FeLife.10087" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=26637788" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlvVCntbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2015&author=F.+Mairauthor=S.+Jollerauthor=R.+Hoeppliauthor=L.+Onderauthor=M.+Hahnauthor=B.+Ludewigauthor=A.+Waismanauthor=B.+Becher&title=The+NF-kappaB-inducing+kinase+is+essential+for+the+developmental+programming+of+skin-resident+and+IL-17-producing+gammadelta+T+cells&doi=10.7554%2FeLife.10087"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">The NFκB-inducing kinase is essential for the developmental programming of skin-resident and IL-17-producing γδ T cells</span></div><div class="casAuthors">Mair, Florian; Joller, Stefanie; Hoeppli, Romy; Onder, Lucas; Hahn, Matthias; Ludewig, Burkhard; Waisman, Ari; Becher, Burkhard</div><div class="citationInfo"><span class="NLM_cas:title">eLife</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">e10087/1-e10087/16</span>CODEN:
                <span class="NLM_cas:coden">ELIFA8</span>;
        ISSN:<span class="NLM_cas:issn">2050-084X</span>.
    
            (<span class="NLM_cas:orgname">eLife Sciences Publications Ltd.</span>)
        </div><div class="casAbstract">& amp; #x03B3; & amp; #x03B4; T cells contribute to first line immune defense, particularly through their ability for rapid prodn. of proinflammatory cytokines.  The cytokine profile of & amp; #x03B3; & amp; #x03B4; T cells is hard-wired already during thymic development.  Yet, the mol. pathways underlying this phenomenon are incompletely understood.  Here we show that signaling via the NF & amp; #x03BA;B-inducing kinase (NIK) is essential for the formation of a fully functional & amp; #x03B3; & amp; #x03B4; T cell compartment.  In the absence of NIK, development of V & amp; #x03B3;5+ dendritic epidermal T cells (DETCs) was halted in the embryonic thymus, and impaired NIK function caused a selective loss of IL-17 expression by & amp; #x03B3; & amp; #x03B4; T cells.  Using a novel conditional mutant of NIK, we could show in vivo that NIK signaling in thymic epithelial cells is essential for the thymic hardwiring of & amp; #x03B3; & amp; #x03B4; T cell cytokine prodn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpT0H7VbjtfJbVg90H21EOLACvtfcHk0lg_hIFEiQtTPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlvVCntbo%253D&md5=793ba613f113d2da3ea55401e52587d3</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.7554%2FeLife.10087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7554%252FeLife.10087%26sid%3Dliteratum%253Aachs%26aulast%3DMair%26aufirst%3DF.%26aulast%3DJoller%26aufirst%3DS.%26aulast%3DHoeppli%26aufirst%3DR.%26aulast%3DOnder%26aufirst%3DL.%26aulast%3DHahn%26aufirst%3DM.%26aulast%3DLudewig%26aufirst%3DB.%26aulast%3DWaisman%26aufirst%3DA.%26aulast%3DBecher%26aufirst%3DB.%26atitle%3DThe%2520NF-kappaB-inducing%2520kinase%2520is%2520essential%2520for%2520the%2520developmental%2520programming%2520of%2520skin-resident%2520and%2520IL-17-producing%2520gammadelta%2520T%2520cells%26jtitle%3DeLife%26date%3D2015%26volume%3D4%26doi%3D10.7554%2FeLife.10087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eshima, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okabe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kajiura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noma, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinohara, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwabuchi, K.</span></span> <span> </span><span class="NLM_article-title">Significant involvement of nuclear factor-kappaB-inducing kinase in proper differentiation of alphabeta and gammadelta T cells</span>. <i>Immunology</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>141</i></span>,  <span class="NLM_fpage">222</span>– <span class="NLM_lpage">232</span>, <span class="refDoi"> DOI: 10.1111/imm.12186</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.1111%2Fimm.12186" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=24117043" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC2cXktFahtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2014&pages=222-232&author=K.+Eshimaauthor=M.+Okabeauthor=S.+Kajiuraauthor=H.+Nomaauthor=N.+Shinoharaauthor=K.+Iwabuchi&title=Significant+involvement+of+nuclear+factor-kappaB-inducing+kinase+in+proper+differentiation+of+alphabeta+and+gammadelta+T+cells&doi=10.1111%2Fimm.12186"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Significant involvement of nuclear factor-κB-inducing kinase in proper differentiation of αβ and γδ T cells</span></div><div class="casAuthors">Eshima, Koji; Okabe, Motohito; Kajiura, Satoshi; Noma, Haruka; Shinohara, Nobukata; Iwabuchi, Kazuya</div><div class="citationInfo"><span class="NLM_cas:title">Immunology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">222-232</span>CODEN:
                <span class="NLM_cas:coden">IMMUAM</span>;
        ISSN:<span class="NLM_cas:issn">0019-2805</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Nuclear factor-κB-inducing kinase (NIK) is known to play a crit. role in maintaining proper immune function.  This is exemplified in the spontaneous mutant mouse lacking functional NIK, alymphoplasia (aly), which is simultaneously immune-compromised and autoimmune-prone.  To investigate the role of NIK in αβ T-cell repertoire formation, we analyzed T-cell development in aly/aly mice bearing a transgenic T-cell receptor (TCR).  Although there were no apparent abnormalities in the mature αβ T cells of non-transgenic aly/aly mice, the maturation efficiency of idiotypehigh+ T cells in the TCR-transgenic mice was lower in aly/aly mice compared with those found in aly/+ mice, suggesting that the mature αβ T-cell repertoire could be altered by the absence of functional NIK.  In one strain of TCR-transgenic aly/aly mice with a neg. selecting H-2 background, the proportion of CD8low+ idiotypehigh+ cells, which are thought to potentially represent the γδ lineage of T cells, was markedly decreased.  When the γδ T cells in non-transgenic aly/aly mice were investigated, the proportion of γδ T cells in the peripheral organs of aly/aly mice was found to be one-half to one-fifth of those in aly/+ mice.  Analyses of bone marrow chimera mice indicated that NIK in host cells, rather than in donor cells was important for generating a normal no. of peripheral γδ T cells.  Collectively, these results suggest that NIK could be involved in thymic pos. selection of some αβ T cells and that NIK in non-haematopoietic cells is important for the optimal development and/or maintenance of γδ T cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruwpl2eiDwarVg90H21EOLACvtfcHk0lg_hIFEiQtTPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXktFahtg%253D%253D&md5=cd4e578e3494e115e066f06736a65ef1</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1111%2Fimm.12186&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fimm.12186%26sid%3Dliteratum%253Aachs%26aulast%3DEshima%26aufirst%3DK.%26aulast%3DOkabe%26aufirst%3DM.%26aulast%3DKajiura%26aufirst%3DS.%26aulast%3DNoma%26aufirst%3DH.%26aulast%3DShinohara%26aufirst%3DN.%26aulast%3DIwabuchi%26aufirst%3DK.%26atitle%3DSignificant%2520involvement%2520of%2520nuclear%2520factor-kappaB-inducing%2520kinase%2520in%2520proper%2520differentiation%2520of%2520alphabeta%2520and%2520gammadelta%2520T%2520cells%26jtitle%3DImmunology%26date%3D2014%26volume%3D141%26spage%3D222%26epage%3D232%26doi%3D10.1111%2Fimm.12186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">El
Malki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karbach, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huppert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zayoud, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reissig, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuler, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolaev, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karram, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munzel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhlmann, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luhmann, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Stebut, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wortge, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurschus, F. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waisman, A.</span></span> <span> </span><span class="NLM_article-title">An alternative pathway of imiquimod-induced psoriasis-like skin inflammation in the absence of interleukin-17 receptor a signaling</span>. <i>J. Invest. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>133</i></span>,  <span class="NLM_fpage">441</span>– <span class="NLM_lpage">451</span>, <span class="refDoi"> DOI: 10.1038/jid.2012.318</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.1038%2Fjid.2012.318" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=22951726" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlWns73J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=2013&pages=441-451&author=K.+El%0AMalkiauthor=S.+H.+Karbachauthor=J.+Huppertauthor=M.+Zayoudauthor=S.+Reissigauthor=R.+Schulerauthor=A.+Nikolaevauthor=K.+Karramauthor=T.+Munzelauthor=C.+R.+Kuhlmannauthor=H.+J.+Luhmannauthor=E.+von+Stebutauthor=S.+Wortgeauthor=F.+C.+Kurschusauthor=A.+Waisman&title=An+alternative+pathway+of+imiquimod-induced+psoriasis-like+skin+inflammation+in+the+absence+of+interleukin-17+receptor+a+signaling&doi=10.1038%2Fjid.2012.318"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">An Alternative Pathway of Imiquimod-Induced Psoriasis-Like Skin Inflammation in the Absence of Interleukin-17 Receptor A Signaling</span></div><div class="casAuthors">El Malki, Khalifa; Karbach, Susanne H.; Huppert, Jula; Zayoud, Morad; Reissig, Sonja; Schueler, Rebecca; Nikolaev, Alexej; Karram, Khalad; Muenzel, Thomas; Kuhlmann, Christoph R. W.; Luhmann, Heiko J.; von Stebut, Esther; Woertge, Simone; Kurschus, Florian C.; Waisman, Ari</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Investigative Dermatology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">133</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">441-451</span>CODEN:
                <span class="NLM_cas:coden">JIDEAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-202X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Topical application of imiquimod (IMQ) on the skin of mice induces inflammation with common features found in psoriatic skin.  Recently, it was postulated that IL-17 has an important role both in psoriasis and in the IMQ model.  To further investigate the impact of IL-17RA signaling in psoriasis, we generated IL-17 receptor A (IL-17RA)-deficient mice (IL-17RAdel) and challenged these mice with IMQ.  Interestingly, the disease was only partially reduced and delayed but not abolished when compared with controls.  In the absence of IL-17RA, we found persisting signs of inflammation such as neutrophil and macrophage infiltration within the skin.  Surprisingly, already in the naive state, the skin of IL-17RAdel mice contained significantly elevated nos. of Th17- and IL-17-producing γδ T cells, assuming that IL-17RA signaling regulates the population size of Th17 and γδ T cells.  Upon IMQ treatment of IL-17RAdel mice, these cells secreted elevated amts. of tumor necrosis factor-α, IL-6, and IL-22, accompanied by increased levels of the chemokine CXCL2, suggesting an alternative pathway of neutrophil and macrophage skin infiltration.  Hence, our findings have major implications in the potential long-term treatment of psoriasis by IL-17-targeting drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlZh_TcBKGGbVg90H21EOLACvtfcHk0lg_hIFEiQtTPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlWns73J&md5=69b76e9109adad0c2e92c44e522daed4</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1038%2Fjid.2012.318&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fjid.2012.318%26sid%3Dliteratum%253Aachs%26aulast%3DEl%2BMalki%26aufirst%3DK.%26aulast%3DKarbach%26aufirst%3DS.%2BH.%26aulast%3DHuppert%26aufirst%3DJ.%26aulast%3DZayoud%26aufirst%3DM.%26aulast%3DReissig%26aufirst%3DS.%26aulast%3DSchuler%26aufirst%3DR.%26aulast%3DNikolaev%26aufirst%3DA.%26aulast%3DKarram%26aufirst%3DK.%26aulast%3DMunzel%26aufirst%3DT.%26aulast%3DKuhlmann%26aufirst%3DC.%2BR.%26aulast%3DLuhmann%26aufirst%3DH.%2BJ.%26aulast%3Dvon%2BStebut%26aufirst%3DE.%26aulast%3DWortge%26aufirst%3DS.%26aulast%3DKurschus%26aufirst%3DF.%2BC.%26aulast%3DWaisman%26aufirst%3DA.%26atitle%3DAn%2520alternative%2520pathway%2520of%2520imiquimod-induced%2520psoriasis-like%2520skin%2520inflammation%2520in%2520the%2520absence%2520of%2520interleukin-17%2520receptor%2520a%2520signaling%26jtitle%3DJ.%2520Invest.%2520Dermatol.%26date%3D2013%26volume%3D133%26spage%3D441%26epage%3D451%26doi%3D10.1038%2Fjid.2012.318" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chio, I. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brustle, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mak, T. W.</span></span> <span> </span><span class="NLM_article-title">Crucial role for TNF receptor-associated factor 2 (TRAF2) in regulating NFkappaB2 signaling that contributes to autoimmunity</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">18354</span>– <span class="NLM_lpage">18359</span>, <span class="refDoi"> DOI: 10.1073/pnas.1109427108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.1073%2Fpnas.1109427108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=22042853" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsF2itrvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=18354-18359&author=W.+J.+Linauthor=Y.+W.+Suauthor=Y.+C.+Luauthor=Z.+Haoauthor=I.+I.+Chioauthor=N.+J.+Chenauthor=A.+Brustleauthor=W.+Y.+Liauthor=T.+W.+Mak&title=Crucial+role+for+TNF+receptor-associated+factor+2+%28TRAF2%29+in+regulating+NFkappaB2+signaling+that+contributes+to+autoimmunity&doi=10.1073%2Fpnas.1109427108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Crucial role for TNF receptor-associated factor 2 (TRAF2) in regulating NFκB2 signaling that contributes to autoimmunity</span></div><div class="casAuthors">Lin, Wen-Jye; Su, Yu-Wen; Lu, Yong-Chen; Hao, Zhenyue; Chio, Iok In Christine; Chen, Nien-Jung; Brustle, Anne; Li, Wanda Y.; Mak, Tak Wah</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">18354-18359, S18354/1-S18354/7</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">TNF receptor-assocd. factor 2 (TRAF2) is a key intracellular signaling mediator that acts downstream of not only TNFα but also various members of the TNFa superfamily.  Here, we report that, despite their lack of TNFa signaling, TRAF2-/-TNFα-/- mice develop an inflammatory disorder characterized by autoantibody accumulation and organ infiltration by T cells with the phenotypes of activated, effector, and memory cells.  RAG1-/- mice reconstituted with TRAF2-/-TNFα-/- bone marrow cells showed increased nos. of hyperactive T cells and rapidly developed progressive and eventually lethal inflammation.  No inflammation was obsd. in RAG1-/- mice reconstituted with TRAF2-/-TNFα-/-T-cell receptor β-/- or TRAF2-/-TNFα-/-NFκB-induced kinase+/- bone marrow cells.  The pathogenic TRAF2-/-TNFα-/- T cells showed constitutive NFκB2p52 activation and produced elevated levels of T-helper 1 and T-helper 17 cytokines.  Our. results suggest that a regulatory circuit consisting of TRAF2-NFκB-induced kinase-NFκB2p52 is essential for the proper control of effector T-cell polarization and that loss of T-cell TRAF2 function induces constitutive NFκB2p52 activity that drives fatal autoimmune inflammation independently of TNFα signaling.  The involvement of this regulatory circuit in controlling autoimmune responses highlights the delicate balance required to avoid paradoxical adverse events when implementing new targeted anti-inflammatory therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGox81gak_2xvbVg90H21EOLACvtfcHk0lgpF8TNZUddvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsF2itrvN&md5=4e7c755d7db1e9fac89b556342ffa39d</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1109427108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1109427108%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DW.%2BJ.%26aulast%3DSu%26aufirst%3DY.%2BW.%26aulast%3DLu%26aufirst%3DY.%2BC.%26aulast%3DHao%26aufirst%3DZ.%26aulast%3DChio%26aufirst%3DI.%2BI.%26aulast%3DChen%26aufirst%3DN.%2BJ.%26aulast%3DBrustle%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DW.%2BY.%26aulast%3DMak%26aufirst%3DT.%2BW.%26atitle%3DCrucial%2520role%2520for%2520TNF%2520receptor-associated%2520factor%25202%2520%2528TRAF2%2529%2520in%2520regulating%2520NFkappaB2%2520signaling%2520that%2520contributes%2520to%2520autoimmunity%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2011%26volume%3D108%26spage%3D18354%26epage%3D18359%26doi%3D10.1073%2Fpnas.1109427108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, H.</span></span> <span> </span><span class="NLM_article-title">Rutaecarpine inhibited imiquimod-induced psoriasis-like dermatitis via inhibiting the NF-kappaB and TLR7 pathways in mice</span>. <i>Biomed. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">1876</span>– <span class="NLM_lpage">1883</span>, <span class="refDoi"> DOI: 10.1016/j.biopha.2018.10.062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.1016%2Fj.biopha.2018.10.062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=30551443" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlGgtL7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2019&pages=1876-1883&author=Y.+Liauthor=G.+Zhangauthor=M.+Chenauthor=M.+Tongauthor=M.+Zhaoauthor=F.+Tangauthor=R.+Xiaoauthor=H.+Wen&title=Rutaecarpine+inhibited+imiquimod-induced+psoriasis-like+dermatitis+via+inhibiting+the+NF-kappaB+and+TLR7+pathways+in+mice&doi=10.1016%2Fj.biopha.2018.10.062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Rutaecarpine inhibited imiquimod-induced psoriasis-like dermatitis via inhibiting the NF-κB and TLR7 pathways in mice</span></div><div class="casAuthors">Li, Yongjian; Zhang, Guiying; Chen, Mingliang; Tong, Min; Zhao, Ming; Tang, Fang; Xiao, Rong; Wen, Haiquan</div><div class="citationInfo"><span class="NLM_cas:title">Biomedicine & Pharmacotherapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1876-1883</span>CODEN:
                <span class="NLM_cas:coden">BIPHEX</span>;
        ISSN:<span class="NLM_cas:issn">0753-3322</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Psoriasis is a chronic, immune-mediated inflammatory skin disease.  As psoriasis rarely occurs in nonhuman animals, the lack of an ideal animal model reflecting the histopathol. and mol. immunol. characteristics of psoriasis remains an urgent issue.  In the present study, an imiquimod-induced psoriasis-like dermatitis mouse model was constructed under natural immune conditions and verified by evaluations of the Psoriasis Area and Severity Index (PASI) score and Baker score, H&E staining, immunohistochem. examn. of the CD3 and Gr1 levels, measurement of plasmacytoid dendritic cell- (pDC) and Th17-assocd. cytokine levels, and evaluation of p65 phosphorylation and TLR7 expression.  Moreover, rutaecarpine (RUT), the main active ingredient in the traditional Chinese medicine Wu-Zhu-Yu, could improve psoriasis-like dermatitis through effects on pDC- and Th17-assocd. cytokines through NF-κB and toll-like receptor 7 (TLR7) signaling.  Taken together, the imiquimod-induced psoriasis-like dermatitis mouse model can be regarded as an ideal model for evaluating psoriasis pathogenesis and antipsoriatic drugs.  We provided theor. and exptl. evidence for the clin. application of RUT in psoriasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYzmOHp7vLqbVg90H21EOLACvtfcHk0lgpF8TNZUddvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlGgtL7I&md5=5076a975933814d69d25f8997c4791b1</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.biopha.2018.10.062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopha.2018.10.062%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DTong%26aufirst%3DM.%26aulast%3DZhao%26aufirst%3DM.%26aulast%3DTang%26aufirst%3DF.%26aulast%3DXiao%26aufirst%3DR.%26aulast%3DWen%26aufirst%3DH.%26atitle%3DRutaecarpine%2520inhibited%2520imiquimod-induced%2520psoriasis-like%2520dermatitis%2520via%2520inhibiting%2520the%2520NF-kappaB%2520and%2520TLR7%2520pathways%2520in%2520mice%26jtitle%3DBiomed.%2520Pharmacother.%26date%3D2019%26volume%3D109%26spage%3D1876%26epage%3D1883%26doi%3D10.1016%2Fj.biopha.2018.10.062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGee, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sudom, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubenstein, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anwer, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cushing, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayres, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eksterowicz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faulder, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waszkowycz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plotnikova, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrelly, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span> <span> </span><span class="NLM_article-title">Inhibiting NF-kappaB-inducing kinase (NIK): discovery, structure-based design, synthesis, structure-activity relationship, and co-crystal structures</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1238</span>– <span class="NLM_lpage">1244</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.01.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.1016%2Fj.bmcl.2013.01.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=23374866" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVGmt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=1238-1244&author=K.+Liauthor=L.+R.+McGeeauthor=B.+Fisherauthor=A.+Sudomauthor=J.+Liuauthor=S.+M.+Rubensteinauthor=M.+K.+Anwerauthor=T.+D.+Cushingauthor=Y.+Shinauthor=M.+Ayresauthor=F.+Leeauthor=J.+Eksterowiczauthor=P.+Faulderauthor=B.+Waszkowyczauthor=O.+Plotnikovaauthor=E.+Farrellyauthor=S.+H.+Xiaoauthor=G.+Chenauthor=Z.+Wang&title=Inhibiting+NF-kappaB-inducing+kinase+%28NIK%29%3A+discovery%2C+structure-based+design%2C+synthesis%2C+structure-activity+relationship%2C+and+co-crystal+structures&doi=10.1016%2Fj.bmcl.2013.01.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibiting NF-κB-inducing kinase (NIK): Discovery, structure-based design, synthesis, structure-activity relationship, and co-crystal structures</span></div><div class="casAuthors">Li, Kexue; McGee, Lawrence R.; Fisher, Ben; Sudom, Athena; Liu, Jinsong; Rubenstein, Steven M.; Anwer, Mohmed K.; Cushing, Timothy D.; Shin, Youngsook; Ayres, Merrill; Lee, Fei; Eksterowicz, John; Faulder, Paul; Waszkowycz, Bohdan; Plotnikova, Olga; Farrelly, Ellyn; Xiao, Shou-Hua; Chen, Guoqing; Wang, Zhulun</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1238-1244</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The discovery, structure-based design, synthesis, and optimization of NIK inhibitors are described.  Our work began with an HTS hit, imidazopyridinyl pyrimidinamine I.  We utilized homol. modeling and conformational anal. to optimize the indole scaffold leading to the discovery of novel and potent conformationally constrained inhibitors such as compds. II [R1 = Br, C≡CCMe2OH].  Compds. II [R1 = Br] and III were co-crystd. with NIK kinase domain to provide structural insights.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpm5WqvTIrBqrVg90H21EOLACvtfcHk0lht-jW2dBSEbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVGmt7s%253D&md5=a382078cf3bf84a41749783be33a5988</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.01.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.01.012%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DK.%26aulast%3DMcGee%26aufirst%3DL.%2BR.%26aulast%3DFisher%26aufirst%3DB.%26aulast%3DSudom%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DRubenstein%26aufirst%3DS.%2BM.%26aulast%3DAnwer%26aufirst%3DM.%2BK.%26aulast%3DCushing%26aufirst%3DT.%2BD.%26aulast%3DShin%26aufirst%3DY.%26aulast%3DAyres%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DF.%26aulast%3DEksterowicz%26aufirst%3DJ.%26aulast%3DFaulder%26aufirst%3DP.%26aulast%3DWaszkowycz%26aufirst%3DB.%26aulast%3DPlotnikova%26aufirst%3DO.%26aulast%3DFarrelly%26aufirst%3DE.%26aulast%3DXiao%26aufirst%3DS.%2BH.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DZ.%26atitle%3DInhibiting%2520NF-kappaB-inducing%2520kinase%2520%2528NIK%2529%253A%2520discovery%252C%2520structure-based%2520design%252C%2520synthesis%252C%2520structure-activity%2520relationship%252C%2520and%2520co-crystal%2520structures%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D1238%26epage%3D1244%26doi%3D10.1016%2Fj.bmcl.2013.01.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Songyang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, X.</span></span> <span> </span><span class="NLM_article-title">Gain-of-function mutation of card14 leads to spontaneous psoriasis-like skin inflammation through enhanced keratinocyte response to IL-17A</span>. <i>Immunity</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">66</span>– <span class="NLM_lpage">79</span>, <span class="refDoi"> DOI: 10.1016/j.immuni.2018.05.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.1016%2Fj.immuni.2018.05.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=29980436" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1GjsLbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2018&pages=66-79&author=M.+Wangauthor=S.+Zhangauthor=G.+Zhengauthor=J.+Huangauthor=Z.+Songyangauthor=X.+Zhaoauthor=X.+Lin&title=Gain-of-function+mutation+of+card14+leads+to+spontaneous+psoriasis-like+skin+inflammation+through+enhanced+keratinocyte+response+to+IL-17A&doi=10.1016%2Fj.immuni.2018.05.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Gain-of-Function Mutation of Card14 Leads to Spontaneous Psoriasis-like Skin Inflammation through Enhanced Keratinocyte Response to IL-17A</span></div><div class="casAuthors">Wang, Mingchao; Zhang, Shanshan; Zheng, Guoxing; Huang, Junjiu; Zhou, Songyang; Zhao, Xueqiang; Lin, Xin</div><div class="citationInfo"><span class="NLM_cas:title">Immunity</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">66-79.e5</span>CODEN:
                <span class="NLM_cas:coden">IUNIEH</span>;
        ISSN:<span class="NLM_cas:issn">1074-7613</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Genetic mutations of CARD14 (encoding CARMA2) are obsd. in psoriasis patients.  Here we showed that Card14E138A/+ and Card14ΔQ136/+ mice developed spontaneous psoriasis-like skin inflammation, which resulted from constitutively activated CARMA2 via self-aggregation leading to the enhanced activation of the IL-23-IL-17A cytokine axis.  Card14-/- mice displayed attenuated skin inflammation in the imiquimod-induced psoriasis model due to impaired IL-17A signaling in keratinocytes.  CARMA2, mainly expressed in keratinocytes, assocs. with the ACT1-TRAF6 signaling complex and mediates IL-17A-induced NF-κB and MAPK signaling pathway activation, which leads to expression of pro-inflammatory factors.  Thus, CARMA2 serves as a key mediator of IL-17A signaling and its constitutive activation in keratinocytes leads to the onset of psoriasis, which indicates an important role of NF-κB activation in keratinocytes in psoriatic initiation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjgNs_LJtXvbVg90H21EOLACvtfcHk0lht-jW2dBSEbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1GjsLbF&md5=7ebbcf845656a0852f4a82f1b0e7d4ca</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.immuni.2018.05.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.immuni.2018.05.012%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DZheng%26aufirst%3DG.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DSongyang%26aufirst%3DZ.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DLin%26aufirst%3DX.%26atitle%3DGain-of-function%2520mutation%2520of%2520card14%2520leads%2520to%2520spontaneous%2520psoriasis-like%2520skin%2520inflammation%2520through%2520enhanced%2520keratinocyte%2520response%2520to%2520IL-17A%26jtitle%3DImmunity%26date%3D2018%26volume%3D49%26spage%3D66%26epage%3D79%26doi%3D10.1016%2Fj.immuni.2018.05.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Klimov, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tretiakov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gapanovich, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kokaeva, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soboleva, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakaniya, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korsunskaya, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sobolev, V.</span></span> <span> </span><span class="NLM_article-title">Assessment of the role of NO synthase genes polymorphisms in the pathogenesis of psoriasis</span>. <i>J. Adv. Med. Med. Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">6</span>, <span class="refDoi"> DOI: 10.9734/JAMMR/2018/41039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.9734%2FJAMMR%2F2018%2F41039" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2018&pages=1-6&author=E.+Klimovauthor=A.+Tretiakovauthor=E.+Gapanovichauthor=Z.+Kokaevaauthor=A.+Sobolevaauthor=L.+Sakaniyaauthor=I.+Korsunskayaauthor=V.+Sobolev&title=Assessment+of+the+role+of+NO+synthase+genes+polymorphisms+in+the+pathogenesis+of+psoriasis&doi=10.9734%2FJAMMR%2F2018%2F41039"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.9734%2FJAMMR%2F2018%2F41039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.9734%252FJAMMR%252F2018%252F41039%26sid%3Dliteratum%253Aachs%26aulast%3DKlimov%26aufirst%3DE.%26aulast%3DTretiakov%26aufirst%3DA.%26aulast%3DGapanovich%26aufirst%3DE.%26aulast%3DKokaeva%26aufirst%3DZ.%26aulast%3DSoboleva%26aufirst%3DA.%26aulast%3DSakaniya%26aufirst%3DL.%26aulast%3DKorsunskaya%26aufirst%3DI.%26aulast%3DSobolev%26aufirst%3DV.%26atitle%3DAssessment%2520of%2520the%2520role%2520of%2520NO%2520synthase%2520genes%2520polymorphisms%2520in%2520the%2520pathogenesis%2520of%2520psoriasis%26jtitle%3DJ.%2520Adv.%2520Med.%2520Med.%2520Res.%26date%3D2018%26volume%3D26%26spage%3D1%26epage%3D6%26doi%3D10.9734%2FJAMMR%2F2018%2F41039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scholz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yau, A. C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hüffmeier, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burkhardt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmdahl, R.</span></span> <span> </span><span class="NLM_article-title">Mannan-induced NOS2 in macrophages enhances IL-17-driven psoriatic arthritis by innate lymphocytes</span>. <i>Sci. Adv.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>4</i></span>, <span class="NLM_elocation-id">eaas9864</span> <span class="refDoi"> DOI: 10.1126/sciadv.aas9864</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.1126%2Fsciadv.aas9864" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=29774240" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2018&author=J.+Zhongauthor=T.+Scholzauthor=A.+C.+Y.+Yauauthor=S.+Guerardauthor=U.+H%C3%BCffmeierauthor=H.+Burkhardtauthor=R.+Holmdahl&title=Mannan-induced+NOS2+in+macrophages+enhances+IL-17-driven+psoriatic+arthritis+by+innate+lymphocytes&doi=10.1126%2Fsciadv.aas9864"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1126%2Fsciadv.aas9864&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fsciadv.aas9864%26sid%3Dliteratum%253Aachs%26aulast%3DZhong%26aufirst%3DJ.%26aulast%3DScholz%26aufirst%3DT.%26aulast%3DYau%26aufirst%3DA.%2BC.%2BY.%26aulast%3DGuerard%26aufirst%3DS.%26aulast%3DH%25C3%25BCffmeier%26aufirst%3DU.%26aulast%3DBurkhardt%26aufirst%3DH.%26aulast%3DHolmdahl%26aufirst%3DR.%26atitle%3DMannan-induced%2520NOS2%2520in%2520macrophages%2520enhances%2520IL-17-driven%2520psoriatic%2520arthritis%2520by%2520innate%2520lymphocytes%26jtitle%3DSci.%2520Adv.%26date%3D2018%26volume%3D4%26doi%3D10.1126%2Fsciadv.aas9864" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, W.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of bis-aryl ureas and amides based on 2-amino-3-purinylpyridine scaffold as DFG-out B-Raf kinase inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">581</span>– <span class="NLM_lpage">596</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2014.10.039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.1016%2Fj.ejmech.2014.10.039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=25462267" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslOjtL7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2015&pages=581-596&author=W.+Yangauthor=Y.+Chenauthor=X.+Zhouauthor=Y.+Guauthor=W.+Qianauthor=F.+Zhangauthor=W.+Hanauthor=T.+Luauthor=W.+Tang&title=Design%2C+synthesis+and+biological+evaluation+of+bis-aryl+ureas+and+amides+based+on+2-amino-3-purinylpyridine+scaffold+as+DFG-out+B-Raf+kinase+inhibitors&doi=10.1016%2Fj.ejmech.2014.10.039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of bis-aryl ureas and amides based on 2-amino-3-purinylpyridine scaffold as DFG-out B-Raf kinase inhibitors</span></div><div class="casAuthors">Yang, Weimin; Chen, Yadong; Zhou, Xiang; Gu, Yazhou; Qian, Wenqi; Zhang, Fan; Han, Wei; Lu, Tao; Tang, Weifang</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">581-596</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">By combining the scaffolds of UI-125 and Sorafenib, a series of bis-aryl ureas and amides based on 2-amino-3-purinylpyridine moiety were designed and synthesized as novel DFG-out B-RafV600E inhibitors.  Several of these compds. displayed potent antiproliferative activities against melanoma A375 (B-RafV600E) cell lines with IC50 values of 3.190, 2.276, 1.856, 1.632 μM and 1.839 μM, resp., comparable with the pos. control Vemurafenib (IC50 = 3.32 μM).  Selected compds. were tested for the ERK inhibition in human melanoma A375 (B-RafV600E) and SK-MEL-2 (B-RafWT) cell lines by Western blot.  The results revealed that our compds. inhibited the proliferation of melanoma A375 cells (B-RafV600E) through ERK pathway, without paradoxical activation of ERK in melanoma SK-MEL-2 cells (B-RafWT).  Eventually, two compds. were selected to confirm their inhibitory effects on tumor growth in A375 xenograft models in mice.  Compd. I exhibited equiv. antitumor efficacy in vivo (T/C = 44.37%), compared to Sorafenib (T/C = 37.35%), by 23-day repetitive administration of a single dose of 50 mg/kg without significant body wt. loss.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq84bBDYugz1bVg90H21EOLACvtfcHk0lhtSRAO0VwiiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslOjtL7I&md5=6a65e09b0121c8f2f32facbfeae8f86b</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.10.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.10.039%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DGu%26aufirst%3DY.%26aulast%3DQian%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DF.%26aulast%3DHan%26aufirst%3DW.%26aulast%3DLu%26aufirst%3DT.%26aulast%3DTang%26aufirst%3DW.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520bis-aryl%2520ureas%2520and%2520amides%2520based%2520on%25202-amino-3-purinylpyridine%2520scaffold%2520as%2520DFG-out%2520B-Raf%2520kinase%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D89%26spage%3D581%26epage%3D596%26doi%3D10.1016%2Fj.ejmech.2014.10.039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Toledo, C. E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Souza, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraga, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribeiro, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferreira, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitral, R. W. F.</span></span> <span> </span><span class="NLM_article-title">Cellular viability and nitric oxide (NO) production by J774 macrophages in the presence of orthodontic archwires</span>. <i>J. Biomed. Sci. Eng.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">255</span>– <span class="NLM_lpage">262</span>, <span class="refDoi"> DOI: 10.4236/jbise.2012.55032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.4236%2Fjbise.2012.55032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFChurbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2012&pages=255-262&author=C.+E.+P.+Toledoauthor=M.+A.+Souzaauthor=M.+R.+Fragaauthor=L.+C.+Ribeiroauthor=A.+P.+Ferreiraauthor=R.+W.+F.+Vitral&title=Cellular+viability+and+nitric+oxide+%28NO%29+production+by+J774+macrophages+in+the+presence+of+orthodontic+archwires&doi=10.4236%2Fjbise.2012.55032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Cellular viability and nitric oxide (NO) production by J774 macrophages in the presence of orthodontic archwires</span></div><div class="casAuthors">Toledo, Carlos E. P.; Souza, Maria A.; Fraga, Marcelo R.; Ribeiro, Luiz C.; Ferreira, Ana P.; Vitral, Robert W. F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomedical Science and Engineering</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">255-262</span>CODEN:
                <span class="NLM_cas:coden">JBSEC8</span>;
        ISSN:<span class="NLM_cas:issn">1937-6871</span>.
    
            (<span class="NLM_cas:orgname">Scientific Research Publishing, Inc.</span>)
        </div><div class="casAbstract">To assess, in vitro, the cellular viability in a murine macrophage cell line J774 with 9 different orthodontic wires and to evaluate the effects of its NO prodn.  To assess cellular viability by MTT: 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl tetrazolium bromide assay in the cell line J774 with 9 different orthodontic wires and quantify NO prodn. by these macrophages.  Cell cultures were evaluated at 24, 48 and 72 h.  There was no significant difference of the means of cellular viability between the control and the group of wires in the resp. time intervals.  In the comparison with the control group, there was significant difference in the NO prodn. in groups 1, 6, and 9 at 24 h interval.  Group 8 showed significant difference in relation to the control group at final time interval.  Cellular viability in all groups was higher at the final time interval than at the initial time interval.  This increase was significant in the control group.  In the material groups, the final mean of cellular viability at 72 h showed no significant difference when compared with the control group.  NO prodn. in all groups was higher at the final time interval than at the initial time interval.  This increase was significant in the control group.  In the material groups, the final mean of NO prodn. at 72 h was only significant in group 8 (beta-titanium) when compared with the control group.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA3yScnd8EW7Vg90H21EOLACvtfcHk0lhtSRAO0VwiiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFChurbF&md5=2b987fd34c729311fe912320a28a725b</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.4236%2Fjbise.2012.55032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4236%252Fjbise.2012.55032%26sid%3Dliteratum%253Aachs%26aulast%3DToledo%26aufirst%3DC.%2BE.%2BP.%26aulast%3DSouza%26aufirst%3DM.%2BA.%26aulast%3DFraga%26aufirst%3DM.%2BR.%26aulast%3DRibeiro%26aufirst%3DL.%2BC.%26aulast%3DFerreira%26aufirst%3DA.%2BP.%26aulast%3DVitral%26aufirst%3DR.%2BW.%2BF.%26atitle%3DCellular%2520viability%2520and%2520nitric%2520oxide%2520%2528NO%2529%2520production%2520by%2520J774%2520macrophages%2520in%2520the%2520presence%2520of%2520orthodontic%2520archwires%26jtitle%3DJ.%2520Biomed.%2520Sci.%2520Eng.%26date%3D2012%26volume%3D5%26spage%3D255%26epage%3D262%26doi%3D10.4236%2Fjbise.2012.55032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vlessidis, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evmiridis, N. P.</span></span> <span> </span><span class="NLM_article-title">Determination of nitric oxide in biological samples</span>. <i>Microchim. Acta</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>147</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">21</span>, <span class="refDoi"> DOI: 10.1007/s00604-004-0212-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.1007%2Fs00604-004-0212-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BD2cXkvF2ltro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=147&publication_year=2004&pages=1-21&author=D.+Yaoauthor=A.+G.+Vlessidisauthor=N.+P.+Evmiridis&title=Determination+of+nitric+oxide+in+biological+samples&doi=10.1007%2Fs00604-004-0212-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Determination of Nitric Oxide in Biological Samples</span></div><div class="casAuthors">Yao, Dachun; Vlessidis, Athanasios G.; Evmiridis, Nicholaos P.</div><div class="citationInfo"><span class="NLM_cas:title">Microchimica Acta</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">147</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">1-20</span>CODEN:
                <span class="NLM_cas:coden">MIACAQ</span>;
        ISSN:<span class="NLM_cas:issn">0026-3672</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag Wien</span>)
        </div><div class="casAbstract">A review.  NO plays an important role in the regulation of physiol. and pathophysiol. mechanisms, and quite a lot of studies were focused on this kind of special mol.  It is difficult to achieve reliable ex vivo NO measurements with the existing anal. methods, and developing a reliable in vivo monitoring method for NO is still an urgent task.  In this review, the techniques used for the detn. of endogenous NO formed by enzymic action and its reactions with other biol. substances found in living organisms are discussed with respect to applications both in vivo or in vitro.  Various NO (micro)sensors and trap probes based on different principles are presented with their resp. advantages and limitations.  Finally, an NO monitoring system based on the combination of microdialysis sampling and chemiluminescence is introduced which is considered to be a prospective method for in vivo monitoring.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrErxIf0VULrVg90H21EOLACvtfcHk0lhtSRAO0VwiiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXkvF2ltro%253D&md5=25ecb4f809c2e0ad93eee515f6b09bd7</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1007%2Fs00604-004-0212-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00604-004-0212-8%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DD.%26aulast%3DVlessidis%26aufirst%3DA.%2BG.%26aulast%3DEvmiridis%26aufirst%3DN.%2BP.%26atitle%3DDetermination%2520of%2520nitric%2520oxide%2520in%2520biological%2520samples%26jtitle%3DMicrochim.%2520Acta%26date%3D2004%26volume%3D147%26spage%3D1%26epage%3D21%26doi%3D10.1007%2Fs00604-004-0212-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, X. G.</span></span> <span> </span><span class="NLM_article-title">Protective effects of specific cannabinoid receptor 2 agonist GW405833 on concanavalin A-induced acute liver injury in mice</span>. <i>Acta Pharmacol. Sin.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">1404</span>– <span class="NLM_lpage">1411</span>, <span class="refDoi"> DOI: 10.1038/s41401-019-0213-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.1038%2Fs41401-019-0213-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=30918343" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmslKrs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2019&pages=1404-1411&author=Z.+B.+Huangauthor=Y.+X.+Zhengauthor=N.+Liauthor=S.+L.+Caiauthor=Y.+Huangauthor=J.+Wangauthor=X.+W.+Huauthor=Y.+Wangauthor=J.+Wuauthor=X.+G.+Fan&title=Protective+effects+of+specific+cannabinoid+receptor+2+agonist+GW405833+on+concanavalin+A-induced+acute+liver+injury+in+mice&doi=10.1038%2Fs41401-019-0213-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Protective effects of specific cannabinoid receptor 2 agonist GW405833 on concanavalin A-induced acute liver injury in mice</span></div><div class="casAuthors">Huang, Ze-bing; Zheng, Yi-xiang; Li, Ning; Cai, Sheng-lan; Huang, Yan; Wang, Juan; Hu, Xing-wang; Wang, Yang; Wu, Jie; Fan, Xue-gong</div><div class="citationInfo"><span class="NLM_cas:title">Acta Pharmacologica Sinica</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1404-1411</span>CODEN:
                <span class="NLM_cas:coden">APSCG5</span>;
        ISSN:<span class="NLM_cas:issn">1671-4083</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Cannabinoid receptor 2 (CB2R) is highly expressed in immune cells and plays an important role in regulating immune responses.  In the current study, we investigated the effects of GW405833 (GW), a specific CB2R agonist, on acute liver injury induced by Con A (Con A).  In animal expts., acute liver injury was induced in mice by injection of Con A (20 mg/kg, i.v.).  The mice were treated with GW (20 mg/kg, i.p., 30 min after Con A injection) or GW plus the selective CB2R antagonist AM630 (2 mg/kg, i.p., 15 min after Con A injection).  We found that Con A caused severe acute liver injury evidenced by significantly increased serum aminotransferase levels, massive hepatocyte apoptosis, and necrosis, as well as lymphocyte infiltration in liver tissues.  Treatment with GW significantly ameliorated Con A-induced pathol. injury in liver tissue, decreased serum aminotransferase levels, and decreased hepatocyte apoptosis.  The therapeutic effects of GW were prevented by AM630.  In cell expts., we showed that CB2Rs were highly expressed in Jurkat T cells, but little expression in L02 liver cells.  Treatment with GW (10-40 μg/mL) dose-dependently decreased the viability of Jurkat T cells and induced cell apoptosis, which was reversed by AM630.  In the coculture of Jurkat T cells with L02 liver cells, GW dose-dependently protected L02 cells from apoptosis induced by Con A (5 μg/mL).  The protective effect of GW was reversed by AM630 (1 μg/mL).  Our results suggest that GW protects against Con A-induced acute liver injury in mice by inhibiting Jurkat T-cell proliferation through the CB2Rs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiBN1WxVxipLVg90H21EOLACvtfcHk0lh_O3AR72GGjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmslKrs74%253D&md5=1dc9a0008e43ff2710fe779a4253910b</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1038%2Fs41401-019-0213-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41401-019-0213-0%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DZ.%2BB.%26aulast%3DZheng%26aufirst%3DY.%2BX.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DCai%26aufirst%3DS.%2BL.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DX.%2BW.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DFan%26aufirst%3DX.%2BG.%26atitle%3DProtective%2520effects%2520of%2520specific%2520cannabinoid%2520receptor%25202%2520agonist%2520GW405833%2520on%2520concanavalin%2520A-induced%2520acute%2520liver%2520injury%2520in%2520mice%26jtitle%3DActa%2520Pharmacol.%2520Sin.%26date%3D2019%26volume%3D40%26spage%3D1404%26epage%3D1411%26doi%3D10.1038%2Fs41401-019-0213-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, T.</span></span> <span> </span><span class="NLM_article-title">Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-kinase inhibitor with potentially high efficiency against acute myelocytic leukemia</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">1499</span>– <span class="NLM_lpage">1518</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01261</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01261" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlyqurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=1499-1518&author=Y.+Wangauthor=Y.+Zhiauthor=Q.+Jinauthor=S.+Luauthor=G.+Linauthor=H.+Yuanauthor=T.+Yangauthor=Z.+Wangauthor=C.+Yaoauthor=J.+Lingauthor=H.+Guoauthor=T.+Liauthor=J.+Jinauthor=B.+Liauthor=L.+Zhangauthor=Y.+Chenauthor=T.+Lu&title=Discovery+of+4-%28%287H-Pyrrolo%5B2%2C3-d%5Dpyrimidin-4-yl%29amino%29-N-%284-%28%284-methylpiperazin-1-yl%29methyl%29phenyl%29-1H-pyrazole-3-carboxamide+%28FN-1501%29%2C+an+FLT3-+and+CDK-kinase+inhibitor+with+potentially+high+efficiency+against+acute+myelocytic+leukemia&doi=10.1021%2Facs.jmedchem.7b01261"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia</span></div><div class="casAuthors">Wang, Yue; Zhi, Yanle; Jin, Qiaomei; Lu, Shuai; Lin, Guowu; Yuan, Haoliang; Yang, Taotao; Wang, Zhanwei; Yao, Chao; Ling, Jun; Guo, Hao; Li, Tonghui; Jin, Jianlin; Li, Baoquan; Zhang, Li; Chen, Yadong; Lu, Tao</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1499-1518</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of 1-H-pyrazole-3-carboxamide derivs. have been designed and synthesized that exhibit excellent FLT3 and CDK inhibition and antiproliferative activities.  A structure-activity-relationship study illustrates that the incorporation of a pyrimidine-fused heterocycle at position 4 of the pyrazole is crit. for FLT3 and CDK inhibition.  Compd. 50 (FN-1501), which possesses potent inhibitory activities against FLT3, CDK2, CDK4, and CDK6 with IC50 values in the nanomolar range, shows antiproliferative activities against MV4-11 cells (IC50: 0.008 μM), which correlates with the suppression of retinoblastoma phosphorylation, FLT3, ERK, AKT, and STAT5 and the onset of apoptosis.  Acute-toxicity studies in mice show that compd. I (LD50: 186 mg/kg) is safer than AT7519 (32 mg/kg).  In MV4-11 xenografts in a nude-mouse model, compd. I can induce tumor regression at the dose of 15 mg/kg, which is more efficient than cytarabine (50 mg/kg).  Taken together, these results demonstrate the potential of this unique compd. for further development into a drug applied in acute-myeloid-leukemia (AML) therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfX9S4QkGccbVg90H21EOLACvtfcHk0lh_O3AR72GGjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlyqurg%253D&md5=2757ad7559e655c5d96f0a8af8c74aa5</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01261%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhi%26aufirst%3DY.%26aulast%3DJin%26aufirst%3DQ.%26aulast%3DLu%26aufirst%3DS.%26aulast%3DLin%26aufirst%3DG.%26aulast%3DYuan%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DYao%26aufirst%3DC.%26aulast%3DLing%26aufirst%3DJ.%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DT.%26aulast%3DJin%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DT.%26atitle%3DDiscovery%2520of%25204-%2528%25287H-Pyrrolo%255B2%252C3-d%255Dpyrimidin-4-yl%2529amino%2529-N-%25284-%2528%25284-methylpiperazin-1-yl%2529methyl%2529phenyl%2529-1H-pyrazole-3-carboxamide%2520%2528FN-1501%2529%252C%2520an%2520FLT3-%2520and%2520CDK-kinase%2520inhibitor%2520with%2520potentially%2520high%2520efficiency%2520against%2520acute%2520myelocytic%2520leukemia%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D1499%26epage%3D1518%26doi%3D10.1021%2Facs.jmedchem.7b01261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of benzo[cd]indol-2(1H)-ones and pyrrolo[4,3,2-de]quinolin-2(1H)-ones as bromodomain and extra-terminal domain (BET) inhibitors with selectivity for the first bromodomain with potential high efficiency against acute gouty arthritis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">11080</span>– <span class="NLM_lpage">11107</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01010</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01010" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit1yqur7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=11080-11107&author=F.+Jiangauthor=Q.+Huauthor=Z.+Zhangauthor=H.+Liauthor=H.+Liauthor=D.+Zhangauthor=H.+Liauthor=Y.+Maauthor=J.+Xuauthor=H.+Chenauthor=Y.+Cuiauthor=Y.+Zhiauthor=Y.+Zhangauthor=J.+Xuauthor=J.+Zhuauthor=T.+Luauthor=Y.+Chen&title=Discovery+of+benzo%5Bcd%5Dindol-2%281H%29-ones+and+pyrrolo%5B4%2C3%2C2-de%5Dquinolin-2%281H%29-ones+as+bromodomain+and+extra-terminal+domain+%28BET%29+inhibitors+with+selectivity+for+the+first+bromodomain+with+potential+high+efficiency+against+acute+gouty+arthritis&doi=10.1021%2Facs.jmedchem.9b01010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Benzo[cd]indol-2(1H)-ones and Pyrrolo[4,3,2-de]quinolin-2(1H)-ones as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the First Bromodomain with Potential High Efficiency against Acute Gouty Arthritis</span></div><div class="casAuthors">Jiang, Fei; Hu, Qinghua; Zhang, Zhimin; Li, Hongmei; Li, Huili; Zhang, Dewei; Li, Hanwen; Ma, Yu; Xu, Jingjing; Chen, Haifang; Cui, Yong; Zhi, Yanle; Zhang, Yanmin; Xu, Junyu; Zhu, Jiapeng; Lu, Tao; Chen, Yadong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">11080-11107</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The bromodomain and extra-terminal domain (BET) family of proteins are readers which specifically recognize histone-acetylated lysine residues.  Each BET bromodomain protein contains two highly homologous domains: the first bromodomain (BD1) and the second bromodomain (BD2).  Pan-BET bromodomain inhibition is a potential therapy for various cancers and immune-inflammatory diseases, but only few reported inhibitors show selectivity within the BET family.  Herein, we identified a series of benzo[cd]indol-2(1H)-ones and pyrrolo[4,3,2-de]quinolin-2(1H)-ones with good selectivity for BET BD1.  Through structure-based optimization, highly active and selective compds. are ultimately obtained.  The representative compds. are the first reported inhibitors with selectivity more than 100-fold for BRD4(1) over BRD4(2).  Among them, we further show that 68 (LT052) mediates BRD4/NF-κB/NLRP3 signaling inflammatory pathways with comparable protein expression and significantly improves symptoms of gout arthritis in a rat model.  Therefore, selective pharmacol. modulation of individual bromodomains could represent a strategy for the treatment of acute gouty arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrav2e3P7XQ1LVg90H21EOLACvtfcHk0liTmgH3mKGmfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit1yqur7E&md5=5cce669e137812d20f8ba2a9785f4666</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01010%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DF.%26aulast%3DHu%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DMa%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DCui%26aufirst%3DY.%26aulast%3DZhi%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520benzo%255Bcd%255Dindol-2%25281H%2529-ones%2520and%2520pyrrolo%255B4%252C3%252C2-de%255Dquinolin-2%25281H%2529-ones%2520as%2520bromodomain%2520and%2520extra-terminal%2520domain%2520%2528BET%2529%2520inhibitors%2520with%2520selectivity%2520for%2520the%2520first%2520bromodomain%2520with%2520potential%2520high%2520efficiency%2520against%2520acute%2520gouty%2520arthritis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D11080%26epage%3D11107%26doi%3D10.1021%2Facs.jmedchem.9b01010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">van
der Fits, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mourits, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voerman, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kant, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laman, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornelissen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mus, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Florencia, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prens, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubberts, E.</span></span> <span> </span><span class="NLM_article-title">Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>182</i></span>,  <span class="NLM_fpage">5836</span>– <span class="NLM_lpage">5845</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.0802999</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=10.4049%2Fjimmunol.0802999" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=19380832" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BD1MXkslKhtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=182&publication_year=2009&pages=5836-5845&author=L.+van%0Ader+Fitsauthor=S.+Mouritsauthor=J.+S.+Voermanauthor=M.+Kantauthor=L.+Boonauthor=J.+D.+Lamanauthor=F.+Cornelissenauthor=A.+M.+Musauthor=E.+Florenciaauthor=E.+P.+Prensauthor=E.+Lubberts&title=Imiquimod-induced+psoriasis-like+skin+inflammation+in+mice+is+mediated+via+the+IL-23%2FIL-17+axis&doi=10.4049%2Fjimmunol.0802999"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice Is Mediated via the IL-23/IL-17 Axis</span></div><div class="casAuthors">van der Fits, Leslie; Mourits, Sabine; Voerman, Jane S. A.; Kant, Marius; Boon, Louis; Laman, Jon D.; Cornelissen, Ferry; Mus, Anne-Marie; Florencia, Edwin; Prens, Errol P.; Lubberts, Erik</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">182</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">5836-5845</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Topical application of imiquimod (IMQ), a TLR7/8 ligand and potent immune activator, can induce and exacerbate psoriasis, a chronic inflammatory skin disorder.  Recently, a crucial role was proposed for the IL-23/IL-17 axis in psoriasis.  The authors hypothesized that IMQ-induced dermatitis in mice can serve as a model for the anal. of pathogenic mechanisms in psoriasis-like dermatitis and assessed its IL-23/IL-17 axis dependency.  Daily application of IMQ on mouse back skin induced inflamed scaly skin lesions resembling plaque type psoriasis.  These lesions showed increased epidermal proliferation, abnormal differentiation, epidermal accumulation of neutrophils in microabcesses, neoangiogenesis, and infiltrates consisting of CD4+ T cells, CD11c+ dendritic cells, and plasmacytoid dendritic cells.  IMQ induced epidermal expression of IL-23, IL-17A, and IL-17F, as well as an increase in splenic Th17 cells.  IMQ-induced dermatitis was partially dependent on the presence of T cells, whereas disease development was almost completely blocked in mice deficient for IL-23 or the IL-17 receptor, demonstrating a pivotal role of the IL-23/IL-17 axis.  In conclusion, the sole application of the innate TLR7/8 ligand IMQ rapidly induces a dermatitis closely resembling human psoriasis, critically dependent on the IL-23/IL-17 axis.  This rapid and convenient model allows further elucidation of pathogenic mechanisms and evaluation of new therapies in psoriasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWu9yN1SM3ibVg90H21EOLACvtfcHk0liTmgH3mKGmfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXkslKhtrs%253D&md5=3e895f11e5cbfd9ee20a83ad34a4f419</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.0802999&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.0802999%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2Bder%2BFits%26aufirst%3DL.%26aulast%3DMourits%26aufirst%3DS.%26aulast%3DVoerman%26aufirst%3DJ.%2BS.%26aulast%3DKant%26aufirst%3DM.%26aulast%3DBoon%26aufirst%3DL.%26aulast%3DLaman%26aufirst%3DJ.%2BD.%26aulast%3DCornelissen%26aufirst%3DF.%26aulast%3DMus%26aufirst%3DA.%2BM.%26aulast%3DFlorencia%26aufirst%3DE.%26aulast%3DPrens%26aufirst%3DE.%2BP.%26aulast%3DLubberts%26aufirst%3DE.%26atitle%3DImiquimod-induced%2520psoriasis-like%2520skin%2520inflammation%2520in%2520mice%2520is%2520mediated%2520via%2520the%2520IL-23%252FIL-17%2520axis%26jtitle%3DJ.%2520Immunol.%26date%3D2009%26volume%3D182%26spage%3D5836%26epage%3D5845%26doi%3D10.4049%2Fjimmunol.0802999" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, L.</span></span> <span> </span><span class="NLM_article-title">One-pot synthesis of polysubstituted spirofluorene-indene via Ru(II)-catalyzed [3 + 2] annulation and intramolecular friedel-crafts cyclization</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">9973</span>– <span class="NLM_lpage">9979</span>, <span class="refDoi"> DOI: 10.1021/acs.joc.5b01517</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.joc.5b01517" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFKqsrbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2015&pages=9973-9979&author=Y.+Q.+Zhuauthor=L.+Dong&title=One-pot+synthesis+of+polysubstituted+spirofluorene-indene+via+Ru%28II%29-catalyzed+%5B3+%2B+2%5D+annulation+and+intramolecular+friedel-crafts+cyclization&doi=10.1021%2Facs.joc.5b01517"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">One-Pot Synthesis of Polysubstituted Spirofluorene-Indene via Ru(II)-Catalyzed [3 + 2] Annulation and Intramolecular Friedel-Crafts Cyclization</span></div><div class="casAuthors">Zhu, Yu-Qin; Dong, Lin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">9973-9979</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Ru(II)-catalyzed one-pot synthesis of polysubstituted spirofluorene-indenes via [3+2] annulation and then intramol. Friedel-Crafts alkylation has been achieved.  The simple method provides a broad scope of aryl ketones and internal alkynes, achieving PAHs skeletons in moderate to good yields.  E.g., in presence of [RuCl2(p-cymene)]2, AgBF4, Cu(acac)2, and pivalic acid, annulation and Friedel-Crafts alkylation of aryl ketone I with diphenylacetylene gave 80% II.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcIlhk51SFbLVg90H21EOLACvtfcHk0liTmgH3mKGmfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFKqsrbL&md5=b0d19f74a69840d028730088d1b8c1fc</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Facs.joc.5b01517&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.joc.5b01517%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DY.%2BQ.%26aulast%3DDong%26aufirst%3DL.%26atitle%3DOne-pot%2520synthesis%2520of%2520polysubstituted%2520spirofluorene-indene%2520via%2520Ru%2528II%2529-catalyzed%2520%255B3%2520%252B%25202%255D%2520annulation%2520and%2520intramolecular%2520friedel-crafts%2520cyclization%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2015%26volume%3D80%26spage%3D9973%26epage%3D9979%26doi%3D10.1021%2Facs.joc.5b01517" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4G3E" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4G3E','PDB','4G3E'); return false;">PDB: 4G3E</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6G4Y" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6G4Y','PDB','6G4Y'); return false;">PDB: 6G4Y</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i148"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00055">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_74027"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c00055?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00055</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">% Ctrl of compound <b>12f</b> against the 268 wild-type kinases, IC<sub>50</sub> of compound <b>12f</b> against the selected kianses, reagents and antibodies used for biological evaluation in vitro or in vivo, toxicity screening of selected target compounds on normal T cells, <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra for target compounds, HPLC spectra for target compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00055/suppl_file/jm0c00055_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular modeling information involved in ligand <b>1</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00055/suppl_file/jm0c00055_si_002.pdb">PDB</a>)</p></li><li><p class="inline">Molecular modeling information involved in the overlapping of ligand <b>12k</b> to <b>1</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00055/suppl_file/jm0c00055_si_003.pdb">PDB</a>)</p></li><li><p class="inline">Molecular modeling information involved in ligand <b>12f</b>_1 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00055/suppl_file/jm0c00055_si_004.pdb">PDB</a>)</p></li><li><p class="inline">Molecular modeling information involved in ligand <b>12f</b>_2 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00055/suppl_file/jm0c00055_si_005.pdb">PDB</a>)</p></li><li><p class="inline">Molecular formula strings and some data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00055/suppl_file/jm0c00055_si_006.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00055/suppl_file/jm0c00055_si_001.pdf">jm0c00055_si_001.pdf (6.63 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00055/suppl_file/jm0c00055_si_002.pdb">jm0c00055_si_002.pdb (747.05 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00055/suppl_file/jm0c00055_si_003.pdb">jm0c00055_si_003.pdb (590.45 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00055/suppl_file/jm0c00055_si_004.pdb">jm0c00055_si_004.pdb (393.08 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00055/suppl_file/jm0c00055_si_005.pdb">jm0c00055_si_005.pdb (403.26 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00055/suppl_file/jm0c00055_si_006.csv">jm0c00055_si_006.csv (3.77 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c00055&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-13%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c00055%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c00055" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                10MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-b425991822a79ada59b3.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-fb88834b824b41b135ad.js"></script>

<script type="text/javascript" src="/wro/ke1q~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"66797e0f494dd1af","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
